Date of event requiring this shell company
report. Not applicable
(Name, Telephone, E-mail and/or Facsimile
number and Address of Company Contact Person)
Securities registered
or to be registered pursuant to Section 12(b) of the Act.
* Not for trading, but only in connection
with the registration of the American Depositary Shares pursuant to requirements of the Securities and Exchange Commission.
Securities registered
or to be registered pursuant to Section 12(g) of the Act.
Securities for which
there is a reporting obligation pursuant to Section 15(d) of the Act.
Indicate the number
of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the
annual report.
Indicate by check
mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
If this report is
an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934.
Note—Checking
the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 from their obligations under those Sections.
Indicate by check
mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check
mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).
Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
Indicate by check
mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
If “Other”
has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has
elected to follow.
If this is an annual
report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
This Amendment No. 2 on Form 20-F/A
(the “Amended Annual Report”) amends the Annual Report on Form 20-F of Oasmia Pharmaceutical AB originally filed with
the Securities and Exchange Commission (the “SEC”) on August 24, 2017 (the “Original Filing”), as amended
by Amendment No. 1 thereto filed on October 31, 2017 (the “Prior Filing”). This Amendment No. 2 on Form 20-F/A is
filed solely to revise Item 15 A. of the Original Filing.
Other than the foregoing, this Amended Annual Report speaks as of the original
date of the Original Filing or, where applicable, the Prior Filing, does not reflect events that may have occurred subsequent
to the date of the Original Filing or, where applicable, the Prior Filing and does not modify or update in any way disclosures
made in the Original Filing or, where applicable, the Prior Filing.
This document contains information
required for the annual report on Form 20-F for the fiscal year ended April 30, 2017 of Oasmia Pharmaceutical AB (the “Form
20-F”). Unless the context specifically indicates otherwise, references in this Form 20-F to “Oasmia Pharmaceutical
AB”, “Oasmia Pharmaceutical”, “Oasmia”, “we”, “our”, “ours”,
“us”, the “Company” or similar terms refer to Oasmia Pharmaceutical AB.
All references in this annual
report to “$” are to U.S. dollars, all references to “SEK” are to Swedish kronor and all references to
“TSEK” are to Swedish kronor in thousands. Solely for the convenience of the reader some, but not all, Swedish krona
and Euro amounts have been translated into U.S. dollars at the relevant exchange rate posted by the Federal Reserve Bank. These
translations should not be considered representations that any such amounts have been, could have been or could be converted into
U.S. dollars at that or any other exchange rate as of that or any other date.
This annual report contains
estimates and forward-looking statements, principally in “Risk Factors,” “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” and “Business.” Some of the matters discussed concerning
our operations and financial performance include estimates and forward-looking statements within the meaning of the Securities
Act and the Exchange Act.
These forward-looking statements
are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause our actual results of operations,
financial condition, liquidity, performance, prospects, opportunities, achievements or industry results, as well as those of the
markets we serve or intend to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements.
These forward-looking statements are based on assumptions regarding our present and future business strategies and the environment
in which we expect to operate in the future. Important factors that could cause those differences include, but are not limited
to:
Additional factors that could
cause actual results, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results
to differ materially include, but are not limited to, those discussed under “Risk Factors” in this annual report.
Additional risks that we may currently deem immaterial or that are not presently known to us could also cause the forward-looking
events discussed in this annual report not to occur. The words “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “expect” and similar words are intended to
identify estimates and forward-looking statements. Estimates and forward-looking statements speak only at the date they were made,
and we undertake no obligation to update or to review any estimate and/or forward-looking statement because of new information,
future events or other factors. Estimates and forward-looking statements involve risks and uncertainties and are not guarantees
of future performance. Our future results may differ materially from those expressed in these estimates and forward-looking statements.
In light of the risks and uncertainties described above, the estimates and forward-looking statements discussed in this annual
report might not occur and our future results and our performance may differ materially from those expressed in these forward-looking
statements due to, inclusive of, but not limited to, the factors mentioned above. Because of these uncertainties, you should not
make any investment decision based solely on these estimates and forward-looking statements.
PART I
ITEM 1. IDENTITY
OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
Not applicable.
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
ITEM 3. KEY INFORMATION
|
A.
|
Selected
financial information
|
You should read the following
selected financial data in conjunction with our financial statements and the related notes thereto appearing elsewhere in this
annual report and in the section of this annual report entitled “Item 5. Operating and financial review.”
The following table summarizes
our consolidated financial data as of the dates and for the periods indicated. The selected consolidated financial data for the
fiscal years presented have been derived from our consolidated financial statements, which have been prepared in accordance with
International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”). Furthermore, the recommendation
RFR 1, Supplementary accounting regulations for Groups, issued by the Swedish Financial Reporting Board, has been applied. We
have prepared the consolidated financial information set forth below on the same basis as our audited consolidated financial statements.
Our consolidated financial
statements are prepared and presented in Swedish krona “SEK”, which is our functional currency. All tables, if not
expressly otherwise stated, in this annual report are therefore in Swedish krona.
Our historical results are
not necessarily indicative of the results that may be expected in the future. The following summary consolidated financial data
should be read in conjunction with the section “Item 5. Operating and financial review” and our consolidated financial
statements included elsewhere in this annual report, including our discussions therein regarding the material weakness in our
internal control over financial reporting identified by our auditors and the Company’s future financing and going concern.
Key figures are translated
into USD as additional information as a service to readers of this annual report in the US. The US Dollar is not the functional
currency of Oasmia, which is SEK. The conversion of currency has been made by use of a convenience rate for all figures including
those from previous periods. This rate is the closing rate as per August 18, 2017 which was 8.1082 SEK per one USD.
Consolidated income statement data:
|
|
2017
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
|
(TUSD)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
21
|
|
|
|
172
|
|
|
|
6,373
|
|
|
|
2,070
|
|
|
|
60
|
|
Change in inventories of products in progress and finished goods
|
|
|
(173
|
)
|
|
|
(1,405
|
)
|
|
|
9,509
|
|
|
|
-
|
|
|
|
-
|
|
Capitalized development cost
|
|
|
866
|
|
|
|
7,023
|
|
|
|
16,727
|
|
|
|
16,797
|
|
|
|
29,464
|
|
Other operating income
|
|
|
52
|
|
|
|
420
|
|
|
|
2
|
|
|
|
221
|
|
|
|
4,454
|
|
Raw materials, consumables and goods for resale
|
|
|
(368
|
)
|
|
|
(2,984
|
)
|
|
|
(4,733
|
)
|
|
|
(10,062
|
)
|
|
|
(6,835
|
)
|
Other external expenses
|
|
|
(9,855
|
)
|
|
|
(79,904
|
)
|
|
|
(98,104
|
)
|
|
|
(60,740
|
)
|
|
|
(75,189
|
)
|
Employee benefit expenses
|
|
|
(7,313
|
)
|
|
|
(59,295
|
)
|
|
|
(57,661
|
)
|
|
|
(50,530
|
)
|
|
|
(45,101
|
)
|
Depreciation, amortization and impairment
|
|
|
(556
|
)
|
|
|
4,508
|
)
|
|
|
(4,804
|
)
|
|
|
(5,190
|
)
|
|
|
(4,941
|
)
|
Other operating expenses
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(792
|
)
|
|
|
(3
|
)
|
Operating income (loss)
|
|
|
(17,326
|
)
|
|
|
(140,481
|
)
|
|
|
(132,691
|
)
|
|
|
(108,225
|
)
|
|
|
(98,091
|
)
|
Financial income
|
|
|
10
|
|
|
|
85
|
|
|
|
786
|
|
|
|
210
|
|
|
|
192
|
|
Financial expenses
|
|
|
(2,448
|
)
|
|
|
(19,847
|
)
|
|
|
(9,634
|
)
|
|
|
(9,482
|
)
|
|
|
(7,213
|
)
|
Financial income and expenses - net
|
|
|
(2,437
|
)
|
|
|
(19,762
|
)
|
|
|
(8,848
|
)
|
|
|
(9,272
|
)
|
|
|
(7,021
|
)
|
Income (loss) before taxes
|
|
|
(19,763
|
)
|
|
|
(160,243
|
)
|
|
|
(141,539
|
)
|
|
|
(117,497
|
)
|
|
|
(105,112
|
)
|
Income taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Income (loss) for the period
|
|
|
(19,763
|
)
|
|
|
(160,243
|
)
|
|
|
(141,539
|
)
|
|
|
(117,497
|
)
|
|
|
(105,112
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per
share, before and after dilution, SEK
(1)
|
|
|
(0.18
|
)
|
|
|
(1.42
|
)
|
|
|
(1.39
|
)
|
|
|
(1.28
|
)
|
|
|
(1.27
|
)
|
Weighted average number
of shares, in thousands before and after dilution
(1)
|
|
|
112,994
|
|
|
|
112,994
|
|
|
|
101,753
|
|
|
|
91,655
|
|
|
|
82,848
|
|
(1)
Recalculation of historical
figures has been performed with regards to capitalization issue components in the preferential rights share issue carried out
in the fiscal quarter January 31, 2015.
Consolidated statement of financial position data:
|
|
2017
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
|
(TUSD)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total non-current assets
|
|
|
58,147
|
|
|
|
471,464
|
|
|
|
443,010
|
|
|
|
427,879
|
|
|
|
414,106
|
|
Liquid assets
|
|
|
3,453
|
|
|
|
28,001
|
|
|
|
46,214
|
|
|
|
76,990
|
|
|
|
48,241
|
|
Total current assets
|
|
|
6,181
|
|
|
|
50,119
|
|
|
|
72,570
|
|
|
|
86,690
|
|
|
|
54,276
|
|
Total assets
|
|
|
64,328
|
|
|
|
521,583
|
|
|
|
515,579
|
|
|
|
514,569
|
|
|
|
468,383
|
|
Total equity
|
|
|
37,045
|
|
|
|
300,371
|
|
|
|
326,053
|
|
|
|
375,710
|
|
|
|
281,907
|
|
Total non-current liabilities
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
891
|
|
Total current liabilities
|
|
|
27,283
|
|
|
|
221,212
|
|
|
|
189,527
|
|
|
|
138,858
|
|
|
|
185,584
|
|
Total liabilities
|
|
|
27,283
|
|
|
|
221,212
|
|
|
|
189,527
|
|
|
|
138,858
|
|
|
|
186,476
|
|
Consolidated cash flow statement data:
|
|
2017
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
|
(TUSD)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
(TSEK)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating activities
|
|
|
(16,405
|
)
|
|
|
(133,011
|
)
|
|
|
(128,126
|
)
|
|
|
(107,666
|
)
|
|
|
(86,899
|
)
|
Cash flow from investing activities
|
|
|
1,485
|
|
|
|
12,039
|
|
|
|
10,066
|
|
|
|
(69,755
|
)
|
|
|
(35,682
|
)
|
Cash flow from financing activities
|
|
|
15,140
|
|
|
|
122,755
|
|
|
|
117,449
|
|
|
|
156,017
|
|
|
|
107,865
|
|
EXCHANGE RATE INFORMATION
Fluctuations in the
exchange rate between the Swedish krona and the U.S. dollar will affect the U.S. dollar amounts received by owners of the ADSs
on conversion of dividends, if any, paid in kronor on the Ordinary Shares and will affect the U.S. dollar price of the ADSs on
Nasdaq. The table below shows the period end, average, high and low exchange rates of kronor per U.S. dollar for the periods shown.
Average rates are computed by using the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the last
business day of each month during the relevant year indicated or each business day during the relevant month indicated. The rates
set forth below are provided solely for your convenience and may differ from the actual rates used in the preparation of our consolidated
financial statements included in this annual report and other financial data appearing in this annual report
|
|
Period End
|
|
|
Average
|
|
|
High
|
|
|
Low
|
|
Year Ended April 30:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2013
|
|
|
6.4817
|
|
|
|
6.6747
|
|
|
|
7.2655
|
|
|
|
6.2880
|
|
2014
|
|
|
6.5049
|
|
|
|
6.5244
|
|
|
|
6.8171
|
|
|
|
6.3237
|
|
2015
|
|
|
8.3778
|
|
|
|
7.5000
|
|
|
|
8.8180
|
|
|
|
6.4864
|
|
2016
|
|
|
8.0267
|
|
|
|
8.4162
|
|
|
|
8.7679
|
|
|
|
8.0267
|
|
2017
|
|
|
8.8635
|
|
|
|
8.7399
|
|
|
|
9.4207
|
|
|
|
7.9761
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Month Ended:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 2017
|
|
|
8.9349
|
|
|
|
8.9147
|
|
|
|
9.0664
|
|
|
|
8.7701
|
|
April 2017
|
|
|
8.8635
|
|
|
|
8.9616
|
|
|
|
9.0635
|
|
|
|
8.7675
|
|
May 2017
|
|
|
8.6788
|
|
|
|
8.7826
|
|
|
|
8.9130
|
|
|
|
8.6731
|
|
June 2017
|
|
|
8.4400
|
|
|
|
8.6779
|
|
|
|
8.7941
|
|
|
|
8.4400
|
|
July 2017
|
|
|
8.0752
|
|
|
|
8.3129
|
|
|
|
8.5031
|
|
|
|
8.0752
|
|
August 2017 (through August 18, 2017)
|
|
|
8.1082
|
|
|
|
8.1305
|
|
|
|
8.1928
|
|
|
|
8.0847
|
|
B. Capitalization and indebtedness
Not applicable
C. Reason for the Offer and Use of Proceeds
Not applicable
D. Risk factors.
Our business faces significant
risks and uncertainties. You should carefully consider the following risk factors and all other information set forth in this
Annual Report on Form 20-F, including our consolidated financial statements, before making an investment decision regarding our
securities. The risks and uncertainties described below are those significant risk factors, currently known and specific to us,
which we believe are relevant to an investment in our securities. The risk factors are not placed in order of priority and should
not be construed as comprehensive. Additional risks and uncertainties not currently known to us or those we now deem immaterial
may also harm us and adversely affect your investment in the ADSs. If any of these risks materialize, our business, results of
operations, financial condition and future prospects could suffer and the price of the ADSs could decline and you could lose part
or all of your investment. In addition to the information disclosed in this annual report, investors should make their own assessment
of each risk factor and its potential impact on our future development as well as an assessment of the impact of general conditions,
including market conditions and world events.
Risks Related to Our Product and Product
Candidates
We are substantially dependent on the
success of our product and product candidates, none of which may receive full regulatory approval or be successfully commercialized.
Up until today, we have invested nearly all
of our resources in the research and development of our product candidates, which consist of Paccal Vet-CA1 (“Paccal Vet”)
for cancer in dogs, Paclical for ovarian cancer and other cancers in humans, Docecal for breast cancer in humans, Doxophos Vet
for lymphoma in dogs, Doxophos for breast cancer and other cancers in humans, and OAS-19 for various cancers in humans. One of
product candidates, Paclical, has been approved for full commercial distribution in Russia. Another one of our product candidates,
Paccal Vet-CA1 (“Paccal Vet”) was previously conditionally approved by FDA. However this conditional approval was
withdrawn January 2017. Our near-term prospects, including our ability to finance our company and to enter into strategic collaborations
and generate revenue, are directly dependent upon the successful development and commercialization of our product and product
candidates, particularly Paccal Vet and Paclical.
The development and commercial success of
our product and product candidates will depend on a number of factors, including, without limitation, the following:
|
•
|
timely
initiation and successful completion of preclinical studies and clinical trials for our
product candidates;
|
|
•
|
demonstration
to the satisfaction of the United States Food and Drug Administration (“FDA”),
the European Medicines Agency (“EMA”) and other applicable regulatory authorities
of the safety and efficacy of our product and product candidates, as well as to obtain
regulatory and marketing approval for our product and product candidates in the U.S.,
Europe and elsewhere;
|
|
•
|
continued
compliance with all clinical and regulatory requirements applicable to our product and
product candidates;
|
|
•
|
maintenance
of an acceptable safety profile of our products following regulatory approval;
|
|
•
|
competition
with other treatments;
|
|
•
|
creation,
maintenance and protection of our intellectual property portfolio, including patents
and trade secrets, and regulatory exclusivity for our product and product candidates;
|
|
•
|
effectiveness
of our and our partners’ marketing, sales and distribution strategy and operations;
|
|
•
|
ability
of our third-party manufacturers to manufacture supplies of our product and product candidates
and to develop, validate and maintain commercially viable manufacturing processes;
|
|
•
|
ability
to launch commercial sales of our product and product candidates following regulatory
approval, whether alone or in collaboration with others;
|
|
•
|
acceptance
of our animal health product and product candidates by veterinarians, pet owners and
the animal health community; and
|
|
•
|
acceptance
of our human health product candidates from physicians, health care payers, patients
and the medical community.
|
Since many of these factors are beyond our
control, we cannot assure you that we will ever be able to generate sufficient revenue or any revenue from the sale of our product
and product candidates. Our failure in any of the above-mentioned factors or in successfully commercializing one or more of our
product and product candidates, or any significant delay in doing so, could have a material adverse effect on our business, results
of operations and financial condition, and the value of your investment could substantially decline.
Our product and product candidates may
not achieve market acceptance, which could limit our ability to generate revenue from new products.
Even if we develop our product and product
candidates and gain regulatory approvals for our products, unless veterinarians, physicians, and patients accept our products,
we may not be able to sell our products and generate significant revenue. We cannot assure you that our current product and product
candidates or any other planned products will achieve market acceptance and revenue if and when they obtain the requisite regulatory
approvals. Market acceptance of any product depends on a number of factors, including but not limited to:
|
•
|
the
indication and warnings approved by regulatory authorities in the product label;
|
|
•
|
continued
demonstration of efficacy and safety in commercial use;
|
|
•
|
physicians’
or veterinarians’ willingness to prescribe the product;
|
|
•
|
reimbursement
from third-party payors such as government health care systems and insurance companies;
|
|
•
|
the
price of the product, including pet owners’ willingness to pay for treatment;
|
|
•
|
the
nature of any post-approval risk management plans mandated by regulatory authorities;
|
|
•
|
the
effectiveness of marketing and distribution support.
|
Any failure by our product and product candidates
to achieve market acceptance or commercial success could have a material adverse effect on our business, results of operations
and financial condition.
Problems in our manufacturing process,
failure to comply with manufacturing regulations or unexpected increases in our manufacturing costs could harm our business, results
of operations and financial condition.
We are responsible for the manufacture and
supply of Paccal Vet, Paclical, and our other product candidates for our commercial partners and for use in clinical trials. The
manufacturing of our product and product candidates necessitates compliance with US FDA, EU EMA and international current Good
Manufacturing Practice (“cGMP”) and other international regulatory requirements. Although we contract with third parties
such as Baxter Oncology GmbH for a certain amount of the manufacturing of Paccal Vet, Paclical and our other product candidates,
the market authorization for Paccal Vet and Paclical remains with us. As such, even if we could potentially have a claim against
one or more third parties, we are legally liable for any noncompliance related to Paccal Vet and Paclical and we expect to retain
legal responsibility for future product candidates as well.
If we are unable to manufacture, or contract
to manufacture, our product and product candidates in accordance with regulatory specifications, or if there are disruptions in
the manufacturing process due to damage, loss or failure to pass regulatory inspections of manufacturing facilities, we may not
be able to meet the demand for our products or supply sufficient product for use in clinical trials, and this may harm our ability
to commercialize Paccal Vet, Paclical and our other product candidates on a timely or cost-competitive basis, or preclude us from
doing so at all. In addition, we are in the process of expanding and changing parts of our manufacturing facilities in order to
meet future demand and FDA requirements, a program which requires significant time and resources. We also expect to expand and
upgrade other parts of our manufacturing facilities in the future. These activities may lead to delays, interruptions in supply,
or may prove to be more costly than we currently anticipate. Any problems in our manufacturing process could have a material adverse
effect on our business, results of operations and financial condition.
In addition, under our license agreements,
we expect to generate revenue from the supply of commercial products to our partners at a fixed percentage of our cost of goods
sold, and thus any increases in our manufacturing costs could materially and adversely affect our margins and our financial condition.
Before we can begin commercial manufacture
of Paccal Vet, Paclical or our other product candidates for sale in the U.S., we must obtain FDA regulatory approval for the product,
which requires a successful FDA inspection of our manufacturing facilities, processes and quality systems in addition to other
product-related approvals. Although we successfully passed an FDA Pre-Approval Inspection and a FDA routine GMP inspection of
our manufacturing facility in Uppsala, Sweden, our pharmaceutical facilities are continuously subject to inspection by the FDA
and foreign (EMA) regulatory authorities, even after product approval. Due to the complexity of the processes used to manufacture
our product and product candidates, we may be unable to pass federal, state or international regulatory inspections in a cost
effective manner, whether initially on at any time thereafter. If we are unable to comply with manufacturing regulations, we may
be subject to fines, unanticipated compliance expenses, recall or seizure of any approved products, or legal actions such as injunctions
or criminal or civil prosecution. These possible sanctions could materially and adversely affect our business, results of operations
and financial condition. See also “— Risks Related to Development and Regulatory Approval of Our Product and
Product Candidates — The regulatory approval process is uncertain, requires us to utilize significant resources,
and may prevent us or our commercial partners from obtaining approvals for the commercialization of some or all of our drug candidates.”
We expect to face substantial competition,
which may result in others discovering, developing or commercializing products before, or more successfully than, we do.
The development and commercialization of new
drug products is highly competitive. We face competition with respect to our current product and product candidates, and will
face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major
pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. In addition to existing therapeutic
treatments for the indications we are targeting with our product and product candidates, we also face potential competition from
other drug candidates in development by other companies. Our potential competitors include large health care companies, such as
Celgene, Merck & Co., Inc., Sanofi S.A., Eli Lilly and Company, Roche, Bayer AG, Novartis AG and Boehringer Ingelheim GmbH.
Several of these companies also has a presence in animal health. We also know of several smaller early stage companies that are
developing products for use in the animal or human health products market. We expect that Paccal Vet and Doxophos Vet will face
competition from Palladia, made by Zoetis, Inc. and Blontress and Tactress, made by Aratana Therapeutics, Inc. We may also face
competition from generic medicines and products approved for use in humans that are used off-label for pets. Some of the potential
competitive compounds referred to above are being developed by large, well-financed and experienced pharmaceutical and biotechnology
companies or have been partnered with such companies, which may give them development, regulatory and marketing advantages over
our products.
Our commercial opportunity could be reduced
or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe
side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain
FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete
may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products. Generic
products are currently on the market for the indications that we are pursuing. If our product candidates achieve marketing approval,
we expect that they will be priced at a significant premium over competing generic products.
Some of the companies against which we are
competing or against which we may compete in the future have significantly greater financial resources and expertise in research
and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large and established companies. These third
parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial
sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our
programs.
If we are unable to compete successfully,
we may be unable to grow and sustain our revenue, which could materially and adversely affect our business, results of operations
and financial condition.
Generic products may be more cost-effective
than our products.
In addition to the competition that we may
face from products produced by other companies in general, we may also face competition from generic alternatives to our products.
For example, Paclical is expected to compete with the generic form of Taxol. Generic alternatives are generally less expensive,
and competitors who market generic drugs are becoming more aggressive in terms of pricing. Consequently, generic products constitute
an increasing percentage of both overall human and animal health sales in certain regions. If human and animal health care customers
increase their use of new or existing generic products, or if we are unable to compete with existing generic products, our business,
results of operations and financial condition could be materially and adversely affected.
Serious adverse events or other safety
risks could require us to abandon development and preclude, delay or limit approval of our product and product candidates, or
limit the scope of any approved label or market acceptance.
If any of Paccal Vet, Paclical, or any of
our other product candidates, prior to or after any approval for commercial sale, causes serious or unexpected side effects, or
become associated with other safety risks such as misuse, abuse or diversion, a number of potentially significant negative consequences
could result, including, without limitation:
|
•
|
regulatory
authorities may interrupt, delay or halt clinical trials;
|
|
•
|
regulatory
authorities may deny regulatory approval of our product candidates;
|
|
•
|
regulatory
authorities may require certain labeling statements, such as warnings or contraindications
or limitations on the indications for use, or impose restrictions on distribution in
the form of a Risk Evaluation and Mitigation Strategy (“REMS”), in connection
with approval, if any;
|
|
•
|
regulatory
authorities may withdraw their approval, require more onerous labeling statements or
impose a more restrictive REMS of any product that is approved;
|
|
•
|
we
may be required to change the way the product is administered or conduct additional clinical
trials;
|
|
•
|
our
relationships with our commercial partners may suffer;
|
|
•
|
we
could be sued and held liable for harm caused to patients; and
|
|
•
|
our
reputation may suffer.
|
We may voluntarily suspend or terminate our
clinical trials if at any time we believe that they present an unacceptable risk to participants or if preliminary data demonstrate
that our product and product candidates are unlikely to receive regulatory approval or are unlikely to be successfully commercialized.
In addition, regulatory agencies, an Institutional Review Board (“IRB”), or data safety monitoring boards may at any
time recommend the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators
in the clinical trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory
requirements, or that they present an unacceptable safety risk to participants. Although we have never been asked by a regulatory
agency, IRB or data safety monitoring board to temporarily or permanently discontinue a clinical trial, if we elect or are forced
to suspend or terminate a clinical trial of Paccal Vet, Paclical or any of our other product candidates, the commercial prospects
for that product may be harmed and our ability to generate product revenue from that product may be delayed or eliminated. Furthermore,
any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and
could substantially increase the costs of commercializing our product and product candidates and materially impair our ability
to generate revenue from the commercialization of these products either by us or by our commercial partners and could have a material
adverse effect on our reputation, business, results of operations and financial condition.
If we fail to obtain and sustain an
adequate level of reimbursement for our products by third-party payers, sales and profitability will be adversely affected.
The course of medical treatment for human
patients is, and will continue to be, expensive. We expect that most patients and their families will not be capable of paying
for our products themselves. Accordingly, it is unlikely that there will be a commercially viable market for Paclical or our other
human health care product candidates without reimbursement from third-party payors. Additionally, even if there is a commercially
viable market, if the level of third-party reimbursement is insufficient from the patient’s perspective, our revenue and
gross margins will be materially and adversely affected.
A current trend in the U.S. health care industry,
as well as in other countries around the world, is toward cost containment. Large public and private payers, managed care organizations,
group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of,
and reimbursement levels for, particular treatments. Third-party payers, such as government programs, including Medicare in the
U.S. and private health care insurers, carefully review and have increasingly been challenging the coverage of, and prices charged
for, medical products and services. Many third-party payers limit coverage of or reimbursement for newly-approved health care
products. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other
factors. Cost-control initiatives could decrease the price we or our partners establish for products, which could result in lower
product revenue and profitability.
Reimbursement systems in international markets
vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. Our partners
may elect to reduce the price of our products in order to increase the likelihood of obtaining reimbursement approvals. In many
countries, products cannot be commercially launched until reimbursement is approved and the negotiation process in some countries
can exceed 12 months. In addition, pricing and reimbursement decisions in certain countries can be affected by decisions taken
in other countries, which can lead to mandatory price reductions and/or additional reimbursement restrictions across a number
of other countries, which may thereby adversely affect our sales and profitability. If countries set prices that are not sufficient
to allow us or our partners to generate a profit, our partners may refuse to launch the product in such countries or withdraw
the product from the market, which would adversely affect our sales and profitability and could materially and adversely affect
our business, results of operations and financial condition.
We may not be successful in our efforts
to expand our pipeline of product candidates.
One element of our strategy is to expand our
pipeline of pharmaceuticals based on our XR17 technology and advance these product candidates through clinical development for
the treatment of a variety of indications. Although our research and development efforts to date have resulted in a number of
development programs based on XR17 technology, we may not ultimately be able to develop product candidates that are safe and effective.
Even if we are successful in continuing to expand our pipeline, the potential product candidates that we identify may not be suitable
for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate
that they are unlikely to receive marketing approval and achieve market acceptance. In addition, if we attempt to apply XR17 technology
to develop product candidates for indications outside of cancer, we will need to conduct genotoxicity, carcinogenicity and immunotoxicity
trials, in which the results may be uncertain. If we do not successfully develop and commercialize product candidates based upon
our technological approach, we will not be able to obtain product revenue in future periods, which would make it unlikely that
we would ever achieve profitability.
The veterinary market we are seeking
to enter with Paccal Vet and our other animal health products is untested.
The market for cancer drugs for dogs is nascent
and changing. Consequently, it is difficult to assess to what extent cancer drugs might be accepted by veterinarians, which complicates
both the estimate of the market size as well as our share thereof, if any. If a market does not develop, or our share thereof
is not meaningful, it could have a material adverse effect on our business, results of operations and financial condition.
For our animal health products, changes
in distribution channels could negatively impact our market share and distribution of our animal health products.
Since our animal health product and product
candidates are designed to be given intravenously by veterinarians, pet owners will not be able to obtain our products over-the-counter
or via the internet. Increasingly, pet owners purchase animal health products from sources other than veterinarians, such as internet-based
retailers, “big-box” retail stores or other over-the-counter distribution channels. This trend has been demonstrated
by the significant shift away from the veterinarian distribution channel in the sale of parasiticides and vaccines in recent years.
Pet owners also could decrease their reliance on, and visits to, veterinarians as they rely more on internet-based animal health
information. Since we market our animal health products through the veterinarian distribution channel, any decrease in visits
to veterinarians by pet owners could reduce our market share for such products and materially and adversely affect our operating
results and financial condition.
Business interruptions could delay us
in the process of developing our product and product candidates and could disrupt our product sales.
Loss of our manufacturing facilities, stored
inventory or laboratory facilities through accidents, fire or other causes could have an adverse effect on our ability to meet
demand for our products, to continue product development activities and to conduct our business. Failure to supply our partners
with commercial products may lead to adverse consequences, including the right of certain partners to take over responsibility
for product supply. We have insurance coverage to compensate us for such business interruptions, but should such coverage prove
insufficient to fully compensate us for damage to our business resulting from any significant property or casualty loss to our
inventory or facilities, it could have a material adverse effect on our business, results of operations and financial condition.
Product recalls or inventory losses
caused by unforeseen events, cold chain interruption and testing difficulties may adversely affect our operating results and financial
condition.
Paccal Vet, Paclical and our other product
candidates are manufactured and distributed using technically complex processes requiring specialized facilities, highly specific
raw materials and other production constraints. The complexity of these processes, as well as the strict company and government
standards for the manufacture of our products, subjects us to production risks. While product batches released for use in clinical
trials or for commercialization undergo sample testing, some defects may only be identified following product release. In addition,
process deviations or unanticipated effects of approved process changes may result in these intermediate products not complying
with stability requirements or specifications. Most of our products must be stored and transported at temperatures within a certain
range, which is known as “strict cold chain” storage and transportation. If these environmental conditions deviate,
our products’ remaining shelf lives could be impaired or their efficacy and safety could become adversely affected, making
them no longer suitable for use. The occurrence or suspected occurrence of production and distribution difficulties can lead to
lost inventories, and in some cases product recalls, with consequential reputational damage and the risk of product liability.
The investigation and remediation of any identified problems can cause production delays, substantial expense, lost sales and
delays of new product launches, any of which could have a material adverse effect on our business, results of operations and financial
condition.
Related to Our Financial Position and Capital
Needs
Our independent registered public accounting
firm included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated
financial statements included in this annual report.
Our audited consolidated financial statements
were prepared assuming that we will continue as a going concern. However, the report of our independent registered public accounting
firm included elsewhere in this annual report contains an explanatory paragraph on our consolidated financial statements stating
there is substantial doubt about our ability to continue as a going concern, meaning that we may not be able to continue in operation
for the foreseeable future or be able to realize assets and discharge liabilities in the ordinary course of operations. Such an
opinion could materially limit our ability to raise additional funds through the issuance of new debt or equity securities or
otherwise. There is no assurance that sufficient financing will be available when needed to allow us to continue as a going concern.
The perception that we may not be able to continue as a going concern may also make it more difficult to raise additional funds
or operate our business due to concerns about our ability to meet our contractual obligations.
Oasmia has one product approved, but this
does not yet create a sufficient cash flow from its business. For this reason, Oasmia continuously works with various financing
alternatives. This work includes the fact that the Company is in discussions with potential partners for licensing of distribution
and sales rights, negotiations with new and existing investors, financiers and lenders and that the company ensures enough resources
to secure that forecasted future revenue streams from regions where the company's products registered, are realized.
Available consolidated liquid assets and unutilized
credit facilities as of April 30, 2017 are not sufficient to provide the required capital to pursue the planned activities during
the next 12 months. In light of available financing alternatives and the recent developments in the Company, the Board of Directors
assesses that the prospects for financing of the Company´s operations in the coming year are good. Should funding not be
obtained in sufficient quantities there is a risk that the conditions for continued operation do not exist.
Our independent registered public accounting
firm has advised us that it has identified a material weakness in our internal control over financial reporting relating to inadequate
financial statement preparation and review procedures.
In connection with the audit of our financial
statements as of and for the fiscal year ended April 30, 2015 and 2014 our independent registered public accounting firm reported
to our audit committee that it had identified a material weakness in our internal control over financial reporting related to
inadequate financial statement preparation and review procedures. During the year ended April 30, 2017, we have performed the
remedial activities described below to address the material weakness identified by our independent registered public accounting
firm. However there has not yet been a sufficient time period to allow management to assess whether these actions have been implemented
successfully, and determine that the newly-designed controls will operate as designed, both routinely and effectively. Accordingly,
we cannot yet conclude that the material weakness previously identified has been fully remediated. Under standards established
by the Public Company Accounting Oversight Board (United States), a material weakness is a deficiency or combination of deficiencies
in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our
annual or interim financial statements will not be prevented or detected and corrected on a timely basis. Specifically, our independent
registered public accounting firm determined that we did not have adequate procedures and controls to ensure that accurate financial
statements could be prepared and reviewed on a timely basis, including:
|
•
|
sufficient
resources and processes in place, including controls in the finance and accounting department,
to adequately perform a timely financial statement close process resulting in errors
in period-end accruals related to capitalized research and development expenses.
|
|
•
|
adequate
internal review processes in place over critical accounting areas including timely operation
whereby management identifies and resolves significant or complex accounting matters.
|
As a result of this material weakness, during
the financial year ending April 30, 2017 we have implemented the following changes:
|
•
|
continued
to improve necessary procedures to capture all expenses for capitalized research and
development expenses;
|
|
•
|
further
enhanced the internal review processes of critical and significant accounting areas by
involving the management group deeper in such judgments and estimates;
|
|
•
|
strengthened
the finance department by recruitments and organizational change and by hiring additional
personnel;
|
|
•
|
improved
knowledge of IFRS standards, as adopted by the IASB, through additional education in
IFRS standards and also specific SEC reporting in the U.S.;
|
|
•
|
continued
to implement and improve formalized written policies and procedures for the timely accrual
of capitalized research and development expenses;
|
|
•
|
enhanced
oversight procedures in an effort to ensure that the accrual process has been performed
prior to finalization of the financial statements at each reporting period; and
|
|
•
|
formalized
accounting evaluation of non-routine judgments and estimations.
|
We concurred with the findings in the previous
fiscal year from our independent registered public accounting firm. We have been working to remediate the material weakness. The
actions that we took were subject to ongoing senior management review and audit committee oversight; however, as there has not
yet been a sufficient time period to allow management to assess whether these actions have been implemented successfully, and
determine that the newly-designed controls will operate as designed, both routinely and effectively, we cannot yet conclude that
the material weakness previously identified has been fully remediated. We will continue to strengthen our procedures; however,
our initiatives may not prove to be sufficient to avoid any material weakness in the future.
We will be required to disclose changes made
in our internal control over financial reporting and procedures on a semi-annual basis and our management will be required to
assess the effectiveness of these controls annually. However, for as long as we are an “emerging growth company” under
the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal
control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We could be an “emerging growth company”
for up to five years. An independent assessment of the effectiveness of our internal control over financial reporting could detect
problems that our management’s assessment might not. Additional undetected material weaknesses in our internal control over
financial reporting could lead to financial statement restatements and require us to incur additional expenses of remediation,
and adversely affect our reputation, financial condition and operating results.
We face litigation risks as a result
of the material weakness in our internal control over financial reporting identified by our independent registered public accounting
firm.
In connection with the audit of our financial
statements as of and for the fiscal years ended April 30, 2015 and April 30, 2014 our independent registered public accounting
firm reported to our audit committee that it had identified a material weakness in internal control over financial reporting related
to inadequate financial statement preparation and review procedures. See “— Our independent registered public
accounting firm has advised us that it has identified a material weakness in our internal control over financial reporting relating
to inadequate financial statement reparation and review procedures.”
As a result of such material weakness and
our disclosure thereof, we face the potential for litigation by current or former shareholders based on their purported inability
to accurately evaluate our financial performance from reviewing our audited financial statements, based on an alleged material
statement or omission contained in our audited financial statements or based on other claims arising from our inadequate financial
statement preparation and review procedures. As of the date of this annual report, we have no knowledge of any such shareholder
litigation. However, we can provide no assurance that such shareholder litigation will not arise in the future. Any such shareholder
litigation, whether successful or not, could have a material adverse effect on our business, results of operations and financial
condition.
Our concentration of ownership could
be disadvantageous to shareholders.
Alceco International S.A. (“Alceco”),
as of July 31, 2017, owned approximately 12,52 percent of our shares. Granitplattan AB and Granen through Per Arwidssonas of July
31, 2017, owned approximately 13,11 percent of our shares. Alceco and Per Arwidsson can thus, exercise significant influence over
all matters requiring shareholder approval, and may be able to prevent a change in control or take other measures that may benefit
Alceco or Per Arwidsson but could be disadvantageous to other shareholders. Moreover, the sale of a substantial number of our
shares by Alceco and/or Per Arwidsson within a short period of time could cause our share price to decrease, make it more difficult
for us to raise funds through future offerings of Ordinary Shares or acquire other businesses using Ordinary Shares as consideration.
Additionally, Alceco and Per Arwidsson may have conflicting interests with us. See “— There are relationships
among our directors and our largest shareholders that could pose a conflict of interest.”
There are relationships among our directors
and our largest shareholders that could pose a conflict of interest.
There are relationships among some of the
members of our board of directors with each other and with our largest shareholders that could pose a conflict of interest. Two
of our directors, our Executive Chairman Julian Aleksov and Bo Cederstrand are co-owners of Alceco, a holding company based in
Luxembourg that conducts no business and exists only for financial management. Alceco owns 21,648,765 of the Ordinary Shares as
of July 31, 2017 and is our largest shareholder. In addition to being partners in Alceco, Messrs. Aleksov and Cederstrand also
have a familial relationship. Mr. Aleksov is the partner of Mr. Cederstrand’s daughter and the father of his two grandchildren.
Alceco has also extended a credit facility of SEK 40 million to us, which as of the date of this annual report has not been drawn
upon.
Another director, Alexander Kotsinas, is an
independent consultant for Nexttobe AB, which is the companys largest creditor, from whom the company have a loan of SEK 102.4
million, which has an interest rate of 3.5 per cent and falls due for payment on 30 September 2017.
These directors may have actual or apparent
conflicts of interest with respect to matters involving or affecting us and Alceco and/or Nexttobe. Examples of possible conflicts
include:
|
•
|
the
board of directors could have to decide whether to use funds for operating expenses or
the repayment of a loan to Nexttobe;
|
|
•
|
issues
or disputes could arise under the commercial agreements that exist between us and Alceco
and Nexttobe;
|
|
•
|
under
the terms of Alceco’s loan agreements, one or more Alceco creditors could become
shareholders and could exercise their voting rights in a manner that could conflict with
your interests;
|
|
•
|
Nexttobe,
a venture capital company, could own or come to own interests in companies that compete
with us; and
|
|
•
|
given
the close relationship between Messrs. Cederstrand and Aleksov, Mr. Cederstrand could
be conflicted as to any board decision on the compensation and employment status of Mr.
Aleksov.
|
See also “Related Party Transactions.”
Apart from the conflicts of interest policy
contained in our Code of Ethics and Business Conduct, we and Alceco, Nexttobe AB and Granitplattan AB have not established any
formal procedures for us, Alceco, Nexttobe AB and Granitplattan AB to resolve potential or actual conflicts of interest between
us. There can be no assurance that any of the foregoing conflicts will be resolved in a manner that does not adversely affect
our business, financial condition or results of operations.
U.S. investors may have difficulty enforcing
civil liabilities against us, our directors or members of senior management and the experts named in this annual report.
All of our directors and officers named in
this annual report are non-residents of the U.S., and all or a substantial portion of the assets of such persons are located outside
the U.S. As a result, it may not be possible to serve process on such persons or our company in the U.S. or to enforce judgments
obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the U.S. There is doubt
as to whether Swedish courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments
of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the
U.S. or elsewhere may be unenforceable in Sweden. An award for monetary damages under the U.S. securities laws would be considered
punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The
enforceability of any judgment in Sweden will depend on the particular facts of the case as well as the laws and treaties in effect
at the time. The U.S. and Sweden do not currently have a treaty providing for recognition and enforcement of judgments (other
than arbitration awards) in civil and commercial matters.
We have incurred significant losses
since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
Since our inception on April 15, 1988, we
have incurred significant operating losses. We incurred net losses of SEK 160.24 million, SEK 141.54 million and SEK 117.50 million
for the fiscal years ended April 30, 2017, April 30, 2016 and April 30, 2015. To date, we have financed our operations primarily
through private placements of shares in our company, through loans (including convertible debt instruments) and through one-time
milestone payments from our commercial partners. We have devoted substantially all of our financial resources and efforts to research
and development, including preclinical studies and clinical trials. We expect to continue to incur significant expenses and operating
losses over the next few years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate
that our expenses will increase substantially as we:
|
•
|
initiate
and conduct a Phase I/II program for Docecal for the treatment of breast cancer;
|
|
•
|
conduct
additional efficacy studies in dogs to collect all the necessary efficacy data for full
FDA approval of Paccal Vet;
|
|
•
|
continue
research and development for and commence pre-clinical and clinical trials of Docecal,
Doxophos, Doxophos Vet and OAS-19;
|
|
•
|
seek
to discover and develop additional product candidates;
|
|
•
|
seek
regulatory approvals for any product candidates that successfully complete clinical trials;
|
|
•
|
ultimately
establish a sales, marketing and distribution infrastructure and scale up external manufacturing
capabilities to commercialize any products that we choose not to license to a third party
and for which we may obtain regulatory approval;
|
|
•
|
maintain,
expand and protect our intellectual property portfolio;
|
|
•
|
hire
additional clinical and scientific personnel; and
|
|
•
|
add
operational, financial and management information systems and personnel, including personnel
to support our product development and planned future commercialization efforts.
|
To become and remain profitable, we must succeed
in developing and eventually commercializing products that generate significant revenue. This will require us to be successful
in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates,
discovering additional product candidates, potentially entering into collaboration and license agreements, obtaining regulatory
approval for product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval.
We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do,
may never achieve profitability.
Because of the numerous risks and uncertainties
associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses
or when, or if, we will be able to achieve profitability. If we are required by the FDA or by other regulatory authorities outside
of the U.S. to perform studies in addition to those currently expected, or if there are any delays in completing our clinical
trials or the development of any of our product candidates, our expenses could increase.
Even if we do achieve profitability, we may
not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and
development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could
also cause you to lose all or part of your investment.
We may need substantial additional funding,
which may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced
to delay, reduce or eliminate our product development programs or our commercialization efforts.
Our operations have consumed substantial cash
since inception. Excluding receipts from milestone fees, our cash flow used for operating activities for the fiscal years ended
April 30, 2017, 2016 and 2015 was SEK 133.01 million, SEK 128.13 million and SEK 107.67 million respectively, with development
costs, which are capitalized, for those years totaling SEK 7.02 million, SEK 16.73 million and SEK 16.80 million respectively.
We expect our operating and management and administrative expenses and cash used for operations to continue to be significant
and to increase substantially in connection with our planned research, development and continued product commercialization efforts. We may need to raise additional capital to fund our operations and continue to
conduct clinical trials to support potential regulatory approval of marketing applications. If we are unable to raise capital
when needed or on attractive terms, we could be forced to:
|
•
|
delay,
reduce or eliminate our research and development programs or any future commercialization
efforts;
|
|
•
|
relinquish
or license on unfavorable terms our rights to technologies, our product, or product candidates
that we otherwise would seek to develop or commercialize ourselves;
|
|
•
|
seek
collaborators for our product or one or more of our product candidates at an earlier
stage than otherwise would be desirable or on terms that are less favorable than might
otherwise be available; or
|
|
•
|
cease
operations altogether.
|
We do not expect our existing capital resources
to enable us to conduct Phase II development of Paclical for the treatment of metastatic breast cancer, conduct additional efficacy
studies in dogs for full FDA approval of Paccal Vet or continue research and development for and commence clinical trials of Docecal,
Doxophos Vet, Doxophos and OAS-19. Accordingly, we expect that we will need to raise substantial additional funds in the future.
Our future capital requirements will depend on many factors, including:
|
•
|
the
revenue, if any, related to commercial sales of our product and product candidates for
which we receive marketing approval;
|
|
•
|
the
Phase II clinical program for Paclical for the treatment metastatic breast cancer;
|
|
•
|
the
scope, progress, results and costs of preclinical development, laboratory testing and
clinical trials for our other product candidates, including those of Docecal, Doxophos
Vet, Doxophos and OAS-19;
|
|
•
|
our
ability to enter into collaborative agreements for the development and commercialization
of our product candidates;
|
|
•
|
the
number and development requirements of other product candidates that we pursue;
|
|
•
|
the
costs, timing and outcome of regulatory review of our product candidates or any future
product candidates, both in the U.S. and outside the U.S.;
|
|
•
|
the
costs and timing of future commercialization activities, including product manufacturing,
marketing, sales and distribution, for our product or any of our product candidates for
which we receive marketing approval;
|
|
•
|
any
product liability or other lawsuits related to our products;
|
|
•
|
the
expenses needed to attract and retain skilled personnel; and
|
|
•
|
the
costs involved in preparing, filing and prosecuting patent applications, maintaining
and enforcing our intellectual property rights and defending any intellectual property-related
claims, both in the U.S. and outside the U.S.
|
Identifying potential product candidates and
conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete,
and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition,
our product and our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will
be derived from sales of products that we do not expect to be commercially available for several months, if at all. Accordingly,
we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may
not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions
or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.
The Company may need substantial additional
funding, which may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when
needed, or to extend or replace current credits, the Company could be forced to delay, reduce or eliminate its product development
programmes or its commercialisation efforts.
Our operations have consumed substantial cash
since inception. Excluding receipts from milestone fees, our cash flow used for operating activities for the fiscal years ended
April 30, 2017, 2016 and 2015 was SEK 133.01 million, SEK 128.13 million and SEK 107.67 million respectively, with development
costs, which are capitalized, for those years totaling SEK 7.02 million, SEK 16.73 million and SEK 16.80 million respectively.
The Company’s cash flow, excluding revenue
from milestone payments, which are used for operating activities, for the period 1 May 2016 to 30 April 2017, amounted to approximately
SEK 133.01 million, with capitalised development costs for the period totalling approximately SEK 7.02 million. The Company expects
the operating, management and administrative expenses of the business to remain significant and even to increase sharply as a
result of the Company’s planned research and development and continued product commercialisation. Even if the proceeds from
the Rights Issue is received as planned, Oasmia will have limited financial resources. The Company may need to raise additional
capital, including by extending existing or replacing credits following this Offer to obtain financing for continued clinical
trials in support of potential marketing approvals. If the Company is unable to raise capital when needed or on beneficial terms,
or to extend or replace current credits, the Company could be forced to:
|
•
|
delay,
reduce or eliminate its research and development programmes or any future commercialisation
efforts;
|
|
•
|
relinquish
or license on unfavourable terms the Company’s rights to technologies, products,
or product candidates that the Company otherwise would seek to develop or commercialise
itself;
|
|
•
|
seek
collaborators for the Company’s product or one or more of its product candidates
at an earlier stage than otherwise would be desirable or on terms that are less favourable
than might otherwise be available; or
|
|
•
|
cease
operations altogether, in which case all shareholders would loose their entire paid in
share capital.
|
In view of the current liquidity position,
the Company’s current credit facilities, the proceeds from this Rights Issue (see events after closing date April 30, 2017),
which is estimated to amount to SEK 150 million after issuance expenses, and provided that the Company’s credit that is
due in September 2017, the Company’s convertible loan 2017:2 (which is due in April 2018), and the debt in the form of non-negotiable
promissory notes that replaced the Company’s convertible loan 2016:2 (which are due in June 2018) are extended or replaced,
the Board of Directors believes that the Company is sufficiently funded and able to carry out its operating plan for the coming
twelve months. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could be required
to expend its capital resources sooner than the Company currently expects. The Company does not expect its presently available
capital resources to be sufficient to fully commercialize its products and product candidates. The Company therefore expects it
will have to raise further capital in the future. The Company’s future capital requirements depend on many factors, including:
|
•
|
potential
revenue relating to commercial sales of the Company’s products and product candidates
for which the Company has received marketing approval, including royalties and milestone
payments from existing and future commercial partners;
|
|
•
|
the
scope, progress, results and costs of preclinical development, laboratory testing and
clinical trials for the Company’s other product candidates, including Docecal,
Doxophos Vet, Doxophos, OAS-19 and KB 9520;
|
|
•
|
the
Company’s ability to enter into collaborative agreements for the development and
commercialisation of the Company’s product candidates;
|
|
•
|
the
number of product candidates, and their development requirements, that the Company is
trying to develop;
|
|
•
|
the
costs, timing and outcome of regulatory review of the Company’s product candidates
or any future product candidates;
|
|
•
|
the
costs and timing of future commercialization activities including manufacturing, marketing,
sales and distribution of the Company’s products or any of its product candidates
for which the Company receives marketing approval;
|
|
•
|
any
product liability or other legal proceedings relating to the Company’s products;
|
|
•
|
the
expenses necessary to attract and retain skilled personnel; and
·
|
|
•
|
the
costs involved in preparing, filing and prosecuting patent applications, maintaining
and enforcing the Company’s intellectual property rights and defending any intellectual
property-related claims, both in the USA and outside the USA.
|
Identifying potential product candidates and
conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete.
The Company may never generate the necessary data or results required to obtain regulatory approval and achieve product sales.
In addition, the Company’s products and its product candidates, if approved, may not achieve commercial success. The Company’s
potential commercial revenues will come from future sales of products and these can be difficult to predict. Therefore, the Company
must continue to rely on additional funding to achieve its business goals. Adequate additional financing may not be available
to the Company on acceptable terms, or at all. In addition, the Company may seek additional capital due to favorable market conditions
or strategic considerations, even if the Company believes it has sufficient funds for its current or future operating plans.
We do not currently intend to pay dividends
on the Ordinary Shares or make any other distribution of earnings to holders of the Ordinary Shares.
Since our inception, we have not declared
or paid any dividends on the Ordinary Shares. We intend to retain any earnings for use in our business and do not currently intend
to pay dividends on the Ordinary Shares. The declaration and payment of any future dividends will be at the discretion of our
board of directors and will depend upon our results of operations, cash requirements, financial condition, contractual restrictions,
restrictions imposed by our indebtedness, any future debt agreements or applicable laws and other factors that our board of directors
may deem relevant. This policy may have a material adverse effect on the value of your Ordinary Shares. See “Dividend Policy.”
The milestone payments we receive are not reliable sources
of income and in some cases may be required to be returned at a later date.
Much of our income has consisted of, and may
in the future take the form of, milestone payments, which are contractual one-time payments from our partners as we reach certain
targets. There have been cases in which we have not reached the targets and there is no guarantee that we will be able to reach
such targets in the future. We may also be required to repay already obtained milestone payments if the agreed upon schedules
are not kept or if the required marketing approvals are not obtained. Further, milestone payments often occur irregularly over
time, causing fluctuations in our sales and earnings. Milestone payments are not sustainable earnings and any dependence on milestone
payments could have a material adverse effect on our business, results of operations and financial condition. See also “Business — Strategic
Alliances and Collaborations.”
Our limited operating history may make
it difficult for you to evaluate the success of our business to date and to assess our future viability.
We commenced active operations in 1999, and
our operations thus far have been limited to organizing and staffing our company, business planning, raising capital, identifying
potential product candidates, undertaking preclinical studies and conducting clinical trials. To date we have had no commercial
operations. All but three of our product candidates are still in preclinical development. We have not yet demonstrated our ability
to successfully complete later stage clinical trials, obtain full regulatory approvals, manufacture a commercial scale product,
or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product
commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they
could be if we had a longer operating history.
In addition, as a business with a limited
operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.
We will need to expand our capabilities to support commercial activities. We may not be successful in adding such capabilities.
We expect our financial condition and operating
results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which
are beyond our control. Accordingly, you should not rely upon the results of any past annual or interim periods as indications
of future operating performance.
Risks Related to Development and Regulatory
Approval of Our Product and Product Candidates
There is a high rate of failure for
drug candidates proceeding through clinical trials.
Generally, there is a high rate of failure
for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our later stage clinical trials
similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving
promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, the FDA or other
regulatory authorities may disagree with our interpretation of the data. For instance, because a large percentage of subjects
in our pivotal trials for Paclical and our other product candidates in cancer treatment, are being enrolled at sites outside the
U.S., differences in efficacy results between U.S. and non-U.S. sites could cause the FDA to require additional trials. In the
event that:
|
•
|
we
obtain negative results from the Paccal Vet trials,
|
|
•
|
we
receive poor clinical results for our other product candidates,
|
|
•
|
the
FDA places a clinical hold on our Phase III trials due to potential chemistry, manufacturing
and controls issues or other hurdles, or
|
|
•
|
the
FDA does not approve our New Animal Drug Application (“NADA”) for Paccal
Vet or our New Drug Application (“NDA”) for Paclical or for our other product
candidates,
|
then:
|
•
|
we
may not be able to generate sufficient revenue or obtain financing to continue our operations,
|
|
•
|
our
ability to execute our current business plan will be materially impaired,
|
|
•
|
our
reputation in the industry and in the investment community would likely be significantly
damaged, and
|
|
•
|
the
price of the Ordinary Shares would likely decrease significantly.
|
Any of these results could materially and
adversely affect our business, results of operations or financial condition.
Clinical trials for our product candidates
are expensive, time consuming, uncertain and susceptible to change, delay or termination.
Clinical trials are expensive, time consuming
and difficult to design and implement. The result of a clinical trial may be undesirable and can result in a clinical trial cancellation
or the need for re-evaluation and supplementation. Even if the results of our clinical trials are favorable, the clinical trials
for several of our product candidates are expected to continue for several years and may even take significantly longer to complete.
In addition, we, the FDA, other regulatory authorities or ethical review boards in the U.S., EU or elsewhere, may suspend, delay
or terminate our clinical trials at any time, for various reasons, including:
|
•
|
lack
of effectiveness of any product candidate during clinical trials;
|
|
•
|
discovery
of serious or unexpected toxicities or side effects experienced by trial participants
or other safety issues;
|
|
•
|
slower
than expected rates of subject recruitment and enrollment rates in clinical trials;
|
|
•
|
difficulty
in retaining subjects who have initiated a clinical trial but may have withdrawn due
to adverse side effects from the therapy, insufficient efficacy, fatigue with the clinical
trial process or for any other reason;
|
|
•
|
delays
or inability in manufacturing or obtaining sufficient quantities of materials for use
in clinical trials due to manufacturing or regulatory constraints;
|
|
•
|
inadequacy
of or changes in our manufacturing process or product formulation;
|
|
•
|
delays
in obtaining regulatory authorization to commence a trial, including experiencing “clinical
holds” or delays requiring suspension or termination of a trial by a regulatory
agency, such as the FDA, before or after a trial is commenced;
|
|
•
|
changes
in applicable regulatory policies and regulations;
|
|
•
|
delays
or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols
with prospective clinical trial sites;
|
|
•
|
delay
or failure to supply product for use in clinical trials which conforms to regulatory
specification;
|
|
•
|
unfavorable
results from ongoing pre-clinical studies and clinical trials;
|
|
•
|
failure
of our contract research organizations (“CROs”), or other third-party contractors
to comply with all contractual requirements or to perform their services in a timely
or acceptable manner;
|
|
•
|
failure
by us, our employees, our CROs or their employees to comply with all applicable FDA or
other regulatory requirements relating to the conduct of clinical trials;
|
|
•
|
scheduling
conflicts with participating clinicians and clinical institutions;
|
|
•
|
failure
to design appropriate clinical trial protocols; or
|
|
•
|
regulatory
concerns with pharmaceutical products generally and the potential for abuse.
|
Any of the foregoing could have a material
adverse effect on our business, results of operations and financial condition.
The regulatory approval process is uncertain,
requires us to utilize significant resources, and may prevent us or our commercial partners from obtaining approvals for the commercialization
of some or all of our drug candidates.
The research, testing, manufacturing, labeling,
approval, sale, marketing and testing of our product and product candidates are subject to extensive regulation by regulatory
authorities in the U.S. and Europe, and regulatory requirements applicable to our product and product candidates differ from country
to country. Neither we nor any commercial partner is permitted to market any of our current or future product candidates in the
U.S. until we receive approval from the FDA of a NADA for our animal health products or an NDA for our human health products.
We received conditional approval for Paccal Vet from the FDA in February 2014, with the condition to perform additional follow-up
efficacy studies for full approval. However, this conditional approval was withdrawn in in January 2017 in order to investigate
another dosage regimen. We have not yet received any type of approval for any of our other current product candidates. Obtaining
approval of either an NADA or an NDA can be an uncertain process that requires us to utilize significant resources. Furthermore,
regulatory authorities possess broad discretion regarding processing time and usually request additional information and raise
questions, which have to be answered. There is considerable uncertainty regarding the times at which products may be approved.
In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative
or judicially imposed sanctions including; warning letters, civil and criminal penalties, injunctions, withdrawal of approved
products from the market, product seizure or detention, product recalls, total or partial suspension of production, and refusal
to approve pending applications or supplements to approved applications.
The process required by the FDA and most foreign
regulatory authorities before human health care pharmaceuticals may be marketed generally involves nonclinical laboratory and
animal tests; submission of an Investigational New Drug (“IND”) application, which must become effective before clinical
trials may begin; adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug
for its intended use or uses; pre-approval inspection of manufacturing facilities and clinical trial sites; and FDA approval of
an NDA, which must occur before a drug can be marketed or sold.
In order to gain approval to market a veterinary
drug product for a particular animal species, we must provide the FDA and foreign regulatory authorities with acceptable data
from animal safety and efficacy studies in the target animal for the intended indication applied for in the NADA or other regulatory
filing. Conditional approval is available under the FDA Minor Use and Minor Species (“MUMS”) designation, which gives
the sponsor the right to promote a product before all the efficacy data necessary for full approval are available. If approved,
this provides the sponsor with seven years of market exclusivity. Even for conditional approval, the development of animal health
products is a lengthy, expensive and uncertain process, and delay or failure can occur at any stage of any of our development
efforts. Success in prior target animal studies or even in the treatment of humans with a product candidate does not ensure that
our studies will be successful and the results of development efforts by other parties may not be indicative of the results of
our studies and other development efforts.
Regulatory approval of a NADA or an NDA, or
any supplements of either, is not guaranteed, and the approval process requires us to utilize significant resources, could take
several years, and is subject to the substantial discretion of the FDA. Despite the time and expense exerted, failure can occur
at any stage, and we could encounter problems that cause us to abandon or have to repeat or perform additional studies. If our
product or any of our current or future product candidates fails to demonstrate safety and efficacy in our studies, or for any
other reason does not gain regulatory approval, our business and results of operations will be materially and adversely harmed.
In addition, separate regulatory approvals
are required in order to market any product in many jurisdictions, including the U.S., the European Economic Area, which consists
of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein, and many others. Approval procedures vary
among countries and can involve additional studies and testing, and the time required to obtain approval may differ from that
required to obtain FDA approval. Studies conducted in one country may not be accepted by regulatory authorities in other countries.
Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign
regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a
failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others.
The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may be unable
to file for regulatory approvals or do so on a timely basis and, even if we were able to, we may not receive necessary approvals
to commercialize our products in any market. Any of these results could have a material adverse effect on our business, results
of operations and financial condition.
Even if we receive regulatory approval
for any of our current or future product candidates, we will be subject to ongoing FDA and other regulatory body obligations and
continued regulatory review, which may result in significant additional expense. Additionally, our product and any product candidates,
if approved, will be subject to labeling and manufacturing requirements and could be subject to other restrictions. Failure to
comply with these regulatory requirements or the occurrence of unanticipated problems with our products could result in significant
penalties.
Any regulatory approvals that we or any of
our collaborators receive for any of our current or future product candidates may be subject to conditions of approval or limitations
on the approved indicated uses for which the product may be marketed, or may contain requirements for potentially costly surveillance
to monitor the safety and efficacy of the product candidate. In addition, our product and any of our current or future product
candidates, if approved by the FDA or other regulatory bodies, will be subject to extensive and ongoing regulatory requirements
regarding the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion
and recordkeeping. These requirements will include submissions of safety and other post-marketing information and reports, registration,
as well as continued compliance with cGMP, Good Laboratory Practice and Good Clinical Practice for any studies that we conduct
post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements,
may result in, among other things:
|
•
|
restrictions
on the marketing or manufacturing of the product, withdrawal of the product from the
market, or voluntary or mandatory product recalls;
|
|
•
|
fines,
warning letters or holds on target studies;
|
|
•
|
refusal
by the FDA or other applicable regulatory body to approve pending applications or supplements
to approved applications filed by us or our strategic collaborators, or suspension or
revocation of product license approvals;
|
|
•
|
product
seizure or detention, or refusal to permit the import or export of products; and
|
|
•
|
injunctions
or the imposition of civil or criminal penalties
|
The policies of the FDA and other regulatory
bodies may change, and additional government regulations may be promulgated that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the U.S. or elsewhere. If we are slow or unable to adapt to changes in or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business,
results of operations and financial condition.
Our product and any of our current or
future product candidates, if approved, may cause or contribute to adverse medical events that we are required to report to the
FDA and regulatory authorities in other countries and, if we fail to do so, we could be subject to sanctions that would materially
harm our business.
If we are successful in commercializing our
product and any of our current or future product candidates, regulations of the FDA and of the regulatory authorities in other
countries require that we report certain information about adverse medical events if those products may have caused or contributed
to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse
event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe.
We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us
as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail
to comply with our reporting obligations, the FDA and regulatory authorities in other countries could take action including criminal
prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future
products, which could have a material adverse effect on our business, results of operations and financial condition.
Legislative or regulatory reforms with
respect to human or animal health products may make it more difficult and costly for us to obtain regulatory clearance or approval
of any of our current or future product candidates and to produce, market, and distribute our products after clearance or approval
is obtained.
From time to time, new legislation is drafted
and introduced in the U.S. Congress and lawmaking bodies in other countries that could significantly change the statutory provisions
governing the testing, regulatory clearance or approval, manufacture, and marketing of regulated products. In addition, FDA regulations
and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products.
Similar changes in laws or regulations can occur in other countries Any new regulations or revisions or reinterpretations of existing
regulations in the U.S. or in other countries may impose additional costs or lengthen review times of our product applications
and any of our current or future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation
or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other
things, require:
|
•
|
requests
for additional endpoints or studies;
|
|
•
|
changes
to manufacturing methods;
|
|
•
|
recall,
replacement, or discontinuance of certain products; and
|
|
•
|
additional
record keeping.
|
Each of these would likely entail substantial
time and cost and could have a material adverse effect on our financial results. In addition, delays in receipt of or failure
to receive regulatory clearances or approvals for any future products could materially and adversely affect our business, results
of operations and financial condition.
Our ability to market our product and
product candidates in the U.S., if approved, will be limited to use for the treatment of the indications for which they are approved,
and if we want to expand the indications for which we may market our product and product candidates, we will need to obtain additional
FDA approvals, which may not be granted.
We plan to seek full FDA approval in the U.S.
for Paccal Vet for mammary carcinoma and squamous-cell carcinoma in dogs, Paclical for ovarian cancer in humans, Docecal for breast
cancer in humans, Doxophos Vet for lymphoma in dogs, Doxophos for breast cancer in humans, and OAS-19 for various cancers in humans.
If our product candidates are approved, the FDA will restrict our ability to market or advertise them for anything other than
the indications for which they are approved, which could limit their use. If we decide to attempt to develop, promote and commercialize
new treatment indications and protocols for our product and product candidates in the future, we could not predict when, or if,
we would ever receive the approvals required to do so. We would be required to conduct additional studies to support such applications
for additional use, which would consume additional resources and may produce results that do not result in FDA approvals. If we
do not obtain additional FDA approvals, our ability to expand our business in the U.S. would be adversely affected, which could
materially and adversely affect our business, results of operations and financial condition.
The anticipated development of a Risk
Evaluation and Mitigation Strategy (REMS) for Paclical and our other human health product candidates could cause delays in the
approval process and would add additional layers of regulatory requirements that could impact our ability to commercialize our
human health product candidates in the U.S. and reduce their market potential.
As a condition of approval of an NDA, the
FDA may require a REMS to ensure that the benefits of the drug outweigh the potential risks. REMS elements can include medication
guides, communication plans for health care professionals, and elements to assure safe use (“ETASU”). ETASU can include,
but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. Moreover, product approval may require substantial post-approval testing
and surveillance to monitor the drug’s safety or efficacy. We may be required to adopt a REMS for Paclical and our other
human health product candidates to ensure that the benefits outweigh the risks of abuse, misuse, diversion and other potential
safety concerns. Even if the risk of abuse, misuse or diversion are not as high as for some other products, there can be no assurance
that the FDA will approve a manageable REMS for Paclical and our other human health product candidates, which could create material
and significant limits on our ability to successfully commercialize our human health product candidates in the U.S. Delays in
the REMS approval process could result in delays in the NDA approval process. In addition, as part of the REMS, the FDA could
require significant restrictions, such as restrictions on the prescription, distribution and patient use of the product, which
could significantly impact our ability to effectively commercialize Paclical and our other human health candidates, and dramatically
reduce their market potential thereby adversely impacting our business, financial condition and results of operations. Even if
initial REMS are not highly restrictive, if, after launch, Paclical or our other human health product candidates were to be subject
to significant abuse/non-medical use or diversion from licit channels, this could lead to negative regulatory consequences, including
a more restrictive REMS, which could materially and adversely affect our business, results of operations and financial condition.
If we are found in violation of “fraud
and abuse” laws, we may be required to pay a penalty and/or be suspended from participation in government-run health care
programs, which may adversely affect our business, financial condition and results of operations.
If we are successful in obtaining marketing
approval for our products in the U.S. and elsewhere, we will be subject to various health care “fraud and abuse” laws,
including anti-kickback laws, false claims laws and other laws intended to reduce fraud and abuse in government-run health care
programs, which could affect us, particularly upon successful commercialization of our products in the U.S. For example, the Medicare
and Medicaid Patient Protection Act of 1987 (otherwise known as the federal “Anti-Kickback Statute”) makes it illegal
for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit,
receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription
of a particular drug for which payment may be made under a U.S. health care program such as Medicare or Medicaid. Under U.S. federal
government regulations, some arrangements, known as safe harbors, are deemed not to violate the Anti-Kickback Statute. Although
we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written,
and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible
that our practices may be challenged under the Anti-Kickback Statute and similar laws in other jurisdictions. False claims laws
prohibit anyone from knowingly and willfully presenting or causing to be presented for payment to third-party payers, including
government payers, reimbursement claims for drugs or services that are false or fraudulent, claims for items or services that
were not provided as claimed, or claims for medically unnecessary items or services. Cases have been brought under false claims
laws alleging that off-label promotion of pharmaceutical products or the payment of kickbacks to pharmaceutical providers has
resulted in the submission of false claims to governmental health care programs. Under laws such as the Health Insurance Portability
and Accountability Act of 1996 in the U.S., we are prohibited from knowingly and willfully executing a plan to defraud any health
care benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact
or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care
benefits, items or services. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including
fines and/or exemption or suspension from government-run health care programs such as Medicare and Medicaid and debarment from
contracting with the U.S. and other governments. In addition, in the U.S. individuals have the ability to bring actions on behalf
of the government under the federal False Claims Act as well as under state false claims laws.
Many states in the U.S. have adopted laws
similar to the Anti-Kickback Statute, some of which apply to the referral of patients for health care services reimbursed by any
source, not just governmental payers. In addition, California and a few other states in the U.S. have passed laws that require
pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical
Manufacturers and/or the Pharmaceutical Research and Manufacturers of America Code on Interactions with Health Care Professionals.
In addition, several states impose other marketing restrictions or require pharmaceutical companies to make marketing or price
disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail
to comply with an applicable state law requirement we could be subject to penalties.
We have yet to receive definitive guidance
on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing
these laws, and it is possible that some of our practices may be challenged under these laws. While we believe we have structured
our business arrangements to comply with these laws, it is possible that the government could allege violations of, or convict
us of violating, these laws. If we are found in violation of one of these laws, we could be required to pay a penalty and could
be suspended or excluded from participation in certain government-run health care programs, and our business, results of operations
and financial condition may be materially and adversely affected.
Risks Related to Our Business and Industry
If we fail to attract and keep senior
management and key scientific personnel, we may be unable to successfully develop our product or our current or future product
candidates, conduct our in-licensing and development efforts or commercialize our product or any of our current or future product
candidates.
Our future growth and success depends in part
on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. We are highly dependent
upon our senior management, particularly Julian Aleksov, our Executive Chairman, as well as our senior scientists and other members
of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development
of our current or future product pipeline, completion of our planned development efforts or the commercialization of our product
and product candidates. Although we have entered into an employment agreement with Julian Aleksov, the agreement does not provide
for a fixed term of service, and does not contain any competition or non-solicitation clauses after the termination of employment.
It is possible that current or former employees of Oasmia could put forward claims for an alleged right to our patents and demand
compensation therefor. However, all our employees have signed an agreement where they assign all their inventions and intellectual
property rights generated by them in their work to us. In addition, there is a law in Sweden that regulates the right to patentable
inventions made by employees which gives the employer the rights to the inventions if they are invented in the course of the employees
work. If one or more of the key personnel were to leave us and engage in competing operations, our business, results of operations
and financial condition could be materially and adversely affected. To date, none of our key personnel has left us or, to our
knowledge, engaged in competing operations, nor has any departure of key personnel had any material effect on Oasmia.
We may have trouble hiring additional
qualified personnel.
As we expand our development and commercial
activities, we will need to hire additional personnel and could experience difficulties attracting and retaining qualified employees.
Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess
the skills and experience required by that industry. We may not be able to attract and retain quality personnel on favorable terms,
or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that such personnel
have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former
employers own their research output. Any of these difficulties could have a material adverse effect on our business, results of
operations and financial condition.
Incentive programme.
Oasmia’s Extraordinary General Meeting
in November 2016 passed a resolution on an incentive plan, under which options will be issued to the Company’s senior management
and Board members. These incentive plans were replaced by the incentive plans approved by an Extraordinary General Meeting in
June 2017; see “ITEM 6 B. Compensation.”
The purpose of the Company’s incentive
s plan is to encourage employees and Board members to dedicate their best efforts to the interests of the Company in order to
be able to share in and help promote positive value growth in the Company’s share price in the period covered by the plan,
and to enable Oasmia to retain and recruit competent and committed employees. There is a risk that these goals will not be achieved,
however, which could result in the participants in incentive plans performing their work less efficiently than expected. There
is also a risk that Oasmia and the participants in the incentive plans may interpret the terms and conditions of the plans in
different ways, or that other disputes concerning the incentive plan could arise, which could add to the expense and reduce or
completely counteract the effectiveness of the plan. Further, share-based incentive plan are always associated with an element
of tax risk, since the Company’s assessment of applicable tax legislation may prove to be incorrect, which could lead to
a higher tax burden in the future and in Oasmia being subject to tax-related penalties. In addition, other unforeseen costs related
to incentive programs may arise.
We are subject to risks relating to
legal proceedings.
We are subject to various claims and legal
actions arising in the ordinary course of its business. Any such litigation could be very costly and could distract our management
from focusing on operating our business. The existence of any such litigation could harm our business, results of operations and
financial condition. Results of actual and potential litigation are inherently uncertain. Additionally, in the past we have been
subject to fines by a foreign exchange relating to our disclosures. See “Business — Foreign Exchanges.”
An unfavorable result in a legal proceeding could adversely affect our reputation, financial condition and operating results.
If product liability lawsuits are successfully
brought against us, we will incur substantial liabilities and may be required to limit the commercialization of Paccal Vet, Paclical
and our other product candidates.
We and our partners face potential product
liability exposure related to the testing of our product and product candidates in human and animal clinical trials. We will face
exposure to claims by an even greater number of persons if we begin to market and distribute our products commercially in the
U.S. and elsewhere, including those relating to misuse of Paccal Vet, Paclical and our other product candidates. Now, and in the
future, an individual may bring a liability claim against us alleging that our product or one of our product candidates caused
an injury. While we continue to take, what we believe to be appropriate precautions including SEK 20 million, approximately $2.47
million, in product liability insurance coverage as of the date of this annual report), we may be unable to avoid significant
liability if any product liability lawsuit is brought against us. It should be noted that the amount of the product liability
insurance is revised continuously of the insurance broker. If we cannot successfully defend ourselves against product liability
claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
|
•
|
decreased
demand for Paccal Vet, Paclical and our other product candidates, if such product candidates
are approved;
|
|
•
|
injury
to our reputation;
|
|
•
|
withdrawal
of clinical trial participants;
|
|
•
|
costs
of related litigation;
|
|
•
|
substantial
monetary awards to patients, pet owners and others;
|
|
•
|
increased
cost of liability insurance;
|
|
•
|
our
inability to successfully commercialize our products.
|
Furthermore, in the future there may be a
need to expand the scope of our insurance coverage, which could result in significantly increased costs or the inability to obtain
sufficient insurance coverage. Any of these occurrences could have a material adverse effect on our business, results of operations
and financial condition.
Failure of our information technology
systems could significantly disrupt the operation of our business.
Our ability to execute our business plan and
to comply with regulatory requirements with respect to data control and data integrity depends, in part, on the continued and
uninterrupted performance of our information technology systems (“IT systems”). These systems are vulnerable to damage
from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters. Moreover,
despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins,
computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems
that could affect our IT systems, there are no assurances that electronic break-ins, computer viruses and similar disruptive problems,
and/or sustained or repeated system failures or problems arising during the upgrade of any of our IT systems that interrupt our
ability to generate and maintain data will not occur. The occurrence of any of the foregoing with respect to our IT systems could
have a material adverse effect on our business, results of operations or financial condition.
We are subject to the U.S. Foreign Corrupt
Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing
our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures,
and legal expenses, which could adversely affect our business, results of operations and financial condition.
Our operations are subject to certain anti-corruption
laws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), and other anti-corruption laws that apply in countries
where we do business. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from
bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business
or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a high risk
of potential FCPA violations and we participate in collaborations and relationships with third parties whose actions could potentially
subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect
of future regulatory requirements to which our international operations might be subject or the manner in which existing laws
might be administered or interpreted.
We are also subject to other laws and regulations
governing our international operations, including regulations administered in the U.S. and in the EU, including applicable export
control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations (collectively,
“Trade Control Laws”).
There can be no assurance that we will be
completely effective in ensuring our compliance with all applicable anticorruption laws, including the FCPA or other legal requirements,
such as Trade Control Laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or Trade Control
Laws by U.S., EU or other authorities could have an adverse impact on our reputation, our business, results of operations and
financial condition. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or Trade
Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, as well
as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well
as on our business, results of operations and financial condition.
We are exposed to risks related to currency
exchange rates.
Currency risks arise when future commercial
transactions or reported assets or liabilities are denominated in a currency other than our functional currency, the Swedish krona.
Our primary contract manufacturer and all of our clinical trials are located outside of Sweden. Because our financial statements
are presented in kronor, changes in currency exchange rates have had and could continue to have a significant effect on our operating
results. Exchange rate fluctuations between local currencies and the krona create risk in several ways, including the following:
|
•
|
weakening
of the krona may increase the krona cost of overseas research and development expenses
and the cost of sourced product components outside Sweden;
|
|
•
|
strengthening
of the krona may decrease the value of our revenues denominated in other currencies;
|
|
•
|
the
exchange rates on non-kronor transactions and cash deposits can distort our financial
results; and
|
|
•
|
the
pricing and profit margins of Paccal Vet, Paclical and our other product candidates may
be affected by currency fluctuations.
|
In addition, to the extent our need for contract
manufacturing increases once our products reach the commercial market, our exposure to currency risks will increase proportionally.
We do not engage in regular hedging transactions, since to date our currency exposure has been mostly related to purchased services
for product development, which has been irregular and difficult to anticipate. It is possible that fluctuations in currency exchange
rates could have a material adverse effect on our business, results of operations and financial condition.
If we are unable to use our net operating
loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable tax legislation,
our business, results of operations and financial condition may be adversely affected.
As a Swedish resident trading entity, we are
subject to Swedish corporate taxation. As of April 30, 2017, we had cumulative carry forward tax losses of SEK 878.34 million,
as of April 30, 2016, we had cumulative carry forward tax losses of SEK 720.58 million and as of April 30, 2015 we had cumulative
carry forward tax losses of SEK 518.74 million. Due to a decision by the Swedish tax authority in the financial year, the carry
forward tax losses for previous years 2016 and 2015 have been decreased by SEK 2.65 million for each year respectively. These
losses are available to carry forward and offset against future operating profits, unlimited in time. If, however, there are unexpected
adverse changes to the Swedish tax law, our business, results of operations and financial condition may be adversely affected.
Risks Related to Our Reliance upon Third
Parties
We depend substantially on the commercial
expertise of our commercial partners.
We do not have a sales and marketing operation
and expect to rely, in certain geographical areas such as Japan and the CIS, on the expertise and commercial skills of our commercial
partners to sell Paccal Vet, Paclical, Doxophos Vet, and our other product candidates in selected territories. We have entered
into agreements for the commercialization of Paccal Vet in Japan, where Paccal Vet is licensed to Nippon Zenyaku Kogyo, and Russia
and the CIS, where we retain commercialization rights. We have entered into agreements for the commercialization of Paclical with
Medison Pharma in Israel and Turkey and with Hetero Group in Russia and the CIS, as well as Ukraine, Georgia and Turkmenistan.
The commercial success of Paclical and many of our other product candidates in each of these markets will depend entirely on the
expertise and commercial skills of our commercial partners, whereas we will be responsible for the distribution and sales of Paccal
Vet and Doxophos Vet. In addition, it is customary that in these types of commercial agreements our partners are entitled to price
our products, which means that much of our financial performance will be dependent on our partners. Our partners also have the
right, under certain circumstances, to terminate their agreements with us. See “Business — Strategic Alliances
and Collaborations” for descriptions of the agreements with our commercial partners. A failure by our partners to successfully
market Paccal Vet, Paclical, Doxophos Vet and our other product candidates, or the termination of agreements with our partners,
would have a material adverse effect on our business, results of operations and financial condition.
As referred to elsewhere herein, we have entered
into various licensing and distribution agreements with established pharmaceutical companies to sell Paccal Vet. Specifically,
we had entered into an agreement for the global commercialization of Paccal Vet with Abbott Animal Health, the assets of which
were acquired by Zoetis on February 10, 2015. In connection with Zoetis’ purchase of Abbott Animal Health, Zoetis terminated
the distribution arrangement effective September 30, 2015.
We currently have no sales and marketing
organization for the distribution of Paccal Vet or Doxophos Vet as a result of the termination of the Distribution Agreement with
Zoetis. If we are unable to establish a direct sales force in the U.S. to promote our products, the commercial opportunity for
our products may be diminished.
We currently have no sales and marketing organization
for the distribution of Paccal Vet or Doxophos Vet as a result of the pending termination of the Distribution Agreement with Zoetis,
which covered the entire world except for Japan and the CIS. While we have established an entity through which Oasmia intends
to distribute these products in the United States, the Company currently has no sales and marketing organization for these products.
The Company will incur significant additional expenses and commit significant additional management resources to establish our
sales force. The Company may not be able to establish these capabilities despite these additional expenditures. The Company will
also have to compete with other pharmaceutical and biotechnology companies to recruit, hire and train sales and marketing personnel.
If the Company elects to rely on third parties
to sell these products in the U.S., it may receive less revenue than the Company we sold our products directly. In addition, while
the Company anticipates using due diligence in monitoring their activities, it may have little or no control over the sales efforts
of those third parties. In the event the Company is unable to develop its own sales force or collaborate with a third party to
sell these products, the Company may not be able to commercialize these products which would negatively impact its ability to
generate revenue.
We depend on the financial ability of
our commercial partners.
We have few customers, each representing a
large part of sales and also of accounts receivable. If one customer fails to pay his liability to us we will have to book
a credit loss in our income statement which might represent a large part of the accounts receivable.
To a certain extent we build up our inventory
based on forecasts for special geographical markets or from specific customers. If the customers fail to purchase according to
this forecast there is a risk that we will not be able to sell these products to other customers before they expire or before
the expiry date is so close that the products are unattractive for a customer. In that case we might have to write down the inventory
value over the income statement.
We rely on contract manufacturers for
the production of our products, which can create production uncertainties.
Our own production facility has the technical
capacity for production of our finished products up to a limited commercial scale. We produced the launch supply of Paccal Vet,
but we do not have adequate capacity to supply the product in the long term. As such, full-scale production of our products for
commercial use will be carried out by contract manufacturers. Production at our primary contract manufacturer is expected to commence
shortly. If it proves difficult for contract manufacturers to scale-up production, full-scale production may be delayed, which
could then delay the product launch schedule.
We will also be required to validate full-scale
production and submit documentation to the relevant health authorities in connection with the scaling-up of the production to
full-scale production. These agencies must approve the production at the manufacturers we select. We will be relying upon the
contract manufacturers to provide us with the appropriate information for the regulators, and if the documentation is incomplete
or incorrect there is a risk that the product launch will be delayed, which may have a material adverse effect on our financial
position and performance.
We depend on a limited number of suppliers
for materials and components required to manufacture Paccal Vet, Paclical and our other product candidates. The loss of these
suppliers, or their failure to supply us on a timely basis, could cause delays in our current and future capacity and adversely
affect our business.
The majority of the raw materials used in
the production of our pharmaceuticals are purchased from a limited number of suppliers. As a result, we may not be able to obtain
sufficient quantities of critical materials and components in the future. A delay or interruption by our suppliers may harm our
business, results of operations and financial condition. In addition, the lead time needed to establish a relationship with a
new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The
time and effort to qualify for and, in some cases, obtain regulatory approval for a new supplier could result in additional costs,
diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Our dependence
on a limited number of suppliers exposes us to numerous risks, including:
|
•
|
our
suppliers could cease or reduce production or deliveries, raise prices or renegotiate
terms;
|
|
•
|
we
may be unable to locate a suitable replacement suppliers on acceptable terms or on a
timely basis, or at all; and
|
|
•
|
delays
caused by supply issues may harm our reputation, frustrate our customers and cause them
to turn to our competitors for future needs.
|
Any one of these occurrences could have a
material adverse effect on our business, results of operations and financial condition.
Risks Related to Our Intellectual Property
We may be forced to litigate to enforce
or defend our intellectual property rights, or the intellectual property rights of our licensors.
We may be forced to litigate to enforce or
defend our intellectual property rights against infringement and unauthorized use by competitors. In so doing, we may place our
intellectual property at risk of being invalidated, held unenforceable, or narrowed in scope. Further, an adverse result in any
litigation or defense proceedings may place pending applications at risk of non-issuance. In addition, if any licensor fails to
enforce or defend its intellectual property rights, this may adversely affect our ability to develop and commercialize our product
and product candidates as well as our ability to prevent competitors from making, using, and selling competing products. Any such
litigation could be very costly and could distract our management from focusing on operating our business. The existence or outcome
of any such litigation could harm our business, results of operations and financial condition.
Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential and proprietary
information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements
of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a material adverse effect on the price of the Ordinary Shares.
We may be unable to adequately prevent
disclosure of trade secrets and other proprietary information.
We rely on trade secrets to protect our proprietary
know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable. However,
trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside
scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information.
These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in
the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets
and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our
proprietary rights. Failure to obtain or maintain trade secret protection or failure to adequately protect our intellectual property
could enable competitors to develop generic products or use our proprietary information to develop other products that compete
with our products or cause additional, material adverse effects upon our business, results of operations and financial condition.
The transfer of technology and knowledge to
contract manufacturers pursuant to the production of our products also creates a risk of uncontrolled distribution and copying
of concepts, methods and processes relating to our products. Such uncontrolled distribution and copying could have a material
adverse effect on the value of our products if used for the production of competing drugs or otherwise used commercially without
our obtaining financial compensation.
We may become subject to third parties’
claims alleging infringement of patents and proprietary rights or seeking to invalidate our patents or proprietary rights, which
would be costly, time-consuming and, if successfully asserted against us, delay or prevent the development and commercialization
of our product and our current or future product candidates.
There has been substantial litigation and
other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry, as well as patent challenge
proceedings, including interference and administrative law proceedings before the U.S. Patent and Trademark Office (“U.S.
PTO”) and the European Patent Office (“EPO”), and oppositions and other comparable proceedings in other jurisdictions.
Recently, under U.S. patent reform laws, new procedures including
inter partes
review and post grant review have been implemented.
As stated below, the novel implementation of such reform laws presents uncertainty regarding the outcome of challenges to our
patents in the future.
We cannot assure you that our product or any
of our current or future product candidates will not infringe existing or future patents. We may be unaware of patents that have
already issued that a third party might assert are infringed by our product or one of our current or future product candidates.
Because patent applications can take many years to issue and may be confidential for eighteen months or more after filing, there
may be applications now pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing
our product or any of our current or future product candidates. In addition, third parties may obtain patents in the future and
claim that use of our technologies infringes upon these patents. Moreover, we may face claims from non-practicing entities (commonly
referred to as “patent trolls”), which have no relevant product revenue and against whom our own patent portfolio
may thus have no deterrent effect.
We may be subject to third-party claims in
the future against us or our collaborators that would cause us to incur substantial expenses and, if successful against us, could
cause us to pay substantial damages, including treble damages and attorney’s fees if we are found to be willfully infringing
a third party’s patents. If a patent infringement suit were brought against us or our collaborators, we or our collaborators
could be forced to stop or delay research, development, manufacturing or sales of the product candidate that is the subject of
the suit. As a result of patent infringement claims, or in order to avoid potential claims, we or our collaborators may choose
to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties
or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to obtain
a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately,
we could be prevented from commercializing a product, or forced to redesign it, or to cease some aspect of our business operations
if, as a result of actual or threatened patent infringement claims, we or our collaborators are unable to enter into licenses
on acceptable terms. Even if we are successful in defending such claims, infringement and other intellectual property litigation
can be expensive and time-consuming to litigate and divert management’s attention from our core business. Any of these events
could harm our business significantly.
In addition to infringement claims against
us, if third parties have prepared and filed patent applications in the U.S. that also claim technology to which we have rights,
we may have to participate in interference proceedings in the U.S. PTO to determine the priority of invention. Third parties may
also attempt to initiate reexamination, post grant review or
inter partes
review of our patents in the U.S. PTO. We may
also become involved in similar opposition proceedings in the EPO or comparable offices in other jurisdictions regarding our intellectual
property rights with respect to our products and technology. Any of these claims could have a material adverse effect on our business,
results of operations and financial condition.
If our efforts to protect the proprietary
nature of the intellectual property related to our product or any of our current or future product candidates are not adequate,
we may not be able to compete effectively in our market.
We rely upon a combination of patents, trade
secret protection as well as confidentiality and license agreements to protect the intellectual property related to our product
and our current product candidates and our development programs.
Composition-of-matter patents on an active
pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical
products, as such patents provide protection without regard to any particular method of use or manufacture. We cannot be certain
that the claims in our patent application covering composition-of-matter of our product and our product candidates will be considered
patentable by the U.S. PTO and courts in the U.S., or by the patent offices and courts in foreign countries. Method-of-use patents
protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing
a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, for our
animal health products particularly, even if competitors do not actively promote their products for our targeted indications,
veterinarians may recommend that pet owners use these products off label, or pet owners may do so themselves. Although off-label
use may infringe or contribute to the infringement of method-of-use patents, we believe the practice is common and such infringement
is difficult to prevent or prosecute.
The strength of patents in the field of human
and animal health products involves complex legal and scientific questions and can be uncertain. The patent applications that
we own or license may fail to result in issued patents in the U.S. or in other foreign countries. Even if the patents do successfully
issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed,
invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately
protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection
provided by the patent applications we own, in-license or pursue with respect to our product or any of our current or future product
candidates is threatened, it could threaten our ability to commercialize our product or any of our current or future product candidates.
Further, if we encounter delays in our development efforts, the period of time during which we could market our product or any
of our current or future product candidates under patent protection would be reduced. Since patent applications in the U.S. and
most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any
patent application related to our product and product candidates. Furthermore, for patent applications in which claims are entitled
to a priority date before March 16, 2013, an interference proceeding can be initiated by a third party or instituted by the U.S.
PTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For patent
applications containing a claim not entitled to a priority date before March 16, 2013, there is a greater level of uncertainty
in the patent law with the passage of the America Invents Act, some provisions of which went into effect on that date whereas
the America Invents Act itself first went into effect on September 16, 2011 and brought about significant changes to the U.S.
patent laws that have yet to be well defined, and which introduces new procedures for challenging pending patent applications
and issued patents. A primary change under this reform is creating a “first to file” system in the U.S., which requires
us to minimize the time from invention to filing of a patent application.
Even where laws provide protection, costly
and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome
of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors
could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property
portfolios than we have.
We also rely on trade secret protection and
confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to
enforce and any other elements of our product development processes that involve proprietary know-how, information or technology
that is not covered by patents. Although we endeavor to execute confidentiality agreements with all of our employees, consultants,
advisors and any third parties who have access to our proprietary know-how, information or technology, we cannot be certain that
we have executed such agreements with all parties who may have helped to develop our intellectual property or had access to our
proprietary information, nor that our agreements will not be breached. We cannot guarantee that our trade secrets and other confidential
proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently
develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary
rights to the same extent or in the same manner as the laws of the EU or the U.S. As a result, we may encounter significant problems
in protecting and defending our intellectual property both in the U.S. and elsewhere. If we are unable to prevent material disclosure
of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive
advantage in our market, which could materially and adversely affect our business, results of operations and financial condition.
Any disclosure to or misappropriation by third
parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological
achievements, thus eroding our competitive position in our market.
Changes in patent law could diminish
the value of patents in general, thereby impairing our ability to protect our products.
As is the case with other biopharmaceutical
companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in
the biopharmaceutical industry involves both technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical
patents is costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing
wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing
the scope of patent protection available in certain circumstances or weakening the rights of patent owners in other situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal
courts, and the U.S. PTO, the laws and regulations governing patents could change in ways that would weaken our ability to obtain
new patents or to enforce our existing licensed patents and patents that we might obtain in the future. Similarly, changes in
EU patent law and elsewhere could negatively affect the value of our patents registered outside of the U.S.
Obtaining and maintaining our patent
protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with any of these requirements.
The U.S. PTO and various foreign governmental
patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent
process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter
the market earlier than would otherwise have been the case, which could have a material adverse effect on our business, results
of operations and financial condition.
We may not be able to protect our intellectual
property rights throughout the world.
Filing, prosecuting and defending patents
on product and product candidates throughout the world is prohibitively expensive. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products
to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may
compete with our products in jurisdictions where we do not have any issued or licensed patents and our patent claims or other
intellectual property rights may not be effective or sufficient to prevent them from so competing.
Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents
or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights
in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.
Risks related to the ADSs and the Warrants
A trading market for the ADSs was only
recently established.
In connection with our initial public offering,
we listed the ADSs on the NASDAQ Capital Market (“Nasdaq”) and trading commenced on October 23, 2015. No public market
for the ADSs existed prior to that offering.
However, there can be no assurance that an
active trading market for the ADSs will develop or be sustained in the future. The initial offering price was determined by negotiations
among the lead underwriters and us. Among the factors considered in determining the initial offering price were our future prospects
and the prospects of our industry in general, our revenue, net income and certain other financial and operating information in
recent periods, and the financial ratios, market prices of securities and certain financial and operating information of companies
engaged in activities similar to ours. However, there can be no assurance that the ADSs will ever trade at a price equal to or
greater than the offering price.
In addition, the market price of the ADSs
may be volatile. Many factors may have a material adverse effect on the market price of the ADSs, including, but not limited to:
|
•
|
announcements
of the failure to obtain regulatory approvals or receipt of a “complete response
letter” from the FDA;
|
|
•
|
announcements
of restricted label indications or patient populations, or changes or delays in regulatory
review processes;
|
|
•
|
announcements
of therapeutic innovations or new products by us or our competitors;
|
|
•
|
adverse
actions taken by regulatory agencies with respect to our clinical trials, manufacturing
supply chain or sales and marketing activities;
|
|
•
|
changes
or developments in laws or regulations applicable to Paccal Vet, Paclical, or our other
product candidates;
|
|
•
|
the
failure of our testing and clinical trials;
|
|
•
|
product
liability claims, other litigation or public concern about the safety of our product,
product candidates or future products;
|
|
•
|
any
adverse changes to our relationship with licensors, manufacturers or suppliers;
|
|
•
|
the
loss of any of our key scientific or management personnel;
|
|
•
|
any
major changes in our board of directors or management;
|
|
•
|
the
failure to retain our existing, or obtain new, commercial partners;
|
|
•
|
announcements
concerning our competitors or the pharmaceutical industry in general;
|
|
•
|
the
achievement of expected product sales and profitability;
|
|
•
|
the
failure to obtain reimbursements for our products or price reductions;
|
|
•
|
manufacture,
supply or distribution shortages;
|
|
•
|
actual
or anticipated fluctuations in our cash position or operating results;
|
|
•
|
manufacturing
and supply issues related to our product or our current or future product candidates
for our development programs and commercialization;
|
|
•
|
changes
in financial estimates or recommendations by securities analysts;
|
|
•
|
the
termination of any of our existing license agreements;
|
|
•
|
announcements
relating to future licensing or development agreements;
|
|
•
|
potential
acquisitions;
|
|
•
|
the
trading volume of ADSs on Nasdaq and of the Ordinary Shares on NASDAQ Stockholm and the
Frankfurt Stock Exchange;
|
|
•
|
sales
of the ADSs or Ordinary Shares by us, our executive officers or directors or our shareholders;
|
|
•
|
fluctuations
in the U.S. equity markets;
|
|
•
|
changes
in accounting principles;
|
|
•
|
market
conditions in the human and animal health sectors; and
|
|
•
|
general
economic conditions in the U.S. and elsewhere.
|
In addition, the stock market in general,
and Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of the
ADSs, regardless of our actual operating performance.
The multiple listing of the Ordinary
Shares and the ADSs may adversely affect the liquidity and value of the ADSs.
The Ordinary Shares will continue to be listed
on NASDAQ Stockholm and the Frankfurt Stock Exchange, and the ADSs trade on the NASDAQ Capital Market. We cannot predict the effect
of this multiple listing on the value of the Ordinary Shares and the ADSs. However, it is possible the multiple listing of the
Ordinary Shares and ADSs may dilute the liquidity of these securities in one or all three markets and may adversely affect the
development of an active trading market for the ADSs in the U.S. The price of the ADSs could also be adversely affected by trading
in the Ordinary Shares on NASDAQ Stockholm and the Frankfurt Stock Exchange. Although currently we have no plans to do so, we
may decide to delist the Ordinary Shares from either exchange in the future. We cannot predict the effect such delisting of the
Ordinary Shares would have on the market price of the ADSs on Nasdaq.
If securities or industry analysts do
not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding the ADSs or the
Ordinary Shares, the price of these securities and their trading volume could decline.
The trading market for the ADSs and the Ordinary
Shares will be influenced by the research and reports that industry or securities analysts publish about us or our business. We
do not currently have and may never obtain research coverage by securities and industry analysts. If we do not obtain adequate
securities or industry analyst coverage, the trading price for the ADSs and the Ordinary Shares may be negatively impacted. In
the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading
opinion regarding us, our business model, our products, our intellectual property or the ADSs or our ordinary share performance,
or if our target studies and operating results fail to meet the expectations of analysts, the prices of the ADSs and the Ordinary
Shares may decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could
lose visibility in the financial markets, which in turn could cause the prices of the ADSs and the Ordinary Shares, as well as
their respective trading volume to decline.
Substantial future sales of the Ordinary
Shares or the ADSs in the public market, or the perception that these sales could occur, could cause the price of the ADSs to
decline.
Additional sales of the Ordinary Shares in
the public market, or the perception that such sales could occur, could cause the market price of the Ordinary Shares to decline.
As of the date of this annual report, we had 172 881 108 Ordinary Shares issued and outstanding, including those underlying
presently issued and outstanding ADS but excluding all such Ordinary Shares underlying the ADSs issuable upon exercise of the
Warrants and excluding any exercise by the underwriters of the option to purchase Ordinary Shares. All ADSs are freely transferable
without restriction or additional registration under the Securities Act. The Ordinary Shares held by our directors, officers,
and large institutional shareholders are available for sale since the expiration of the lock-up period has occurred. The remaining
Ordinary Shares are also available for sale since they are not subject to contractual and legal restrictions on resale. To the
extent shares are sold into the market, the market price of the ADSs could decline.
There is presently no public market
for the Warrants to purchase ADSs and none is expected to develop.
There is presently no established public trading
market for the Warrants and we do not expect a market to develop. Without an active market, the liquidity of the Warrants will
be limited. Further, the existence of the Warrants may act to reduce both the trading volume and the trading price of our common
stock.
Speculative nature of Warrants.
The Warrants do not confer any rights of ownership
of ADSs on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire
ADSs at a fixed price for a limited period of time. Specifically, holders of the Warrants may exercise their right to acquire
ADSs and pay an initial exercise price of $4.06, subject to adjustment, prior to ten (10) years from the date of issuance, after
which date any unexercised Warrants will expire and have no further value. There can be no assurance that the market price of
the ADSs will ever equal or exceed the exercise price of the Warrants, and consequently, whether it will ever be profitable for
holders of the Warrants to exercise them.
You may not have the same voting rights
as the holders of the Ordinary Shares and may not receive voting materials in time to be able to exercise your right to vote.
Holders of ADSs are not shareholders of our
company and therefore do not have direct voting rights or the right to attend shareholders’ meetings. ADS holders do have
the right to instruct the depositary how to vote the Ordinary Shares underlying their ADSs, but the depositary will only send
voting materials to ADS holders if we ask it to. Therefore, you may not receive voting materials or you may not receive voting
materials in time to instruct the depositary to vote, and it is possible that you, or persons who hold their ADSs through brokers
or other securities intermediaries, will not have the opportunity to exercise a right to vote. The Warrants confer no equity ownership
in our company, nor do they provide voting rights until exercised and the underlying ADSs are issued.
You may not receive distributions on
the Ordinary Shares represented by the ADSs or any value for them if it is illegal or impractical to make them available to holders
of ADSs.
The depositary for the ADSs has agreed to
pay to you the cash dividends or other distributions it or the custodian receives on the Ordinary Shares or other deposited securities
after deducting its fees and expenses. You will receive these distributions in proportion to the number of the Ordinary Shares
your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical
to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit the distribution
of the ADSs, Ordinary Shares, rights or anything else to holders of the ADSs. This means that you may not receive the distributions
we make on the Ordinary Shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions
may have a material adverse effect on the value of your ADSs.
As a foreign private issuer, we are
exempt from a number of U.S. securities laws and rules promulgated thereunder and are permitted to file less information with
the SEC than U.S. companies must. This will limit the information available to holders of the ADSs.
We currently qualify as a “foreign private
issuer,” as defined in the SEC’s rules and regulations and, consequently, we are not subject to all of the disclosure
requirements applicable to companies organized within the U.S. For example, we are exempt from certain rules under the U.S. Securities
Exchange Act of 1934, as amended (the “Exchange Act”), that regulate disclosure obligations and procedural requirements
related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act.
In addition, our officers and directors are exempt from the reporting and “short-swing” profit recovery provisions
of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we
are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies.
We are also not subject to Regulation FD under the Exchange Act, which would prohibit us from selectively disclosing material
nonpublic information to certain persons without concurrently making a widespread public disclosure of such information. Accordingly,
there may be less publicly available information concerning our company than there is for U.S. public companies.
As a foreign private issuer, we will file
an annual report on Form 20-F within four months of the close of each fiscal year ended April 30 and reports on Form 6-K relating
to certain material events promptly after we publicly announce these events. However, because of the above exemptions for foreign
private issuers, our shareholders will not be afforded the same protections or information generally available to investors holding
shares in public companies organized in the U.S.
As a foreign private issuer, we are
not subject to certain Nasdaq corporate governance rules applicable to U.S. listed companies.
We rely on a provision in Nasdaq’s Listed
Company Manual that allows us to follow Swedish corporate law and the Swedish Companies Act (SFS 2005:551) (the “Swedish
Companies Act”) with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance
practices that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on
Nasdaq.
For example, we are exempt from Nasdaq regulations
that require a listed U.S. company to:
|
•
|
have
a majority of the board of directors consist of independent directors;
|
|
•
|
require
non-executive directors to meet on a regular basis without management present;
|
|
•
|
promptly
disclose any waivers of the code of ethics for directors or executive officers that should
address certain specified items;
|
|
•
|
have
an independent nominating committee;
|
|
•
|
solicit
proxies and provide proxy statements for all shareholder meetings; and
|
|
•
|
seek
shareholder approval for the implementation of certain equity compensation plans and
issuances of Ordinary Shares.
|
As a foreign private issuer, we are permitted
to, and we will, follow home country practice in lieu of the above requirements. The determination of foreign private issuer is
made annually on the last business day of an issuer’s most recently completed second fiscal quarter, and, accordingly, the
next determination will be made with respect to us as of the end of our second quarter of the current fiscal year. If we do not
meet the SEC’s requirements for foreign private issuer, we will be subject to a number of additional rules and regulations,
including those identified above, and as a result we may incur significant regulatory compliance costs.
In accordance with our Nasdaq listing, our
audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act, and Rule 10A-3 of the Exchange
Act, both of which are also applicable to Nasdaq-listed U.S. companies. Because we are a foreign private issuer, however, our
audit committee is not subject to additional Nasdaq requirements applicable to listed U.S. companies, including an affirmative
determination that all members of the audit committee are “independent,” using more stringent criteria than those
applicable to us as a foreign private issuer.
We are an “emerging growth company,”
as defined in the JOBS Act, and as a result of the reduced disclosure and governance requirements applicable to emerging growth
companies, the ADS and Ordinary Shares may be less attractive to investors.
We are an “emerging growth company,”
as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are
applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. We cannot predict if investors will
find the ADSs or the Ordinary Shares less attractive because we will rely on these exemptions. If some investors find the ADSs
or the Ordinary Shares less attractive as a result, there may be a less active trading market for the ADSs or the Ordinary Shares
and the price of the ADSs may be more volatile. We may take advantage of these reporting exemptions until we are no longer an
emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year: (a)
following the fifth anniversary of the completion of the initial public offering, (b) in which we have total annual gross revenue
of at least USD$1.0 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of the
Ordinary Shares that is held by non-affiliates exceeds USD$700 million as of the prior October 31; and (2) the date on which we
have issued more than USD$1.0 billion in non-convertible debt during the prior three-year period.
If we fail to establish and maintain
proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be
impaired.
Section 404(a) of the Sarbanes-Oxley Act requires
that beginning with our annual report for the year ending April 30, 2017, management shall assess and report annually on the effectiveness
of our internal control over financial reporting and identify any material weaknesses in our internal controls over financial
reporting. Although Section 404(b) of the Sarbanes-Oxley Act requires our independent registered public accounting firm to issue
an annual report that addresses the effectiveness of our internal control over financial reporting, we have opted to rely on the
exemptions provided in the JOBS Act, and consequently will not be required to comply with SEC rules that implement Section 404(b)
of the Sarbanes-Oxley Act until such time as we are no longer an emerging growth company.
Our first Section 404(a) assessment will take
place beginning with our annual report for the year ending April 30, 2017. Although remedial activities to address the material
weakness identified by our independent registered public accounting firm have been carried out, the presence of a material
weakness in previous year could result in financial statement errors which, in turn, could lead to errors in our financial reports
or delays in our financial reporting, and could require us to restate our operating results or require our auditors to issue a
qualified audit report. For the fiscal years ended April 30, 2015 and April 30, 2014, our independent registered public accounting
firm reported to our audit committee that it had identified a material weakness in internal control over financial reporting related
to inadequate financial statement preparation and review procedures. See “Our independent registered public accounting firm
has advised us that it has identified a material weakness in our internal control over financial reporting relating to inadequate
financial statement preparation and review procedures.” In order to maintain and improve the effectiveness of our disclosure
controls and procedures and our internal controls over financial reporting, we will need to expend significant resources and provide
significant management oversight. Implementing any appropriate changes to our internal controls may require specific compliance
training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant
period of time to complete and divert management’s attention from other business concerns. These changes may not, however,
be effective in maintaining the adequacy of our internal controls.
If we are unable to conclude that we have
effective internal control over financial reporting or, at the appropriate time, our independent auditors are unwilling or unable
to provide us with an unqualified report on the effectiveness of our internal control over financial reporting as required by
Section 404(b) of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, the price of the Ordinary Shares
could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the
requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to remain listed on Nasdaq.
We will incur significant increased
costs as a result of operating as a company whose ADSs are publicly traded in the U.S., and our management will be required to
devote substantial time to new compliance initiatives.
As a company with publicly traded ADSs in
the U.S., we will incur significant legal, accounting, insurance and other expenses that we have not previously incurred. In addition,
the Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform Act, Consumer Protection Act and related rules implemented by the SEC and
Nasdaq have imposed various requirements on public companies, including requiring establishment and maintenance of effective disclosure
and financial controls. Our management and other personnel will need to devote a substantial amount of time to these compliance
initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities
more time-consuming and costly. We estimate that our annual compliance expenses will be approximately SEK 3 million in each of
the next two fiscal years. Among other matters, we expect these rules and regulations to make it more difficult and more expensive
for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same
or similar coverage. These laws and regulations could also make it more difficult and expensive for us to attract and retain qualified
persons to serve on our board of directors, our board committees or as our executive officers. Furthermore, if we are unable to
satisfy our obligations as a public company, we could be subject to delisting of the ADSs, fines, sanctions and other regulatory
action and potentially civil litigation.
The rights of our shareholders may differ
from the rights typically offered to shareholders of a U.S. corporation.
We are incorporated under Swedish law. The
rights of holders of Ordinary Shares and, therefore, certain of the rights of holders of ADSs, are governed by Swedish law, including
the provisions of the Swedish Companies Act, and by our Articles of Association. These rights differ in certain respects from
the rights of shareholders in typical U.S. corporations.
We may be or may become a passive foreign
investment company (“PFIC”) for U.S. federal income tax purposes.
Whether we are or may be a PFIC is a complex
determination based on the classification of various assets and income under the PFIC rules. Further, a determination as to whether
or not we are a PFIC must be made annually and our circumstances may change in any given year. We do not intend to make decisions
regarding our business operations with the specific purpose of reducing the likelihood of our becoming a PFIC. Accordingly, our
business plan may result in our engaging in activities that could cause us to become a PFIC. If we are or become a PFIC, U.S.
Holders may be subject to increased U.S. federal income taxes on a sale or other disposition of our ADSs and on the receipt of
certain distributions and will be subject to increased U.S. federal income tax reporting requirements. Moreover, we may not decide
to provide the information that would enable U.S. Holders to make an election to treat us as a “qualified electing fund”
(a “QEF”), which election could mitigate the adverse U.S. federal income tax consequences of us being classified as
a PFIC if we were so classified. See “Taxation — Passive Foreign Investment Company Status” for a
more detailed discussion of the consequences if we are treated as a PFIC.
ITEM 4. INFORMATION ON THE COMPANY
A. History and Development of the Company
Oasmia Pharmaceutical AB is a pharmaceutical
company which develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. The product
development aims to manufacture novel formulations based on well-established cytostatic which, in comparison with current alternatives,
show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on
in-house research within nanotechnology and company patents. The Company’s shares are listed at NASDAQ Stockholm, NASDAQ
Capital Markets and the Frankfurt Stock Exchange.
We are a Swedish public company. Our principal
executive offices are located in Uppsala, Sweden.
Company information
Company name: OASMIA PHARMACEUTICAL AB
Address: Vallongatan 1, 752 28 Uppsala, Sweden
Contact information: +46 18 50 54 40
Fax: +46 18 51 08 73
Email address: info@oasmia.com
Website: www.oasmia.com
B. Business
overview.
We are a pharmaceutical
company focused on innovative treatments within human and animal oncology. Our product and product candidates utilize a
proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered
active pharmaceutical ingredients, without the addition of toxic solvents. We believe our formulation may result in improved
safety, efficacy and ease of administration over existing drugs. Our initial development and commercialization efforts are
focused on creating novel formulations of well-established chemotherapeutic drugs that can be used for the treatment of
cancer in both humans and companion animals. We have four human oncology product candidates in pre-clinical and/or clinical
development, and two veterinary oncology product candidates. We disclosed top line Phase III data for our lead human oncology
product candidate in the fourth quarter of 2014 and positive overall survival data in April 2016. In February 2014, we
received conditional approval by the United States Food and Drug Administration (“FDA”) for our initial
veterinary oncology product, which made us eligible for royalties and potential milestone payments from Abbott Animal Health,
the animal health division of Abbott Laboratories. Our lead products utilize paclitaxel, the active ingredient of Taxol and
Abraxane, two widely used cancer drugs marketed by Bristol-Myers Squibb and Celgene, respectively. Based on the potential
benefits of our proprietary formulation technology, we are pursuing a strategy to replace the use of existing
paclitaxel-based products in multiple cancers with our novel formulations. Our formulation is currently called Paclical or
Apealea, depending on market, for human indications, and is marketed under the name Paccal Vet-CA1 (“Paccal Vet”)
for veterinary indications. We own the global commercial rights to Paclical, excluding Israel, Turkey, Russia, the
Commonwealth of Independent States (“CIS”), Ukraine, Georgia and Turkmenistan. The Company withdrew the
conditional approval for Paccal Vet-CA1 in January 2017 in order to change treatment regime. We own the global commercial
rights of Paccal Vet, excluding Japan. The Board of Directors took a decision in May 2017 to spin the veterinary assets off
to our fully owned US subsidiary. The company has received marketing approval of Doxophos in Russia, a key milestone
following the recently established relationship with Hetero Group, its new marketing and distribution partner.
A phase III study with our
lead human oncology product candidate, Paclical, for the treatment of epithelial ovarian cancer has been completed. We have received
orphan designation for Paclical in the EU and the U.S. Results regarding progression free survival are available and we filed
an MAA in the EU based upon these results in February 2016. We obtained overall survival, OS, data in April 2016 and we will file
to the FDA in 2017. We previously submitted an application to market Paclical in Russia, and we received market authorization
in April 2015 and were entered into the Russian reimbursement system in January 2016. We are also conducting and planning additional
clinical trials to evaluate Paclical in other cancer types.
Paccal Vet is the first injectable
chemotherapeutic agent authorized for marketing for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. We
obtained conditional approval by the FDA for Paccal Vet for the treatment of mammary carcinoma and squamous cell carcinoma under
the Minor Use and Minor Species (“MUMS”) designation in the U.S. MUMS designation is a status similar to orphan designation
for human drugs, making the sponsor eligible for incentives to support the approval or conditional approval of the designated
drug, including seven years of market exclusivity in the U.S, during which period a different drug company cannot pursue full
or conditional approval of a generic version or another brand name version of the drug in the same form for the same intended
use. The Company withdraw its current label and plan to initiate a new study confirming changed dosing regimen.
In order to receive the MUMS
designation in the U.S. for Paccal Vet, we were required to show that squamous cell carcinoma and mammary carcinoma, the drug’s
two indications, occur infrequently and in less than 70,000 dogs in the U.S. each year. To receive conditional approval pursuant
to the MUMS designation, we were also required to show (i) that our manufacturing process for Paccal Vet satisfied certain criteria,
including purity and stability (see “Government Regulation — Requirements for Approval of Veterinary Pharmaceuticals
for Pets — Defined Manufacturing Process”); (ii) that the production and use of Paccal Vet satisfied certain
human and environmental safety criteria (see “Government Regulation — Requirements for Approval of Veterinary
Pharmaceuticals for Pets — Safe for Humans and the Environment”); and (iii) a reasonable expectation of
effectiveness in treating mammary carcinoma and squamous cell carcinoma. To receive full approval, we will need to show that the
manufacturing and safety criteria described above remain satisfied.
“[The] FDA’s Center
for Veterinary Medicine determined that the drug’s two indications fit the ‘minor use in a major species’ category.
Both mammary carcinoma and squamous cell carcinoma — within the limitations described on the label — occur
infrequently and in a small number of dogs each year (fewer than 70,000 dogs in the U.S. in one year).”
Reference: FDA
http://www.fda.gov/animalveterinary/resourcesforyou/ucm402476.htm
“[The] FDA’s Center
for Veterinary Medicine granted Oasmia Pharmaceutical AB’s request to declare the drug a “designated” animal
drug for its two label indications. This designation status qualifies the company to receive financial incentives. First, it gives
Oasmia Pharmaceutical AB seven years of exclusive marketing rights, beginning on February 27, 2014, the date that FDA conditionally
approved PACCAL VET-CA1. During this 7-year period, a different drug company cannot pursue approval or conditional approval of
a generic copy or another pioneer (brand name) version of the same drug in the same form for the same intended use.”
Reference to FDA (quotes):
http://www.fda.gov/animalveterinary/resourcesforyou/ucm402476.htm
In Europe, we intend to submit
a Marketing Authorization Application (“MAA”) to the European Medicines Agency (“EMA”) for Paccal Vet
for the treatment of squamous cell carcinoma, mammary carcinoma and mast cell tumors (mast cells develop in bone marrow and are
found in connective tissue throughout the body. Mast cells are, among other items, involved in the defense against parasitic infestations
and infections. They contain histamine and are associated with allergic reactions based on data from the ongoing phase III studies.
In addition to Paccal Vet
and Paclical, we have five additional product candidates:
|
•
|
Docecal
is a proprietary, patented formulation of docetaxel. Docetaxel is the active ingredient
in Taxotere, a product marketed by Sanofi. Taxotere, one of the most commercially-successful
and widely used chemotherapeutic medications, generated annual worldwide sales of more
than $2.8 billion in 2010, the year its patent expired. We have completed a number of
pre-clinical studies and are performing a clinical phase I study as well as a safety
and tolerance study. Both studies are expected to be finalized during 2017. We retain
global rights to Docecal.
|
|
•
|
Doxophos
Vet and Doxophos are a proprietary, patented formulation of doxorubicin, one of the most
effective and commonly used substances for the treatment of cancer. Doxorubicin is the
active ingredient in Doxil and Adriamycin. Our product candidate is called Doxophos Vet
for veterinary indications and Doxophos for human indications. Doxophos Vet is being
developed for the treatment of lymphoma, one of the most common cancers in dogs. A Phase
I dose-finding clinical trial with Doxophos Vet was completed during the fourth quarter
of 2014 and the study report was completed in June of 2015. We have completed a number
of pre-clinical studies of Doxophos. In December 2015 we submitted a request for market
authorization of Doxophos in Russia. Oasmia got market approval in Russia and CIS in
August 2017.
|
|
•
|
OAS-19
is a proprietary combination of two widely used chemotherapeutic agents in a single formulation
that can be administered in a single dose. In the past, cancers were often treated with
a single chemotherapeutic agent but combination therapies have become more prevalent
in clinical practice, including the combined use of multiple traditional chemotherapeutic
agents and the combined use of newer cancer therapies in conjunction with traditional
chemotherapeutic agents, which often require multiple infusions that can be time consuming
and costly. By combining two chemotherapeutic agents in a single formulation, we believe
that OAS-19 could offer physicians the ability to dose chemotherapy in a single infusion
instead of two sequential infusions, which we believe decreases infusion times, the number
of clinical visits, and associated treatment costs. We are currently evaluating OAS-19
in preclinical studies. We retain global rights to OAS-19.
|
|
•
|
KB9520
is a substance acquired from Karo Pharma in November 2016. In pre-clinical studies, the
substancehas shown that it contributes to reduced side effects of treatment with cytostatics
when intake of KB9520 and cytostatic treatment are combined. KB9520 has also demonstrated
good efficacy for several types of cancer in pre-clinical models. In these disease models,
treatment has shown a significant reduction in tumour size by stimulating apoptosis (programmed
cell death) and inhibiting cell growth. The company has created an internal project group
for the continued development of this substance. In parallel, the company is also looking
for a partner with whom Oasmia can drive this forward.
|
We believe that our strategy
of applying our formulation technology to existing chemotherapeutic drugs will allow us to use the 505(b)(2) regulatory pathway
in the United States to obtain regulatory approval for our human product candidates. The 505(b)(2) regulatory pathway permits
the filing of a New Drug Application (“NDA”) where at least some of the information required for approval comes from
studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. We believe this
pathway is attractive as it has the potential to prevent the need for costly and time consuming clinical trials. We believe we
will first be able to apply this to Paclical in the United States referencing Taxol.
Our Product and Product Candidates
The following tables summarize key information about our product
and our most advanced product candidates:
Product
Candidate
|
|
Commercial
Rights
|
|
Stage
of Development & Anticipated Milestones
|
Paclitaxel
|
|
|
|
|
Paclical
|
|
Oasmia:
Global (excluding Israel, Turkey, Russia/CIS,
Ukraine, Georgia and Turkmenistan)
Medison Pharma:
Israel and Turkey
Hetero Group:
Russia/CIS, Ukraine, Georgia and Turkmenistan
|
|
·
Final results, overall survival
data, from Phase III trial vs. Taxol was disclosed in April 2016
·
Applied for marketing authorization
in EU in February 2016 and aim to apply in the U.S. in late 2017 or early 2018
·
Received for marketing authorization
in Russia in April of 2015
|
Paccal Vet
|
|
Oasmia:
Global (excluding Japan, Russia/CIS)
Nippon Zenyaku Kogyo:
Japan
Oasmia:
Russia/CIS
|
|
·
Conditional U.S. approval received in
February 2014, withdrawn in January 2017
·
Conduct studies to support a new
dosing regimen
·
Apply for marketing authorization
with the EMA
|
|
|
|
|
|
Docetaxel
|
|
|
|
|
Docecal
|
|
Oasmia:
Global
|
|
·
Pre-clinical studies ongoing
·
Phase I pharmacokinetic
clinical trial in metastatic breast cancer is ongoing
·
Phase II safety and tolerance
clinical trial in metastatic breast cancer is ongoing
·
Aim to apply for marketing
application in Russia during 2018
|
|
|
|
|
|
Doxorubicin
|
|
|
|
|
Doxophos Vet
|
|
Oasmia:
Global (excluding Russia/CIS)
Oasmia:
Russia/CIS
|
|
·
Dose-finding clinical trial
completed
·
Proof of Concept study is
ongoing
|
Doxophos
|
|
Oasmia:
Global
|
|
·
Pre-clinical studies ongoing
·
Submitted for MAA in Russia
December 2015
|
|
|
|
|
|
Combination
|
|
|
|
|
OAS-19
|
|
Oasmia:
Global
|
|
·
Currently in pre-clinical
development
·
Initiate a Phase I dose-finding
clinical trial
|
Definitions
The following definitions are used throughout
this document;
·
|
—
|
Phase
I: The first clinical study initiated with a compound. This can be either a dose-finding study or a PK-study.
|
·
|
—
|
Phase
II: A clinical study to assess safety and efficacy in a smaller study in the intended indication.
|
·
|
—
|
Phase
III: A clinical study to show efficacy and safety and to be used as a basis for an application to obtain marketing
authorization.
|
The label phase I is also
used for veterinary studies although the nomenclature of the Center for Veterinary Medicine at the FDA (“CVM”) is
“Dose characterization study” for phase I. Phase II is referred to herein as “Dose confirmation study”
and phase III “field study”.
Paclical, Our Lead Human Oncology Candidate
Paclical Overview
Paclical is our XR17 formulation of paclitaxel
for human use. Our XR17 technology increases the solubility of paclitaxel without the use of toxic solvents, which we believe
facilitates the ease of administration and allows for higher doses than some of the other existing products on the market (250
mg/m
2
compared to 175 mg/m
2
).
Based on the potential benefits of XR17, we
are pursuing a strategy to replace the use of existing paclitaxel-based products in treating multiple types of cancer. Our initial
focus is to obtain regulatory approval for the treatment of ovarian cancer and expand use through additional regulatory approvals,
starting with breast cancer. Since we are not conducting any human clinical studies in the U.S. we are not required to file an
IND.
We have obtained orphan designation for epithelial
ovarian cancer in the EU and in the U.S. based on the hypothesis that Paclical provides potential benefits to safety and tolerability
compared to Taxol, which is currently used as a treatment for epithelial ovarian cancer. Both Paclical and Taxol are being administered
in combination with carboplatin, a platinum-based chemotherapeutic that is the current standard of care for ovarian cancer. Carboplatin
has historically been given as a monotherapy for the treatment of ovarian cancer, an incremental survival benefit by adding Taxol.
On June 16, 2014, Oasmia announced that the primary endpoint for the Phase III study with Paclical for treatment of ovarian cancer
had been met. The endpoint was to demonstrate that Paclical and Taxol, both in combination with carboplatin, have the same progression-free
survival time. Further, we disclosed final results which showed a positive risk/benefit profile in the fourth quarter of 2014.
This data served as the basis of an MAA to the EMA, which we submitted in February 2016. We continued to follow patients from
the Phase III clinical trial to measure overall survival and received final data in April 2016. We expect to be able to utilize
the Section 505(b)(2) regulatory pathway for Paclical in the United States. We do not currently plan to conduct any other pivotal
study of Paclical for epithelial ovarian cancer at this time since only one study is needed for submission to the FDA and EMA,
although we intend to include other supportive studies in our Section 505(b)(2) application.
In addition to the development of Paclical
in ovarian cancer, we intend to enhance the commercial potential of Paclical by demonstrating the potential safety, efficacy,
and convenience advantages of Paclical over other paclitaxel-based therapies in additional clinical trials. For example, we have
recently completed a pharmacokinetic study to compare Paclical with Abraxane. In addition, this data can be used in our discussions
with payor organizations and physicians to help drive market acceptance of Paclical.
In addition to our efforts in the EU and the
U.S., we submitted an application for marketing authorization for Paclical in Russia in September 2012 and received approval in
April of 2015 and was approved for their reimbursement system in January 2016.
Paclical Market
The two leading paclitaxel-based products
on the market are Taxol and Abraxane, two widely used cancer drugs. Taxol generated $1.6 billion in sales in 2000 alone, prior
to losing its patent protection in 2001. In 2013, Taxol generated $92 million in post-patent sales. Abraxane, which received FDA
approval in 2005 for metastatic breast cancer, followed by approvals for lung (in 2012) and pancreatic cancer (in 2013), generated
$649 million in worldwide annual sales in 2013 and generated $1,161 million in 2015. Abraxane is sold by Celgene worldwide except
in Japan where Otsuka Holdings Co., Ltd. own the rights. In order to deliver paclitaxel, Taxol contains the solvent Cremophor
EL. The toxicity of Cremophor EL limits the dose of Taxol that can be administered during a reasonable time, potentially limiting
the efficacy of the drug. In addition, patients receiving Taxol require pre-medication with steroids and antihistamines to prevent
the toxic side effects associated with the combination of paclitaxel and Cremophor EL. Abraxane was developed as a Cremophor-free
product containing paclitaxel suspended in human albumin. Because Abraxane contains no Cremophor solvent, Abraxane’s recommended
dosing enables the delivery of 50% more paclitaxel while maintaining a similar safety profile, and requires no routine pre-medication
to prevent hypersensitivity reactions or the immediate allergic effects that often prevent or limit treatment. Like Abraxane,
Paclical is free of Cremophor EL, but unlike Abraxane, Paclical does not contain human albumin.
Our initial indication for Paclical is epithelial
ovarian cancer, which is the fifth leading cause of cancer death among American women, and an indication for which Abraxane has
no approval. There are clinical studies and case reports that indicate that Abraxane is used off-label by oncologists to treat
certain types of epithelial ovarian cancer, but we cannot estimate how frequently they do so or whether Abraxane is used off-label
to treat second line epithelial ovarian cancer. It is easier to find publications on platinum resistant epithelial ovarian cancer
and first line epithelial ovarian cancer than on second line epithelial ovarian cancer (Paclical’s intended indication),
but it is not possible to say if that reflects the usage. Epithelial ovarian cancers account for about 85% to 90% of ovarian cancers,
and are the most aggressive and dangerous sub-type. According to the National Cancer Institute, in 2014, the most recent year
in which data are available, there were over 222,000 women living with ovarian cancer in the U.S. The five year survival rate
for ovarian cancer from 2007 to 2013 was 46.5%, and it is estimated that 22,440 women will develop and 14,080 women will die from
ovarian cancer in 2017. In the EU, the five year survival rate for ovarian cancer was 37.6% from 2000 – 2007 according
to a study published in
The Lancet
. In 2012, there were 44,149 diagnosed cases of ovarian cancer in the EU, according to
the European Cancer Observatory/International Agency for Research on Cancer, while 29,758 women died of ovarian cancer. In the
U.S., 51% of women with ovarian cancer are diagnosed with stage III cancer, characterized by microscopically confirmed peritoneal
metastasis outside the pelvis and/or regional lymph node metastasis. Common chemotherapy drugs used for the treatment for ovarian
cancer include cisplatin or carboplatin, and paclitaxel or docetaxel, which are most often given in combination.
Our second indication, breast cancer, will
be targeted with weekly administration of Paclical. Breast cancer is by far the most frequent cancer among women. The WHO estimates
that 1.38 million women worldwide are diagnosed with breast cancer each year. Roughly 458,000 women worldwide die from the disease
annually.
Although we may choose to license Paclical
to a commercial partner, we also believe we could successfully market and sell the product ourselves. There have been numerous
examples of successful oncology drugs, including Abraxane, launched by small companies.
Paclical Phase III Clinical Trial
We have completed a Phase III open, randomized,
multi-center trial in patients with recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer to
compare the efficacy and safety of Paclical to Taxol, both in combination with carboplatin. Carboplatin was historically given
as a monotherapy for the treatment of ovarian cancer but some studies have demonstrated an incremental survival benefit from adding
Taxol, which has increased the use of the two drugs in combination. Top-line progression free survival results were disclosed
in the second quarter of 2014. Since there are no human clinical studies in the U.S. we are not required to file an IND.
The study was designed to achieve the following
primary objectives:
|
•
|
For
progression free survival, to show non-inferiority of Paclical (250 mg/m
2
)
versus Taxol (175 mg/m
2
) using computed tomography (“CT”) scans,
as assessed according to RECIST by central review.
|
|
•
|
For
overall survival, to show non-inferiority of Paclical (250 mg/m
2
) versus Taxol
(175 mg/m
2
).
|
Inclusion criteria included patients, in total
789 patients, who relapsed at least six months after ending the first line or second line treatment including platinum based therapy.
Paclical was administered as a one-hour intravenous infusion at its recommended dose of 250 mg/m
2
to 391 patients.
Taxol was administered as a three-hour intravenous infusion at its recommended dose of 175 mg/m
2
to 391 patients. Both
drugs were dosed in six three-week cycles, which is consistent with clinical practice. After completing the treatment cycles,
patients were managed by their respective physicians and tracked for certain measures, including progression free survival and
overall survival.
Tumor response was evaluated with a biomarker,
CA 125, and through CT scans. CA 125 is used in clinical practice to assess when to re-treat a patient, as it is generally accepted
as a sign of disease progression. We received guidance from Russian regulators that CA 125 would be an acceptable endpoint for
regulatory submission. In an interim analysis we assessed the response to Paclical and to Taxol with regard to concentration average
of CA 125 during the treatment period. The objective to show non-inferiority of the two treatments was met. The results of the
interim analysis were used in a submission for marketing authorization to Russian authorities. Beyond the Russian market, we believe
the use of both CA 125 and CT scan data in one study will give us the opportunity to include a comparison of progression free
survival based on CA 125 and based on CT evaluation in the final analysis.
On June 16, 2014, we announced the results
of this trial. The primary end-point has been analyzed and it shows a progression free survival of 10.3 months in the Paclical
+ carboplatin group and 10.1 months in the control group (Taxol + carboplatin). The protocol objective to show non-inferiority
(or similar efficacy) was thus met (p-value of 0.09).
A protocol amendment increased the frequency
of CT scans to be performed every three months after end of treatment. An analysis of the Progression Free Survival rate (“PFS”)
in this subset of patients showed a PFS for Paclical of 12.2 month and 10.2 months for Taxol. The non-inferiority criteria were
met also regarding the secondary efficacy variables. Even though the data on efficacy were not significantly different, PFS tended
to be better in the Paclical group regardless of patient population; more frequent CTs showed the most pronounced differences.
OS
The safety profile of Paclical active substance
dose of 250 mg/m
2
, is rather similar to the safety profile of Taxol, active substance of 175 mg/m
2
. The
number of patients with serious myelosuppression is substantial, but many of them were detected in the hematology analyses and
were without clinical signs. Further, when needed, myelosuppression is easily managed in the clinic.
Considering both efficacy and safety of Paclical,
including a comparatively short infusion time and less frequent use of pre-medications, we believe that the benefits of Paclical
outweigh the potential risks of the treatment.
Paclical Phase I and Phase I/II Clinical
Trials
Paclical Phase I/II Dose Escalation Trial
We evaluated Paclical in a dose escalating
Phase I/II trial to define the maximum tolerated dose and desired dose to use in clinical trials of Paclical. Thirty-four patients
with different kinds of cancers were included in the trial. Patients received escalating doses (90 – 275 mg/m
2
) of Paclical, until the dose-limiting toxicity was noted. Dose-limiting toxicity (“DLT”) is the emergence of
side effects during treatment that are severe enough to prevent further increases in dosage of the treatment. Paclical was given
as a one-hour intravenous infusion every 21 days for three cycles. No premedication was administered prior to Paclical administration.
Eight patients experienced at least one adverse
event classified as DLT. The first occurred at 225 mg/m
2
and consisted of fatigue, skin reaction, and stomatitis. The
following 4 patients experiencing DLT occurred at 250 mg/m
2
where one patient experienced myalgia, arthralgia and leukopenia
classified as DLT during both first and second treatment cycle. Additional three patients experienced neuropathy whereof one also
experienced stomatitis and febrile neutropenia at this dose. Three patients experienced DLTs at the 275 mg/m
2
dose
level; all three experienced fatigue, one in combination with small intestinal obstruction and one in combination with peripheral
sensory neuropathy.
Stomatitis (at 250 mg/m
2
), myalgia,
arthralgia (at 250 mg/m
2
), and small intestinal obstruction (at 270 mg/m
2
) fulfilled the criteria of serious
adverse event. Other serious adverse events considered related to Paclical were pyrexia (2 patients) and hemoglobin decrease (2
patients).
The maximum tolerated dose was established
at 250 mg/m
2
, which is 75 mg/m
2
greater than the recommended dose for Taxol of 175 mg/m
2
and
similar to the recommended dose for Abraxane of 260 mg/m
2
. No hypersensitivity reactions were reported despite the
fact that no premedication was given before the administration of Paclical. In addition to the foregoing results, this trial indicated
that Paclical was effective when administered with a one hour infusion period, while Taxol requires three hours.
The patient population consisted of terminally
ill patients for whom no further treatment was available. Further, no patient received more than 3 cycles. Considering these circumstances,
we consider the efficacy results, 10 patients with stable disease to be promising.
The most important result from this trial,
in our view, was that Paclical can be given without pre-treatment, the maximum tolerated dose is 250 mg/m
2
and the
infusion period is one hour. This demonstrates that there are benefits associated with Paclical compared to Taxol since Taxol
requires pre-treatment, the maximum tolerated dose is 175 mg/m
2
and the infusion for Taxol is three hours.
Pharmacokinetic Comparison with Taxol
The pharmacokinetic properties of paclitaxel
following an intravenous infusion of Paclical at a dose of 175 mg/m
2
were evaluated in a Phase I crossover pharmacokinetic
study comparing the pharmacokinetics of Paclical and Taxol in humans. The mean unbound plasma concentrations, which indicate the
levels of paclitaxel in the bloodstream that are not bound to common blood proteins and therefore can readily cross cell membranes,
were similar for the two formulations (see Figure 2). We believe that this supports the thesis that the paclitaxel-related effects
for Paclical and Taxol when given at the same dose and during the same infusion time should be comparable and should have the
same temporal course of action. We believe that this trial supports the pursuit of the 505(b)(2) regulatory path in the U.S.
Figure 2: Mean curves of unbound plasma concentration
of paclitaxel after identical doses of Paclical and Taxol, 175 mg/m
2
over 3 hours.
Paclitaxel Mean Cu after Paclical and Taxol
Pharmacokinetic Comparison with Abraxane
The pharmacokinetic properties of paclitaxel
have also been evaluated following an intravenous infusion of Paclical or Abraxane at a dose of 260 mg/m
2
in order
to compare the pharmacokinetics of Paclical and Abraxane in humans. The study was a cross-over study and both the mean total plasma
concentrations and the mean unbound plasma concentrations were compared, and both were similar for the two formulations (see Figure
X and Y). We interpret these findings as an indication of similar paclitaxel related effects of the two compounds.
Figure X Mean (±SD) Total Plasma Paclitaxel
Concentrations Following IV Administration of Paclical or Abraxane — All Patients
Figure Y Mean (±SD) Unbound Plasma
Paclitaxel Concentrations Following IV Administration of Paclical or Abraxane — All Patients
The results from the above described study
of a head-to-head pharmacokinetic comparison between Paclical and Abraxane announced on August 4, 2015. that the concentration
of both total and unbound paclitaxel in plasma was similar.
Our formulation is currently called Paclical
for human indications, and Paccal Vet-CA1 (“Paccal Vet”) for veterinary indications. We own the global commercial
rights to Paclical, excluding Israel, Turkey, Russia, the Commonwealth of Independent States (“CIS”), Ukraine, Georgia
and Turkmenistan. We have licensed the global commercial rights to Paccal Vet for sale in Japan, Russia and the CIS. Paclical
received marketing approval in Russia and the CIS in April 2015.
Paclical Phase I
A phase I study exploring the dose of weekly
administration of paclical in patients with metastatic breastcancer have been finalized during 2016. By looking at all events,
not only those occurring following the first treatment, a suggested dose for further development of weekly paclical was identified
to 170 mg/m
2
. However, the main object of the follow-up study intended to explore the number of cycles for weekly paclical
treatment was not obtained.
XR17 Phase I Clinical Trial
A phase I clinical study to investigate the
pharmacokinetics and safety and tolerability of three doses of our patented excipient XR 17 and XMeNa in healthy subjects were
finalized during 2016. The conclusion of the study is that the half time of the excipients is short, 2-3h and that it is well
tolerated and safe. Adverse events were seen occasionally and a dose dependent relationship were noted with infusion site reactions.
Paccal Vet, Our Initial Animal Health Product
Paccal Vet Overview
Paccal Vet is a novel XR17 based formulation
of paclitaxel. Paclitaxel is a well-established, widely used chemotherapeutic that on its own is practically insoluble in water.
Paccal Vet is our initial product in veterinary oncology. Our former commercial partner, Abbott Animal Health, a leading animal
health company, launched the product in mid-2014, at which time we were eligible to receive royalties that start at a minimum
approximately one third of net sales. The Investigative New Animal Drug (“INAD”) number for Paccal Vet is 011609,
which we requested on March 20, 2007.
In February 2014, we received conditional
approval from the FDA for Paccal Vet for the treatment of nonresectable stage III, IV or V mammary carcinoma and resectable and
nonresectable squamous-cell carcinoma, both for dogs that have not received previous chemotherapy or radiotherapy. The conditional
approval was withdrawn in January 2017 in order to redesign the dose regimen allowing treatment in less specialized veterinarian
clinics.
To receive conditional approval pursuant to
the MUMS designation, we were also required to (i) show that our manufacturing process for Paccal Vet satisfied certain criteria,
including purity and stability (see “Government Regulation — Requirements for Approval of Veterinary Pharmaceuticals
for Pets — Defined Manufacturing Process”); (ii) show that the production and use of Paccal Vet satisfied
certain human and environmental safety criteria (see “Government Regulation — Requirements for Approval
of Veterinary Pharmaceuticals for Pets — Safe for Humans and the Environment”); and (iii) provide a reasonable
expectation of effectiveness in treating mammary carcinoma and squamous cell carcinoma.
Conditional approval allows veterinarians
to treat dogs with Paccal Vet in the approved indications. Conditional approval grants Paccal Vet seven years of market exclusivity,
and gives us the right to promote the product before all of the efficacy data necessary for a full approval are available. Conditional
approval also allows us to keep the product on the market for up to five years, through annual renewals, while collecting the
remaining required efficacy data.
“[The] FDA’s Center for Veterinary
Medicine determined that the drug’s two indications fit the ‘minor use in a major species’ category. Both mammary
carcinoma and squamous cell carcinoma — within the limitations described on the label occur infrequently and in
a small number of dogs each year (fewer than 70,000 dogs in the U.S. in one year).”
“The company has shown that, when used
according to the label, PACCAL VET-CA1 is safe and has a ‘reasonable expectation of effectiveness.’”
Reference: FDA
http://www.fda.gov/animalveterinary/resourcesforyou/ucm402476.htm
The study
Paccal Vet Prospective Single-Arm
Trial in Mast Cell Tumors in Dogs
was a single-arm study. This was because the comparator used in clinical trials is the standard
of care, the most commonly used treatment for the indication. When we started to develop Paccal Vet there were no chemotherapeutics
approved for dogs. One can of course always compare to no treatment or the vehicle (“placebo”). With a disease such
as cancer, it is not ethical not to treat, and that was the reason for the single arm study.
When it was possible for us to apply for conditional
approval, discussions were held with CVM/FDA and it was concluded that data from a comparative study were not needed to obtain
the conditional approval. Although, according to CVM/FDA, the number of dogs with the specific indications treated in the study
Paccal Vet in Malignant High-Grade Solid Tumors in Dogs,
was too low to meet requirements of reasonable expectation of
effectiveness. Therefore, it was decided through discussions with CVM/FDA, to include dogs from a study not done by Oasmia (mammary
carcinoma) and to conduct a small study (squamous cell carcinoma) in order to meet the requirements of a conditional approval.
EMA CVMP Scientific Advice and FDA protocol
concurrence were requested and received for the pivotal clinical study protocol(s) for full approval. The study protocol was submitted
to EMA for scientific advice. An answer was obtained on July 12, 2012 (EMA/CVMP/SAWP/296308/2012). The questions asked by Oasmia
referred to study design, primary objective/end-point, the use of placebo as comparator, sample size calculations, quality of
life scale, the use of anti-emetics, and the possibility to use safety data from previous studies. The answers to some of the
questions were ambiguous and clarifications were requested on August 10, 2012, and answered on September 13, 2012 (EMA/CVMP/SAWP/548291/2012).
EMA’s comments were addressed in the final study protocol.
The Clinical Study Protocol(s) have received
FDA “concurrence” which means FDA agrees with the design of the clinical protocol(s), and as such also agrees with
the numbers of dogs to be in the study(s). FDA as a status quo requires a minimum of 150 dogs. EMA does not generally require
a specific minimum number of dogs such as 150 dogs, but the numbers should be based on a hypothesis that is statistically valid.
Oasmia asked in scientific advice to EMA CVMP October 2013 specifically, “Does the CVMP agree that this number of dogs is
sufficient?” EMA CVMP Answer (excerpted) “As outlined in the CVMP GL on statistical principles for clinical trials
for veterinary medicinal products (EMA/CVMP/EWP/81976/2010) ‘the number of animals in a clinical trial should always be
large enough to provide reliable answers to the questions addressed. This number is usually determined by the primary objective
of the trial’. Thus, a formal sample size calculation is considered necessary in the planned confirmatory clinical trial.
Based on the treatment effects specified in the company’s position, the planned sample size initially appears reasonable.”
Paccal Vet Market
According to the Animal Cancer Foundation,
approximately six million dogs per year are diagnosed with cancer in the U.S., slightly less than 10% of the population. Based
on a population of 60 million dogs in the EU, we estimate almost six million dogs per year are diagnosed with cancer in Europe.
We estimate that between 36,000 and 41,250 dogs are treated annually for mammary carcinoma, while the number of diagnoses for
squamous cell carcinoma in dogs is less than 10,000 annually. This is the reason Paccal Vet was eligible for conditional approval,
the drug’s two indications fit the “minor use in a minor species” category. As mentioned earlier both mammary
carcinoma and squamous cell carcinoma occur infrequently and in a small number of dogs each year (fewer than 70,000 dogs in the
U.S. each year).
Based on the referenced sources for the U.S.
and Europe, we believe that the incidence rates and overall prevalence of cancer in dogs is similar for cats. Solid tumors, with
or without metastatic disease, are one of the most common forms of cancer in dogs and cats. Aside from Paccal Vet, there are currently
no injectable chemotherapeutic drugs specifically approved for use in pets in the U.S., although, as an alternative, human drugs
are often used off-label. Taxol and Abraxane, both of which deliver paclitaxel, cannot safely be used in dogs. Taxol has toxicity
associated with Cremophor El (polyoxyethylated castor oil) (“Cremophor”), and dogs have a resistance to human albumin,
which is found in Abraxane.
The first drug to be approved specifically
for the treatment of cancer in dogs was Zoetis’ Palladia, a toceranib phosphate tablet, which is indicated for the treatment
of mast cell tumors and launched in 2009. While Zoetis does not disclose sales of Palladia, we believe the product is well known
to veterinarians.
Mammary carcinoma and squamous-cell carcinoma
are two of the most common types of solid tumors in dogs. Skin cancers, which include squamous-cell carcinomas, comprise one third
of all canine cancers. Mammary tumors are the most common type of cancer in female dogs, accounting for about half of all tumors
and affecting up to 25% of female dogs that are not spayed.
Paccal Vet in Malignant High-Grade Solid
Tumors in Dogs
We evaluated Paccal Vet in an open-label,
single arm, dose-escalating clinical field study to determine a clinically safe and effective dose and to evaluate single-dose
pharmacokinetics in tumor-bearing dogs. This was our first clinical report of a Cremophor-free formulation of paclitaxel, suggesting
successful administration without premedication in dogs. We ran this study as a single-arm study because the objective of this
study, and other early phase studies, was to assess appropriate dosage and to assess certain particular safety aspects of Paccal
Vet, for which a control group was not required.
The study included 27 dogs, with one-quarter
of the dogs diagnosed with mast cell tumors, another quarter diagnosed with mammary tumors, and the others diagnosed with lymphoma,
squamous cell carcinoma and other types of tumors. The dogs were treated with Paccal Vet for at least three cycles and up to five
cycles, with each treatment cycle consisting of separate infusions approximately 21 days apart. The majority of dogs were treated
with 150 mg/m
2
, which was the dose of Paccal Vet used in subsequent studies. We used data from this study to receive
conditional approval in mammary carcinoma and squamous cell carcinoma from the FDA.
Paccal Vet in Mast Cell Tumors in Dogs
The safety and efficacy of Paclical for the
treatment of grade II or III mast cell tumors in dogs that cannot be safely removed surgically were evaluated in a randomized,
masked, controlled, multinational 14-week clinical field study. The objective was to demonstrate clinical superiority of Paccal
Vet compared to active control lomustine, an oral chemotherapeutic commonly used for dogs. Efficacy was evaluated by the portion
of dogs with a confirmed overall response, defined as complete response or partial response, 14 weeks after four consecutive three-week
treatment cycles.
Paccal Vet in Mammary Carcinoma
We received conditional approval for mammary
carcinoma indication from the FDA in February 2014. This approval was based on safety data for Paccal Vet and the limited efficacy
data for the indication.
Efficacy data relating to mammary carcinoma
were obtained from the study with Paccal Vet on malignant high-grade solid tumors. In that study, seven dogs with mammary carcinoma
were treated, four of which responded to treatment (one complete response and three partial responses). Furthermore, two of the
seven dogs survived over a year after the treatment was completed. In addition to the dogs from the previous study, literature
data on three dogs previously treated at University of Wisconsin was added, for a total of 10 cases of mammary carcinoma, of which
six responded.
Paccal Vet in Squamous Cell Carcinoma
We also received conditional approval for
squamous cell carcinoma indication for Paccal Vet from the FDA in February 2014. This approval was likewise based on safety data
for Paccal Vet and limited efficacy data for the indication.
The study of Paccal Vet in malignant high-grade
solid tumors included only three cases of squamous cell carcinoma, and as this was not enough to show reasonable expectation of
efficacy, we conducted a small, exploratory study in dogs with this indication. In this study, 14 dogs with various types of squamous
cell carcinoma were treated with Paccal Vet for four cycles. Two of the dogs responded to treatment and another two dogs had prolonged
stable disease, which, according to the protocol, was considered a response to treatment. A dog with squamous cell carcinoma had
also been treated in a compassionate use program in the U.S., and this dog was also included in the efficacy analysis, which consisted
of a total of 18 dogs, with six dogs showing BORR and two dogs having prolonged periods of stable disease.
Paccal Vet Single-Arm Trial in Mast
Cell Tumors in Dogs
We conducted a single-arm, open-label, multi-center,
clinical trial to determine the efficacy and safety of Paccal Vet in client-owned dogs with grade II or III mast cell tumors.
Mast cell tumors are graded histologically from I to III: grade I tumors are benign and local, curable with surgery alone; grade
II tumors are intermediate and approximately 25% of these metastasize; and grade III tumors are advanced with high metastatic
potential and short overall survival despite aggressive treatment.
Dogs that received at least one dose of treatment
(29 dogs) were included in the analysis of safety, and 28 of those dogs had tumor measurements and were included in an efficacy
analysis. The dogs were administered an intravenous dose of 150 mg/m
2
of Paccal Vet once every 21 days for three cycles.
Clinical safety was assessed by clinicopathological analyses and recording of adverse events. Following the end of the study,
the owners were contacted to provide information used to assess progression free survival.
BORR at any time during treatment was seen
in 54% of dogs whereas complete or partial response was observed in 31% of dogs at the end of the study. It took an average of
247 days from the start of the treatment until the cancer reappeared in the dog. Adverse events were reductions in the number
of two types of white blood cells, neutrophils and leucophils. These events, which are common with chemotherapy, were short lasting
and seen only sub-clinically (i.e. the dogs did not display any evidence of fever or other symptoms, other than in the blood sample
analyses).
The difference between this study and the
one including 249 dogs called Paccal Vet in Mast Cell Tumors in Dogs is the response rate, BORR. In this study including 29 dogs
the BORR is assessed at any time during the treatment period. In the study including 249 dogs the BORR was assessed after 4 treatment
cycles.
Paccal Vet Planned Clinical Studies
We will perform a dose characterization study
in order to ascertain a lower dose of Paccal Vet. We have applied for MUMS-designation in several indications and are expecting
a positive opinion from FDA in at least one indication, which will be the target for the next clinical program. It is our intension
to start the dose characterization study before the end of the calendar year 2017.
When the results from the dose characterization
study are available we will discuss the updated clinical program for Paccal Vet with the FDA and EMA. A dose confirmation study
will commence immediately after these discussions.
Paclical & Paccal Vet Preclinical
Data including data in healthy dogs
We conducted a comprehensive program of preclinical
testing of Paclical, including several
in vitro
and
in vivo
studies. Key findings from our preclinical program include:
|
•
|
In
vitro
studies in ten different human tumor cell lines showed that the cytotoxic activity
of Paclical was somewhat more effective than Taxol in the more sensitive cell lines whereas
the activity of Taxol was more active in three of the six investigated resistant cell
lines. A comparison of the cytotoxicity of Paclical and Taxol was also made in vivo in
rats. The tumor density of living tumor cells five days after drug administration, showed
no difference between the two paclitaxel formulations but there was a considerably lower
cell survival than that of placebo treated rats.
|
|
•
|
In
a comparative pharmacokinetic study of paclitaxel in rats receiving either Taxol or Paclical,
higher concentrations of total paclitaxel were observed after dosing with Taxol compared
to dosing with the same dose of Paclical. However, when studying the unbound concentrations,
no obvious difference between the two formulations could be seen.
|
|
•
|
The
hematological toxicity of Paclical was studied in rats and found to be similar to Taxol
in terms of extent and duration. A strong rebound in the white blood cell count followed
the initial decrease, and at days 16 to 17 following a single dose, the white blood cell
counts were stabilized at the baseline level. Since efficacy and hematological toxicity
were similar in rats being dosed with identical doses of Paclical and Taxol, it would
appear as the unbound drug is the determinant factor of efficacy and safety of paclitaxel.
|
|
•
|
Repeat
dose toxicity studies were performed in rats. The mortality rate at 10 mg/kg
Taxol was high and the dose in the 10 mg/kg group was reduced to 5 mg/kg. All
animals that received 10 mg/kg of Paclical survived.
|
|
•
|
In
a repeat dose toxicity study in healthy dogs (n=21) the pharmacokinetic profile of Paclical
was evaluated. Following a 30 minute intravenous infusion of 100-150 mg/m2 of paclitaxel
(Paclical), the distribution of paclitaxel into the tissue was rapid and the distribution
phase ended within one hour after the start of infusion.
|
|
•
|
The
toxicity profile of Paclical in dogs has been shown to be consistent with the pharmacological
action i.e. bone marrow suppression being the most apparent toxicity. Gastrointestinal
disorders such as diarrhea and vomiting have also been commonly observed. None of the
severe hypersensitivity reactions that has been reported in dogs with Cremophor EL based
vehicles were observed with Paclical.
|
|
•
|
Toxicity
investigations conducted with the excipient XR17 showed increases in liver enzymes, bile
acids and total bilirubin as well as the presence of pigmented Kupffer cells at high
doses. The exposure in dogs was 8.3- and 12-fold at doses of 75 and 108 mg/kg, respectively
compared to the mean AUC following a clinical dose of 166 mg/m
2
in humans. No
histological findings of significance were observed in low dose animals. Major toxic
reactions were not seen until doses reached almost five times higher than the doses given
to Paclical patients.
|
Docecal
Overview
Docecal is our patented formulation of docetaxel,
the active ingredient in Taxotere, a widely used chemotherapeutic medication that generated annual worldwide sales of more than
$2.8 billion in 2010, when its patent expired. Taxotere contains the solvent polysorbate 80, which is potentially linked to adverse
side effects such as acute hypersensitivity and edema. To minimize these effects, patients typically undergo premedication with
steroids. Like Paclical, Docecal is free of toxic solvents. We believe Docecal may be able to deliver equal, or potentially greater,
amounts of docetaxel as Taxotere without the effects of polysorbate 80 and, if approved, compete with Taxotere and generic versions
thereof. Since there are no human clinical studies in the U.S. we are not required to file an IND.
Docecal Preclinical Studies
The anti-proliferative effects of Docecal
were investigated in a panel of six human cancer cell lines and compared with the effects of commercially available Taxotere using
a standard cell proliferation assay. For all of the tested cell-lines, Docecal was as effective as Taxotere in inhibiting cell
growth.
Rats were injected with Docecal once weekly
for 28 days with doses of 4.2 mg/kg or 6.0 mg/kg or with Taxotere 4.2 mg/kg. The Docecal group showed Docecal-related signs such
as erythema, paleness, wounds on the tails, limpness and local skin reactions seen as dry skin with scale formations in both sexes
following both treatments. The effects were most pronounced in the 6 mg/kg group. Changes in hematology, clinical chemistry, organ
mass, macroscopic and microscopic findings were seen in both sexes. In the absence of any histological examination in the Docecal
4.2 mg/kg group, the significance of these differences cannot be assessed.
A no-observed-adverse-effect level, or the
highest exposure of docetaxel having no adverse effect, was not established in this study with Docecal. However, we believe that
the failure to establish a no-observed-adverse-effect level has not hindered the approval process for other APIs used in the treatment
of cancer and will not hinder the Docecal approval process.
Docecal Clinical Studies
Docecal is an XR17 based formulation of docetaxel
intended for treatment of metastatic breastcancer. A clinical phase I pharmacokinetic study and a phase II safety and tolerance
study are ongoing. The pharmacokinetic phase I study, comparing Docecal with Taxotere is ongoing in three countries and the recruitment
of patients started in September 2016. The safety and tolerance study is a randomized trial also comparing Docecal and Taxotere
started recruitment of patients in March 2016 and has approval to be run in three countries.
If successful, we plan to discuss the results
and a proposed clinical development plan with both the EMA and the FDA.
We enrolled the first patient in a study in
March 2016 to assess the need for pre-medication and possibly to fulfill the requirements of the Russian authorities in order
to obtain market authorization in Russia and the CIS.
Doxophos Vet
Doxophos Vet Overview
Doxophos Vet is a patented formulation of
doxorubicin, one of the most effective and commonly used chemotherapeutic agents for the treatment of cancer, which we are developing
for the treatment of lymphoma in dogs. Lymphoma is the most common cancer in dogs, and the FDA have granted MUMS designation for
Doxophos Vet for lymphoma. We completed a dose-finding study in the fourth quarter of 2014 and the results were obtained in June
of 2015. The INAD number for Doxophos Vet is 011910, which we requested on March 10, 2010.
Doxophos Vet Clinical Trials
Upon determining the dose in the dose ranging
study, a proof of concept study in dogs with lymphoma was started during the first quarter of 2015, which as a result of the MUMS
designation, may enable us to apply for a conditional approval. The aim of the study is to assess the response rate in dogs with
lymphoma, but also to monitor progression to estimate progression free survival.
A large field study with Doxophos Vet is needed
to obtain full approval, and this study is planned to start following completion of the proof of concept study and discussions
with FDA and EMA.
Doxophos Vet Preclinical Data including
data from healthy dogs
|
·
|
A
preclinical study using six human cancer cell lines was conducted in rats where the activity
Doxophos was compared to standard doxorubicin. Doxophos was as effective in inhibiting
cell growth as standard doxorubicin in all of the tested cell lines and had a comparable
pharmacokinetic profile in rats.
|
|
·
|
The
tissue distribution of doxorubicin was compared following a single intravenous injection
of Doxophos or standard doxorubicin in mice. There were no major differences between
the two formulations indicating that existing toxicity data from the literature for doxorubicin
also would be applicable for Doxophos. At 30 min following administration, the organs
that showed the highest radioactivity was the kidney and liver followed by the spleen.
At 6 h the highest level was found in the faeces and high levels were found in the kidney
medulla and spleen.
|
|
·
|
Repeat
dose toxicity in rats showed that the incidence and severity of the clinical effects
were similar in the Doxophos and standard doxorubicin exposed rats (6 mg/kg) and less
frequent or less severe in rats receiving the lower dose of Doxophos (4 mg/kg). Expected
changes were observed in most hematology parameters and were similar for Doxophos and
standard doxorubicin treated rats.
|
|
·
|
Rats
treated with standard doxorubicin had a higher incidence of fluid-filled abdomens (ascites),
which could be a sign of (right sided) heart failure. However, histopathological examination
failed to show any differences between the two treatments and a lower cardiotoxicity
potential of Doxophos compared to standard doxorubicin was thus not seen in this study.
|
|
·
|
A
dose-finding study in healthy dogs was conducted where the maximum tolerated dose was
determined to 35 mg/m
2
.
|
|
·
|
A
pivotal target animal safety study in dogs with intravenous dosing of Doxophos Vet at
25, 30 and 35 mg/m
2
(4 dogs per sex and dose group), showed dose-dependent
toxicities known to be associated with doxorubicin namely; cardiotoxicity, gastrointestinal
toxicity, bone marrow suppression, whisker loss etc.
|
Doxophos
Doxophos Overview
Doxophos is a proprietary formulation of doxorubicin.
Despite the efficacy of doxorubicin, significant cardiovascular toxicity, including irreversible cardiomyopathy, has been observed
and the cumulative dose should not exceed 550 mg/m
2
. We have filed a MAA in Russia for Doxophos as a hybrid/improved
generic.
Doxophos Market
The two leading doxorubicin-based products
are Adriamycin and Doxil, or Caelyx when marketed outside of the U.S. Doxil is a lipid, or fat, encapsulation of doxorubicin introduced
as a replacement for Adriamycin.
OAS-19
OAS-19 Overview
Historically, chemotherapeutic agents were
used as single agents. However, combination therapies have become standard treatment for a number of cancers, such as ovarian
cancer, first line breast cancer, prostate cancer and lung cancer. OAS-19 is an XR17 based combination of two widely-used chemotherapy
drugs in a single micelle. OAS-19 applies a dual chemotherapeutic agent encapsulation and release mechanism in one infusion and
may provide us with a new platform for further product candidate development. Since there are no human clinical studies in the
U.S. we are not required to file an IND.
OAS-19 Preclinical Studies
Male and female rats received four intravenous
administrations of OAS-19, one week apart, at the doses of 0 (micelle excipient only), 4.2, 6 and 8.5 mg/kg/week. Mortality was
noted in highly-dosed males only, while effects on food consumption and body weight gain were observed at all doses and in both
genders, with a dose-dependent relationship. Treatment-related changes were noted almost at all doses, albeit without a clear
dose-dependent relationship, in organs/tissues of the hemolymphoietic, gastrointestinal, urinary, genital, musculoskeletal, nervous
and integumentary systems. The toxic effects observed in target organs were those expected to occur after administration of the
underlying agents included in OAS-19.
Under the applied conditions, 6 mg/kg was
considered the maximum tolerated dose, while the lowest observed adverse effect level (LOAEL) was the lowest tested dose of 4.2
mg/kg/week.
The dose to be used in humans will be established
in the first clinical trial, but it is estimated that 6 mg/kg corresponds to six to eight times the human dose.
OAS-19 Planned Studies
We plan to develop a clinical program for
this product candidate.
Market Overview
Our initial development efforts are focused
on the fields of human and veterinary oncology. We believe that our XR17 technology can be applied to address commercially attractive
opportunities in these two markets based on the limitations of existing therapies.
Human Oncology Market Opportunity
Cancer is a serious, widespread and growing
disease. According to the World Health Organization (“WHO”), approximately 8.8 million people died of cancer in 2015,
and it is expected to rise by 70% over the next two decades.
Despite the development and introduction of
new drugs to treat cancer, chemotherapeutic agents, used in combination with other treatments such as surgery or radiation, remain
the primary treatment of cancer worldwide. Chemotherapeutic agents generally work by blocking cell division, thereby inhibiting
the reproduction of cancer cells and suppressing tumor growth. Many new drugs that have obtained marketing approval for the treatment
of cancer are used in combination with chemotherapeutic agents. In addition, many drug candidates in development across the industry,
like most chemotherapeutics, are not water soluble and will require innovative formulations to enable intravenous use. We believe
that the widespread use of chemotherapeutic agents worldwide and the potential use of our formulation technology with new drug
candidates present a large commercial opportunity.
Animal Health Market Opportunity
The U.S. is the single largest pet market,
with 78 million pet dogs and 86 million pet cats, according to the American Pet Products Association (“APPA”) 2015
- 2016 National Pet Owners Survey. According to The European Pet Food Industry Federation 2014 Facts & Figures, there are
approximately 63 million pet dogs and 72 million pet cats in the EU.
Dogs in particular are receiving increased
amounts of veterinary care. According to APPA, approximately 78% of dog owners in the U.S. treated their dogs with medications
in 2010, as compared to 50% in 1998. The increased spending is largely due to a changing attitude of owners toward their pets,
as they increasingly view pets as family members. Accordingly, owners are willing to seek quality medical care for their pets.
While the actual number of dogs in need of chemotherapy that actually received such treatment is unknown, one study estimated
the number of dogs receiving cancer treatment in 2008 in the United States to be over one million, and that the average age of
the dog when cancer is detected is eight years. Also, in Sweden pet insurance is becoming more widespread. It is estimated that
eighty to ninety percent of dogs are covered by medical insurance, and approximately eighty percent of such insurance policies
includes coverage for chemotherapy. The approximate life expectancy of dogs that do not receive treatment could be one to two
months after the diagnosis, whereas for a dog that is treated with chemotherapy it could be one year from the diagnosis. It should
be noted that this is an example since it is impossible to generalize the life expectancy since it depends on for instance the
type of tumor and treatment.
Due to the limited number of registered available
oncology treatments for companion animals, we believe that there is a significant commercial opportunity to apply our formulation
technology within veterinary oncology. According to the Center for Cancer Research and CanineCancer.com, approximately six million
dogs in the U.S. are diagnosed with cancer each year, of which approximately one third have cutaneous, or skin, cancers. Current
treatments consist largely of surgery, chemotherapy, and radiation therapy. For dogs in need of chemotherapy, the standard of
care has largely been the off-label use of injectable human chemotherapeutic agents such as cisplatin, doxorubicin, carboplatin,
and vincristine. Due to the fact that existing injectable chemotherapeutic agents have been formulated for humans and have not
been optimized for animals, combined with broad acceptance of their anti-cancer effect, we believe that our intravenous chemotherapy
labeled specifically for use in dogs will be viewed favorably by the veterinary community.
Based on the attributes of XR17, we believe
that there is a significant commercial opportunity to apply our proprietary formulation technology within veterinary oncology
to enable the safe delivery of well-established chemotherapeutics, approved for the first time specifically for animal use.
Competition
Our industry is highly competitive and subject
to rapid and significant technological change. While we have significant development experience and scientific knowledge, we may
face competition from both large and small pharmaceutical and biotechnology companies, including specialty pharmaceutical and
veterinary pharmaceutical companies and generic drug companies, as well as academic institutions, government agencies and research
institutions, among others.
Our competition will be determined in part
by the potential indications for which our products are developed and ultimately approved by regulatory authorities. It is likely
that the timing of market introductions of some of our potential products or our competitors’ products will be an important
competitive factor. Accordingly, the speed with which we can develop our compounds, conduct preclinical studies and clinical trials
to obtain approval and manufacture or obtain supplies of commercial quantities of any approved products should also be important
competitive factors. We expect that competition among products approved for sale will be based on additional factors, such as
product efficacy, safety, reliability, availability, price and patent position.
Human Health
We believe that Paclical will compete, directly
or indirectly, with Bristol-Myers Squibb’s Taxol and its generic equivalents, Celgene’s Abraxane and other cancer
therapies, including alternative formulations of paclitaxel, or other chemotherapeutic agents, that have been or are being developed
by other pharmaceutical and biotechnology companies.
Animal Health
We expect that Paccal Vet will face competition
from Palladia, made by Zoetis, Inc. We expect that Doxophos Vet will face limited competition from Tactress® and Blantress®,
made by Aratana Therapeutics, Inc., and that both Paccal Vet and Doxophos Vet will compete with the off-label use of chemotherapeutic
drugs for humans.
Since the development and commercialization
of new veterinary medicines is highly competitive, we expect considerable competition from major pharmaceutical, biotechnology
and specialty animal health companies. We are also aware of several smaller early stage companies that are developing products
for use in the pet therapeutics market.
Strategic Alliances and Collaborations
We have entered into four separate agreements
with established pharmaceutical companies for our products. Each agreement provides the pharmaceutical company with an exclusive
right in a defined geographic territory to market one or more products in all indications. In return, we receive royalty payments
or a profit participation, as well as milestone payments, and we retain the exclusive right with respect to the manufacture and
supply of the product during the commercial life of the product. The various agreements generally are terminable upon a material
breach or insolvency of either of the parties. Under all of the agreements, we supply the products at an agreed upon formula related
to our production cost (subject to annual adjustment) and the pharmaceutical company establishes the price at which the products
are sold in the territory.
Nippon Zenyaku Kogyo, Japan
We entered into a development, supply and
exclusive license agreement with Nippon Zenyaku Kogyo, Co. Ltd. (“Nippon”) in April 2010 (the “Nippon Agreement”).
The Nippon Agreement grants Nippon the exclusive right to market Paccal Vet in Japan. The initial term of the Nippon Agreement
is the later to occur of (i) 10 years from the date of the Nippon Agreement, or (ii) upon the expiration of the patent rights
granted under the Nippon Agreement. Nippon is solely responsible for all sales and marketing costs as well as the requisite clinical
trials in order to obtain marketing approval for Paccal Vet in Japan.
We receive royalties of (i) 27% of Nippon’s
gross profits for net sales up to $7.5 million and (ii) 36% of Nippon’s gross profits for net sales above $7.5 million.
The Nippon Agreement also includes various milestone payments, the first of which, €0.55 million, we received upon entering
into the Nippon Agreement. The remaining milestone payments are payable upon our achieving certain marketing approvals and net
sales thresholds, including €0.7 million upon marketing authorization, €1.0 million when annual net sales reach $7.5
million and €1.0 million when annual net sales reach $12.5 million. We may be required to repay the first milestone payment
if marketing approval cannot be obtained or if we are guilty of a breach of contract that results in the termination of the Nippon
Agreement or the withdrawal of the product from the market. We may also be liable to compensate Nippon for costs incurred in relation
to obtaining marketing approval.
We are responsible to Nippon for maintaining
the quality of the product, but Nippon is solely responsible for pharmacovigilance. The Nippon Agreement may be terminated by
either party if the other party commits a material breach or becomes insolvent. In the event that the Nippon Agreement is terminated,
regardless of which party terminates the agreement and the grounds for termination, the marketing approval, if received in Japan,
will be transferred to us.
Medison Pharma, Israel
We entered into a supply and exclusive license
agreement with Medison Pharma, Ltd. (“Medison”) in May 2011 (the “Medison Agreement”). The Medison Agreement
grants Medison exclusive license and distribution rights for Paclical in Israel and Turkey. The initial term of the Medison Agreement
is (i) ten years from the first commercial sale of Paclical in Israel or Turkey, or (ii) the expiration of our patent rights granted
under the Medison Agreement, whichever occurs later. The Medison Agreement provides that Medison will use its commercially reasonable
best efforts to launch Paclical in Israel and Turkey within six months of Paclical obtaining marketing authorization, and will
assume sole responsibility for sales and marketing costs. We are responsible under the Medison Agreement for obtaining marketing
approval for Paclical in Israel and Turkey, while Medison is responsible for obtaining reimbursement approval.
Medison has agreed to purchase specified,
minimum quantities of Paclical once all approvals have been obtained. Should the minimum purchase requirements not be met, we
have the right to terminate exclusivity. We receive royalties of (i) 25% of Medison’s net sales for net sales up to €7.5
million and (ii) 30% of Medison’s net sales for net sales above €7.5 million. The Medison Agreement also includes milestone
payments, the first of which, €0.2 million, we received upon entering into the Medison Agreement, and the second of which,
€0.2 million, we are entitled to receive upon the grant of marketing authorization by the European Commission.
We are responsible under the Medison Agreement
to maintain the quality of the product, but Medison is solely responsible for pharmacovigilance. The Medison Agreement may be
terminated by us if Medison fails to launch Paclical in Israel and Turkey within six months of Paclical obtaining marketing authorization.
The Medison Agreement may also be terminated by either party if the other party fails to remedy a material breach or becomes insolvent.
Pharmasyntez, Russia
We entered into a supply and exclusive marketing,
sales and distribution agreement with the Russian pharmaceutical company Pharmasyntez in February 2013 (the “Pharmasyntez
Agreement”). The agreement was valid as per the date of this report, April 30, 2017, however in June 2017, Oasmia entered
into a new exclusive marketing and distribution agreement with Hetero Group concerning Russia and the CIS countries (including
Ukraine, Georgia and Turkmenistan). The Hetero agreement replaced the previous agreement with Pharmasyntez and has similar terms
and conditions.
Hetero Group, Russia and CIS
We entered into a supply and exclusive marketing,
sales and distribution agreement with the Indian generic pharmaceutical company Hetero Labs LTD in June 2017 (the “Hetero
Agreement”) which is substainsally similar to the Pharmasyntez Agreement which was replaced with the Hetero Agreement. The
Hetero Agreement grants Hetero exclusive license and distribution rights for Paclical in Russia and the CIS, as well as Ukraine,
Georgia and Turkmenistan. The initial term of the Hetero Agreement expires five (5) years, with an opportunity to agree on a two
(2) years prolongation twelve (12) months before expiration. Hetero will have sole responsibility under the Hetero Agreement for
sales and marketing costs in Russia and the CIS. We are responsible for obtaining registration approval in Russia, including performing
any clinical research required to market Paclical. The agreement also contains an option for Hetero Group that the products Doxophos
and Docecal shall be encompassed by the agreement. Hetero Group is responsible for the costs of marketing approval and sales.
Hetero has agreed to purchase specified minimum
quantities of Paclical, and should the minimum purchase requirements not be met, we have the right to terminate exclusivity. The
Hetero Agreement contains rights to milestone payments for Oasmia in the amount of maximum USD 300,000 and Oasmia also has the
right to a certain share of the net profit from sales made under the Agreement. The Company is also responsible for ensuring that
the product meets the agreed quality level and pharmacovigilance.
The Hetero Agreement provides that all profits
from the sale of Paclical in Russia and the CIS be split evenly between us and Hetero. The Hetero Agreement defines profits as
net sales minus (i) our supply price (which are our production costs, subject to annual adjustment) and (ii) Hetero’s distribution
costs. We are liable to Hetero for maintaining the quality of the product and for pharmacovigilance.
The Hetero Agreement may be terminated by
either party if the other party commits a material breach, becomes insolvent or files for bankruptcy. In the event the Hetero
Agreement is terminated, regardless the reason thereof and regardless of which party terminates the agreement and the grounds
for termination, the marketing approvals obtained in any of the marketing areas shall be transferred to us.
Sales- and marketing approval was obtained
in Russia in April 2015. The first shipment of products to the previous license and distributor Pharmasyntez was delivered at
the end of the same year. Paclical was entered into the Russian reimbursement system in January 2016. Russia is divided into more
than 50 hospital regions. Purchases of pharmaceuticals in the Russian hospital regions are carried out through tender offers annually
or on half-year basis depending on the region.
Acquisition of KB9520 from Karo Pharma
In November 2016, the Company acquired the
substance KB9520 from Karo Pharma for SEK 25 million. The purchase price was paid with 3,080,000 newly issued shares at a price
of approximately SEK 8.12 per share. According to the acquisition agreement, in addition to the purchase price, the Company shall
pay a future royalty payment of 20 per cent of all of Oasmia’s future revenue generated from the product.
Intellectual Property
Our success depends in significant part on
our ability to protect the proprietary nature of XR17, our product and product candidates, technology and know-how, to operate
without infringing on the proprietary rights of others, and to prevent others from infringing on our proprietary rights. We have
sought, and plan to continue to seek, patent protection in the U.S., the EU and other countries for our proprietary technologies.
Our intellectual property portfolio consists of our trademark-protected product Paccal Vet and our product candidates Paclical,
Docecal, Doxophos Vet, and Doxophos. All of these drugs are based on our excipient model developed with nanotechnology and are
protected by patents in all countries which we consider to be the U.S., we already have 12 issued patents with one further pending
patent application under active prosecution. All of our patents are part of one or more of eleven different patent families. A
patent family is a collection of patents and patent applications, regional and national, which cover an invention or a group of
related inventions.
See below for information regarding the patent
families currently used in our product and product candidates.
Patent
families
|
|
Products
patent family
applies to
|
|
Status
(US)
|
|
Status
(EU)
|
|
Status
(Japan)
|
|
Status
(Israel)
|
|
Status
(Eurasia)
|
|
Expiration
date
|
Taxol containing compositions
|
|
Paccal Vet, Paclical
|
|
Granted
|
|
Granted
|
|
Granted
|
|
—
|
|
—
|
|
2022
|
Anticancer compositions
|
|
Paccal Vet, Paclical, Docecal, Doxophos
|
|
Granted
|
|
Granted
|
|
—
|
|
—
|
|
—
|
|
2022
|
Water insoluble
|
|
Paccal Vet, Paclical, Docecal
|
|
Granted
|
|
Pending
|
|
Granted
|
|
—
|
|
Granted
|
|
2028
|
Water soluble
|
|
Doxophos Vet, Doxophos
|
|
Granted
|
|
Pending
|
|
Granted
|
|
—
|
|
Granted
|
|
2028
|
Tax-Dox-Mix
|
|
OAS-19
|
|
Granted
|
|
Pending
|
|
Granted
|
|
—
|
|
Granted
|
|
2028
|
Our strategy for intellectual property rights
is intended to protect our core technologies and their application. Our protection for intellectual property rights is continually
surveyed and is currently considered to be satisfactory. We are to a large extent dependent on our patents.
The term of individual patents depends upon
the countries in which they are obtained. In most countries in which we have filed, the patent term is 20 years from the date
of filing. In the U.S., a patent’s term may be lengthened by patent term adjustment, which compensates a patentee for administrative
delays by the U.S. Patent & Trademark Office (“PTO”) in granting a patent, or shortened if a patent is terminally
disclaimed over another patent.
The term of a patent that covers an FDA-approved
drug may also be eligible for extension, which permits term restoration as compensation for the time period lost during the FDA
regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman
Act, permit an extension of up to five years beyond the expiration of the patent. See “— Regulatory.” The
length of the patent term extension is related to the length of time the drug is under regulatory review. Extensions cannot extend
the remaining term of a patent beyond 14 years from the date of product approval and only one patent applicable to an approved
drug may be extended. Similar provisions to extend the term of a patent that covers an approved drug are available in Europe and
other non-U.S. jurisdictions. In the future, if and when our pharmaceutical product candidates receive FDA approval, we may apply
for extensions on patents covering those products.
To protect our rights to any of our issued
patents and proprietary information, we may need to litigate against infringing third parties, avail ourselves of the courts or
participate in hearings to determine the scope and validity of those patents or other proprietary rights. For a more comprehensive
summary of the risks related to our intellectual property, see “Risk Factors — Risks Related to Our Intellectual
Property.”
We require our employees, consultants, outside
scientific collaborators, researchers and other advisors to execute confidentiality agreements upon the commencement of employment
or consulting relationships with us. In addition, our employment agreements with all of our employees expressly grant us the exclusive
rights to any inventions or other patentable material they produce in connection with their employment with us. Swedish law provides
that (i) we own the exclusive intellectual property rights to any inventions or other patentable material produced by any of our
research and development employees in connection with their employment, and (ii) we own non-exclusive rights to use any inventions
or other patentable material produced by any of our other employees in connection with their employment, along with a right of
first refusal if the employee were to attempt to sell exclusive rights to the invention or other patentable material. Accordingly,
if an employee were to seek to enforce a claim to any of our patents, we would either own the exclusive rights in the patent already
or have the right to purchase such rights from the employee. We also rely on trademarks, trade secrets, know-how and continuing
innovation to develop our competitive position. In addition, we have a number of domain names registered, including oasmia.se
and oasmia.com.
Manufacturing and Supplies
We are responsible for the manufacture and
supply of our products for commercial and clinical trial purposes. On December 3, 2013, we announced that we have successfully
passed an FDA Pre-Approval Inspection of our manufacturing facility in Uppsala, Sweden. We have entered into agreements with contract
manufacturers, to help us meet the anticipated demand for our products and XR17 excipient.
On May 14, 2014, the Swedish Medicinal Products
Agency had approved Oasmia’s production facility concerning manufacture for sales of human pharmaceuticals in the EU. Oasmia
has previously a GMP license for veterinary pharmaceuticals. Thus, Oasmia presently has a fully approved production facility for
manufacture of cytostatics for the EU market.
Baxter Oncology GmbH
We entered into a non-exclusive commercial
manufacturing and supply agreement with Baxter Oncology GmbH (“Baxter Oncology”) in February 2011 (the “Baxter
Agreement”) which we expect to utilize as manufacturing requirements increase. The Baxter Agreement provides that Baxter
Oncology will be responsible for the production of Paccal Vet and Paclical once the commercial demand reaches a requisite level.
Baxter will perform complete analytical testing and release of semi-finished product. Final labeling, packaging and product release
for the market will be performed by Oasmia. The Baxter Agreement was expanded in June 2014 to enable inclusion of other product
candidates from our product portfolio. The Baxter Agreement’s initial term is for five years, with automatic one-year renewals.
The Baxter Agreement may be terminated by
either party if the other party commits a material breach or becomes insolvent.
Syntagon
We entered into a non-exclusive manufacturing
agreement with Syntagon AB (“Syntagon”) in August 2013 (the “Syntagon Agreement”). The Syntagon Agreement
provides that Syntagon will undertake process development and production for the manufacturing of technical batches of XR17. The
manufacturing will be performed with certain process adaptations due to the increased scale. Syntagon may not sub-contract any
activities it is to perform pursuant to the Syntagon Agreement without our prior written approval. Syntagon indemnifies us against
any liability, claim, lawsuit or judgment that we incur due to any defective product or any other breach of the agreement by Syntagon.
The Syntagon Agreement’s initial term
is until December 31, 2018, with automatic one-year renewals. The Syntagon Agreement may be terminated by either party if the
other party fails to cure a breach or becomes insolvent.
Raw Materials
Our most important raw materials are two different
types of retinoic acids, 13 Cis Retinoid Acid and AllTrans Retinoid Acid, and a third compound known as L-Cysteic acid methyl
ester. Both of the retinoic acids are commercially available from numerous suppliers that meet our demands for quality and documentation.
Sigma-Aldrich Production GmbH manufactures L-Cysteic acid methyl ester specifically for us. Prices for the raw materials have
not been affected thus far by any political, environmental, or economic crises.
Commercialization
Human Oncology
We entered into a supply and exclusive marketing,
sales and distribution agreement with the Indian generic pharmaceutical company Hetero in June 2017 (the “Hetero Agreement”).
The Hetero Agreement granted Hetero exclusive license and distribution rights for Paclical in Russia and the CIS, as well as Ukraine,
Georgia and Turkmenistan We may retain some rights to commercialize our product candidates in the U.S. or the EU, if we receive
marketing approval for our product candidates in markets which we believe it is possible to access through a focused, specialized
field force. Outside of the U.S. and Europe, we expect to enter into distribution and other marketing arrangements with third
parties for any of our product candidates that receive marketing approval.
Subject to receiving marketing approvals,
we expect to commence commercialization activities by either entering into regional or global license and commercialization agreements,
or by directly commercializing Paclical ourselves using a targeted sales force to identify key cancer centers to support the launch
of the product. These activities could form the basis of a sales and marketing organization that we will use to market our other
products as they may receive marketing approval.
We have entered into a collaboration agreement
with Medison for the distribution of Paclical in Israel and Turkey.
Veterinary Oncology
We have entered into commercialization agreements
with Nippon Zenyaku Kogyu, granting commercial rights to Paccal Vet and Paclical in Japan. We believe that the value of our veterinary
oncology candidates will be enhanced by having at least one large commercial partner, given the nature of the animal health market
and the broad distribution of veterinarians, as well as the fact that there are only a limited number of experienced sales professionals
available, and we have limited experience in developing a sales force.
Facilities
Our office is located in Uppsala, Sweden,
where we lease and occupy six floors of a seven-floor building that encompasses approximately 43,000 square feet. Each floor is
leased separately. The lease for the second floor expires on December 31, 2018, for the fifth floor expires March 31, 2020 and
the leases for the remaining floors expire on December 31, 2019. The leases can be terminated by either party with nine months’
notice, and any leases that are not terminated are automatically extended for an additional term of three years. The building
currently contains our entire business, including our research, laboratory and cGMP production facilities, as well as our administrative
offices. We also have storage premises in Fyrislund, Uppsala with a lease period until January 31, 2021 and December 31, 2023
respectively. We believe that our facilities are sufficient to meet our current needs.
Legal Proceedings
We are not a party to any material legal proceedings.
Government Regulation
Clinical trials, the pharmaceutical approval
process, and the marketing of pharmaceutical products, both for animals and for humans, is intensively regulated in the U.S. and
in all major foreign countries.
Human Health Product Regulation in the
U.S.
In the U.S., the FDA regulates pharmaceuticals
under the Federal Food, Drug, and Cosmetic Act (“FDCA”) and related regulations. Pharmaceuticals are also subject
to other federal, state, and local statutes and regulations. Failure to comply with applicable U.S. regulatory requirements at
any time during the product development process, approval process or after approval may subject an applicant to administrative
or judicial sanctions. These sanctions could include the imposition by the FDA of an Institutional Review Board (“IRB”),
a clinical hold on trials, a refusal to approve pending applications or supplements, withdrawal of an approval, warning letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties
or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.
The FDA and comparable regulatory agencies
in state and local jurisdictions impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical
products. These agencies and other federal, state and local entities regulate research and development activities and the testing,
manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping, approval, advertising and
promotion of our human and animal health products.
The FDA’s policies may change and additional
government regulations may be enacted that could prevent or delay regulatory approval of Paclical or our other future human health
product candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature or extent
of adverse governmental regulation that might arise from future legislative or administrative action, either in the U.S. or elsewhere.
Marketing Approval
The process required by the FDA before human
health care pharmaceuticals may be marketed in the U.S. generally involves the following:
|
•
|
nonclinical
laboratory and animal tests;
|
|
•
|
submission
of an IND application which must become effective before clinical trials may begin;
|
|
•
|
adequate
and well-controlled human clinical trials to establish the safety and efficacy of the
proposed drug for its intended use or uses;
|
|
•
|
pre-approval
inspection of manufacturing facilities and clinical trial sites; and
|
|
•
|
FDA
approval of an NDA, which must occur before a drug can be marketed or sold.
|
We will need to successfully complete extensive
additional clinical trials in order to be in a position to submit an NDA to the FDA. We must reach agreement with the FDA on the
proposed protocols for our future clinical trials in the U.S. A separate submission to the FDA must be made for each successive
clinical trial to be conducted during product development. Further, an independent IRB for each site proposing to conduct the
clinical trial must review and approve the plan for any clinical trial before it commences at that site, and an informed consent
must also be obtained from each study subject. Regulatory authorities, a data safety monitoring board or the sponsor, may suspend
or terminate a clinical trial at any time on numerous grounds.
Our objective is to conduct additional clinical
trials for Paclical and, if those trials are successful, seek marketing approval from the FDA and other worldwide regulatory bodies.
To achieve this objective, we have completed a Phase III clinical trial of Paclical for the treatment of ovarian cancer, and,
are compiling the data from it. If it is successful, we expect to file for marketing approval first in the EU and then in the
U.S. We plan to follow this process also with respect to the other indications that we discuss in this annual report, such as
metastatic breast cancer.
For purposes of NDA approval for human health
products, human clinical trials are typically conducted in phases that may overlap.
|
•
|
Phase
I.
The drug is initially introduced into healthy human subjects and tested
for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In
the case of some products for severe or life-threatening diseases, especially when the
product may be too inherently toxic to ethically administer to healthy volunteers, the
initial human testing is often conducted in patients.
|
|
•
|
Phase
II.
This phase involves trials in a limited subject population to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of
the product for specific targeted diseases and to determine dosage tolerance and optimal
dosage. Phase II studies may be sub-categorized to Phase IIa studies which are smaller,
pilot studies to evaluate limited drug exposure and efficacy signals, and Phase IIb studies
which are larger studies testing more rigorously both safety and efficacy.
|
|
•
|
Phase
III.
This phase involves trials undertaken to further evaluate dosage,
clinical efficacy and safety in an expanded subject population, often at geographically
dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit
ratio of the product and provide an adequate basis for product labeling.
|
All of these trials must be conducted in accordance
with Good Clinical Practice (“GCP”) requirements in order for the data to be considered reliable for regulatory purposes.
New Drug Applications
In order to obtain approval to market a pharmaceutical
in the U.S., a marketing application must be submitted to the FDA that provides data establishing to the FDA’s satisfaction
the safety and effectiveness of the investigational drug for the proposed indication. Each NDA submission requires a substantial
user fee payment unless a waiver or exemption applies (such as with the Orphan Drug Designation discussed below). The NDA submission
fee currently exceeds $1,958,000, and the manufacturer and/or sponsor under an approved NDA are also subject to annual product
and establishment user fees, currently exceeding $98,000 per product and $526,000 per establishment. These fees are typically
increased annually. The NDA includes all relevant data available from pertinent non-clinical studies and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s
chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials
intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies
initiated by investigators.
The FDA will initially review the NDA for
completeness before it accepts it for filing. The FDA has 60 days from its receipt of an NDA to determine whether the application
will be accepted for filing based on the agency’s threshold determination that the application is sufficiently complete
to permit substantive review. After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other
things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured
in accordance with cGMP to assure and preserve the product’s identity, strength, quality and purity. The FDA may refer applications
for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application
should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but
it considers such recommendations carefully when making decisions.
Based on pivotal Phase III trial results submitted
in an NDA, upon the request of an applicant, the FDA may grant a Priority Review designation to a product, which sets the target
date for FDA action on the application at six to eight months, rather than the standard ten to twelve months. The FDA can extend
these reviews by three months. Priority review is given where preliminary estimates indicate that a product, if approved, has
the potential to provide a significant improvement compared to marketed products or offers a therapy where no satisfactory alternative
therapy exists. Priority Review designation does not change the scientific/medical standard for approval or the quality of evidence
necessary to support approval.
After the FDA completes its initial review
of an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter
to communicate that the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional
clinical, nonclinical or manufacturing data that must be received before the application can be approved, with no implication
regarding the ultimate approvability of the application.
Before approving an NDA, the FDA will inspect
the facilities at which the product is manufactured, even if such facilities are located overseas. The FDA will not approve the
product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications.
Additionally, before approving an NDA, the
FDA may inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that any of the application, manufacturing
process or manufacturing facilities is not acceptable, it typically will outline the deficiencies and often will request additional
testing or information. This may significantly delay further review of the application. If the FDA finds that a clinical site
did not conduct the clinical trial in accordance with GCP, the FDA may determine that if the data generated by the clinical site
should be excluded from the primary efficacy analyses provided in the NDA. Additionally, notwithstanding the submission of any
requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval.
The testing and approval process for a drug
requires substantial time, effort and financial resources, and this process may take several years to complete. Data obtained
from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit
or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or
unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing
our products.
The FDA may require, or companies may pursue,
additional clinical trials after a product is approved. These so-called Phase IV studies may be made a condition to be satisfied
for continuing drug approval. The results of Phase IV studies can confirm the effectiveness of a product candidate and can provide
important safety information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market
studies to specifically address safety issues identified by the agency.
Any approvals that we may ultimately receive
could be withdrawn if required post-marketing trials or analyses do not meet the FDA requirements, which could materially harm
the commercial prospects for Paclical or Paccal Vet.
The FDA also has authority to require a Risk
Evaluation and Mitigation Strategy (“REMS”) from manufacturers to ensure that the benefits of a drug or biological
product outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is
determined as part of the review of the NDA. Based on statutory standards, elements of a REMS may include “dear doctor letters,”
a medication guide, more elaborate targeted educational programs, and in some cases restrictions on distribution. These elements
are negotiated as part of the NDA approval, and in some cases if consensus is not obtained until after the Prescription Drug User
Fee Act review cycle, the approval date may be delayed. Once adopted, REMS are subject to periodic assessment and modification.
Even if a product candidate receives regulatory
approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant
limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans,
restrictions on distribution, or post-marketing study requirements. Further, even after regulatory approval is obtained, later
discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal
of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval for Paclical, or obtaining approval
but for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental regulations
may arise from future U.S. or foreign governmental action.
Section 505(b)(2) New Drug Applications
Most drug products obtain FDA marketing approval
pursuant to an NDA or an Abbreviated New Drug Application (“ANDA,” described below under “— The Drug
Price Competition and Patent Term Restoration Act — Orange Book Listing”). A third alternative is a special
type of NDA, commonly referred to as a Section 505(b)(2) NDA, which enables the applicant to rely, in part, on the FDA’s
previous approval of a similar product, or published literature, in support of its application.
Section 505(b)(2) NDAs often provide an alternate
path to FDA approval for new or improved formulations or new uses of previously approved products. Section 505(b)(2) permits the
filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant
and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance
on the FDA’s previous approval is scientifically appropriate, it may eliminate the need to conduct certain preclinical or
clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support
the change from the approved product. The FDA may then approve the new product candidate for all or some of the label indications
for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.
To the extent that the Section 505(b)(2) applicant
is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any
patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval
of a Section 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any
non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the
referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until
the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2)
applicant.
Disclosure of Clinical Trial Information
Sponsors of clinical trials of certain FDA-regulated
products, including prescription drugs, are required to register and disclose certain clinical trial information on a public website
maintained by the U.S. National Institutes of Health. Though we are not required to register, since our studies are outside of
the U.S., we do so voluntarily. Information related to the product, patient population, phase of investigation, study sites and
investigator, and other aspects of the clinical trial is made public as part of the registration. Sponsors are also obligated
to disclose the results of these trials after completion. Disclosure of the results of these trials can be delayed until the product
or new indication being studied has been approved. Competitors may use this publicly-available information to gain knowledge regarding
the design and progress of our development programs.
Orphan Drug Designation
Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease
or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the U.S. and for which
there is no reasonable expectation that the cost of developing and making a drug or biological product available in the U.S. for
this type of disease or condition will be recovered from sales of the product. Orphan Drug Designation is intended to assist and
encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to providing
a seven year term of market exclusivity upon final FDA approval, Orphan Drug Designation also positions a company to be able to
leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver
of expensive FDA user fees for the potential submission of an NDA, and certain tax credits. Orphan product designation must be
requested before submitting an NDA. After the FDA grants orphan product designation, the identity of the therapeutic agent and
its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten
the duration of the regulatory review and approval process.
If a product that has orphan designation subsequently
receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan
product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product
for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan
product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has
exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains
approval of the same drug or biological product as defined by the FDA or if our drug or biological candidate is determined to
be contained within the competitor’s product for the same indication or disease. If a drug or biological product designated
as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to
orphan product exclusivity. Orphan drug status in the EU has similar but not identical benefits in the EU.
We have been granted Orphan Drug Designation
for Paclical for the treatment of epithelial ovarian cancer in the U.S. and have received orphan drug status in the EU.
The Drug Price Competition and Patent Term
Restoration Act
The Drug Price Competition and Patent Term
Restoration Act, also known as the Hatch-Waxman Act, requires pharmaceutical companies to divulge certain information regarding
their products which have the effect of making it easier for other companies to manufacture generic drugs to compete with those
products.
Orange Book Listing.
In
seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant’s
product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA’s
Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange
Book can, in turn, be cited by potential generic competitors in support of approval of an ANDA. An ANDA provides for marketing
of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown
through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence
testing, ANDA applicants are not required to conduct, or submit results of pre-clinical or clinical tests to prove the safety
or effectiveness of their drug product. Drugs approved in this way are commonly referred to as “generic equivalents”
to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.
The ANDA applicant is required to certify
to the FDA any patents listed for the approved product in the FDA’s Orange Book. Specifically, the applicant must certify
that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has
not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is
invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement, certifying
that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use, rather than certify
to a listed method-of-use patent.
If the applicant does not challenge the listed
patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.
A certification that the new product will
not infringe on the already approved product’s listed patents, or that such patents are invalid, is called a Paragraph IV
certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice
of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA
and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification.
The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents
the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision
in the infringement case that is favorable to the ANDA applicant.
The ANDA application also will not be approved
until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.
Exclusivity.
Upon NDA approval
of a New Chemical Entity (“NCE”), which is a drug that contains no active moiety that has been approved by the FDA
in any other NDA, that drug receives five years of marketing exclusivity during which time the FDA cannot receive any ANDA seeking
approval of a generic version of that drug. Certain changes to a drug, such as the addition of a new indication to the package
insert, are associated with a three-year period of exclusivity during which the FDA cannot approval an ANDA for a generic drug
that includes the change.
An ANDA may be submitted one year before NCE
exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be
a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period.
Patent Term Extension.
After
NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension
is calculated as half of the drug’s testing phase — the time between IND submission and NDA submission — and
all of the review phase — the time between NDA submission and approval up to a maximum of five years. The time
can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after
the extension may not exceed 14 years.
For patents that might expire during the application
phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one
year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced
by one year. The director of the PTO must determine that approval of the drug covered by the patent for which a patent extension
is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.
Environmental Regulations.
The
U.S. generally requires an environmental assessment, which discusses a company’s proposed action, possible alternatives
to the action, and whether the further analysis of an environmental impact statement is necessary. Certain exemptions are available
from the requirement to perform an environmental assessment and an environmental impact statement. Once an exemption is claimed,
a company must state to the FDA that no extraordinary circumstances exist that may significantly affect the environment. We will
claim an exemption, under the category for biologic products, from the requirement to provide an environmental assessment and
an environmental impact statement for Paclical, and will furthermore state to the FDA that to our knowledge, no extraordinary
circumstances exist that may significantly affect the environment.
FDA Post-Approval Requirements
Following the approval of an NDA, the FDA
continues to require adverse event reporting and submission of periodic reports. The FDA also may require post-marketing testing,
known as Phase IV testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions
on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging,
and labeling procedures must continue to conform to cGMP after approval. Drug manufacturers and certain of their subcontractors
are required to register their establishments with FDA and certain state agencies. Registration with the FDA subjects entities
to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance
with cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control
to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company
fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized
problems are subsequently discovered.
Patient Protection and Affordable Health
Care Act
In March 2010, the Patient Protection and
Affordable Health Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, “PPACA”),
was enacted, which includes measures that have or will significantly change the way health care is financed by both governmental
and private insurers. The fees, discounts and other provisions of this law are expected to have a significant negative effect
on the profitability of pharmaceuticals.
Many of the details regarding the implementation
of PPACA are yet to be determined, and at this time, it remains unclear the full effect that PPACA would have on our business.
Human Health Product Regulation in the
European Union
In addition to regulations in the U.S., we
are and will be subject, either directly or through our distribution partners, to a variety of regulations in other jurisdictions
governing, among other things, clinical trials and any commercial sales and distribution of our products, if approved.
Whether or not we obtain FDA approval for
a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencement
of clinical trials or marketing of the product in those countries. Certain countries outside of the U.S. have a process that requires
the submission of a clinical trial application prior to the commencement of human clinical trials. In Europe, for example, a Clinical
Trial Application (“CTA”) must be submitted to the competent national health authority and to independent ethics committees
in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country’s
requirements, clinical trial development may proceed in that country.
The requirements and process governing the
conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, even though there is already
some degree of legal harmonization in the EU Member States resulting from the national implementation of underlying EU legislation.
In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory requirements.
To obtain regulatory approval of an investigational
drug under EU regulatory systems, we must submit a marketing authorization application. This application is similar to the NDA
in the U.S., with the exception of, among other things, country-specific document requirements. Drugs can be authorized in the
EU by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the decentralized procedure
or (iv) national authorization procedures.
The EMA implemented the centralized procedure
for the approval of human drugs to facilitate marketing authorizations that are valid throughout the EU. This procedure results
in a single marketing authorization granted by the European Commission that is valid across the EU, as well as in Iceland, Liechtenstein
and Norway (the “European Community”). The centralized procedure is compulsory for human drugs that are: (i) derived
from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of
certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and
viral diseases, (iii) officially designated orphan drugs, and (iv) advanced-therapy medicines, such as gene-therapy, somatic cell-therapy
or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used for human drugs which
do not fall within the above mentioned categories if the human drug (a) contains a new active substance which, on the date of
entry into force of Regulation (EC) No. 726/2004, was not authorized in the European Community; or (b) the applicant shows that
the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization
in the centralized procedure is in the interests of patients or animal health at European Community level.
Under the centralized procedure in the EU,
the maximum timeframe for the evaluation of a MAA by the EMA is 210 days, though the date count stops whenever the Committee for
Medicinal Products for Human Use (“CHMP”) asks the applicant for additional written or oral information, with adoption
of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation might be granted by the CHMP
in exceptional cases, as when a medicinal product is expected to be of a major public health interest from the point of view of
therapeutic innovation, defined by three cumulative criteria: (i) the seriousness of the disease to be treated; (ii) the absence
of an appropriate alternative therapeutic approach; and (iii) anticipation of exceptional high therapeutic benefit. In this circumstance,
EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter. We
submitted an application for marketing authorization for Paclical in the first half of 2016.
The Mutual Recognition Procedure (“MRP”),
for the approval of human drugs is an alternative approach to facilitate individual national marketing authorizations within the
EU. Basically, the MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is applicable
to the majority of conventional medicinal products, and is based on the principle of recognition of an already existing national
marketing authorization by one or more Member States.
The characteristic of the MRP is that the
procedure builds on an already existing marketing authorization in a Member State of the EU that is used as reference in order
to obtain marketing authorizations in other EU Member States. In the MRP, a marketing authorization for a drug already exists
in one or more Member States of the EU and subsequently marketing authorization applications are made in other EU Member States
by referring to the initial marketing authorization. The Member State in which the marketing authorization was first granted will
then act as the reference Member State. The Member States where the marketing authorization is subsequently applied for act as
concerned Member States.
The MRP is based on the principle of the mutual
recognition by EU Member States of their respective national marketing authorizations. Based on a marketing authorization in the
reference Member State, the applicant may apply for marketing authorizations in other Member States. In such case, the reference
Member State shall update its existing assessment report about the drug in 90 days. After the assessment is completed, copies
of the report are sent to all Member States, together with the approved summary of product characteristics, labeling and package
leaflet. The concerned Member States then have 90 days to recognize the decision of the reference Member State and the summary
of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after
acknowledgement of the agreement.
Should any Member State refuse to recognize
the marketing authorization by the reference Member State, on the grounds of potential serious risk to public health, the issue
will be referred to a coordination group. Within a timeframe of 60 days, Member States shall, within the coordination group, make
all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The
opinion of this EMA Committee is then forwarded to the Commission, for the start of the decision making process. As in the centralized
procedure, this process entails consulting various European Commission Directorates General and the Standing Committee on Human
Medicinal Products or Veterinary Medicinal Products, as appropriate.
Human Health Product Regulation in the
Rest of World
For other countries outside of the EU, such
as countries in Eastern Europe or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing
and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP
and the other applicable regulatory requirements. We have submitted an application for marketing approval for Paclical in Russia,
and received Russian approval on April 20, 2015. We will also initiate a Phase III clinical trial of Docecal for the treatment
of metastatic breast cancer, and, if it is successful, expect to file for marketing approval in Russia in 2018.
If we fail to comply with applicable foreign
regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal
of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
Animal Health Product Regulation in
the U.S.
Three federal regulatory agencies regulate
the health aspects of animal health products in the U.S.: the FDA, the United States Department of Agriculture (the “USDA”)
and the Environmental Protection Agency (the “EPA”).
The CVM regulates animal pharmaceuticals under
the Food, Drug and Cosmetics Act. The USDA Center for Veterinary Biologics regulates veterinary vaccines and some biologics pursuant
to the Virus, Serum, Toxin Act. The EPA regulates veterinary pesticides under the Federal Insecticide, Fungicide and Rodenticide
Act. Many topical products used for treatment of flea and tick infestations are regulated by the EPA.
Our product and all of our current animal
health product candidates are animal pharmaceuticals regulated by the CVM. Manufacturers of animal health pharmaceuticals, including
us, must show their products to be safe, effective and produced by a consistent method of manufacture. The CVM’s basis for
approving a drug application is documented in a Freedom of Information Summary. We will be required to conduct post-approval monitoring
of products and to submit reports of product quality defects, adverse events or unexpected results to the CVM’s Surveillance
and Compliance group.
To begin the development process for our products
in the U.S., we will establish an INAD file with the CVM. We will then hold a pre-development meeting with the CVM to reach a
general agreement on the plans for providing the data necessary to fulfill requirements for a New Animal Drug Application (“NADA”).
During development, we will submit pivotal protocols to the CVM for review and concurrence prior to conducting the required studies.
We will gather and submit data on manufacturing, safety and effectiveness to the CVM for review, and this review will be conducted
according to timelines specified in the Animal Drug User Fee Act. Once all data have been submitted and reviewed for each technical
section — safety, effectiveness and CMC — the CVM will issue to us a technical section complete
letter as each section review is completed, and when all three letters have been issued, we will compile the Freedom of Information
Summary, the proposed labeling, and all other relevant information, and submit these as an administrative NADA for CVM review.
Generally, if there are no deficiencies in the submission, the NADA will be issued within four to six months after the submission
of the administrative NADA. After approval, we will be required to collect reports of any adverse events and submit them to the
CVM on a regular basis.
Animal Health Product Regulation in
the European Union
The EMA regulates the scientific evaluation
of medicines developed by pharmaceutical companies for use in the EU. Its veterinary review section is distinct from the review
section for human pharmaceuticals mentioned previously. The Committee for Medicinal Products for Veterinary Use (the “CVMP”),
is responsible for scientific review of the submissions for animal pharmaceuticals and vaccines but the EMA makes the final decision
on the approval of products. Once a centralized marketing authorization is granted by the EMA, it is valid in all EU and European
Economic Area-European Free Trade Association states. In general, the requirements for regulatory approval of an animal health
product in the EU are similar to those in the U.S., requiring demonstrated evidence of purity, safety, efficacy and consistency
of manufacturing processes.
The EMA is responsible for coordinating scientific
evaluation of applications for marketing approval for pet therapeutics in the EU. To perform these evaluations the EMA established
a specific scientific committee called the CVMP, which considers applications submitted by companies for the marketing approval
of individual pet therapeutics and evaluates whether or not the medicines meet the necessary quality, safety and efficacy requirements.
Assessments conducted by the CVMP are based on scientific criteria and are intended to ensure that pet therapeutics reaching the
marketplace have a positive benefit-risk balance in favor of the pet population for which they are intended. Based on the CVMP’s
recommendation, a centralized marketing authorization is granted by the EMA, which allows the product to be marketed in any of
the EU states. The CVMP is also responsible for various post-authorization and maintenance activities, including the assessment
of modifications or extensions to an existing marketing authorization.
To obtain authorization from the EMA, we must
submit a marketing authorization application called a dossier. The dossier is the EMA’s equivalent of the FDA’s NADA
and includes data from studies showing the quality, safety and efficacy of the product. The CVMP reviews and evaluates the dossier.
For any dossier, a rapporteur and co-rapporteur are appointed from the members of the CVMP. Their role is to lead the scientific
evaluation and prepare the assessment report. The rapporteur can utilize experts to assist it in performing its assessment. The
report is critiqued by the co-rapporteur and other members of the CVMP before the CVMP makes its determination. The final opinion
of the CVMP is generally given within 210 days of the submission of a dossier.
Animal Health Product Regulation in
the Rest of World
Each other country has its own regulatory
requirements for approving and marketing veterinary pharmaceuticals. Many country specific regulatory laws contain provisions
that include requirements for labeling, safety, efficacy and manufacturers’ quality control procedures to assure the consistency
of the products, as well as company records and reports. With the exception of the EU, the regulatory agencies of most other countries
generally refer to the FDA, USDA, EMA, and other international animal health entities, including the World Organization for Animal
Health and the Codex Alimentarius Commission, in establishing standards and regulations for veterinary pharmaceuticals and vaccines.
Requirements for Approval of Veterinary
Pharmaceuticals for Pets
As a condition to regulatory approval for
sale of animal products, regulatory agencies worldwide require that a product used for pets is demonstrated to be:
|
•
|
be
safe for the intended use in the intended species;
|
|
•
|
have
substantial evidence of effectiveness for the intended use;
|
|
•
|
have
a defined manufacturing process that ensures that the product can be made with high quality
consistency; and
|
|
•
|
be
safe for humans handling the product and for the environment.
|
Safe for the intended use.
To
determine that a new veterinary drug is safe for use, regulatory bodies will require us to provide data from a safety study generated
in laboratory dogs and cats tested at doses higher than the intended label dose, over a period of time determined by the intended
length of dosing of the product. In the case of the CVM, the design and review of the safety study and the study protocol are
completed prior to initiation of the study to help assure that the data generated will meet FDA requirements. These studies are
conducted under rigorous quality control, including Good Laboratory Practice, to assure integrity of the data. They are designed
to clearly define a safety margin, identify any potential safety concerns, and establish a safe dose for the product. This dose
and effectiveness is then evaluated in the pivotal field effectiveness study where the product is studied in the animal patient
population in which the product is intended to be used. Field safety data, obtained in a variety of breeds and animals kept under
various conditions, are evaluated to assure that the product will be safe in the target population. Safety studies are governed
by regulations and regulatory pronouncements that provide the parameters of required safety studies and are utilized by regulatory
bodies in the U.S., the EU and Japan.
Effectiveness for the intended use.
Early pilot studies may be done in laboratory dogs or cats to establish effectiveness and the dose range for each
product. Data on how well the drug is absorbed when dosed by different routes and the relationship of the dose to the effectiveness
are studied. When an effective dose is established, a study protocol to test the product in real world conditions is developed
prior to beginning the study. In the case of the CVM, the pivotal effectiveness field study protocol is submitted for review and
concurrence prior to study initiation, to help assure that the data generated will meet requirements.
The pivotal field effectiveness study must
be conducted with the formulation of the product that is intended to be commercialized, and is a multi-site, randomized, controlled
study, generally with a placebo control. To reduce bias in the study, the individuals conducting the assessment are not told which
group is the test group and which is the placebo group. In both the U.S. and the EU, the number of patients enrolled in the pivotal
field effectiveness studies is required to be at least 100 animal subjects treated with the test product and a comparable number
of subjects in the control group that receive the placebo. In many cases, a pivotal field study may be designed with clinical
sites in both the EU and the U.S., and this single study may satisfy regulatory requirements in both the EU and the U.S.
Defined Manufacturing Process.
To
assure that the product can be manufactured consistently, regulatory agencies will require us to provide documentation of the
process by which the API is made and the controls applicable to that process that assure the API and the formulation of the final
commercial product meet certain criteria, including purity and stability. The drug development process is known as Chemistry,
Manufacturing and Controls (“CMC”). After a product is approved, we will be required to communicate with the regulatory
bodies any changes in the procedures or manufacturing site. Both API and commercial formulations are required to be manufactured
at facilities that practice cGMP.
Safe for Humans and the Environment.
Certain exemptions are available from the requirement to provide an environmental impact statement for animal health
products. Similar to the process for human health products, once an exemption is claimed, a company must state to the FDA that
no extraordinary circumstances exist that may significantly affect the environment. We have claimed an exemption, under the category
for drugs intended for nonfood animals, from the requirement to provide an environmental impact statement for Paccal Vet, and
have stated to the FDA that to our knowledge, no extraordinary circumstances exist that may significantly affect the human environment.
The FDA agrees with us that the proposed uses of our drug fall within the claimed categorical exemption and it is not aware of
any extraordinary circumstances. Thus, in the U.S. we are not required to perform either an environmental assessment or an environmental
impact statement. For approval in the EU, a risk assessment for potential human exposure will be required.
Labeling, All Other Information, and Freedom
of Information Summary.
We also will be required to submit the intended label for the product, and also any information
regarding additional research that has been conducted with the drug, to the CVM and other regulatory bodies for review. We will
draft, and submit for regulatory review, the Freedom of Information Summary for use in the U.S. This summary outlines the studies
and provides substantial information that CVM uses to assess the drug’s safety and effectiveness and then publishes on its
website.
C. Organizational Structure
As per April 30, 2017, the Group consists
of the parent company Oasmia Pharmaceutical AB and the subsidiaries Oasmia Incentive AB
*)
, Qdoxx Pharma AB, Oasmia
Pharmaceutical, Inc. and Oasmia Pharmaceutical Asia Pacific Limited.
Subsidiaries
|
|
Country of
incorporation
|
|
Ownership
|
|
|
Votes
|
|
Qdoxx Pharma AB
|
|
Sweden
|
|
|
100
|
%
|
|
|
100
|
%
|
Oasmia Incentive AB
*)
|
|
Sweden
|
|
|
100
|
%
|
|
|
100
|
%
|
Oasmia Pharmaceutical, Inc.
|
|
USA
|
|
|
100
|
%
|
|
|
100
|
%
|
Oasmia Pharmaceutical Asia Pacific Limited
|
|
Hongkong
|
|
|
100
|
%
|
|
|
100
|
%
|
*)
company named changed from earlier Oasmia Animal
Health AB
D. Property, Plant and Equipment
See "—B.
Business Overview—Facilities" for a description of our leased premises. Our equipment includes computers, office equipment,
furniture and manufacturing equipment with a net book value at April 30, 2017 and 2016 of SEK 18,368 thousand
and SEK 21,172 thousand, respectively. Our manufacturing equipment is owned by the Company and placed in Uppsala and in
Germany for the use by a Company vendor who provides contract manufacturing services to the Company. The net book value of our
manufacturing equipment at April 30, 2017 was SEK 15,776 thousand compared to SEK 18,144 thousand at April 30, 2016. None of our
research and manufacturing equipment is leased and there are no liens or encumbrances on our equipment.
We currently do not
have any material commitments to acquire tangible fixed assets; however, it is possible that we may need to acquire additional
manufacturing equipment in the near-term. It is uncertain at this time what, if any, additional manufacturing equipment we may
need to acquire. The timing and amount of any manufacturing equipment purchases we make in the future will be determined based
on the terms and conditions and Company needs.
ITEM 4A. UNRESOLVED STAFF COMMENTS
Not applicable
ITEM 5. OPERATING AND FINACIAL REVIEW AND PROSPECTS
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the related notes
and other financial information included elsewhere in this annual report. Some of the information contained in this discussion
and analysis or set forth elsewhere in this annual report, including information with respect to our plans and strategy for our
business, includes forward-looking statements that involve risks and uncertainties. You should review the “Risk Factors”
section of this annual report for a discussion of important factors that could cause our actual results to differ materially from
the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
A . Operating Results Overview
Overview
We
are a pharmaceutical company focused on innovative treatments within human and animal oncology. Our product and product candidates
utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered
active pharmaceutical ingredients, without the addition of toxic solvents. We believe our formulation may result in improved safety,
efficacy and ease of administration over existing drugs. Our initial development and commercialization efforts are focused on
creating novel formulations of well-established chemotherapeutic drugs that can be used for the treatment of cancer in both humans
and companion animals. We have five human oncology product candidates in pre-clinical and/or clinical development, and two veterinary
oncology product candidates. In October 2016, Oasmia acquired a cancer project from Karo Pharma with promising results in pre-clinical
models for a number of different types of cancer. We disclosed positive Overall Survival results from Phase III study of or lead
human product for treatment of ovarian cancer in the April, 2016. In February 2014, we received conditional approval by the United
States Food and Drug Administration (“FDA”) for our initial veterinary oncology product. However, this conditional
approval was withdrawn in in January 2017
in
order to investigate another dosage regimen.
Our lead products utilize paclitaxel, the
active ingredient of Taxol and Abraxane, two widely used cancer drugs marketed by Bristol-Myers Squibb and Celgene, respectively.
Based on the potential benefits of our proprietary formulation technology, we are pursuing a strategy to replace the use of existing
paclitaxel-based products in multiple cancers with our novel formulations. Our formulation is currently called Paclical for human
indications, and is marketed under the name Paccal Vet-CA1 (“Paccal Vet”) for veterinary indications. In the submission
of a marketing authorization application (MAA) to the European Medicines Agency (EMA), the name Apealea is used instead of Paclical.
We own the global commercial rights to Paclical, excluding Israel, Turkey, Russia, the Commonwealth of Independent States (“CIS”),
Ukraine, Georgia and Turkmenistan. We have licensed the commercial rights to Paccal Vet for sale in Japan, Russia and the CIS.
Paclical received marketing approval in Russia and the CIS in April 2015 and Doxophos in August 2017.
Since we do not have sales and marketing operations,
we have entered into various licensing and distribution agreements with established pharmaceutical companies to sell Paclical,
Paccal Vet, and our other product candidates. We have entered into an agreement with Hetero Group for the commercialization of
Paclical in Russia and the CIS, as well as Ukraine, Georgia and Turkmenistan, and a separate agreement with Medison Pharma for
the commercialization of Paclical in Israel and Turkey. Furthermore, we have entered into an agreement with Nippon Zenyaku Kogyo
for the commercialization of Paccal Vet in Japan.
Paccal Vet is the first injectable chemotherapeutic
agent authorized for marketing for the treatment of squamous cell carcinoma (a cancer occurring in certain cells in the skin and
the lining of other organs) and mammary carcinoma (a cancer occurring in the lining of the milk ducts of the mammary glands) in
dogs. We received conditional approval by the FDA for Paccal Vet for the treatment of mammary carcinoma and squamous cell carcinoma
under the Minor Use and Minor Species (“MUMS”) designation in the U.S. MUMS designation is a status similar to orphan
designation for human drugs, making the sponsor eligible for incentives to support the approval or conditional approval of the
designated drug, including seven years of market exclusivity in the U.S. For a description of the qualifications for Paccal Vet
to receive the MUMS designation, conditional approval and full approval for dogs, see “Business — Overview.”
We have withdrawn the conditional approval and in January 2017 and plan to investigate another dosage regimen.
From our inception through April 30, 2017,
marketing and distribution agreements have yielded net cash of SEK 87.83 million in upfront fees and milestone payments and SEK
8.0 million in royalties and sales revenue.
In addition to these partnerships, we will
eventually directly commercialize Paclical ourselves using a targeted sales strategy or find a collaboration partner depending
on our possibility to negotiate satisfactory terms for Oasmia. Currently we retain the rights to commercialize Paclical outside
of Russia, CIS, Turkey and Israel. On August 4, 2015, we announced the results of a preliminary study of a head-to-head pharmacokinetic
comparison between Paclical and Abraxane, which found that the concentration of both total an unbound paclitaxel in plasma was
similar.
We are a newly-commercial stage company with
one product for human use approved for marketing and sale, and given our recent change from development stage to commercial stage,
we have not generated any significant revenue other than milestone payments from our commercial partners. We have incurred significant
net losses since our inception on April 15, 1988. We incurred net losses of SEK 160.24 million, SEK 141.54 million and SEK 117.50
million for the fiscal years ended April 30, 2017, April 30, 2016 and April 30, 2015. These losses have resulted principally from
costs incurred in connection with research and development activities and general and administrative costs associated with our
operations. As of April 30, 2017, we had a deficit accumulated during development stage of SEK 786.85 million and cash and cash
equivalents of SEK 28.00 million. We expect to continue to incur operating losses in the near future as we continue our clinical
and preclinical development programs, apply for marketing approval for our product candidates and, subject to obtaining regulatory
approval of our product candidates, establish sales and marketing partnerships in preparation for the potential commercialization
of our product candidates.
Oasmia has one product approved in Russia,
Paclical, but this does not yet create a sufficient cash flow from its own business. For this reason, Oasmia continuously works
with various financing alternatives. This work includes that the company is in discussions with potential partners for licensing
of distribution and sales rights, negotiations with new and existing investors, financiers and lenders and that the company ensures
enough resources to secure that forecasted future revenue streams from regions where the company's products registered, are realized.
Available consolidated liquid assets and unutilized
credit facilities as of April 30, 2017 are not sufficient to provide the required capital to pursue the planned activities during
the next 12 months. In light of available financing alternatives and the recent developments in the Company, the Board of Directors
assesses that the prospects for financing of the Company´s operations in the coming year are good. Should funding not be
obtained in sufficient quantities there is a risk that the conditions for continued operation do not exist.
Other than what is disclosed in this annual
report, there are at present no significant trends known to us that are reasonably likely to have a material effect on our financial
situation.
Events after balance sheet date of April
30, 2017
As a result of reporting in the EU Clinical
Trials registry regarding the OAS- 12DOC BIO study, the Company clarified in a press release in May, 2017 that work at one of
the clinics participating in the study has been ended. This does not affect the ongoing study, which is proceeding as planned.
Oasmia held an extra general meeting on Friday,
2 June 2017 the meeting resolved to authorize the Board of Directors to decide whether to carry out a rights issue in the Company
and to issue subscription warrants in the Company.
On 8 June 2017, the Board of Directors of
Oasmia decided to replace its convertible loan 2016:2 with new debt, in the form of simple debt instruments. The total amount
of the new debt securities amounts to SEK 42 million, which corresponds to the total nominal amount of the previous convertible
loan.
*)
After
the closing date, Oasmia agreed with the holders of the 42 convertible debt instruments to replace these with non-negotiable promissory
notes
Of these 42 original convertible debt instruments, SEK 9,500,000 was later repaid during the
quarter, while the rest were replaced with non-negitionable promissory notes, totaling SEK 33,500,000. Those were added as of
July 31, 2017 at 8.5 percent interest and expire on June 30, 2018.
The term for the new debt was up to one (1)
year, however, the debt can be pre-paid by Oasmia before they fall due. Interest on the new debt accrues from June 9, 2017 at
an interest rate of 8.5% annually, and therefore, corresponds to the interest rate for the convertibles. See Item 5.A Operating
Results Overview - Events after balance sheet date of April 30, 2017)
The Company held a capital market day on June
15, 2017, at which the management presented the business and discussed, among other things, the market and strategy regarding
the Company's human and veterinary products.
The board of directors resolved upon a rights
issue of approximately SEK 163.9 million
The Company entered into a new exclusive marketing
and distribution agreement with Hetero Group concerning Russia and the CIS countries (including Ukraine, Georgia and Turkmenistan)
that replaced the previous distribution agreement with Pharmasyntez.
The subscription period for Oasmia Pharmaceutical
AB’s (“Oasmia” or the “Company”) rights issue ended on July 5, 2017. The result of the rights issue
showed that 23,517,699 shares, representing approximately 46.6 per cent of the shares offered, were subscribed for by the exercise
of subscription rights. Additionally, subscription forms corresponding to 2,073,805 shares, representing approximately 4.1 per
cent of the shares offered, have been received for subscription without preferential rights. The remaining 24,847,762 shares,
representing approximately 49.3 per cent of the shares offered, will be allotted to those who have committed to subscribe and
pay for any remaining part of the right issue, in accordance with the underwriting agreements entered into with the Company. The
issued amount in the rights issue, which accordingly was fully subscribed, amounted to in total approximately SEK 164 million
(before transaction related costs).
Through the
rights issue, Oasmia’s share capital increased by SEK 5,043,926.60 to SEK 17,653,743.20. The number of shares increased
by 50,439,266 to 176,537,432
.
The company has received marketing approval
of Doxophos in Russia, a key milestone following the recently established relationship with Hetero Group, its new marketing and
distribution partner.
Doxophos is a hybrid and novel nanoparticle
formulation of doxorubicin, one of the most commonly used anti-cancer substances in the world, well-recognized for its treatment
of lung, breast and prostate cancer, among others. Doxorubicin is the active substance in the prominent oncology family of brands
including Adriamycin® and Doxil®, totaling an estimated market value of $800 million USD in 2015 and expected
to reach $1.4 billion by 2024.
Trend information
We are currently in an early stage to commercialize
products on the market. Accordingly, any trends within the markets in which we operate are expected to have more direct impact
on our business in the event that we are successful in commercializing Paclical.
Over the past few years, there has been increasing
pressure to reduce drug prices in the developed markets as a consequence of political initiatives and regulations aiming to curb
continuous increases in healthcare spending. We expect this trend to continue in the years ahead and accordingly any revenue we
may earn in the future will likely be negatively affected by such political initiatives and regulations. However, we believe spending
in the healthcare industry, as compared to many other industries, is less linked to economic trends. Furthermore, while falling
drug prices in the mature drug markets such as the U.S. and the EU are having a negative impact on general sales growth levels
for the biopharmaceutical industry as a whole in those markets, we expect such sales growth to continue at higher levels in emerging
markets. We also expect that demographic developments, increased treatment penetration, especially in newly established drug markets,
and better diagnostic tools will result in continuing growth in overall global drug sales.
Financial Operations Overview
Net sales.
We generate
net sales pursuant to agreements with our commercial partners. These agreements generally include some of the following sources
of revenue: an initial payment, additional milestone payments dependent upon the achievement of certain clinical, regulatory or
commercial milestones, invoiced supply price for products delivered to commercial partners and royalties on product sales of licensed
products when such product sales occur. Net sales also include amounts earned from the sale of miscellaneous supplies, such as
sterile water. We recognize net sales when the amount earned can be measured in a reliable way and when we have determined it
is likely that future economic benefits will accrue to us and certain criteria have been met, which will vary based on specific
contractual arrangements. Revenue from licensing arrangements and product sales during the fiscal year ended April 30, 2017 amounted
to SEK zero, for the fiscal year ended April 30, 2016 amounted to SEK 6,077 thousand and for the fiscal year ended April 30, 2015
amounted to SEK 2,002 thousand.
Change in inventory of products in process
and finished goods
Change in inventory of products in process
and finished goods consists of the change in book value of products in process and finished goods and refers to manufacturing
of ordered products which are planned to be sold on the Russian market during the coming months.
Capitalized development cost.
Capitalized
development cost consists of expenditures for materials and services used in development of the intangible asset and employee
benefit expenses for staff engaged in developing the intangible asset. Expenditures for research and development operations are
generally expensed as they occur. Development costs which are attributable to clinical trials and registration are capitalized
to the extent that they are expected to generate future economic benefits. We have determined that the beginning of Phase III
trials is the earliest point for capitalization of development expense. This has been applied for Paccal Vet and Paclical, for
which all conditions for capitalization are fulfilled. These conditions are generally met when it is probable that expected future
economic benefits attributable to an asset will flow to us and the asset’s cost can be measured reliably. The disclosure
of the development costs in Phase III is accounted for gross, i.e. the costs are included in various operating expenses whereas
the capitalized part is disclosed on a specific line in the income statement.
Other operating income.
Other
operating income comprises revenues that are not generated in the ordinary course of business.
Operating expenses.
Operating
expenses includes four categories described below.
Raw materials, consumables and goods for
resale.
Raw materials, consumables and goods for resale consist of materials and consumables for manufacturing
of pharmaceuticals for sales, clinical trials, cost of analysis for such pharmaceuticals and handling of waste.
Other external expenses.
Other
external expenses consist mainly of external fees paid for clinical trials, fees paid for regulatory, administration and other
services such as rent of facility and cost for utilities.
Employee benefit expenses.
Employee
benefit expenses consist of salaries to employees, remuneration to board members, social security cost and other employee benefits
and expenses.
Depreciation and amortization.
Depreciation
consists of depreciation for machinery, equipment and patents. The capitalized development expense is not yet subject to amortization.
Financial income.
Financial
income consists primarily of interest earned by investing our cash reserves in short-term interest-bearing deposit accounts.
Financial expenses.
Financial
expenses consist primarily of interest expense on interest-bearing loans.
Income taxes.
As a Swedish
resident trading equity, we are subject to Swedish corporate taxation. Since we have been loss-making since inception, no corporate
taxes have been recorded.
Results of operations
Comparison of Fiscal Years Ended April
30, 2017 and April 30, 2016
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Net sales
|
|
|
172
|
|
|
|
6,373
|
|
Change in inventory of products in progress and finished goods
|
|
|
(1,405
|
)
|
|
|
9,509
|
|
Capitalized development cost
|
|
|
7,023
|
|
|
|
16,727
|
|
Other operating income
|
|
|
420
|
|
|
|
2
|
|
Operating expenses
|
|
|
(146,691
|
)
|
|
|
(165,302
|
)
|
Financial income
|
|
|
85
|
|
|
|
786
|
|
Financial expense
|
|
|
(19,847
|
)
|
|
|
(9,634
|
)
|
Income taxes
|
|
|
-
|
|
|
|
-
|
|
Income for the period
|
|
|
(160,243
|
)
|
|
|
(141,539
|
)
|
Net sales
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Net sales
|
|
|
173
|
|
|
|
6,373
|
|
Revenues from royalties and sales of products
were SEK 0 in the year ended April 30, 2017 and 6,077 in the year ended April 30, 2016.
Revenues from sales of research collaboration
amounted to SEK 200 thousand in the year ended April 30, 2016 and zero in the fiscal year ended April 30, 2017. There were revenues
from sales of water for injection amounting to SEK 172 thousand in the year ended April 30, 2017 and SEK 96 thousand in 2016.
Change in inventory of products in progress
and finished goods
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Change in inventory of products in progress and finished goods
|
|
|
(1,405
|
)
|
|
|
9,509
|
|
Change in inventory of products in progress,
amounting to SEK (1,405) thousand in the year ending April 30, 2017, derives from the production of semi-finished products that
will be included in the production of goods for sale as well as from a write-down of inventories of finished goods that were intended
for sale on the Russian market of SEK 5,324 thousand. Change in inventories of products in progress and finished goods amounted
to TSEK 9,509 in the previous financial year. The tender process in Russia has taken considerably more time than originally estimated.
This leads to obsolescence problems in the inventories produced for sale in Russia. Inventories of finished goods were therefore
written down during the financial year as described above.
Capitalized development cost
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Capitalized development cost
|
|
|
7,023
|
|
|
|
16,727
|
|
Capitalized development cost decreased by
SEK 9,704 thousand, or 58,0 %, from SEK 16.73 million in the year ended April 30, 2016 to SEK 7.02 million in the year ended April
30, 2017. In both years there were two product candidates, Paccal Vet and Paclical, subject to capitalization. For Paclical, capitalization
decreased by SEK 2.42 million, from SEK 9.98 million to SEK 7.56 million. For Paccal Vet, capitalization decreased by SEK 7.28
million from SEK 6.75 million to SEK (0.54) million in the year ending April 30, 2016. The decrease in capitalized development
costs during the financial year is primarily because the Paccal Vet study for the treatment of mammary cancer in dogs had low
activity compared to the previous year. In addition, fewer costs have been capitalized for Paclical, mainly since the study on
ovarian cancer is completed and there has therefore been less activity.
Other operating income
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Other operating income
|
|
|
420
|
|
|
|
2
|
|
For the year ended April 30, 2017, other operating
income increased to SEK 420 thousand, compared to SEK 2 thousand in the prior year. The increase was primarily related to favorable
exchange gains of SEK 202 thousand in the year ended April 30, 2017 compared to SEK 2 thousand for the year ended April 30, 2016.
Operating expenses
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Raw materials, consumables and goods for resale
|
|
|
2,984
|
|
|
|
4,733
|
|
Other external expenses
|
|
|
79,904
|
|
|
|
98,104
|
|
Employee benefit expenses
|
|
|
59,295
|
|
|
|
57,661
|
|
Depreciation, amortization and impairment
|
|
|
4,508
|
|
|
|
4,804
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
146,691
|
|
|
|
165,302
|
|
Operating expenses including depreciation
and amortization decreased by SEK 18.61 million, or 11.3%, from SEK 165.3 million to SEK 146.7 million, for the year ended April
30, 2017 compared to the financial year before.
The decrease is mainly attributable to lower
costs for clinical studies during the period. The Paclical Vet study for the treatment of mammary cancer in dogs has had lower
activity during the financial year compared to the previous year. Furthermore, the costs for production-related method development
and contract production were lower during the financial year compared to the previous year. These lower expenses are counteracted
by the bad debt loss of SEK 5,065 thousand and the write-down of SEK 5,324 thousand for inventories of finished goods that were
charged to the income statement during the financial year.
Financial income
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Financial income
|
|
|
85
|
|
|
|
786
|
|
Financial income in the year ended April 30,
2017 amounted to SEK 85 thousand, compared to SEK 786 thousand in previous year. The decrease is mainly due to decreased foreign
exchange gains related to bank balances in foreign currencies.
Financial expense
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Financial expense
|
|
|
19,847
|
|
|
|
9,634
|
|
Financial expense is primarily attributable
to interest on loans from Nexttobe AB and Convertible loans.
In December 30, 2016, Oasmia had a loan of
SEK 94.4 million from Nexttobe AB. This loan, including accrued interest of SEK 8,0 million was replaced with a new loan of SEK
102.4 million in the financial year ended April 30, 2017, which carries an interest rate of 3.5 percent and is due for payment
on September 30, 2017. Interest expense on the loan from Nexttobe amounts to SEK 6.5 million in the year ended April 30, 2017
compared to SEK 7.6 million in the year ended April 30, 2016.
At the end of the previous financial year,
in April 2016, a convertible loan comprising 28 convertible instruments was issued at a price of SEK 1,000,000 per convertible
instrument, totalling SEK 28,000 thousand. This convertible loan, which carried interest of 8.5%, fell due on April 14, 2017.
Upon maturity accrued interest of SEK 2.4 million was paid and 2 convertible instruments of SEK 1,000,000, in total SEK 2,000,000,
were repaid. The remaining convertible instruments were replaced by a new convertible loan comprising 26 convertible instruments
at a price of SEK 1,000,000 per convertible instrument, in total SEK 26,000 thousand. This convertible loan falls due for payment
on April 18, 2018, unless there is prior conversion, and carries interest of 8.5 percent. These convertible instruments can be
converted at a price of SEK 8.00 per share. Full conversion would entail the issue of 3,250,000 new shares.
In June 2016, a convertible loan comprising
42 convertible instruments was issued at a price of SEK 1,000,000 per convertible instrument. After a deduction for issue expenses
this generated TSEK 37,395 for the company. This convertible loan falls due for payment on June 9, 2017, unless there is prior
conversion, and carries interest of 8.5%. These convertible instruments can be converted at a price of SEK 12.00 per share. Full
conversion would entail the issue of 3,500,000 new shares.
On March 31, 2017, a convertible loan comprising
42 convertible instruments was issued at a price of SEK 1,000,000.60 per convertible instrument, in total TSEK 42,000. After a
deduction for issue expenses this generated TSEK 41,734 for the Company.
This convertible loan carried no interest
and was converted to 7,058,856 new shares on April 25, 2017 at a conversion price of SEK 5.95 per share. This conversion entailed
dilution of the Company’s shares of 5.6%.
Convertible loansl financial liabilities valued
at amortized cost;
Relative to a bond loan, convertible debt
instruments provide both the right to carry interest and the opportunity to receive a certain number of shares instead of repayment
of the loan. This additional benefit means that the interest rate of the convertible debt instruments is lower than the market
interest rate for an equivalent bond loan. The fair value of the benefit Oasmia received due to the lower interest rate is recorded,
after a deduction for issue expenses, directly against equity. The debt component of the convertibles, i.e. excluding the equity
component indicated above, is recorded after a deduction for issue expenses at its fair value as a liability in the balance sheet
the first time it is recorded. The interest expense is calculated thereafter according to the effective interest method and is
charged to the income statement.
Interest expense on above described convertible
loan programs amounts to SEK 6.3 million in the year ended April 30, 2017 compared to SEK 0.1 million in the year ended April
30, 2016.
Furthermore, Oasmia had a bank loan from Nordea
amounting to SEK 20 million that were repaid on December 30, 2016. Interest expense for this loan was SEK 0.1 million in the fiscal
year ending April 30, 2017 and SEK 0.4 million 2016.
Financial expenses also consist of exchange
losses related to bank balances in foreign currencies. Exchange losses from bank balances in foreign currencies decreased by SEK
1.2 million in the year ended April 30, 2017 compared to the year ended April 30, 2016.
Comparison of Fiscal Years Ended April
30, 2016 and April 30, 2015
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Net sales
|
|
|
6,373
|
|
|
|
2,070
|
|
Change in inventory of products in progress and finished goods
|
|
|
9,509
|
|
|
|
-
|
|
Capitalized development cost
|
|
|
16,727
|
|
|
|
16,797
|
|
Other operating income
|
|
|
2
|
|
|
|
221
|
|
Operating expenses
|
|
|
(165,302
|
)
|
|
|
(127,313
|
)
|
Financial income
|
|
|
786
|
|
|
|
210
|
|
Financial expense
|
|
|
(9,634
|
)
|
|
|
(9,482
|
)
|
Income taxes
|
|
|
-
|
|
|
|
-
|
|
Income for the period
|
|
|
(141,539
|
)
|
|
|
(117,497
|
)
|
Net sales
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Net sales
|
|
|
6,373
|
|
|
|
2,070
|
|
Revenues from royalties and sales of products
were SEK 6,077 thousand in the year ended April 30, 2016 and 2,002 in the year ended April 30, 2015.
Revenues from sales of research collaboration
amounted to SEK 200 thousand in the year ended April 30, 2016 and zero in the fiscal year ended April 30, 2015. There were revenues
from sales of water for injection amounting to SEK 96 thousand in the year ended April 30, 2016 and SEK 68 thousand in 2015.
Change in inventory of products in progress
and finished goods
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Change in inventory of products in progress and finished goods
|
|
|
9,509
|
|
|
|
-
|
|
Change in inventory of products in progress,
amounting to SEK 9,509 thousand in the year ending April 30, 2016, is derived from the production of goods that are intended to
be sold on the Russian market. This production has led to the building up of both raw material and consumables stocks and finished
and semi-finished products stocks.
Capitalized development cost
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Capitalized development cost
|
|
|
16,727
|
|
|
|
16,797
|
|
Capitalized development cost decreased by
SEK 70 thousand, or 0,4 %, from SEK 16.80 million in the year ended April 30, 2015 to SEK 16.73 million in the year ended April
30, 2016. In both years there were two product candidates, Paccal Vet and Paclical, subject to capitalization. For Paclical, capitalization
increased by SEK 0.79 million, from SEK 9.19 million to SEK 9.98 million. For Paccal Vet, capitalization decreased by SEK 0.86
million from SEK 7.61 million to SEK 6.75 million in the year ending April 30, 2016. The main reason for the increase in capitalization
regarding Paclical is increased regulatory expenses in connection to the application for marketing approval in the EU.
Other operating income
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Other operating income
|
|
|
2
|
|
|
|
221
|
|
For the year ended April 30, 2016, other operating
income decreased to SEK 2 thousand, compared to SEK 221 thousand in the prior financial year. The decrease was primarily related
to grants received for staff amounting to SEK 153 thousand in the prior year compared to zero for the year ended April 30, 2016.
Operating expenses
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Raw materials, consumables and goods for resale
|
|
|
4,733
|
|
|
|
10,062
|
|
Other external expenses
|
|
|
98,104
|
|
|
|
60,739
|
|
Employee benefit expenses
|
|
|
57,661
|
|
|
|
50,530
|
|
Depreciation, amortization and impairment
|
|
|
4,804
|
|
|
|
5,190
|
|
Other operating expenses
|
|
|
-
|
|
|
|
792
|
|
Total operating expenses
|
|
|
165,302
|
|
|
|
127,313
|
|
Operating expenses including depreciation
and amortization increased by SEK 37.99 million, or 29.8%, from SEK 127.3 million to SEK 165.3 million, for the year ended April
30, 2016 compared to the year before.
The increase in other external expenses is
mainly related to expenses for clinical trials initiated in the fiscal year, primarily the Docecal and XR17 studies. Furthermore
expenses for purchasing of raw materials and essentials for production in Oasmia and its contract manufacturers have increased
in order to meet the need for products both for sales and clinical trials. The increase in employee benefit expenses is mainly
due to increased payroll expenses which in turn is mainly related to strengthening of the management team and finance department
and the annual payroll assessment.
Financial income
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Financial income
|
|
|
786
|
|
|
|
210
|
|
Financial income in the year ended April 30,
2016 amounted to SEK 0.79 million, compared to SEK 0.21 million in previous year. The increase is mainly due to increased foreign
exchange gains related to bank balances in foreign currencies.
Financial expense
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Financial expense
|
|
|
9,634
|
|
|
|
9,482
|
|
Financial expense is primarily attributable
to interest on loans from Nexttobe. In December 30, 2015, the loan of SEK 87 million and accrued interest amounting to SEK 7.4
million was replaced by a new loan. The new loan amounts to SEK 94.4 million and matures December 30, 2016. Interest expenses
on the loan from Nexttobe amounts to SEK 7.6 million in the year ended April 30, 2016 compared to SEK 8.3 million in the year
ended April 30, 2015.
Furthermore, Oasmia has a bank loan from Nordea
amounting to SEK 20 million with a maturity in December 30, 2016. Interest expense for this loan was SEK 0.4 million in the fiscal
year ending April 30, 2016 and SEK 1.1 million 2015. Oasmia Pharmaceutical AB has SEK 20 million placed in a restricted interest
fund accounts as a pledge for the bank loan.
Financial expenses also consist of exchange
losses related to bank balances in foreign currencies. Exchange losses from bank balances in foreign currencies increased by SEK
1.2 million in the year ended April 30, 2016 compared to the year ended April 30, 2015.
Jumpstart Our Business Startups Act (“JOBS
Act”)
On April 5, 2012, the JOBS Act was signed
into law in the United States. The JOBS Act permits an emerging growth company such as us to take advantage of relief from certain
regulatory burdens that are otherwise generally applicable to public companies. Among the relief available is an exemption from
the auditor attestation requirement under Section 404 of the Sarbanes-Oxley Act in the assessment of an emerging growth company’s
internal control over financial reporting. We have elected to rely on this exemption and will not provide such an attestation
from our auditors. In addition, we are in the process of evaluating the benefits of relying on other exemptions and reduced reporting
requirements afforded by the JOBS Act, including the exemption from complying with any requirement that may be adopted by PCAOB
regarding mandatory audit firm rotation or requiring any supplement to the auditor’s report provide additional information
about the audit and the financial statements (auditor discussion and analysis).
We will remain an emerging growth company
until the earliest of (a) the last day of our fiscal year during which we have total annual gross revenue of at least $1.0 billion;
(b) the last day of our fiscal year following the fifth anniversary of the completion of our initial public offering; (c) the
date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (d) the
date on which we are deemed to be a “large accelerated filer” under the Exchange Act, which would occur if the market
value of our ADSs that are held by non-affiliates exceeds $700 million as of the last business day of our most recently completed
second fiscal quarter. Once we cease to be an emerging growth company, we will not be entitled to the exemptions and other relief
provided in the JOBS Act.
B. Liquidity and Capital Resources.
Sources of funds
Our primary uses of cash are to fund research
and development expenses and capital expenditures. However, since we during 2015/2016 have launched Paclical in Russia and entered
into a commercialization phase we have an increasing use of cash for production of commercial products.
In recent years, we have largely funded our
operations and growth from loans, share issuances and milestone payments from our partners and licensees. Our cash flows may fluctuate,
are difficult to forecast and will depend on many factors including:
|
•
|
the realization
of revenue from our product and product candidates, which will rely upon the timing of regulatory approvals, the marketing
efforts of our commercial partners, and the price levels achieved by our partners;
|
|
|
|
|
•
|
The need of additional
funds in a period with increasing commercial activities depending on increasing production and growing working capital;
|
|
|
|
|
•
|
the extent of success in our pre-clinical
and clinical stage research programs which will determine the amount of funding required to further the development of
our product candidates;
|
|
•
|
the outcome, timing
and cost of regulatory approvals of Paccal Vet, Paclical, Doxophos Vet and our other product candidates;
|
|
|
|
|
•
|
the timing of achievement
of the milestones receivable if Paccal Vet, Paclical, Doxophos Vet and our other product candidates are approved and launched
in the U.S. and elsewhere;
|
|
|
|
|
•
|
the extent to which
we seek to retain development rights to our pipeline of new product candidates or whether we seek to license such candidates
to a partner who will fund future research and development expenditure in return for a right to share in future commercial
revenue;
|
|
|
|
|
•
|
the terms and timing
of new strategic collaborations;
|
|
|
|
|
•
|
the number and characteristics
of the product candidates that we seek to develop;
|
|
|
|
|
•
|
the costs involved
in filing and prosecuting patent applications and enforcing and defending potential patent claims; and
|
|
|
|
|
•
|
the costs of hiring
additional skilled employees to support our continued growth.
|
Borrowing and unutilized credit facilities
On April 30, 2017 we had the following loans
and credit lines: (i) one loan from Nexttobe amounting to SEK 102.4 million, due September 30, 2017 with an fixed annual interest
rate of 3.5%, (ii) 26 convertible debt instruments of SEK 1 million each, due April 14, 2018 with an interest rate of 8.5 %, (iii)
42 convertible debt instruments of SEK 1 million each, due in June 9, 2017
*)
with an interest rate of 8.5 %, , (iv)
one unutilized SEK 5 million credit facility with Nordea with a variable interest rate upon utilization, and (v) one unutilized
credit facility of SEK 40 million with Alceco, with a fixed interest rate of 5% upon utilization.
*)
After
the closing date, Oasmia agreed with the holders of the 42 convertible debt instruments to replace these with non-negotiable promissory
notes
Of these 42 original convertible debt instruments, SEK 9 500 thousand was later repaid during
the quarter, while the rest were replaced with non-negitionable promissory notes, totaling SEK 33,500,000. Those were added as
of July 31, 2017 at 8.5 percent interest and expire on June 30, 2018.
The term for the new debt
was up to one (1) year, however, the debt can be pre-paid by Oasmia before they fall due. Interest on the new debt accrue from
9 June 2017 at an interest rate of 8.5% annually, and therefore, corresponds to the interest rate for the convertibles. See Item
5.A Operating Results Overview - Events after balance sheet date of April 30, 2017).
Available consolidated
liquid assets and unutilized credit facilities as of April 30, 2017 are not sufficient to provide the required capital to
pursue the planned activities during the next 12 months. In light of available financing alternatives and the recent
developments, new largest shareholder and new market approval for Doxophos and also the new relationship with Hetero Group,
its new marketing and distribution partner, the Board of Directors assesses that the prospects for financing of the
Company´s operations in the coming year are good. Should funding not be obtained in sufficient quantities there is a
risk that the conditions for continued operation do not exist.
Comparison of Fiscal Years Ended April
30, 2017 and April 30, 2016
Summary of cash flows
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Cash flow from operating activities
|
|
|
(133,011
|
)
|
|
|
(128,126
|
)
|
Cash flow from investing activities
|
|
|
12,039
|
|
|
|
10,066
|
|
Cash flow from financing activities
|
|
|
122,755
|
|
|
|
117,449
|
|
Cash flow from operating activities
The negative cash flow from operating activities
for the fiscal year ended April 30, 2017, SEK 133.01 million, consists of the operating income loss, SEK 140.48 million, adjusted
for depreciation and amortization, SEK 15.31 million, unfavorable changes in working capital, SEK 5.42 million, plus interest
received, SEK 0.09 million, less interest paid, SEK 2.52 million. The significant items in the changes in working capital included
a decrease in accounts payable of SEK 6.62 million, an increase in inventories of SEK 2.78 million, an increase in accounts receivable
of SEK 0.20 million, an increase in other current liabilities of SEK 7.76 million and an increase of other short term receivables
of SEK 3.58 million.
Cash flow from investing activities
For the fiscal year ended April 30, 2017,
cash flow provided in investing activities amounted to SEK 12.04 million. This amount included intangible assets of SEK 7.45 million,
which consisted of capitalized development costs of SEK 7.02 million and patents of SEK 0.42 million. Investments in tangible
assets amounted to SEK 0.52 million, which primarily related to the purchase of production equipment.
Disposal of short term investments generated
SEK 20 million in cash.
Cash flow from financing activities
For the fiscal year ended April 30, 2017,
cash flow provided by financing activities amounted to SEK 122.76 million compared to SEK 117.45 million in the previous financial
year. This amount mainly consisted of new private placement of SEK 70.0 million, issue of two convertible debt instruments totaling
SEK 84.0 million and issue expenses of SEK 9.25 million and outflow of SEK 2.0 million for repayment of convertible debt instrument.
In April 2017, a private placement of 26 convertible
debt instruments (no. 2017:2) at a price of SEK 1,000,000 and a total amount of SEK 26.0 million were directed issued, by means
of partly set-off, to current holders of convertibles (2016:1) which matured April 14
th
, 2017. Accrued interest and
repayment of SEK 2.0 million were settled by the company. The convertible debt instruments are due on April 18, 2018 if conversion
is not made before then. The loan carries an interest of 8.5 % and can be converted to a price of SEK 8.00 per share. Full conversion
would entail that 3,250,000 new share were issued.
In March 2017, a private placement of 42 convertible
debt instruments (no 2017:1) at a price of SEK 1,000,004.60 each were issued, which provided the Company with SEK 42,000,193 in
gross proceeds. After deductions for issue expenses amounting to SEK 266 thousand the share issue and issue of convertible debt
instruments provided the company in April 2017 with SEK 41,734 thousand in liquidity. The loan was interest free the conversion
price was SEK 5.95. per share. The convertible debt instruments were converted into 7,058,856 ordinary shares in Oasmia on due
date April 25, 2017.
In November 2016, the former second largest
shareholder, Nexttobe AB, extended its loan to the company. The new loan includes accrued interest for 2016 and amounts to SEK
102.4 million and replaced the loan of SEK 94.4 million. The interest for the new loan is set to 3.5 % and the loan is due September
30, 2017.
In October, 2016 a private placement was consummated
wherein 8,750,000 Ordinary Shares were issued. The issue price was SEK 8.00 per share and gross proceeds provided the Company
with SEK 70.0 million in proceeds.
In October, 2016, an offset issue of 3,080,000
Ordinary Shares were issued in order to pay a purchase of SEK 25 million pursuant to an agreement on the acquisition pf a cancer
project of Karo Pharma. The issue price was approximately SEK 8.12 per share.
In June 2016, a private placement of 42 convertible
debt instruments (no 2016:2) at a price of SEK 1,000,000 each were issued, which provided the Company with SEK 42,000 thousands
in gross proceeds. After deductions for issue expenses amounting to SEK 4,605 thousand the issue of convertible debt instruments
provided the company in June and July 2016 with SEK 37,395 thousand in liquidity. The convertible debt instruments are due on
June 9, 2017 if conversion is not made before then. The loan carries an interest of 8.5 % and can be converted to a price of SEK
12.00 per share. Full conversion would entail that 3,500,000 new share was issued.
Comparison of Fiscal Years Ended April
30, 2016 and April 30, 2015
Summary of cash flows
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Cash flow from operating activities
|
|
|
(128,126
|
)
|
|
|
(107,666
|
)
|
Cash flow from investing activities
|
|
|
10,066
|
|
|
|
(69,755
|
)
|
Cash flow from financing activities
|
|
|
117,449
|
|
|
|
156,017
|
|
Cash flow from operating activities
The negative cash flow from operating activities
for the fiscal year ended April 30, 2016, SEK 128.13 million, consists of the operating income loss, SEK 132.69 million, adjusted
for depreciation and amortization, SEK 4.81 million, positive changes in working capital, SEK 0.63 million, plus interest received,
SEK 0.79 million, less interest paid, SEK 1.66 million. The significant items in the changes in working capital included an increase
in accounts payable of SEK 13.22 million, an increase in inventories of SEK 11.30 million, an increase in accounts receivable
of SEK 4.80 million and an increase in other current liabilities of SEK 4.08 million.
Cash flow from investing activities
For the fiscal year ended April 30, 2016,
cash flow provided in investing activities amounted to SEK 10.07 million. This amount included intangible assets of SEK 17.96
million, which consisted of capitalized development costs of SEK 16.73 million and patents of SEK 1.23 million. Investments in
tangible assets amounted to SEK 1.97 million, which primarily related to the purchase of production equipment.
Disposal of short term investments generated
SEK 30 million in cash.
Cash flow from financing activities
For the fiscal year ended April 30, 2016,
cash flow provided by financing activities amounted to SEK 117.45 million. This amount mainly consisted of new share issues of
SEK 106.2 million, issue of convertible instruments of SEK 28 million and issue expenses of SEK 16.8 million.
In October, 2015 Oasmia completed a stock
listing on the Nasdaq Capital Market in New York, and a thereby conducted an Initial Public Offering, which increased the number
of Ordinary Shares by 7,684,500 and 1,280,750 Warrants were issued. Each of these Warrants can be exercised for ADSs, each of
which represents three Ordinary Shares at an exercise price of USD 4.06 per ADS, or USD 1.35 per share. For these Warrants, the
purchase price was USD 0.0025 each and the Company was provided with SEK 27 thousand. In addition, 140,352 underwriters’
warrants have been issued as partial payment to the underwriters. These warrants can each be exercised for one ordinary share
at an exercise price of USD 1.69 each. The gross issue amount was SEK 88.723 million which after deductions for issue expenses,
amounting to SEK 13.366 million provided the Company with net proceeds of SEK 75.357 million.
In April, 2016, a private placement was consummated
wherein another 1,666,666 Ordinary Shares were issued. The issue price was SEK 10.50 per share and gross proceeds provided the
Company with SEK 17.5 million in proceeds.
In connection with the above mentioned private
placement, 28 convertible debt instruments (2016:1) at a price of SEK 1,000,000 each were also issued, which provided the Company
with SEK 28,000 thousand in gross proceeds. After deductions for issue expenses amounting to SEK 3,408 thousand, the share issue
and issue of convertible debt instruments provided the company in April 2016 with SEK 42,092 thousand in liquidity. The convertible
debt instruments are due on April 14, 2017 if conversion is not made before then. The loan carries an interest of 8.5 % and can
be converted to a price of SEK 11.70 per share. Full conversion would entail that 2,393,162 new share were issued.
On October 22, 2015, Oasmia entered into an
agreement with Nexttobe whereby the Nexttobe loan will be extended through December 2016. The new loan amounts to SEK 94.4 million
and will be due December 30, 2016.
On December 5, 2013, we reported that we were
granted a new bank loan from Nordea. Since January 1, 2015, the Company has SEK 20 million placed in a blocked fixed income fund
as a pledge for the SEK 20 million bank loan. The current SEK 20 million bank loan has a maturity date of September 30, 2016.
C. Research and Development, Patents and licenses, etc.
For a description of Oasmia’s Research
and Development projects and activities please see Item 4. B.
Research and Development Expenses
Research and development expenses are incurred
for the development of new products and processes and include conducting clinical trials, development materials, payroll, including
scientists and professionals for product registration and approval, external advisors and the allotted cost of manufacturing facility
for research and development purposes. Expenditures for research and development are expensed as they occur. Development costs
attributable to clinical trials and registration are capitalized to the extent that they are expected to generate future economic
benefits. We have determined the beginning of Phase III as the earliest point for capitalization of development expense. This
has been applied to two pharmaceutical candidates, for which all conditions for capitalization are fulfilled. Funds spent on research
and development as included in the income statement lines, is disclosed below.
Comparison of Fiscal Years Ended April
30, 2017 and April 30, 2016
|
|
Year Ended April 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(in TSEK)
|
|
Raw materials, consumables
|
|
|
1,228
|
|
|
|
1,208
|
|
Other external expenses
|
|
|
50,048
|
|
|
|
68,934
|
|
Employee benefit expenses
|
|
|
43,408
|
|
|
|
39,951
|
|
Depreciation
|
|
|
3,178
|
|
|
|
3,518
|
|
Total spent on research and development activities
|
|
|
97,862
|
|
|
|
113,611
|
|
Comparison of Fiscal Years Ended April
30, 2016 and April 30, 2015
|
|
Year Ended April 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(in TSEK)
|
|
Raw materials, consumables
|
|
|
1,208
|
|
|
|
7,394
|
|
Other external expenses
|
|
|
68,934
|
|
|
|
44,487
|
|
Employee benefit expenses
|
|
|
39,951
|
|
|
|
35,019
|
|
Depreciation
|
|
|
3,518
|
|
|
|
3,925
|
|
Total spent on research and development activities
|
|
|
113,611
|
|
|
|
90,825
|
|
The reason research and development expenses
are not disclosed separately for each product candidate is that all costs cannot be allocated to each product candidate separately.
Intangible assets; Amortization and impairment
tests
Amortization of the intangible assets is carried
out on a straight-line basis over the period that the expected benefits are expected to generate earnings for the company, which
is from the date that commercial sale to final customers is commenced. This point in time frequently occurs after receiving full
approval for the indication (e.g., a cancer-type) of a product candidate in a specific market.
At the end of each fiscal year, we perform
an assessment of whether there is a need for impairment of the capitalized development cost. The impairment test on intangible
assets is based on a discounted cash flow model per cash generating unit (CGU). The CGUs are the regional markets for the two
product candidates in Phase III. We have made the judgment that there is no need for impairment since of the two pharmaceutical
candidates that are capitalized one has already received conditional approval, and approval for the other lies, according to management
estimates, within the foreseeable future. We estimate that future profits motivate the value of the assets.
The impairment tests require us to use a number
of assumptions, including market factors specific to the pharmaceutical business, potential pricing for our product and product
candidates, the amount and timing of estimated future cash flows and the time value of money. In general, cost estimates (cash
outflows) can normally be estimated with a higher degree of accuracy than revenues (cash inflows). Some specific areas of uncertainty
are described below.
We have no history on which to base our forecasts.
The cytostatic market for dogs is completely new so for this segment there is no product on which to study volumes and prices.
The cytostatic market for human use is well known but there have been substantial changes in recent years as patents have expired
and generic products have been introduced. One product whose patent has not expired is Abraxane, which is commercially available
in many countries, with a higher price than that of generic products but with notable differences in price in those countries
where it is on the market.
One further market uncertainty is that we
do not yet have distributors or licensees for our human product candidates in the majority of countries and therefore have not
received any parameters by which to estimate our net sales.
Another uncertainty is cost of goods sold.
The only experience that we have with manufacturing is with small-scale production in our plant in Uppsala. We expect that large
scale production in Uppsala and elsewhere will reduce the cost of goods sold per unit over time.
Our estimates have been calculated by the
following procedures.
Animal Health
We have access to statistics for the number
of dogs in the U.S. and the rates of cancer incidence among dogs. We cannot be certain how many dogs with cancer will be treated
so we have estimated very small numbers of sales for the first few years. We also cannot be certain what revenue can be derived
per patient. We have received estimates from Abbott Animal Health for the amounts dog owners are willing to pay for treatment,
not specifically for cytostatic but for other treatments (as there have been no cytostatic for dogs available on any market before
we received conditional approval for Paccal Vet from the FDA). Cost of goods sold has been estimated by calculating all components
at our plant and at the plants of our sub-contractor.
Human Health
We have access to figures on populations per
country, cancer incidents per year, per cancer type and per country as well as net sales and prices for existing cytostatic. We
also have access to the number of patients treated with taxanes. Of this figure we have estimated very small numbers for the first
few years. Cost of goods sold has been estimated in the same way as in animal health above.
Since until just recently we had no product
approved, we have not been able to verify any of our estimates. There have been no major changes to any of our assumptions, other
than that we have had to move back our estimate of the first year of market approval per product due to the approval processes
with the relevant authorities taking more time than we had originally anticipated.
If our products are not approved, or the probability
of their approval is diminished, capitalized expenditures will be carried as expenses. We annually evaluate whether a need for
impairment exists for all intangible assets.
D. Trend information
See “Item 5.A Operating results”
E. Off-balance Sheet Arrangements.
As of April 30, 2017, we have no off-balance
sheet arrangements that have or are reasonably likely to have current or future material effect on our financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity or capital resources.
F. Tabular disclosure of contractual obligations.
The following table summarizes our contractual
commitments and obligations as of April 30, 2017.
|
|
Payments Due by Period
|
|
|
|
Total
|
|
|
Less than
1 year
|
|
|
1 – 3
years
|
|
|
3 – 5
years
|
|
|
More
than
5 years
|
|
|
|
(in TSEK)
|
|
Operating
lease obligations
(1)
|
|
|
22,106
|
|
|
|
6,369
|
|
|
|
10,907
|
|
|
|
2,789
|
|
|
|
2,041
|
|
Purchase obligations
(2)
|
|
|
138,203
|
|
|
|
6,835
|
|
|
|
46,728
|
|
|
|
63,480
|
|
|
|
21,160
|
|
Interest Payments
|
|
|
8,471
|
|
|
|
8,471
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Short-term debt obligations
(3)
|
|
|
170,419
|
|
|
|
170,419
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Total contractual cash obligations
|
|
|
339,200
|
|
|
|
192,094
|
|
|
|
57,635
|
|
|
|
66,289
|
|
|
|
23,201
|
|
|
(1)
|
Consists of
the leasing of premises and lease of office equipment. Leasing of premises amounts to
SEK 6.2 million and lease of office equipment SEK 0.2 million in the year ending April
30, 2018. The expiration dates for the leasing contracts regarding premises are December
31, 2018, December 31, 2019, March 31, 2020, January 31, 2021 and December 31, 2023.
Leases automatically extend for an additional 1-3 years if not terminated within 6-9
months’ notice.
|
|
(2)
|
Mainly consists
of a purchase contract with obligations for Oasmia to purchase a minimum number of product
vials for each contract year.
|
|
(3)
|
Short-term
obligations include repayment of loan to Nexttobe AB of SEK 102.4 million and repayment
of convertible debt instruments of SEK 68 million.
|
Contracts with our venders that allow us to
cancel the contract on short notice without financial penalty are excluded from the above table.
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
|
A.
|
Directors
and senior management.
|
The following table sets forth the names,
ages and positions of our executive officers and directors as of the date of this Annual Report:
Name
|
|
Age
|
|
Position
|
Executive
Director:
|
|
|
|
|
Julian Aleksov
|
|
52
|
|
Executive Chairman
of the Board
|
Executive
Officers:
|
|
|
|
|
Mikael Asp
|
|
54
|
|
Chief Executive
Officer and Head of Quality Assurance
|
Fredrik Gynnerstedt
|
|
41
|
|
Chief Financial
Officer
|
Anders Blom
|
|
48
|
|
Executive Vice President
|
Non-Executive
Directors:
|
|
|
|
|
Bo Cederstrand
|
|
78
|
|
Director
|
Alexander Kotsinas
|
|
49
|
|
Director
|
Lars Bergkvist
|
|
53
|
|
Director
|
The following is a brief summary of the business
experience of our executive officers and directors. The current business address for all of our executive officers and directors
is Vallongatan 1, 752 28, Uppsala, Sweden.
Executive Officers
Julian Aleksov
is a co-founder of Oasmia,
and has served as Chief Executive Officer and a director since 1999, though he was a director of Oasmia’s predecessor from
1998 to 1999. On May 28, 2015, he resigned as our Chief Executive Officer and was appointed as our Executive Chairman of the Board.
During the Extraordinary General Meeting held in November 2016 he was appointed Vice Executive Chairman, however in February 2017
he was re-appointed as Executive Chairman of the Board. He is an economist with extensive experience in coordinating research
projects and strategic development of global intellectual property assets. Prior to becoming the CEO, he oversaw our research
and strategic development within bio-organic chemistry, with a focus on retinoids and alpha-protein bindings, while also managing
our global intangible assets registrations and financing. He has been a partner and member of the board of Alceco, one of our
principal stockholders, since 2000. He attended the Deutsche Schule in Stockholm for his basic education, and thereafter studied
economics on several levels.
Anders Blom
has served as Executive
Vice President since September 1, 2014. He has 15 years of experience from international strategic business development and finance
at Galderma (former Q-Med AB) and Pharmacia. Anders was previously CEO of Nexttobe which is also the largest creditor in Oasmia.
Nexttobe is a life science focused venture capital firm based in Uppsala. He has a Master of Business Administration degree from
Uppsala University.
Fredrik Gynnerstedt
has served as Chief
Financial Officer since November 21, 2016 and possesses 15 years’ experience in international business administration and
activities. Previously, Fredrik was employed as the Director of Collaboration at Karnov Group. Prior to that role, he served as
Chief Financial Officer for publicly held Bringwell AB, and as auditor and consultant at Ernst & Young. Fredrik has a Master’s
degree in Business Administration from Stockholm University.
Mikael Asp
has served as Head of Quality
Assurance since 2013. On May 28, 2015, he was appointed as our Chief Executive Officer. He has 25 years of experience with a variety
of companies in the international pharmaceutical sector including Xellia, Pfizer, Wyeth and Pharmacia in research and development,
production and quality assurance. He has been a Qualified Person since 2013. He has a Master’s degree in chemical engineering
from Royal Institute of Technology, Stockholm.
Non-Executive Directors
Bo Cederstrand
has been a director
since 2000 and was Chairman of the Board from 2000 to 2011. He has approximately 40 years of experience as CEO and partner in
a number of small and medium-sized companies specializing in pets or pet products, most of which he founded. He has extensive
experience in international trade and production and has been very active within trade branch associations. He has been a partner
and member of the board of Alceco, one of our principal stockholders, since 2000. He is a deputy board member at Fruges Aktiebolag
AB and was a previous board member of Arkenbutikerna. He studied at the Stockholm School of Economics.
Alexander Kotsinas
has served on our
board of directors since September 2013. He is currently working as an independent consultant for Nexttobe AB since 2016 and has
worked as a Partner at Nexttobe AB from 2011 to 2016. He has been Vice President at Investor AB and has worked at Ericsson. He
was the Vice President and CFO at Q-Med AB from 2008 to 2011, and was the CFO at Life Europe AB in 2007 and at Tre-Hi3G Access
AB from 2003 to 2006. He has a Master of Science degree in Applied Physics from the Royal Institute of Technology, Stockholm and
a Bachelor of Science Economics from the Stockholm School of Economics.
Lars Bergkvist
has served on our board
of directors since May 2015. From 2001 through 2011, he was the chief executive officer at Arken Zoo. Since 2012, he has acted
as the chairman of the board of Jaktia AB, Master Design AB and Chainformation AB, as a member of the board of directors of FDT
AB, a public company, and as a member of the advisory board of Skyltspektrum AB. He received a degree in Accounting and Finance
from Stockholm’s School of Economics in 1986.
B. Compensation
Compensation of Directors and Executive
Management Board
The following discussion provides the amount
of compensation paid, and benefits in kind granted, by us to our directors and executive officers for services in all capacities
to us for the year ended April 30, 2017.
Directors Compensation
For the year ended April 30, 2017, the table
below sets forth the compensation paid to our directors. Mr. Lönner was named as the Executive Chairman of the Board on November
21, 2016 and resigned from his position on February 27, 2017. The compensation in the case of Mr. Aleksov reflects the compensation
paid for his services as our Executive Chairman of the Board and Vice Executive Chairmane from November 21, 2016 until February
27, 2017.
Year Ended April 30, 2017 Directors Compensation
Name
|
|
Salary/
Fees
|
|
|
Variable
remuneration
|
|
|
Benefits
Excluding
Pension
|
|
|
Pension
Benefit
|
|
|
Total
|
|
|
|
(In TSEK)
|
|
Anders
Lönner
(1)
Chairman
of the Board
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Julian
Aleksov
Executive Chairman of the
Board and former Vice Executive Chairman
|
|
|
1,698
|
(2)
|
|
|
23
|
|
|
|
644
|
|
|
|
449
|
|
|
|
2,814
|
|
Bo
Cederstrand
Director
|
|
|
150
|
|
|
|
|
|
|
|
25
|
|
|
|
|
|
|
|
175
|
|
Horst
Domdey
(3)
Director
|
|
|
96
|
|
|
|
|
|
|
|
30
|
|
|
|
|
|
|
|
126
|
|
Alexander
Kotsinas
Director
|
|
|
89
|
|
|
|
|
|
|
|
28
|
|
|
|
|
|
|
|
117
|
|
Hans
Sundin
(3)
Director
|
|
|
537
|
|
|
|
16
|
|
|
|
88
|
|
|
|
|
|
|
|
641
|
|
Hans
Liljeblad
(4)
Director
|
|
|
63
|
|
|
|
|
|
|
|
19
|
|
|
|
|
|
|
|
82
|
|
Lars
Bergkvist
Director
|
|
|
150
|
|
|
|
|
|
|
|
47
|
|
|
|
|
|
|
|
197
|
|
Mikael
Asp
CEO
|
|
|
1,366
|
|
|
|
|
|
|
|
479
|
|
|
|
230
|
|
|
|
2,075
|
|
Other
senior executives (2 people at end of year, 2 people on average during financial year)
5)
|
|
|
3,127
|
|
|
|
13
|
|
|
|
1,134
|
|
|
|
621
|
|
|
|
4,895
|
|
Total
|
|
|
7,275
|
|
|
|
51
|
|
|
|
2,495
|
|
|
|
1,300
|
|
|
|
11,122
|
|
|
(1)
|
Mr. Lönner
was appointed as Chairman of the Board in November 21, 2016 and resigned as a member of the board of directors in February
27, 2017.
|
|
|
|
|
(2)
|
Elected Chairman
of the Board in May 2015 and switched to Vice Chairman during the period November 2016 through February 2017. Julian Aleksov
is the Executive Chairman and receives a salary.
|
|
|
|
|
(3)
|
Mr. Domdey and Mr
Sundin resigned as members of the board of directors in November, 2016.
|
|
|
|
|
(4)
|
Mr. Liljeblad resigned
as a member of the board of directors in September, 2016.
|
|
|
|
|
(5)
|
In November 2016
management team was increased by one person. One senior executive resigned in March 2017.
|
Remuneration of the Chairman of the Board
and members of the board of directors is decided at each annual general meeting. There is no remuneration for participation in
the nomination committee or any of the other committees. Upon special agreement, we pay members of the board of directors their
compensation through a company wholly owned by the board member. In such cases, the invoice amount is increased by social security
and VAT. Accordingly, board member fees for Mr. Liljeblad was paid through Advokatfirman Liljeblad och Co KB and Mr. Bergkvist
was paid through Axli AB.
Executive Officers Compensation
Compensation for each executive officer is
comprised of base salary, pension allocation of base salary, directors’ and officers’ liability insurance, and the
medical benefits described below. Executive directors also receives private health insurance and healt care insurence. The total
amount of compensation paid to executive officers, whether or not a director, for the year ended April 30, 2017 was SEK 11,121
thousand.
Bonus Plans
We do not currently pay bonuses to any director
or employee.
Options and Incentive Programs
Oasmia has introduced a share-based incentive
plans comprising options. The purpose of the incentive plans is to encourage Oasmia’s employees and Board members to invest
time and effort in the Company in order to be able to benefit from and help promote positive value growth in the Company’s
share in the period covered by the plans, and to enable Oasmia to retain and recruit competent and committed employees. The incentive
programs 2017:1 and 2017:2 were introduced following a resolution taken by an Extraordinary General Meeting on June 2, 2017. The
incentive plan 2017:2 applies to independent members of the Board, while 2017:1 is aimed at the Company’s independent senior
management team members. The same EGM also decided that options issued under the incentive plans 2016:1 and 2016:2, decided previously
by the Board, will be recalled and cancelled. Plan 2017:1 comprises 3,750,000 options, while plan 2017:2 comprises 3,000,000 options.
The options will be transferred to the participants of the plans at the market value of the options, provisionally estimated to
be SEK 0.31 per warrant, calculated by the independent valuation institution PwC using the Black & Scholes valuation model.
Each option in the plans 2017:1 and 2017:2 will entitle the holder to subscribe for one share in the Company during the period
June 16, 2019 to August 16, 2019. The subscription price per share should correspond to 175 per cent of the volume-weighted average
price of the Company’s shares according to the Nasdaq Stockholm official list in the period June 9, 2017 to June 16, 2017.
In the event that all outstanding options are exercised for shares, the number of shares will increase by a total of 6,750,000,
corresponding to dilution of around 5.4 per cent of the number of issued shares on April 30, 2017.
Health care and medical care
We offer our employees free medical care and
free medicine up to the Swedish high-cost protection ceilings of SEK 1,100 and SEK 2,200, respectively. We also have an agreement
with a provider of occupational health services.
Employment Agreements
Julian Aleksov
Mr. Aleksov signed an employment agreement
with us on January 1, 2000 to serve as our Chief Executive Officer but is presently our Executive Chairman of the Board; this
change in title had no impact on his compensation. The employment agreement is for an unspecified term. As of April 30, 2017,
he receives a base salary of SEK 1,692,000 per annum, reviewed annually, plus private health insurance and pension allocations.
He does not receive a bonus or any additional perquisites or other annual compensation. The health insurance and healthcare insurance
he receives is worth SEK 40,608 and SEK 3,768 annually respectively. His contribution pension plan is handled through Carnegie
Investment Bank, with an annual pension contribution of SEK 405,000 since the beginning of the last full fiscal year, compared
to SEK 421,750 as of the end of the previous fiscal year. He does not receive any additional compensation for serving as a director.
In the event Mr. Aleksov’s employment
is terminated by us, Mr. Aleksov shall be entitled to notice of 24 months. If he voluntarily decides to terminate his employment,
the notice shall be six months. There is no agreement or arrangement for Mr. Aleksov to receive any severance payments or any
additional payments should we undergo a change of control.
Anders Blom
Mr. Blom joined our company on September 1,
2014. As of April 30, 2017, he receives a base salary of SEK 1,593,300 per annum, reviewed annually. His pension plan follows
a staircase model whereas his pension allocation is based on his salary and worth SEK 401,249 annually. The health insurance and
healthcare insurance he receives is worth SEK 24,462 and SEK 7,146 annually respectively. He does not receive any other bonus,
perquisites or any other annual compensation.
If we terminate Mr. Blom’s employment,
he shall be entitled to a notice period of six (6) months. If he voluntarily decides to terminate his employment, the notice period
shall be three (6) months. There is no agreement or arrangement for Mr. Blom to receive any severance payments or any additional
payments should we undergo a change of control.
Mikael Asp
Mr. Asp signed an employment agreement with
us on January 7, 2013. The employment agreement is for an unspecified term. As of April 30, 2017, he receives a base salary of
SEK 1,368,000 per annum, reviewed annually. His pension plan follows a staircase model whereas his pension allocation is based
on his salary and worth SEK 202,138 annually. The health insurance and healthcare insurance he receives is worth SEK 20,677 and
SEK 7,109 annually respectively. He does not receive any other bonus, perquisites or any other annual compensation.
If we terminate Mr. Asp’s employment,
he shall be entitled to a notice period of twelve (12) months. If he voluntarily decides to terminate his employment, the notice
period shall be three (3) months. There is no agreement or arrangement for Mr. Asp to receive any severance payments or any additional
payments should we undergo a change of control.
Fredrik Gynnerstedt
Mr. Gynnerstedt joined our company on November
21, 2016 as CFO for the company. As of April 30, 2017, he receives a base salary of SEK 1,200,000 per annum, reviewed annually.
His pension plan follows a staircase model whereas his pension allocation is based on his salary and worth SEK 103,845 annually.
The healthcare insurance he receives is worth SEK 2,633 annually. He does not receive any other bonus, perquisites or any other
annual compensation.
If we terminate Mr. Gynnerstedt’s employment,
he shall be entitled to a notice period of number of month six (6) months. If he voluntarily decides to terminate his employment,
the notice period shall be three (3) months. There is no agreement or arrangement for Mr. Gynnerstedt to receive any severance
payments or any additional payments should we undergo a change of control.
Limitations on Liability
and Indemnification Matters
Under the Swedish Income Tax Act, if a company
directly indemnifies a member of the board of directors or an executive officer or otherwise holds him or her harmless, the amount
expended will be regarded as salary upon which we must pay social security contributions, and the director or officer will also
be liable for income tax on any such expended amount. Therefore, we maintain directors and officers insurance through XL Insurance
Company SE and Navigators to insure our directors and executive officers against certain liabilities incurred based on their capacity
as a director or an executive officer.
C. Board practice
Board Composition
Our affairs are managed under the direction
of our board of directors, which is currently composed of four members. Two of our directors, i.e., Messrs. Kotsinas and Bergkvist,
qualify as independent directors under Rule 5605(a)(2) of the Nasdaq Marketplace Rules. Messrs. Aleksov and Cederstrand are not
considered independent under Nasdaq or SEC rules. Directors are elected at each annual general meeting for one-year terms. None
of our directors, or our executive officers, has any family relationship with any other director or executive officer, except
that Mr. Aleksov is the partner of Mr. Cederstrand’s daughter and the father of two of his grandchildren.
Tasks of the Board of Directors
The board of directors manages our affairs
on behalf of our shareholders. The board of directors acts in accordance with the Swedish Companies Act (SFS 2005:551) (“Swedish
Companies Act”), our Articles of Association, internal regulations and directions given by the general meeting. In addition,
the board of directors shall ensure that we comply with the Swedish Corporate Governance Code, NASDAQ Stockholm’s Rule Book
for Issuers, SEC regulations as well as other applicable laws and regulations. The principal tasks of the board of directors include
the following:
|
•
|
establishing
our overall operational goals and strategy;
|
|
•
|
appointing,
evaluating and, if necessary, dismissing the chief executive officer;
|
|
•
|
evaluating
our management and deciding if any significant changes in our organization and business
need to be made;
|
|
•
|
analyzing
our financial situation;
|
|
•
|
ensuring
that there is an effective system for follow-up and control of our operations;
|
|
•
|
ensuring
that our internal control of the financial development is satisfactory and that information
concerning the financial development is correctly communicated in our financial reports;
|
|
•
|
ensuring
that there is a satisfactory process for monitoring our compliance with laws and other
regulations relevant to our operations, including applicable accounting standards and
other requirements for listed companies;
|
|
•
|
defining
necessary guidelines to govern our ethical conduct; and
|
|
•
|
ensuring
that our external communications are transparent and that they are accurate, reliable
and relevant.
|
Committees of the Board of Directors and
Corporate Governance
The committees of our board of directors consist
of an audit committee, a compensation committee and a nomination committee. Each of these committees has the responsibilities
described below. Our board of directors may also establish other committees from time to time to assist in the discharge of its
responsibilities.
Subject to certain exceptions, the rules of
Nasdaq permit a foreign private issuer to follow its home country practice in lieu of certain Nasdaq listing requirements. The
Nasdaq listing requirements with respect to which we rely on this exemption, and the corresponding requirements imposed on us
by Swedish law and corporate governance guidelines and the listing requirements of NASDAQ Stockholm, are set forth in the table
below.
Nasdaq
Listing Requirement
|
|
Swedish
requirements
|
A
majority of the board of directors must consist of independent directors
|
|
Policy
that an issuer must have (i) a majority of the board of directors be independent directors, (ii) only one director may also
be an executive employee of the issuer, and (iii) two independent directors should also not be related to major shareholders
(i.e., those who own 10% or more of the Ordinary Shares), or the issuer must explain why the board of directors did not comply
with this policy.
|
Non-executive
directors must meet on a regular basis without management present
|
|
Policy
that the board of directors must meet at least once annually with the issuer’s auditors without management present or
the issuer must explain why the board of directors did not comply with this policy.
|
All
members of the nominating committee must be independent
|
|
Policy
that (i) the nominating committee should consist of at least three members, two of which are independent directors, (ii) the
CEO and other executive employees should not serve on the nominating committee, and (iii) one member of the nominating committee
should not be related to major shareholders, or the issuer must explain why the board of directors did not comply with this
policy.
|
Proxies
must be solicited and proxy statements provided for all shareholder meetings
|
|
Mandatory
requirement that notice of shareholder meeting must include information relating to the matters to be decided at the shareholder
meeting, how to cast votes by proxy and where to find a proxy form.
|
|
|
Policy
that (i) the notice of shareholder meeting should include the nomination committee’s suggestion for chairman of the
issuer, and (ii) the nomination committee should issue a statement on the issuer’s website explaining its proposals
regarding the board of directors, or the issuer must explain why the board of directors did not comply with this policy.
|
Shareholder
approval must be sought for the implementation of certain equity compensation plans and issuances of ordinary shares
|
|
Mandatory
provision applying certain supermajority shareholder approval thresholds for implementation of certain equity compensation
plans and certain issuances of new shares that deviate from existing shareholders’ preferential rights.
|
We are not required to follow the Nasdaq listing
requirements set forth above with respect to having a majority of our board of directors be independent.
Audit Committee
The members of our audit committee are Mr.
Kotsinas and Mr. Lars Bergkvist, all of whom qualify as an “independent director” as such term is defined in Rule
10A-3 under the Exchange Act. Mr. Lars Bergkvist serves as chair of the audit committee. Our board of directors has determined
that Mr. Bergkvist is a financial expert as contemplated by the rules of the SEC implementing Section 407 of the Sarbanes Oxley
Act of 2002. Our audit committee meets at least twice per year with the external auditors and our independent registered public
accounting firm without executive board members present and oversees the monitoring of our internal controls, accounting policies
and financial reporting and provides a forum through which our external auditors and independent registered public accounting
firm reports. The audit committee also oversees the activities of the external auditors and our independent registered public
accounting firm, including their appointment, reappointment, or removal as well as monitoring of their objectivity and independence.
In addition, the audit committee considers the fees paid to the external auditors and independent registered public accounting
firm and determines whether the fee levels for non-audit services, individually and in aggregate, relative to the audit fee are
appropriate so as not to undermine independence.
Compensation Committee
The members of the compensation committee
are Mr. Alexander Kotsinas and Mr. Lars Bergkvist. Each of the members, qualifies as an independent director under Rule 5605(a)(2)
of the Nasdaq Marketplace Rules. Mr. Lars Bergkvist serves as chair of the compensation committee. Our compensation committee
reviews, among other things, the performance of our executive directors and sets the scale and structure of their remuneration
and the basis of their employment agreements with due regard to the interests of the shareholders. No director has a service agreement
with a notice period exceeding one year. During the year ended April 30, 2017, there was one meeting of the compensation committee
Nomination Committee
The nomination committee consists of three
members. The first member, currently Mr. Bo Cederstrand, represents the largest shareholder Alceco International S.A. The second
member, currently Mr. Per Arwidsson, represents the second largest shareholder Granitplattan AB. The third member is Mr. Aleksov.
Mr. Cederstrand serves as chair of the nomination committee and oversees the evaluation of the board of directors’ performance.
The primary task of the nomination committee is to present candidates for the board of directors and the Chairman of the Board
and to decide their compensation. The nomination committee also presents proposals to the annual general meeting of possible remuneration
for committee work and remuneration of external auditor. Proposals of the nomination committee are made public no later than when
notice of the annual general meeting is sent. The nomination committee’s mandate extends to when the next nomination has
been made public. The nomination committee meets at least once a year.
D. Employees
As of April 30, 2017, we had 66 employees,
all of them located in Sweden. We have never had a work stoppage and none of our employees is represented by labor unions or covered
by collective bargaining agreements. The competence and experience of our employees are among Oasmia’s most important assets.
Drug development is a complex process which requires many specialist competencies. A total of 76% of Oasmia’s employees
have a university degree and 39% these also have a Ph.D. Many nationalities are represented among the employees, creating a positive,
challenging and dynamic work environment. Oasmia strives to continually improve and ensure a healthy and safe work environment.
Oasmia will continue to be a safe, healthy and pleasant workplace.
The table below sets forth a breakdown of our employees as at end
of each of the past fiscal years by main category of activity.
|
|
As of April
30,
2017
|
|
|
As of April
30,
2016
|
|
|
As of April
30,
2015
|
|
Quality control, quality assurance and production
|
|
|
31
|
|
|
|
38
|
|
|
|
39
|
|
Finance, accounting, and administration
|
|
|
5
|
|
|
|
10
|
|
|
|
11
|
|
Human resource
|
|
|
2
|
|
|
|
2
|
|
|
|
2
|
|
Research and development
|
|
|
6
|
|
|
|
8
|
|
|
|
9
|
|
Clinical development
|
|
|
4
|
|
|
|
3
|
|
|
|
6
|
|
Regulatory affairs
|
|
|
6
|
|
|
|
5
|
|
|
|
3
|
|
Logistics, clinical supply and facility management
|
|
|
6
|
|
|
|
4
|
|
|
|
4
|
|
Public relations and communications, IT
|
|
|
2
|
|
|
|
2
|
|
|
|
2
|
|
Legal
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
CEO, Executive Vice President, Executive chairman
|
|
|
3
|
|
|
|
2
|
|
|
|
2
|
|
Total
|
|
|
66
|
|
|
|
75
|
|
|
|
79
|
|
E. Share ownership
See "Item 7. MAJOR SHAREHOLDERS
AND RELATED PARTY TRANSACTIONS —A. Major Shareholders."
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY
TRANSACTIONS
A.
Major Shareholders
The following table and related footnotes
set forth information with respect to the beneficial ownership of the Ordinary Shares, as of July 31, 2017, by: (i) each of our
directors and executive officers, and (ii) each person known to us to own beneficially more than 5% of the Ordinary Shares as
of July 31, 2017. As of July 31, 2017, we had 172 881 108 Ordinary Shares issued and outstanding.
Beneficial ownership is determined in accordance
with the rules and regulations of the SEC. In computing the number of Ordinary Shares owned by a person and the percentage ownership
of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise
of any option, warrant or other right or the conversion of any other security. These Ordinary Shares that the person has the right
to acquire within 60 days, however, are not included in the computation of the percentage ownership of any other person. Ownership
of the Ordinary Shares by the “principal shareholders” identified below has been determined by reference to our share
register, which provides us with information regarding the registered holders of the Ordinary Shares but generally provides limited,
or no, information regarding the ultimate beneficial owners of such Ordinary Shares. As a result, we may not be aware of each
person or group of affiliated persons who beneficially owns more than 5% of the Ordinary Shares.
Unless otherwise indicated, the business address
for each of the shareholders in the table below is c/o Oasmia Pharmaceutical AB, Vallongatan 1, 752 28, Uppsala, Sweden.
|
|
Ordinary Shares Beneficially
Owned
|
|
Name of Beneficial Owner
|
|
Number
|
|
|
Percent
|
|
Greater than 5% Shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Arwidsson
Granitplattan AB och Granen AB
(1)
|
|
|
22,667,856
|
|
|
|
13.11
|
|
Alceco International S.A.
|
|
|
21,648,765
|
|
|
|
12.52
|
|
Försäkringsbolaget Avanza Pension
|
|
|
12,300,805
|
|
|
|
7.12
|
|
|
|
|
|
|
|
|
|
|
Directors and Executive Officers
|
|
|
|
|
|
|
|
|
Julian Aleksov
(2)
|
|
|
21,798,561
|
|
|
|
12.61
|
|
Bo Cederstrand
(3)
|
|
|
21,774,765
|
|
|
|
12.60
|
|
Mikael Asp
|
|
|
8,040
|
|
|
|
|
*
|
Anders Blom
|
|
|
61,850
|
|
|
|
|
*
|
Fredrik Gynnerstedt
|
|
|
20,000
|
|
|
|
|
*
|
Alexander Kotsinas
|
|
|
-
|
|
|
|
-
|
|
Lars Bergkvist
|
|
|
-
|
|
|
|
-
|
|
All Named Executive Officers and Directors as a Group (6 persons)
|
|
|
22,014,451
|
|
|
|
12.73
|
|
|
(1)
|
The
business address for Granitplattan AB is Box 55938, SE-102 16, Stockholm, Sweden. Mr
Arwidsson is the control person of Granitplattan AB
|
|
(2)
|
Consists
of 21,648,765 shares held through Alceco and 149,796 held by Mr. Aleksov separately.
Messrs. Aleksov and Cederstrand are the control persons of Alceco.
|
|
(3)
|
Consists
of 21,648,765 shares held through Alceco and 126,000 held by Mr. Cederstrand separately.
Messrs. Aleksov and Cederstrand are the control persons of Alceco.
|
Our shareholders do not have different voting
rights. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.
The following table sets forth information
with respect to the beneficial ownership of our ordinary shares by our major shareholders, which means shareholders that beneficially
own 5% or more of our ordinary shares, as of July 31, 2017, July 31, 2016 and July 31, 2015, each being the most recent
practicable date before reporting for the last three fiscal years.
|
|
2015
|
|
|
2016
|
|
|
2017
|
|
Name
|
|
# of
Shares
|
|
|
% of
issued
Shares*
|
|
|
# of
Shares
|
|
|
% of
issued
Shares*
|
|
|
# of
Shares
|
|
|
% of
issued
Shares*
|
|
Alceco
International S.A.
(1)
|
|
|
35,178,112
|
|
|
|
35.95
|
%
|
|
|
25,536,445
|
|
|
|
23.82
|
%
|
|
|
21,648,765
|
|
|
|
12.52
|
%
|
Granitplattan AB
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
22,667,856
|
|
|
|
13.11
|
%
|
Nexttobe AB
(2)
|
|
|
19,602,173
|
|
|
|
20.03
|
%
|
|
|
19,602,173
|
|
|
|
18.28
|
%
|
|
|
-
|
|
|
|
-
|
|
|
(1)
|
Messrs.
Aleksov and Cederstrand are the control persons of Alceco.
|
|
(2)
|
The
business address for Granitplattan AB is Box 55938, 102 16 Stockholm, Sweden. Mr. Arwidsson
is the control person of Granitplattan AB.
|
B. Related Party Transactions
Transactions with major shareholders and companies controlled
by major shareholders
Alceco, Oasmia’s largest shareholder,
see item 7 A Major Shareholders, has made a credit facility of SEK 40 million available to us. The credit facility is valid until
December 2017, and is renewed automatically for one-year terms, unless terminated by either party at least three months prior
to an expiration date. This credit facility was completely unused at April 30, 2017, as was the case at April 30, 2016.
No other transactions took place between Alceco and Oasmia.
Oasmia had a loan of SEK 94,395 thousand from Nexttobe AB up until
December 30, 2016. This loan including accrued interest of SEK 8,024 thousand was then replaced by a new loan of SEK 102,419 thousand,
which carries interest of 3.5 percent and falls due for payment on September 30, 2017. The loan is recognized at amortized cost
and its fair value based on an estimated market interest rate of 10 percent amounts to SEK 100,616 thousand.
Nexttobe AB was Oasmia’s second largest shareholder up until
October 31, 2016, with a shareholding of 18.3 percent. However, this shareholding was divested as of November 1, 2016, which means
that the relationship with Nexttobe is no longer a related party relationship. Nexttobe had the following transactions with Oasmia
during the last three fiscal years in million SEK:
in SEK million except Interest rate
|
|
April
30,
2017
|
|
|
April 30,
2016
|
|
|
April 30,
2015
|
|
Financial loan from Nexttobe as per April 30
|
|
|
102.4
|
|
|
|
94.4
|
|
|
|
87.00
|
|
Accrued interest as per April 30
|
|
|
1.2
|
|
|
|
2.7
|
|
|
|
2.4
|
|
Interest rate, percent
|
|
|
3.5
|
|
|
|
8.5
|
|
|
|
8.5
|
|
Ardenia Investment Ltd, a company controlled
to equal parts by Oasmia’s founders Bo Cederstrand and Julian Aleksov, is registered as the applicant and holder of the
patents which forms the basis for Oasmia’s business. Through an agreement between Ardenia and Oasmia, the rights to these
patents have been transferred to Oasmia. Ardenia cross charges itsadministration costs for these patents.
Cross charged costs and Oasmia’s outstanding liability as
per April 30 for the last three fiscal years, million SEK:
|
|
May 1, 2016 –
April 30, 2017
|
|
|
May 1, 2015 –
April 30, 2016
|
|
|
May 1, 2014-
April
30, 2015
|
|
Cross charged administration costs
|
|
|
1.37
|
|
|
|
2.23
|
|
|
|
1.40
|
|
Liability as per April 30
|
|
|
0.72
|
|
|
|
0.00
|
|
|
|
0.00
|
|
Transactions with Group companies
The Oasmia group consists of the parent company
Oasmia Pharmaceutical AB and the Swedish subsidiaries Oasmia Incentive AB (name changed from Oasmia Animal Health AB) and Qdoxx
Pharma AB, the Nevada-registered subsidiary Oasmia Pharmaceutical, Inc. and the Hongkong-registered subsidiary Oasmia Pharmaceutical
Asia Pacific Limited.
The Swedish subsidiaries have been dormant the last three years
and have had only minor administration costs which have been covered by the parent company.
No sales of goods or services
have taken place between the parent company and the Swedish subsidiaries.
Oasmia Pharmaceutical, Inc. was founded in
June 2015 by the parent company with a capital contribution of SEK 1.15 million to finance its initial activities. Apart from
this, there were no transactions between the Parent Company and Oasmia Pharmaceutical, Inc. and there were no intra-Group balances
at closing day.
Oasmia Pharmaceutical Asia Pacific Limited
was founded 27 May 2016 by the parent company with a capital contribution of SEK 65,7 thousand to finance its initial activities.
Apart from this, there were no transactions between the Parent Company and Oasmia Pharmaceutical, Inc. and there were no intra-Group
balances at closing day.
Stock Lending Agreement
To facilitate the orderly closing of the initial
offering of ADSs and due to timing considerations related to the technical issuance and registration of new Ordinary Shares under
Swedish law, under the terms of a Stock Lending Agreement dated October 23, 2015, by and among the Company and Alceco and certain
of its affiliates, Alceco and such affiliates agreed to loan temporarily to the Company 7,368,480 Ordinary Shares (the “Borrowed
Shares”) in connection with the initial deposit of Ordinary Shares into the American Depositary Receipt Program immediately
prior to and concurrent with the consummation of the offering and in connection with any future exercise of the Warrants.
We issued to the custodian, whose role is
more fully described in the section entitled “Description of American Depositary Shares, and the custodian has deposited
into the American Depositary Receipt Program, 7,684,500 Ordinary Shares. Following receipt from us of the newly issued Ordinary
Shares equal to the number of the Borrowed Shares, the custodian returned the Borrowed Shares underlying the ADSs to Alceco. In
all events, the ADS that were offered and sold represent the same number of Ordinary Shares in the American Depository Receipt
Program.
A similar Stock Lending Agreement will be
entered into in order to facilitate the issuance of ADSs upon exercise of the Warrants.
We agreed to indemnify and hold harmless Alceco
for any damages in connection with the Stock Lending Agreement and the transactions contemplated thereunder.
Transactions with related individuals
For transactions with related individuals,
see item 6 B. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES Compensation
C. Interests of Experts and Counsel
Not Applicable
ITEM 8. FINANCIAL INFORMATION
A. Consolidated statements and other financial information
See Item 18. Financial Statements, which contains our financial
statements prepared in accordance with IFRS.
B. Significant Changes
Not applicable.
ITEM 9. THE OFFER
AND LISTING
A. Offering and Listing Details
See "Item 9. C. Markets" for
information regarding the price history of our stock.
B. Plan of Distribution
Not Applicable.
C. Markets
The Ordinary Shares have been trading on NASDAQ
Stockholm under the symbol “OASM” since June 24, 2010 and on the Frankfurt Stock Exchange under the symbol “OMAX”
since January 24, 2011 and NASDAQ Capital Market under symbol “OASM” since October 23, 2015.
The following table sets forth, for the periods
indicated, the reported high and low closing sale prices of the Ordinary Shares on NASDAQ Stockholm and, the Frankfurt Stock Exchange
and ADSs on NASDAQ Capital Markets, in kronor and U.S. dollars, in Euros and U.S. dollars and U.S dollars, respectively. U.S.
dollar per ordinary share amounts have been translated into U.S. dollars at $1.00 = SEK 8.1082 and $1.00 = €0.8512 based
on the certified foreign exchange rates published by the Federal Reserve Bank of New York on August 18, 2017.
NASDAQ Stockholm
|
|
Krona
|
|
|
Dollar
|
|
|
|
Price Per Ordinary Share
|
|
|
Price Per Ordinary Share
|
|
|
|
High
|
|
|
Low
|
|
|
High
|
|
|
Low
|
|
Annual (Year Ended April 30):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2013
|
|
|
13.55
|
|
|
|
4.70
|
|
|
|
1.67
|
|
|
|
0.58
|
|
2014
|
|
|
29.80
|
|
|
|
10.00
|
|
|
|
3.68
|
|
|
|
1.23
|
|
2015
|
|
|
23.00
|
|
|
|
18.30
|
|
|
|
2.84
|
|
|
|
2.26
|
|
2016
|
|
|
19.20
|
|
|
|
8.30
|
|
|
|
2.37
|
|
|
|
1.02
|
|
2017
|
|
|
13.75
|
|
|
|
5.00
|
|
|
|
1.70
|
|
|
|
0.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarterly (Fourth Quarter Ended April 30):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second Quarter 2015
|
|
|
22.10
|
|
|
|
18.30
|
|
|
|
2.73
|
|
|
|
2.26
|
|
Third Quarter 2015
|
|
|
20.80
|
|
|
|
18.30
|
|
|
|
2.57
|
|
|
|
2.26
|
|
Fourth Quarter 2015
|
|
|
22.50
|
|
|
|
19.00
|
|
|
|
2.77
|
|
|
|
2.34
|
|
First Quarter 2016
|
|
|
19.20
|
|
|
|
17.00
|
|
|
|
2.37
|
|
|
|
2.10
|
|
Second Quarter 2016
|
|
|
18.30
|
|
|
|
11.25
|
|
|
|
2.26
|
|
|
|
1.39
|
|
Third Quarter 2016
|
|
|
12.65
|
|
|
|
10.15
|
|
|
|
1.56
|
|
|
|
1.25
|
|
Fourth Quarter 2016
|
|
|
13.20
|
|
|
|
8.30
|
|
|
|
1.63
|
|
|
|
1.02
|
|
First Quarter 2017
|
|
|
13.75
|
|
|
|
8.90
|
|
|
|
1.70
|
|
|
|
1.10
|
|
Second Quarter 2017
|
|
|
10.60
|
|
|
|
7.70
|
|
|
|
1.31
|
|
|
|
0.95
|
|
Third Quarter 2017
|
|
|
10.45
|
|
|
|
7.90
|
|
|
|
1.29
|
|
|
|
0.97
|
|
Fourth Quarter 2017
|
|
|
8.15
|
|
|
|
5.00
|
|
|
|
1.01
|
|
|
|
0.62
|
|
First Quarter 2018
|
|
|
6.95
|
|
|
|
2.92
|
|
|
|
0.86
|
|
|
|
0.36
|
|
Second Quarter 2018 (through Aug 18, 2017)
|
|
|
3.13
|
|
|
|
2.81
|
|
|
|
0.39
|
|
|
|
0.35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Most Recent Six Months:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 2017
|
|
|
6.21
|
|
|
|
4.89
|
|
|
|
0.77
|
|
|
|
0.60
|
|
April 2017
|
|
|
6.65
|
|
|
|
6.21
|
|
|
|
0.82
|
|
|
|
0.77
|
|
May 2017
|
|
|
6.80
|
|
|
|
4.99
|
|
|
|
0.84
|
|
|
|
0.62
|
|
June 2017
|
|
|
5.18
|
|
|
|
3.09
|
|
|
|
0.64
|
|
|
|
0.38
|
|
July 2017
|
|
|
3.28
|
|
|
|
2.92
|
|
|
|
0.40
|
|
|
|
0.36
|
|
August 2017 (through Aug 18, 2017)
|
|
|
3.13
|
|
|
|
2.81
|
|
|
|
0.39
|
|
|
|
0.35
|
|
Frankfurt Stock Exchange
|
|
Euro
|
|
|
Dollar
|
|
|
|
Price Per Ordinary Share
|
|
|
Price Per Ordinary Share
|
|
|
|
High
|
|
|
Low
|
|
|
High
|
|
|
Low
|
|
Annual (Year Ended April 30):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2013
|
|
|
1.63
|
|
|
|
0.53
|
|
|
|
1.91
|
|
|
|
0.62
|
|
2014
|
|
|
3.31
|
|
|
|
1.13
|
|
|
|
3.89
|
|
|
|
1.33
|
|
2015
|
|
|
2.48
|
|
|
|
1.87
|
|
|
|
2.91
|
|
|
|
2.19
|
|
2016
|
|
|
2.10
|
|
|
|
0.89
|
|
|
|
2.47
|
|
|
|
1.05
|
|
2017
|
|
|
1.44
|
|
|
|
0.52
|
|
|
|
1.69
|
|
|
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarterly (Fourth Quarter Ended April 30):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second Quarter 2015
|
|
|
2.41
|
|
|
|
1.93
|
|
|
|
2.83
|
|
|
|
2.27
|
|
Third Quarter 2015
|
|
|
2.21
|
|
|
|
1.87
|
|
|
|
2.60
|
|
|
|
2.19
|
|
Fourth Quarter 2015
|
|
|
2.36
|
|
|
|
2.00
|
|
|
|
2.77
|
|
|
|
2.35
|
|
First Quarter 2016
|
|
|
2.10
|
|
|
|
1.76
|
|
|
|
2.47
|
|
|
|
2.07
|
|
Second Quarter 2016
|
|
|
1.93
|
|
|
|
1.18
|
|
|
|
2.27
|
|
|
|
1.39
|
|
Third Quarter 2016
|
|
|
1.35
|
|
|
|
1.06
|
|
|
|
1.59
|
|
|
|
1.25
|
|
Fourth Quarter 2016
|
|
|
1.40
|
|
|
|
0.89
|
|
|
|
1.64
|
|
|
|
1.05
|
|
First Quarter 2017
|
|
|
1.44
|
|
|
|
0.94
|
|
|
|
1.69
|
|
|
|
1.10
|
|
Second Quarter 2017
|
|
|
1.09
|
|
|
|
0.77
|
|
|
|
1.28
|
|
|
|
0.90
|
|
Third Quarter 2017
|
|
|
1.04
|
|
|
|
0.79
|
|
|
|
1.22
|
|
|
|
0.93
|
|
Fourth Quarter 2017
|
|
|
0.86
|
|
|
|
0.52
|
|
|
|
1.01
|
|
|
|
0.61
|
|
First Quarter 2018
|
|
|
0.70
|
|
|
|
0.29
|
|
|
|
0.82
|
|
|
|
0.34
|
|
Second Quarter 2018 (through Aug 11, 2017*)
|
|
|
0.30
|
|
|
|
0.29
|
|
|
|
0.35
|
|
|
|
0.34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Most Recent Six Months:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 2017
|
|
|
0.63
|
|
|
|
0.52
|
|
|
|
0.74
|
|
|
|
0.61
|
|
April 2017
|
|
|
0.70
|
|
|
|
0.62
|
|
|
|
0.82
|
|
|
|
0.73
|
|
May 2017
|
|
|
0.70
|
|
|
|
0.51
|
|
|
|
0.82
|
|
|
|
0.60
|
|
June 2017
|
|
|
0.54
|
|
|
|
0.30
|
|
|
|
0.63
|
|
|
|
0.35
|
|
July 2017
|
|
|
0.32
|
|
|
|
0.29
|
|
|
|
0.38
|
|
|
|
0.34
|
|
August 2017 (through Aug 11, 2017)
|
|
|
0.30
|
|
|
|
0.29
|
|
|
|
0.35
|
|
|
|
0.34
|
|
NASDAQ Capital Markets
|
|
Dollar
|
|
|
|
Price Per ADS (1)
|
|
|
|
High
|
|
|
Low
|
|
Annual (Year Ended April 30):
|
|
|
|
|
|
|
|
|
2016 (from listing October 23, 2015)
|
|
|
4.70
|
|
|
|
2.94
|
|
2017
|
|
|
4.87
|
|
|
|
4.17
|
|
Quarterly (Fourth Quarter Ended April 30):
|
|
|
|
|
|
|
|
|
Second Quarter 2016 (from listing October 23, 2015)
|
|
|
4.29
|
|
|
|
3.70
|
|
Third Quarter 2016
|
|
|
4.29
|
|
|
|
3.26
|
|
Fourth Quarter 2016
|
|
|
4.70
|
|
|
|
2.94
|
|
First Quarter 2017
|
|
|
4.87
|
|
|
|
3.05
|
|
Second Quarter 2017
|
|
|
3.65
|
|
|
|
2.51
|
|
Third Quarter 2017
|
|
|
3.70
|
|
|
|
2.67
|
|
Fourth Quarter 2017
|
|
|
2.85
|
|
|
|
1.66
|
|
First Quarter 2018
|
|
|
2.26
|
|
|
|
0.96
|
|
Second Quarter 2018 (through Aug 18, 2017)
|
|
|
1.13
|
|
|
|
0.96
|
|
|
|
|
|
|
|
|
|
|
Most Recent Six Months:
|
|
|
|
|
|
|
|
|
March 2017
|
|
|
2.02
|
|
|
|
1.66
|
|
April 2017
|
|
|
2.20
|
|
|
|
1.82
|
|
May 2017
|
|
|
2.26
|
|
|
|
1.84
|
|
June 2017
|
|
|
1.86
|
|
|
|
0.96
|
|
July 2017
|
|
|
1.14
|
|
|
|
0.97
|
|
August 2017 (through Aug 18, 2017)
|
|
|
1.13
|
|
|
|
0.96
|
|
|
(1)
|
Each ADS represents
three (3) Ordinary Shares.
|
D. Selling Shareholders
Not applicable.
E. Dilution
Not applicable
F. Expenses of the Issue
Not applicable.
ITEM 10. ADDITIONAL INFORMATION
A. Share capital.
Not applicable
B. Memorandum and articles of association
Our Articles of Association were amended on
September 28, 2015 to raise the range for share capital and number of authorized shares. The share capital shall be no less than
SEK 8,500,000 and not more than SEK 20,000,000 and the number of shares shall be no less than 85,500,000 and not more than 200,000,000.
Except as set forth above, we incorporate
by reference the description of our Articles of Association as in effect upon the closing of our IPO contained in the F-1 registration
statement (File No. 333-205515) originally filed with the SEC July 6, 2015, as amended.
C. Material contracts.
Except as otherwise disclosed in this annual
report (including the Exhibits) and in the F-1 registration statement (File No. 333-205515) originally filed with the SEC July
6, 2015, as amended., we are currently not, and have not been in the two years preceding publication of this annual report, party
to any material contract, other than contracts entered into in the ordinary course of business, fully described in the section
entitled “Item 4.B Business overview”.
D. Exchange controls
There is no Swedish legislation affecting
a) the import or export of capital or b) the remittance of dividends, interest or other payments to non-resident holders of our
securities except that, subject to the provisions in any tax treaty, dividends are subject to withholding tax.
E. Taxation
TAXATION
HOLDERS OF OUR ADSs ARE HEREBY NOTIFIED
THAT THEY SHOULD SEEK SPECIFIC ADVICE BASED ON THEIR PARTICULAR CIRCUMSTANCES FROM AN INDEPENDENT TAX ADVISOR WITH RESPECT TO
THE APPLICATION TO THEM OF U.S. FEDERAL INCOME TAX RULES, AS WELL AS ANY APPLICABLE STATE, LOCAL, NON-U.S. OR OTHER TAX CONSEQUENCES,
AS A RESULT OF THEIR PURCHASE, OWNERSHIP AND DISPOSITION OF THE ADSs.
Material U.S. Federal Income Tax Considerations
Subject to the limitations described below,
the following is a summary of the material U.S. federal income tax consequences of the purchase, ownership and disposition of
ADSs to a “U.S. Holder.” Non-U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income
tax consequences to them of the purchase, ownership and disposition of ADSs. For purposes of this discussion, a “U.S. Holder”
is a beneficial owner of ADSs that is, for U.S. federal income tax purposes:
|
•
|
an
individual who is a citizen or resident of the U.S.;
|
|
•
|
a
corporation (including any entity treated as a corporation for U.S. federal income tax
purposes) created or organized in or under the laws of the U.S., any state thereof or
the District of Columbia;
|
|
•
|
an
estate the income of which is subject to U.S. federal income tax purposes regardless
of its source; or
|
|
•
|
a
trust (A) if a court within the U.S. is able to exercise primary jurisdiction over the
trust’s administration and one or more U.S. persons have the authority to control
all its substantial decisions, or (B) if, in general, it was in existence on August 20,
1996, was treated as a U.S. person under the Code (as defined below) on the previous
day and made a valid election to continue to be so treated.
|
The term “Non-U.S. Holder” means
a beneficial owner of ADSs that, for U.S. federal income tax purposes, is or is treated as an individual, corporation, trust or
estate and is not a U.S. Holder. The term “Holder” means U.S. Holders and Non-U.S. Holders.
This discussion is based on current provisions
of the Internal Revenue Code of 1986 (the “Code”), applicable U.S. Treasury Regulations promulgated thereunder, and
administrative and judicial decisions as of the date hereof, all of which are subject to change, possibly on a retroactive basis
(and any such change could affect the continuing accuracy of this discussion). We will not seek a ruling from the Internal Revenue
Service (the “IRS”) with regard to the U.S. federal income tax treatment of the ADSs and, therefore, there can be
no assurance that the IRS will agree with the conclusions set forth below.
This summary does not purport to be a comprehensive
description of all of the tax considerations that may be relevant to each person’s decision to purchase ADSs. This discussion
does not address all aspects of U.S. federal income taxation that may be relevant to any particular U.S. Holder based on its particular
circumstances. In particular, this discussion considers only U.S. Holders that own or will own ADSs as capital assets within the
meaning of section 1221 of the Code and does not address the potential application of U.S. federal alternative minimum tax or
the U.S. federal income tax consequences to U.S. Holders that are subject to special treatment, including:
|
•
|
broker
dealers or insurance companies;
|
|
•
|
U.S.
Holders who have elected mark-to-market accounting;
|
|
•
|
tax-exempt
organizations or pension funds;
|
|
•
|
regulated
investment companies, real estate investment trusts, insurance companies, financial institutions
or “financial services entities”;
|
|
•
|
U.S.
Holders who hold ADSs as part of a “straddle,” “hedge,” “constructive
sale” or “conversion transaction” or other integrated investment;
|
|
•
|
U.S.
Holders who own or owned, directly, indirectly or by attribution, at least 10% of the
voting power of our Ordinary Shares;
|
|
•
|
U.S.
Holders whose functional currency is not the U.S. Dollar;
|
|
•
|
persons
holding ADSs in connection with a trade or business outside of the United States; and
|
|
•
|
certain
expatriates or former long-term residents of the United States.
|
This discussion does not consider the tax
treatment of holders that are partnerships (including entities treated as partnerships for U.S. federal income tax purposes) or
other pass-through entities or persons who hold ADSs through a partnership or other pass-through entity. Partnerships or partners
of a partnership holding any ADSs should consult their own tax advisors regarding the tax considerations associated with holding
ADSs. In addition, this discussion does not address any aspect of state, local or non-U.S. tax laws, or the possible application
of U.S. federal gift or estate tax.
Taxation of Dividends Paid on ADSs
Assuming that we are not a PFIC (as discussed
below), a U.S. Holder will be required to include in gross income as a dividend the U.S. Dollar amount of any distribution paid
on ADSs, including the amount of non-U.S. taxes, if any, withheld from the amount paid, on the date the distribution is received
to the extent the distribution is paid out of our current or accumulated earnings and profits as determined for U.S. federal income
tax purposes. Distributions in excess of such earnings and profits will be applied against and will reduce the U.S. Holder’s
basis in its ADSs and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of ADSs. We do
not intend to calculate our earnings and profits for U.S. federal income tax purposes. Therefore, a U.S. Holder should expect
that a distribution generally will be treated as a dividend even if that distribution would otherwise be treated as a non-taxable
return of capital under the rules set forth above.
Dividends are generally taxed at ordinary
income rates. However, a maximum U.S. federal income tax rate of 20% will apply to “qualified dividend income” received
by individuals (as well as certain trusts and estates), provided that certain eligibility requirements are met. In particular,
a U.S. Holder will not be entitled to this rate: (i) if the U.S. Holder has not held our ADSs for at least 61 days of the 121-day
period beginning on the date which is 60 days before the ex-dividend date; or (ii) to the extent the U.S. Holder is under an obligation
to make related payments on substantially similar or related property. Any days during which a U.S. Holder has diminished its
risk of loss on our ADSs are not counted towards meeting the 61-day holding period. “Qualified dividend income” includes
dividends paid on shares of “qualified foreign corporations” (which term excludes PFICs) if the foreign corporation
is eligible for the benefits of a comprehensive income tax treaty with the United States which contains an exchange of information
program (a “qualifying treaty”). If we are a PFIC in the year in which a dividend is paid or the preceding year, we
will not be a “qualified foreign corporation” and the dividend will not qualify for the reduced rate of tax (even
assuming that a reduced rate is available at such time). Because of the uncertainty of these matters, including whether or not
we are or will be a PFIC, there is no assurance that any dividends paid on the ADSs will be eligible for these preferential rates
in the hands of such a U.S. Holder, and any dividends paid on the ADSs that are not eligible for these preferential rates will
be taxed as ordinary income to U.S. Holders. Dividends received by corporate shareholders do not qualify for the preferential
tax rate discussed above; moreover, dividends from a non-U.S. corporation generally will not qualify for the dividends received
deduction generally available to U.S. corporate shareholders.
Distributions paid on our ADSs generally will
be foreign-source passive income for U.S. foreign tax credit purposes.
Taxation of the Sale or Exchange of
ADSs
Unless a non-recognition rule applies, on
a sale, exchange or other disposition of ADSs, a U.S. Holder generally will recognize gain or loss in an amount equal to the difference
between the U.S. Dollar amount realized on such sale or exchange and the U.S. Holder’s adjusted tax basis in such ADSs determined
in U.S. Dollars. The initial tax basis of ADSs to a U.S. Holder will be the U.S. Holder’s U.S. Dollar cost for ADSs.
Subject to the application of the PFIC rules
discussed below, such gain or loss generally will be capital gain or loss and will be long-term capital gain or loss if the U.S.
Holder’s holding period of the ADSs exceeds one year at the time of the disposition. Individual U.S. Holders are generally
subject to a maximum tax rate of 20% on long-term capital gain. Corporate U.S. Holders do not have a preferential rate on capital
gains and their capital gain income generally is subject to U.S. federal income tax at the same rate as ordinary income. The deductibility
of capital losses is subject to limitations. Gain or loss recognized by a U.S. Holder on a sale or exchange of ADSs generally
will be treated as U.S.-source income or loss for U.S. foreign tax credit purposes.
Taxation on Exercise, Sale or Lapse
of Warrants
There are no tax consequences to U.S. Holders
on the exercise of the Warrants. A U.S. Holder’s tax basis in the ADSs acquired through the exercise of the Warrants is
the exercise price plus the cost of the warrants ($.01 per Warrant). A U.S. Holder’s holding period in shares acquired through
an exercise of the warrants commences on the date of exercise. The ADSs so acquired are then treated in the same manner as the
U.S. Holder’s other ADSs, discussed above (and are also subject to the PFIC rules discussed below).
If a U.S. Holder sells the Warrants, he will
recognize gain to the extent that the proceeds of the sale exceed his tax basis in the Warrants. For individual U.S. Holders this
gain will be long term capital gain if the Warrants have been held for more than a year at the time of sale, and short-term capital
gain if held for a year or less.
No gain is recognized by a U.S. Holder on
the expiration of the Warrants. A U.S. Holder would have a capital loss on the expiration of the Warrants equal to his tax basis
in the Warrants.
Foreign Tax Credit Considerations
We expect that we will be required to withhold
non-U.S. taxes upon payment to a U.S. Holder of a dividend. If any such withholding were required, a U.S. Holder will have the
option of claiming the amount of any non-U.S. income taxes withheld on a dividend distribution either as a deduction from gross
income or as a dollar-for-dollar credit against its U.S. federal income tax liability. The amount of foreign income taxes that
may be claimed as a credit in any year is subject to complex limitations, which must be determined on an individual basis by each
U.S. Holder.
Passive Foreign Investment Company Status
There may be adverse tax consequences to U.S.
Holders if we are determined to be a PFIC. We will be a PFIC if
(i) 75% or more of our gross income in any
taxable year is passive income. Passive income includes interest, dividends, certain royalties, certain rents and annuities, and
amounts derived by the investment of funds raised in our initial public offering of ADSs and other offerings. Passive income also
includes our pro rata share of the gross income of any company (U.S. or foreign) that is treated as a corporation for U.S. federal
income tax purposes and of which we are considered to own, directly or indirectly, 25% or more of the shares by value (a “25%
subsidiary”), or
(ii) the average value of our assets that
are held for the production of, or produce, passive income is 50% or more of the average value of our total assets during the
taxable year. In making this determination, according to the IRS, “the average value of [our] assets for the taxable year
[is] the average of the fair market values of [our] assets determined as of the end of each quarterly period during [our] taxable
year.” For purposes of determining whether we are a PFIC our assets include our pro rata share of the assets of any 25%
subsidiary.
The determination of whether we are a PFIC
is thus made annually and is based upon the composition of our income and assets and the nature of our activities. Further, each
of our subsidiaries is separately tested to determine if it is a PFIC and, if we are a PFIC, any of our subsidiaries could also
be a PFIC with respect to a U.S. Holder.
Based on the Code, Treasury Regulations promulgated
under the Code and IRS guidance, there can be no assurance that we are not a PFIC now and, if not a PFIC now, that we will not
become a PFIC in the future. If we are a PFIC, and a U.S. Holder does not make an election to treat us as a “qualified electing
fund” (a “QEF”) or does not make a “mark-to-market election” (as described below) the following
consequences would arise:
|
•
|
Excess
distributions by us to such a U.S. Holder would be taxed in a special way. “Excess
distributions” are amounts received by a U.S. Holder with respect to the ADSs in
any taxable year that exceed 125% of the average distributions received by such U.S.
Holder from us in the shorter of either the three previous years or such U.S. Holder’s
holding period for ADSs before the current taxable year. Excess distributions must be
allocated ratably to each day that a U.S. Holder has held the ADSs. A U.S. Holder must
include amounts allocated to the current taxable year and amounts allocated to certain
years prior to us being a PFIC in its gross income as ordinary income for that year.
A U.S. Holder must pay tax on amounts allocated to each prior taxable year when we were
a PFIC at the highest rate in effect for that year on ordinary income and the tax is
subject to an interest charge at the rate applicable to deficiencies for income tax.
|
|
•
|
A
disposition of shares in, or a distribution by, one of our subsidiaries that is a PFIC
will trigger the excess distributions rules described above.
|
|
•
|
The
entire amount of gain that is realized by a U.S. Holder upon the sale or other disposition
of ADSs will also be considered an excess distribution and will be subject to tax as
described above.
|
|
•
|
A
U.S. Holder’s tax basis in shares of the ADSs that were acquired from a decedent
would not receive a step-up to fair market value as of the date of the decedent’s
death but would instead be equal to the decedent’s basis, if lower.
|
In addition, if we are a PFIC, the lower rate
of taxation applicable to qualified dividend income derived by certain non-corporate U.S. Holders, as discussed above, would not
apply to dividends paid with respect to our ADSs.
If a U.S. Holder of PFIC shares makes a timely
QEF election with respect to its PFIC shares, then in lieu of the consequences described above, the U.S. Holder would be required
to include in income each year its pro-rata share of the PFIC’s net capital gain and ordinary income. If we are a PFIC,
we would need to make available the information necessary in order for a U.S. Holder to make this election, but, assuming that
we were characterized as a PFIC, we have not made a decision as to whether or not we would make this information available. Therefore,
U.S. Holders should not assume that they would be able to make a QEF election with respect to the ADSs.
Alternatively, a U.S. Holder that holds “marketable
stock” in a PFIC may avoid the imposition of the additional tax and interest described above by making a mark-to-market
election in the first year of its holding period for its PFIC shares. We believe that the ADSs will be “marketable stock”
for purposes of the mark-to-market election. Generally, stock will be considered “marketable stock” if it is “regularly
traded” on a “qualified exchange” within the meaning of the applicable Treasury regulations. A class of stock
is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities,
on at least 15 days during each calendar quarter. However, there can be no certainty that the ADSs will continue to be sufficiently
traded such as to be treated as “regularly traded”. If a U.S. Holder were to make a timely mark-to-market election
with respect to ADSs that it will own at the close of its taxable year, such electing U.S. Holder would for the year of the election
and each subsequent taxable year include as ordinary income or, to the extent of prior ordinary income, ordinary loss based on
the increase or decrease in the market value of such U.S. Holder’s ADSs for such taxable year. An electing U.S. Holder’s
tax basis in its ADSs will be adjusted to reflect any such income or loss. Any gain or loss on the sale of ADSs will be ordinary
income or loss, except that any loss will be ordinary loss only to the extent of the previously included net mark-to-market gain.
An election to mark-to-market applies to the year for which the election is made and to subsequent years unless the IRS consents
to the revocation of the election. The election is terminated for any year in which the PFIC shares are not “marketable
stock”. If we were a PFIC and then were to cease being a PFIC, a U.S. Holder that marked its ADSs to market would not include
mark-to-market gain or loss with respect to its ADSs for any taxable year that we were no longer a PFIC. If we again were to become
a PFIC in a taxable year after a year in which we were not a PFIC, a U.S. Holder’s original mark-to-market election, unless
revoked or terminated, would continue to apply and such U.S. Holder would be required to include any mark-to-market gain or loss
in such year.
A mark-to-market election applies only to
the non-U.S. corporation for which it is made. If any of our subsidiaries were to be a PFIC, a U.S. Holder likely would remain
subject to the excess distribution rules with respect to its indirectly owned shares in any such subsidiary even if such U.S.
Holder has made a mark-to-market election in our respect.
If we are a PFIC for any year during which
a U.S. Holder holds ADSs we will generally continue to be treated as a PFIC with respect to the U.S. Holder for all succeeding
years during which the U.S. Holder holds ADSs, even if we cease to meet the threshold requirements for PFIC status. As noted above,
if a U.S. Holder was permitted to make a mark-to-market election and did so in a timely manner, we will not be treated as a PFIC
with respect to such U.S. Holder for any year in which we do not meet the threshold requirements for PFIC status. The same rule
appears to apply in the case of a U.S. Holder who was permitted to, and timely made, a QEF election, although the issue is not
entirely free from doubt.
A U.S. Holder that owns any shares of a foreign
corporation classified as a PFIC is generally required to file Form 8621 (Return by a Shareholder of a Passive Foreign Investment
Company or a Qualified Electing Fund) in each year that such shares are held.
U.S. Holders are urged to consult their tax
advisors about the PFIC rules and the related filing requirements. Our U.S. counsel expresses no opinion with respect to our PFIC
status in any prior taxable year or the current taxable year which ends April 30, 2018, and also expresses no opinion with respect
to any predictions regarding our PFIC status in the future.
Certain Reporting Obligations
Section 6038D of the Code generally requires
U.S. individuals (and possibly certain entities that have U.S. individual owners) to file IRS Form 8938 if they hold certain “specified
foreign financial assets,” the aggregate value of which exceeds $50,000 on the last day of the taxable year (or the aggregate
value of which exceeds $75,000 at any time during the taxable year). (Higher reporting thresholds apply to married taxpayers filing
joint returns and to taxpayers living outside the U.S.) The definition of specified foreign financial assets includes not only
financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution,
any stock or security issued by a non-U.S. person including the ADSs. In general, if we were to be treated as a PFIC, a U.S. Holder
would not be required to report ownership of the ADSs under Section 6038D of the Code if such ownership were reported on Form
8621 described above under “Passive Foreign Investment Company Status” and that fact is noted on the Form 8938. U.S.
Holders should consult their own tax advisors to determine whether they are subject to any Form 8938 filing requirements.
Foreign Account Tax Compliance Act
Under certain circumstances, we or our paying
agent may be required, pursuant to Sections 1471 through 1474 of the Code and the regulations promulgated thereunder, any agreement
entered into pursuant to Section 1472(b) of the Code, or any U.S. or non-U.S. fiscal or regulatory legislation, rules, guidance
notes or practices adopted pursuant to any intergovernmental agreement entered into in connection with the implementation of such
sections of the Code or analogous provisions of non-U.S. law (“FATCA”), to withhold U.S. tax at a rate of 30% on all
or a portion of payments of dividends or other corporate distributions which are treated as “foreign pass-thru payments”
made on or after January 1, 2017, if such payments are not in compliance with FATCA. Such payments can generally be made in compliance
with FATCA if the paying agent obtains from the payee a Form W-9 or other information establishing an exemption from such withholding.
The rules regarding FATCA and “foreign pass-thru payments,” including the treatment of proceeds from the disposition
of ADSs, are very complex and U.S. Holders are encouraged to consult their own tax advisors on the impact of the FATCA rules on
them.
Medicare Tax on Net Investment Income
A 3.8% tax is generally imposed on the net
investment income in excess of certain thresholds of certain individuals and on the undistributed net investment income of certain
estates and trusts. For these purposes, “net investment income” will generally include interest, dividends (including
dividends, if any, paid with respect to the ADSs), annuities, royalties, rent, net gain attributable to the disposition of property
not held in a trade or business (including net gain from the sale, exchange or other taxable disposition of ADSs) and certain
other income, but will be reduced by any deductions properly allocable to such income or net gain. U.S. Holders are advised to
consult their own tax advisors regarding additional taxation of net investment income.
U.S. Information Reporting and Backup
Withholding
A U.S. Holder is generally subject to information
reporting requirements with respect to dividends paid in the United States on ADSs and proceeds paid from the sale, exchange,
redemption or other disposition of ADSs. A U.S. Holder is subject to backup withholding (currently at 28%) on dividends paid in
the United States on ADSs and proceeds paid from the sale, exchange, redemption or other disposition of our ADSs unless the U.S.
Holder is a corporation, provides an IRS Form W-9 to the payor or the paying agent, or otherwise establishes a basis for exemption.
Backup withholding is not an additional tax.
Amounts withheld under the backup withholding rules may be credited against a U.S. Holder’s U.S. federal income tax liability,
and a U.S. Holder may obtain a refund from the IRS of any excess amount withheld under the backup withholding rules, provided
that certain information is timely furnished to the IRS. U.S. Holders are urged to consult their own tax advisors regarding the
application of backup withholding and the availability of and procedures for obtaining an exemption from backup withholding in
their particular circumstances.
The foregoing discussion of certain material
U.S. federal income tax considerations is for general information only and is not tax advice. Accordingly, each U.S. Holder should
consult with his, her or its own tax advisor regarding U.S. federal, state, local and non-U.S. income and other tax consequences
of the acquisition, holding and disposing of the ADSs.
F. Dividends and Paying Agents
Not applicable.
G. Statement by Experts
Not applicable.
H. Documents on Display
We are subject to the informational requirements
of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports
on Form 20-F and reports on Form 6-K in limited circumstances; however, we may elect to make additional information
available on Form 6-K.
We are not required to disclose certain other
information that is required from U.S. domestic issuers, including but not limited to detailed executive compensation disclosure
and quarterly disclosure as to our assessment of our internal control over financial reporting. Also, as a foreign private issuer,
we are exempt from the rules of the Securities Exchange Act of 1934 prescribing the furnishing of proxy statements to shareholders
and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Securities Exchange Act of 1934.
As a foreign private issuer, we are also exempt
from the requirements of Regulation FD (Fair Disclosure) that, generally, are meant to ensure that select groups of investors
are not privy to specific information about an issuer before other investors. We are, however, still subject to the anti-fraud
and anti-manipulation rules of the SEC, such as Rule 10b-5. Since many of the disclosure obligations required of us as a foreign
private issuer are different than those required by other U.S. domestic reporting companies, our shareholders, potential shareholders
and the investing public in general should not expect to receive information about us in the same amount and at the same time
as information is received from, or provided by, U.S. domestic reporting companies. We are liable for violations of the rules
and regulations of the SEC, which do apply to us as a foreign private issuer.
You may inspect and copy reports and other
information filed with the SEC at the Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on
the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330 FREE . In addition, the SEC
maintains an Internet website that contains reports and other information about issuers, like us, that file electronically with
the SEC. The address of that website is www.sec.gov.
I. Subsidiary Information
See “ITEM 4. INFORMATION ON THE COMPANY
- C. Organizational Structure” and “Exhibit F-8; Notes to the Consolidated Financial Statements - NOTE 26 HOLDINGS
IN GROUP COMPANIES”
ITEM 11 QUANTITATIVE AND QUALITATIVE DISCLOSURE
ABOUT MARKET RISK
A. Quantitative and Qualitative Disclosures about Credit, Market
and Other Risk
We are exposed to market risks in the ordinary
course of our business. Market risk represents the risk of loss that may impact our financial position, results of operations
or cash flows due to adverse changes in financial market prices and rates, including interest rates, foreign exchange rates and
market prices, of financial instruments. Our market risk exposure is a result of interest rates, foreign currency exchange rates
and market prices.
Interest Rate Risk
Oasmia has on April 30, 2017 SEK 168.7 million
as interest-bearing loans, consisting of a loan from Nexttobe AB of SEK 102.4 million, one convertible loan of SEK 41.5 million
and one convertible loan of SEK 24.8 million.
The loan from Nexttobe AB has a fixed interest
rate until it matures on September 30, 2017. The convertible loans fall due on June 9, 2017 and April 18, 2018 respectively, and
the interest rate until then is fixed. After the closing date, Oasmia agreed with the holders of the 42 convertible debt instruments
to replace these with non-negotiable promissory notes. The term for the new debt was up to one (1) year, however, the debt can
be pre-paid by Oasmia before they fall due. Interest on the new debt accrue from 9 June 2017 at an interest rate of 8.5% annually,
and therefore, corresponds to the interest rate for the convertibles. see Item 5.A Operating Results Overview - Events after balance
sheet date of April 30, 2017). Both the convertible loan and the non-negotiable promissory notes are thus independent from the
short term development of the market interest rates, but there is a risk that these loans at maturity will be prolonged or replaced
by other loans to less favorable terms.
Foreign Currency Exchange Risk
Our foreign currency exposures give rise to
market risk associated with exchange rate movements of the SEK, our functional and reporting currency, mainly against the Euro
but also against USD and other currencies. Although the SEK is our functional currency, a certain portion of our expenses are
denominated in Euro. Our Euro expenses consist principally of payments made to sub-contractors and consultants for clinical trials
and other research and development activities as well as payments made to purchase raw material and to subcontractors for producing
our products. Our sales revenue is to the largest part denominated in EUR.
If the SEK fluctuates significantly against
the Euro, it may have a negative impact on our results of operations. To date, fluctuations in the exchange rates have not materially
affected our results of operations or financial condition for the periods under review.
We have not entered into any currency hedging
transactions to decrease the risk of financial exposure from fluctuations in the exchange.
Market Price Risk
Oasmia have historically invested liquidity
surplus in fixed income funds. These funds are traded in an active financial market and can be realized in one to two banking
days. An official market price is made public each trading day, and this constitutes the funds’ fair value. Fluctuations
in the market price of the funds might negatively affect our income statement. However, as these funds invest in short-term securities
from safe issuers, it is assessed that the market price risk is low. As per April 30, 2017, the company have not invested in fixed
income funds and there is no such risk.
Item 11 D. Safe Harbor
Not applicable
ITEM 12. DESCRIPTION
OF SECURITIES OTHER THAN EQUITY SECURITIES
A. Debt Securities
Not applicable
B. Warrants and Rights
See Item 12 D
C. Other Securities
Not applicable.
D. American Depositary Shares
ADSs
The Bank of New York Mellon, as depositary,
has registered and delivered American Depositary Shares, also referred to as ADSs. Each ADS represents three (3) Ordinary Shares
(or a right to receive three (3) Ordinary Shares) deposited with the principal Stockholm office of Skandinaviska Enskilda Banken
AB, acting as custodian for the depositary (but see “Related Party Transactions — Stock Lending Agreement” for
the mechanics of closing and the timing of share issuances). Each ADS will also represent any other securities, cash or other
property which may be held by the depositary. The depositary’s office at which the ADSs will be administered is located
at 101 Barclay Street, New York, New York 10286. The Bank of New York Mellon’s principal executive office is located at
One Wall Street, New York, New York 10286.
You may hold ADSs either (A) directly (i)
by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs,
registered in your name, or (ii) by having uncertificated ADSs registered in your name, or (B) indirectly by holding a security
entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository
Trust Company, also called DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder.
This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker
or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker
or financial institution to find out what those procedures are.
Registered holders of uncertificated ADSs
will receive statements from the depositary confirming their holdings.
As an ADS holder, we will not treat you as
one of our shareholders and you will not have shareholder rights. Swedish law governs shareholder rights. The depositary will
be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement
among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights
as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.
The
following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the
entire deposit agreement and the form of ADR. Directions on how to obtain copies of those documents are provided under the heading
“Where You Can Find Additional Information” on page 148.
Dividends and Other Distributions
How will you receive dividends and other distributions
on the shares?
The depositary has agreed to pay or distribute
to ADS holders the cash dividends or other distributions it or the custodian receives on Ordinary Shares or other deposited securities,
upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of shares
your ADSs represent.
Cash.
The depositary will convert any cash dividend
or other cash distribution we pay on the Ordinary Shares into U.S. Dollars, if it can do so on a reasonable basis and can transfer
the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained,
the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible
to do so. The depositary will hold the foreign currency it cannot convert for the account of the ADS holders who have not been
paid. It will not invest the foreign currency and it will not be liable for any interest.
Before making a distribution, any withholding
taxes, or other governmental charges that must be paid will be deducted. See the heading “Taxation” appearing on page
98. The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent.
If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the
value of the distribution.
Shares.
The depositary may distribute additional ADSs
representing any Ordinary Shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs.
It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the
net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs
will also represent the new Ordinary Shares. The depositary may sell a portion of the distributed Ordinary Shares (or ADSs representing
those Ordinary Shares) sufficient to pay its fees and expenses in connection with that distribution.
Rights to purchase additional shares.
If we offer holders of our securities any rights
to subscribe for additional shares or any other rights, the depositary may (i) exercise those rights on behalf of ADS holders,
(ii) distribute those rights to ADS holders or (iii) sell those rights and distribute the net proceeds to ADS holders, in each
case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it
will allow the rights to lapse. In that case, you will receive no value for them. The depositary will exercise or distribute rights
only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise
rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new
ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary.
U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise
of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.
Other Distributions.
The depositary will send to ADS holders anything
else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution
in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same
way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed
property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives
satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed
securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict
the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject
to restrictions on transfer.
The depositary is not responsible if it decides
that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register Ordinary
Shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the
distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we
make on our shares or any value for them if it is illegal or impractical for us to make them available to you.
Deposit, Withdrawal and Cancellation
How are ADSs issued?
The depositary will deliver ADSs if you or
your broker deposits shares or evidence of rights to receive Ordinary Shares with the custodian. Upon payment of its fees and expenses
and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate
number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.
How can ADS holders withdraw the deposited
securities?
You may surrender your ADSs for the purpose
of withdrawal at the depositary’s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp
taxes or stock transfer taxes or fees, the depositary will deliver the Ordinary Shares and any other deposited securities underlying
the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and
expense, the depositary will deliver the deposited securities at its office, if feasible. The depositary may charge you a fee and
its expenses for instructing the custodian regarding delivery of deposited securities.
How do ADS holders interchange between certificated
ADSs and uncertificated ADSs?
You may surrender your ADR to the depositary
for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder
a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the
depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs
for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.
Voting Rights
How do you vote?
ADS holders may instruct the depositary how
to vote the number of deposited Ordinary Shares their ADSs represent. If we request the depositary to solicit your voting instructions
(and we are not required to do so), the depositary will notify you of a shareholders’ meeting and send or make voting materials
available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary
how to vote. For instructions to be valid, they much reach the depositary by a date set by the depositary. The depositary will
try, as far as practical, subject to the laws of Sweden and the provisions of our articles of association or similar documents,
to vote or to have its agents vote the Ordinary Shares or other deposited securities as instructed by ADS holders. If we do not
request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary
may try to vote as you instruct, but it is not required to do so.
Except by instructing the depositary as described
above, you won’t be able to exercise voting rights unless you surrender your ADSs and withdraw the Ordinary Shares. However,
you may not know about the meeting enough in advance to withdraw the Ordinary Shares. In any event, the depositary will not exercise
any discretion in voting deposited securities and it will only vote or attempt to vote as instructed.
We cannot assure you that you will receive
the voting materials in time to ensure that you can instruct the depositary to vote your Ordinary Shares. In addition, the depositary
and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions.
This means that you may not be able to exercise voting rights and there may be nothing you can do if your Ordinary Shares are not
voted as you requested.
In order to give you a reasonable opportunity
to instruct the depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to
act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least [45]
days in advance of the meeting date.
Pursuant to the terms of the deposit agreement, the holders of ADSs
will be required to pay the following fees:
|
-
|
a
fee of $5.00 or less per 100 American Depositary Shares (or portion thereof) for the delivery or cancellation of ADS.
|
|
-
|
a
fee of $.05 or less per American Depositary Share (or portion thereof) for any cash distribution to you
|
|
-
|
a
free of $.05 or less per ADS per annum for depositary services
|
|
-
|
Registration
or transfer fees
|
|
-
|
Expenses
of the depositary (costs for converting foreign currency to U.S. dollars and cost for cable, telex and facsimile transmissions)
|
|
-
|
Taxes
and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example
share transfer, taxes, stamp duty or withholding taxes.
|
The Depositary may collect any of its fees
by deduction from any cash distribution payable, or by selling a portion of any securities to be distributed, to owners that are
obligated to pay those fees.
The depositary collects its fees for delivery
and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries
acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed
or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services
by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants
acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion
of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally
refuse to provide fee-attracting services until its fees for those services are paid.
From time to time, the depositary may make
payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program,
waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders.
In performing its duties under the deposit agreement, the depositary may use brokers, dealers or other service providers that are
affiliates of the depositary and that may earn or share fees or commissions.
The depositary may convert currency itself
or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent, fiduciary or broker
on behalf of any other person and earns revenue, including, without limitation, fees and spreads that it will retain for its own
account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion will be the
most favorable rate that could be obtained at the time or as to the method by which that rate will be determined, subject to its
obligations under the deposit agreement.
Payment of Taxes
You will be responsible for any taxes or other
governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse
to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes
or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your American Depositary
Shares to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will,
if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property,
remaining after it has paid the taxes.
Tender and Exchange Offers; Redemption,
Replacement or Cancellation of Deposited Securities
The depositary will not tender deposited securities
in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions
or procedures the depositary may establish.
If deposited securities are redeemed for cash
in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender
of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those
ADSs.
If there is any change in the deposited securities
such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization
affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the
old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement.
However, if the depositary decides it would not be lawful and to hold the replacement securities because those securities could
not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute
the net proceeds upon surrender of the ADSs.
If there is a replacement of the deposited
securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing
the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited
securities.
If there are no deposited securities underlying
ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently
worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.
Amendment and Termination
How may the deposit agreement be amended?
We may agree with the depositary to amend the
deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for
taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or
similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days
after the depositary notifies ADS holders of the amendment.
At the time an amendment becomes effective, you are considered,
by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended
.
How may the deposit agreement be terminated?
The depositary will initiate termination of
the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if
|
•
|
60
days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted
its appointment;
|
|
•
|
we
delist our Ordinary Shares from an exchange on which they were listed and do not list the shares on another exchange;
|
|
•
|
we
appear to be insolvent or enter insolvency proceedings;
|
|
•
|
all
or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;
|
|
•
|
there
are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or
|
|
•
|
there
has been a replacement of deposited securities.
|
If the deposit agreement is terminated, the
depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary
may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other
cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the
ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination
date.
After the termination date and before the depositary
sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may
refuse to accept a surrender for the purpose of withdrawing deposited securities if it would interfere with the selling process.
The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities
have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date,
the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited
securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit
agreement except as described in this paragraph.
Limitations on Obligations and Liability
Limits on our Obligations and the Obligations
of the Depositary; Limits on Liability to Holders of ADSs
The deposit agreement expressly limits our
obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the
depositary:
|
•
|
are
only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;
|
|
•
|
are
not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its
obligations under the deposit agreement;
|
|
•
|
are
not liable if we or it exercises discretion permitted under the deposit agreement;
|
|
•
|
are
not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available
to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach
of the terms of the deposit agreement;
|
|
•
|
have
no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf
or on behalf of any other person;
|
|
•
|
are
not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and
|
|
•
|
may
rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper
person.
|
In the deposit agreement, we and the depositary
agree to indemnify each other under certain circumstances.
Requirements for Depositary Actions
Before the depositary will deliver or register
a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of Ordinary Shares, the depositary may require:
|
•
|
payment
of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for
the transfer of any shares or other deposited securities;
|
|
•
|
satisfactory
proof of the identity and genuineness of any signature or other information it deems necessary; and
|
|
•
|
compliance
with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer
documents.
|
The depositary may refuse to deliver ADSs or
register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary
or we think it advisable to do so.
Your Right to Receive the Shares Underlying
your ADSs
ADS holders have the right to cancel their
ADSs and withdraw the underlying Ordinary Shares at any time except:
|
•
|
when
temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the
transfer of shares is blocked to permit voting at a shareholders' meeting; or (iii) we are paying a dividend on our shares;
|
|
•
|
when
you owe money to pay fees, taxes and similar charges; or
|
|
•
|
when
it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to
the withdrawal of shares or other deposited securities.
|
This right of withdrawal may not be limited
by any other provision of the deposit agreement.
Pre-release of ADSs
The deposit agreement permits the depositary
to deliver ADSs before deposit of the underlying Ordinary Shares. This is called a pre-release of the ADSs. The depositary may
also deliver Ordinary Shares upon cancellation of pre-released ADSs (even if the ADSs are canceled before the pre-release transaction
has been closed out). A pre-release is closed out as soon as the underlying Ordinary Shares are delivered to the depositary. The
depositary may receive ADSs instead of shares to close out a pre-release. The depositary may pre-release ADSs only under the following
conditions: (1) before or at the time of the pre-release, the person to whom the pre-release is being made represents to the depositary
in writing that it or its customer owns the shares or ADSs to be deposited; (2) the pre-release is fully collateralized with cash
or other collateral that the depositary considers appropriate; and (3) the depositary must be able to close out the pre-release
on not more than five business days' notice. In addition, the depositary will limit the number of ADSs that may be outstanding
at any time as a result of pre-release, although the depositary may disregard the limit from time to time if it thinks it is appropriate
to do so.
Direct Registration System
In the deposit agreement, all parties to the
deposit agreement acknowledge that the Direct Registration System, also referred to as DRS, and Profile Modification System, also
referred to as Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered
holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is feature
of DRSs that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary
to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant
without receipt by the depositary of prior authorization from the ADS holder to register that transfer.
In connection with and in accordance with the
arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not
determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer
and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any
requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary’s reliance
on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit
agreement will not constitute negligence or bad faith on the part of the depositary.
Shareholder communications; inspection of
register of holders of ADSs
The depositary will make available for your
inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally
available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those
communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose
of contacting those holders about a matter unrelated to our business or the ADSs.
Warrants
The following summary of certain terms and
provisions of the Warrants is not complete and is subject to, and qualified in its entirety by the provisions of the form of the
ADS Warrant Agreement, also referred to as the Warrant Agreement, under which the Warrants are issued and which governs the terms
and conditions of the Warrants and which is incorporated by reference herein.
Exercisability
For every two initial ADSs sold, we issued
one Warrant to purchase one ADS. The ADS and Warrants were separately issued. The Warrants are exercisable at any time up to the
date that is ten (10) years from the closing date of the offering. The Warrants are exercisable, at the option of each holder,
by delivering to the Warrant Agent a duly executed exercise notice together with the Warrants to be exercised and payment in full
of the exercise price for the number of ADS purchased upon such exercise, together with the ADS issuance fee of $0.05 per ADS and
other applicable charges and taxes. Unless otherwise provided in the Warrant Agreement, the holder will not have the right to exercise
Warrants to the extent that the holder (together with its affiliates), after giving effect to the exercise, would beneficially
own in excess of 4.99% of the outstanding ordinary shares outstanding, after giving effect to the exercise, as such percentage
ownership is determined in accordance with the Warrant Agreement. Currently there are 1,280,750 Warrants outstanding.
Exercise Price
The exercise price per ADS is $4.06 per ADSs.
The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits,
stock combinations, reclassifications or similar events affecting the ordinary shares or the ADSs and also upon any distributions
of assets, including cash, stock or other property to the holders of ordinary shares.
Rights as a Stockholder
Except as otherwise provided in the Warrant
Agreement, a holder of Warrants, as such, does not have the rights or privileges of a holder of the ADSs, including any voting
rights, until the holder exercises those Warrants and ADSs underlying the Warrants are issued.
NOTE 1 GENERAL INFORMATION
Oasmia Pharmaceutical AB (Reg. No. 556332-6676 and the Parent Company
of the Oasmia Group) is a limited company domiciled in Stockholm, Sweden. The address of the company is Vallongatan 1, Uppsala,
where the Company has its office, manufacturing facility and conducts research. The company’s shares are listed on NASDAQ
Stockholm, NASDAQ Capital Market and on the Frankfurt Stock Exchange.
NOTE 2 ACCOUNTING POLICIES
The principal accounting policies applied in
these financial statements are set out below.
Basis of preparation
The consolidated financial statements have
been prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards
Board (IASB) and interpretations issued by the International Financial Reporting Interpretations Committee (IFRIC). Furthermore,
the recommendation RFR 1, Supplementary accounting regulations for Groups, issued by the Swedish Financial Reporting Board, has
been applied.
The preparation of financial statements in
conformity with IFRS requires the use of certain critical estimates for accounting purposes. It also requires management to exercise
its judgment in applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas
where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 3.
The Group’s accounting policies
Changes in accounting policies
New policies 2016/17
None of the standards and interpretations required
for the first time for the financial year that began on May 1, 2016 had a material impact on the consolidated financial statements.
New IFRS standards and interpretations effective
financial year 2017/18 or later that may impact Oasmia’s financial reporting:
IFRS 15 Revenue from Contracts with Customers
This standard comes into force on January 1,
2018 and will thus be applied by Oasmia as from the financial year 2018/2019.
The standard will first and foremost replace
IAS 18 Revenue, which is the standard that regulates the reporting of revenues at the present time. Under IFRS 15 the basic principle
for when a revenue may be recognized is when the acquiring party can use a good or can draw benefit from a service, while IAS 18
concentrates more on when risk is transferred from the vendor to the purchaser. IFRS 15 also requires considerably more disclosures
than IAS 18. IFRS 15 is expected to impact Oasmia’s financial reporting. However, it is still difficult to decide the extent
of the impact, as this is very much dependent on how Oasmia’s revenue situation develops up until the time when IFRS 15 comes
into force.
IFRS 9 Financial instruments
This standard will come into force on January 1, 2018, that is to
say it will be applied by Oasmia as from the financial year 2018/2019.
IFRS 9 will replace IAS 39 Financial Instruments and as regards
the classification and assessment of financial instruments will involve simplifications compared to IAS 39. The introduction of
this standard is not assessed to have any material impact on Oasmia’s financial reports.
IFRS 16 Leases
This standard will come into force on January 1, 2019, which means
that it will be applied by Oasmia as from the financial year 2019/2020.
IFRS 16 states that at the beginning of a leasing agreement the
lessee shall recognize the right to use the leased assets in the balance sheet and at the same time a leasing liability shall be
recognized. Depreciation shall be applied to the assets during the time they are used and leasing rates will be recognized both
as part-payment of the leasing liability and as an interest expense in the income statement. The leasing liability may also be
revalued during the duration of the contract depending on whether certain circumstances, such as new leasing terms and conditions,
are introduced. However, there will be two exceptions. Leased assets of a low value and short-term leasing (with a duration of
no more than 12 months) will be exempted from the obligation to capitalize the right to use an asset and to enter the expected
leasing payments as a liability.
The introduction of IFRS 16 is expected to impact Oasmia’s
financial reporting. The extent of the impact is being investigated by the company.
None of the other standards and interpretations which have not yet
come into force are expected to have a material impact on the Group.
Subsidiaries
Subsidiaries are companies where the Parent Company has a controlling
interest. The Parent Company has a controlling interest in a company when it is exposed to or is entitled to variable return from
its holding in the company and is able to affect the return through its controlling interest in the company. Subsidiaries are included
in the consolidated accounts as from the day on which the controlling interest is transferred to the Group. They are excluded from
the consolidated accounts as from the day on which the controlling interest ends.
The acquisition method is applied to the recognition of acquisitions
of subsidiaries. This means that acquired assets and liabilities are initially measured at fair value. If a deviation then arises
against the acquisition cost, this is recognized as goodwill in the consolidated balance sheet when the deviation is positive and
as an expense in the income statement if it is negative.
Eliminations are made for intra-Group transactions and balance-sheet
items, and for unrealized gains on transactions between Group companies.
Translation of foreign currencies
The Parent Company uses SEK as its functional
currency and reporting currency. Transactions in foreign currency are translated to the functional currency according to the exchange
rates on the transaction date. Translation profits or losses arising from payments for such transactions and from translation of
monetary assets and liabilities in foreign currency at closing day exchange rates are recognized in operations. Currency gains
and losses arising from the translation of bank accounts in foreign currencies are recognized under Net financial items.
Individual subsidiaries have another functional
currency than SEK. In the presentation of the consolidated balance sheet the current rate method is used, whereby assets and liabilities
are translated to the closing day rate of exchange while revenues and expenses are translated using the average exchange rate for
the year. The translation differences that thus arise are recognized in other comprehensive income.
Segment reporting
An operating segment is a part of a company
that conducts business activities from which revenues can be generated and costs can be incurred, and for which independent financial
information is available. Furthermore, the operating results of the segment are reviewed on a regular basis by the company’s
chief operating decision maker as the basis for the decision on allocation of resources to the segment and the evaluation of its
result. The Group management has been identified as the chief operating decision maker. Group management assesses the business
as a whole, that is as one segment, and therefore does not include information by segment in the accounts. Note 4 reports the division
of revenues into product groups and geographic markets as well as the value of non-current assets in Sweden and in other countries.
Information is also provided about the customer structure in the same note.
Property, plant and equipment
Property, plant and equipment are recognized at acquisition cost,
with deductions for depreciation. The acquisition cost includes expenses directly attributable to the acquisition of the asset.
Additional expenses are added to the carrying amount of the asset
or are recognized as a separate asset, depending on what is most suitable, only when it is probable that the future economic benefits
connected with the asset will accrue to the Group and the acquisition cost of the asset can be measured in a reliable way. The
carrying amount of the replaced part will be removed from the balance sheet. All other types of repairs and maintenance are recognized
as expenses in the income statement in the period in which they arise.
Assets are depreciated on a straight-line basis in order to distribute
their acquisition cost to the calculated residual value over the calculated utilization period, as follows:
• Vehicles
|
|
3-5 years
|
|
|
|
• Inventories and production equipment
|
|
5-15 years
|
|
|
|
• Leasehold improvements
|
|
20 years
|
The residual values and utilization period of the assets are reviewed
at every closing day and are adjusted as required. A carrying amount of an asset is immediately depreciated to its recoverable
amount if the carrying amount exceeds its estimated recoverable amount. Profits and losses from divestments are established by
a comparison between the sales revenue and the carrying amount and are recognized in Other operating income or Other operating
expenses.
Intangible assets
Capitalized development costs
Expenditures for research are expensed immediately.
Development costs which are attributable to production and tests of novel or improved products are capitalized to the extent that
they are expected to generate future economic benefits. Oasmia capitalizes development costs consisting of the company’s
work on clinical trials in phase III for the product candidates Paclical/Apealea and Paccal Vet and for which all the preconditions
for capitalization pursuant to IAS 38 have been met.
It is the assessment of the company that it
is technically possible to complete the product candidates and make them available for sale, and that the beginning of a phase
III study is the earliest time when all criteria for capitalization can be met. This assessment is made in the light of several
factors.
Both products are based on a well-known and
well-documented substance, paclitaxel, and Oasmia’s own excipient XR17. The company can therefore reuse data for both product
candidates when applying for market approval and this can potentially lead to a shorter path to approval.
The company has both the resources and the
competence to itself produce these two products for the clinical studies preceding a phase III study. Production takes place in
approved premises with employed personnel.
The company both intends and is able to sell
these products in various markets, both through existing distributors or through its own sales channels.
The oncology markets for both humans and pets are both large and
growing, which means that the company assesses that it is possible that these products will be able to generate considerable economic
benefits in the future.
Other development costs are recognized as an expense as and when
they arise. Development costs previously recognized as an expense are not capitalized as an asset in subsequent periods. Straight-line
amortization is applied to capitalized development costs over the period in which the expected benefits are expected to accrue
to the company, and is begun when a normal level of commercial sales to end customers has been achieved.
Acquired research projects
The Group has acquired a research project that is still in a pre-clinical
phase. This has been capitalized at acquisition cost minus any impairment.
Other intangible assets
The Group capitalizes fees to authorities for
patents to the extent they are expected to generate future economic benefits. They are recognized at acquisition cost, reduced
by the accumulated amortizations. Amortization is performed on a straight-line basis in order to distribute the cost over the estimated
utilization period. The estimated utilization period for patents is a maximum of 20 years.
The capitalized patent expenses comprise registration
costs such as initial expenses for e.g. authorities and legal fees. The gain or loss arising when an intangible asset is divested
or disposed of is determined as the difference between the settlements received and the carrying amount and is recognized in Other
operating income or Other operating expenses
Inventories
Inventories are recognized at the lowest of acquisition cost and
net realizable value. The acquisition cost is established by using the first in, first out method (FIFO).
The acquisition cost for Raw materials and necessities consists
of the purchase price invoiced by the supplier. The acquisition cost for Work in progress and for Finished goods consists of the
costs for the constituent raw materials, with a mark-up for manufacturing costs and quality control costs.
The net realizable value is the estimated sales price in the operating
activities, with deductions for applicable variable selling expenses.
Impairment of non-financial assets
The capitalized development costs and the capitalized
research projects which are not yet current are not amortized, but are instead evaluated annually for any impairment needs. Group
management performs an estimation of the expected utilization period of the assets at every financial statement. If there are indications
that an asset’s value has diminished, the Group establishes the recoverable amount of the asset. This amount is the highest
net realizable value of the asset, with deductions for selling expenses and its value in use. The asset is amortized down to the
recoverable amount via the income statement. In order to establish the impairment need, the assets are grouped into cash generating
units, which is the smallest group of assets that enables positive cash flows that are essentially independent of the cash flow
from other assets or groups of assets. The Group presently has no assets with indeterminable utilization periods.
Financial instruments
Financial instruments are agreements that give rise to a financial
asset or liability. Financial assets are cash, equity instruments in other companies and such agreements that give entitlement
to cash or other financial assets. Financial liabilities are agreements that oblige the company to pay cash or other financial
assets to another company.
This means that there are several receivables and liabilities that
are not financial instruments. For example receivables or liabilities that can be expected to be settled other than in cash or
through other financial assets are not dealt with in accordance with the accounting principles that apply to financial instruments.
The same applies to receivables or liabilities that are not based on agreements.
Financial instruments are recognized in the statement of financial
position when Oasmia is one of the parties in the conditions of the agreement governing the instrument. A financial asset is removed
from the statement of financial position when the rights in the agreement are terminated, as they have been realized or Oasmia
loses control of them. A financial liability is removed from the statement of financial position when the obligation in the agreement
has been fulfilled or in some other way ceases to apply.
Each time a report is drawn up an assessment is made as to whether
there are circumstances indicating that a financial asset needs to be written down. If there is a need for impairment, the amount
written down is identified in the income statement.
Oasmia’s financial instruments are reported at fair value
or at amortized cost:
|
·
|
Fair
value is the price that would be obtained if an asset were sold or paid in the settling of a liability in an orderly transaction
between knowledgeable and independent parties.
|
|
·
|
Amortized
cost is the value at which the asset or liability was valued when it was acquired plus or minus certain adjustments in value.
|
Financial instruments are divided into different categories depending
on their nature and the method used in their valuation. Oasmia reports its financial instruments in three such categories:
|
·
|
Financial
assets and liabilities valued at fair value in the income statement
.
Changes in fair value are recognized in the income
statement.
|
This category includes:
|
o
|
Short-term investments in fixed income funds.
|
|
·
|
Loans
receivable and accounts receivable
|
This category includes:
|
o
|
Cash and cash equivalents valued at nominal value. Where
they are denominated in a currency other than SEK, they are translated at the closing day rate of exchange.
|
|
o
|
Accounts receivable, other current receivables and accrued
revenues are valued at amortized cost.
|
|
·
|
Financial
liabilities valued at amortized cost
|
This category includes:
|
o
|
Borrowings and liabilities to credit institutions which
are valued at nominal value as they have a short duration.
|
|
o
|
Accounts payable and accrued expenses valued at the value
they are expected to be paid at.
|
For further disclosures on Oasmia’s financial
instruments, please see Note 18 Financial instruments and financial risks.
Share capital
Common shares are classified as equity. Transaction
costs which can be attributed directly to new share issues or warrants are recognized, net after tax, in equity as a deduction
from the funds generated by the issue.
Compared to a bond loan, a convertible loan
includes not only an entitlement to receive interest but also the opportunity to receive a certain number of shares instead of
repayment of the loan. This additional advantage means that the rate of interest of the convertible loan is lower than the market
interest rate for a corresponding bond loan. The fair value of the benefit to Oasmia due to this lower rate of interest is booked,
after deductions for issue expenses, directly against equity.
Income tax
Tax revenues and expenses are constituted by current and deferred
tax. Current tax is the tax calculated on the taxable income of each legal entity in the Group for the current or a previous period.
Deferred tax is tax on temporary differences between assets’ and liabilities’ carrying amount and tax base. A deferred
tax revenue also arises to the extent that the tax effect of loss carry-forward is entered as a deferred tax asset. However, a
deferred tax asset is only recognized to the extent that there are convincing reasons that a future taxable surplus will be available,
against which the deferred tax asset can be offset. As it is not yet possible to reliably calculate when Oasmia will achieve such
a surplus, no deferred tax assets have been recognized.
Employee benefits
Current remuneration
Current remuneration to employees is calculated without discounting
and is recognized as an expense when the services concerned are obtained.
Pension obligations
The Group has defined contribution pension
plans. A defined contribution plan is a pension plan under which the Group pays fixed contributions to a separate legal entity.
The Group has no legal or constructive obligations to pay further contributions if this legal entity does not hold sufficient assets
to pay all employee benefits relating to employee service in the current and prior periods. Defined contribution pension plan obligations
are recognized as employee benefits as and when they are earned by employees carrying out services for the company in any given
period. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is
available to the Group.
Severance pay
Severance pay is awarded when notice is given
to an employee by Oasmia before the normal pension date, or when an employee accepts voluntary resignation in exchange for such
payments. The Group recognizes severance pay when it is obliged either to give notice to the employee according to a detailed formal
plan without the possibility of recall, or to pay remuneration when notice is given as a result of an offer made to encourage voluntary
resignation. Benefits which are due more than 12 months after closing day are discounted to the present value.
Revenue recognition
Revenues comprise the fair value of what has been received or will
be received for sold goods, services and necessities as a result of the Group’s business operations. Revenue is recognized
without value added tax, and after elimination of intra-Group sales. The Group recognizes revenue when the amount can be measured
in a reliable manner, it is likely that future economic benefits will accrue to the Group and certain criteria have been fulfilled
for each of the business activities of the Group described below.
a) Sales of goods
Revenues from sales of goods are recognized at the time when they
are delivered to customers, licensees or distributors. This is the time when ownership rights are transferred to the recipient
of the goods.
In addition to sales of registered pharmaceuticals, sales may be
conducted before a drug has been registered, in the following two cases. In the first case, the purchaser is a hospital pharmacy
or veterinary clinic where the company’s clinical trials are ongoing. In the second case, the purchaser is a treating clinic
that has decided to test a drug that has not yet been approved, as registered drugs have not had the desired effect. Both cases
are called compassionate use and the Parent Company has had such sales. In such cases delivery and invoicing of the product are
performed at the same time and the revenue is recognized at this time.
(b) Contract assignments
Contract assignments carried out are recognized as revenue to the
extent that they have been completed at the end of the reporting period, that is by gradual revenue recognition.
(c) Sale of necessities
Oasmia sells necessities, in the form of sterile water that has
been produced in the company’s facility, to another company. The resulting revenues are recognized upon delivery.
(d) Royalties
Royalty revenues arise when a licensee recognizes sales in its market.
Royalty revenues are recognized in the same period as the licensee’s sales.
Leasing
Leasing whereby a significant part of the risks and benefits of
ownership is retained by the lessor is classified as operational leasing. Payments made during the lease term (after deduction
of any incentives from the lessor) are carried as an expense in the income statement on a straight-line basis over the term of
the lease. Oasmia has no financial leasing.
Dividends
Dividends paid to the Parent Company's shareholders are recognized
as liabilities in the consolidated financial statements in the period in which the dividends are approved by Parent Company shareholders.
Cash flow
Cash flow statements are prepared using the indirect method.
NOTE 3 SIGNIFICANT ESTIMATES AND ASSUMPTIONS FOR ACCOUNTING PURPOSES
Estimates and judgments are continually evaluated and are based
on historical experience and other factors, including expectations of future events that are believed to be reasonable under the
current circumstances.
Assumptions and uncertainties related to going concern
Oasmia has incurred losses through and including its fiscal year
ending April 30, 2017. As of April 30, 2017, Oasmia had an accumulated deficit of SEK 786.85 million. The cash flow from operating
activities has also been negative.
Oasmia has one product approved, but this does not yet create a
sufficient cash flow from its own business. For this reason, Oasmia continuously works with various financing alternatives. This
work includes that the company is in discussions with potential partners for licensing of distribution and sales rights, negotiations
with new and existing investors, financiers and lenders and that the company ensures enough resources to secure that forecasted
future revenue streams from regions where the company's products registered, are realized.
Available consolidated liquid assets and unutilized credit facilities
as of April 30, 2017 are not sufficient to provide the required capital to pursue the planned activities during the next 12 months.
In light of available financing alternatives and the recent developments in the Company, the Board of Directors assesses that the
prospects for financing of the Company´s operations in the coming year are good. Should funding not be obtained in sufficient
quantities there is a risk that the conditions for continued operation do not exist.
Significant estimates and assumptions for accounting purposes
Group management makes estimates and assessments about the future.
The resulting estimates for accounting purposes will by definition seldom correspond to the actual outcome. The estimates and assessments
that entail a considerable risk of significant adjustments in the carrying amounts for assets and liabilities in the next financial
year are listed below.
(a) Impairment tests for intangible
assets
The Group capitalizes development costs for
two drug candidates Paclical and Paccal Vet. The capitalized development costs for the financial year ending April 30, 2017 amounted
to SEK 7,898 compared to TSEK 16,727 as per April 30, 2016 and TSEK 16,797 as per April 30, 2015. The Group's accumulated capitalized
development costs, as of April 30, 2017, amounted to SEK 416,922 thousand compared to SEK 409,900 thousand as of April 30, 2016.
An assessment is performed annually of whether there is a need for impairment of these assets. Oasmia’s impairment tests
show that there is no need for impairment. Market approval has been received for Paclical in Russia for the indication of ovarian
cancer in humans and market approval is expected within two to three years for Paccal Vet in the US for the indications of mammary
carcinoma and squamous cell carcinoma in dogs. In Oasmia’s assessment, more market approvals can be expected in the foreseeable
future and expected future profits justify the value of the assets. If the other market approvals were not to be received, if
a considerably lower price than expected was received per treatment, if the market share was lower, or if the likelihood of receiving
approval were to decrease, all or parts of the capitalized expenditure would be carried as expenses. As of April 30, 2017 capitalized
expenditure amounted to 139 % compared to 126 % as of April 30, 2016 of the equity at the same time.
(b) Income taxes
The Group is required to pay tax in Sweden. The Group's companies
have so far showed negative taxable income, and as a result significant taxable deficits exist in the Group. There are at present
no sufficiently convincing indications as to when loss carry-forward will be able to be utilized against future profits, and thus
no deferred tax asset has been taken into consideration in the balance sheet.
Accumulated taxable deficits in the Group are described in Note
16.
(c) Contingent assets
The company has filed to sue a supplier of WFI-equipment regarding
delivered equipment that the company considers to be faulty. The total estimated loss that this faulty equipment has caused the
company amounted to SEK 14,500 thousand, and Oasmia has so far received insurance compensation of SEK 4,250 thousand. Should the
legal action be successful, Oasmia is demanding approximately SEK 9,500 thousand. The trial has begun and the main proceedings
will take place in November 2017 and it is therefore not yet possible to assess when any payment will be received. The company’s
legal counsel has advised management that it is likely that the legal action will be successful, at least regarding part of the
amount claimed, but as this is uncertain no asset has been recognized in the Statement of Financial Position.
(d) Contingent liabilities
A contingent liability is a possible liability whose occurrence
will possibly be confirmed by future events which wholly or partly, are beyond Oasmia’s control and whose probability of
occurring is low or difficult to estimate. It may also be an existing liability, the size of which cannot be calculated or the
settlement of which is unlikely to result in any outflow of resources.
It is obviously in the nature of contingent liabilities that their
occurrence and size are particularly uncertain and therefore they are not recognized in the balance sheet. Instead information
is given about them in Note 24. If it is at all possible to state any amounts for these contingent liabilities, they are, as can
be seen above, largely dependent on management’s assessments.
Important judgements when applying the company’s accounting
policies
The Group capitalizes development costs for two pharmaceutical candidates,
Paclical/Apealea and Paccal Vet. The company assesses that the beginning of a phase III study is the earliest time when all criteria
for capitalization can be fulfilled. It is at this time that the company can assess whether it is technically possible to complete
the intangible asset so that it can be used or sold. If the Group should make the judgment that all capitalization criteria are
no longer fulfilled, these assets would be written off against Group income.
At least once a year, normally when the annual financial statements
are prepared, the Group’s property, plant and equipment and non-current intangible assets are tested to see if there is a
need for impairment. Tests may also be carried out if management assesses that there have been significant changes in the assumptions
that can affect the result of the tests. The question is whether the recoverable amount of the asset is greater than its carrying
amount. Usually these Group assets have no stated market value, and the company therefore applies the value in use method. One
of the important assets that are the subject of impairment testing is the item capitalized development costs for Paccal Vet and
Paclical/Apealea. The impairment testing is based on management’s forecasts for the future economic development of the products
Paccal Vet and Paclical/Apealea. These forecasts are partly based on available statistics, primarily on the incidence of cancer
per type of cancer, but also on management’s assessment of future development that cannot be supported by external statistics
or comparative data. The result of the impairment testing consists of seeing if the value in use is greater than the carrying amount
of the assets. If this is the case, no impairment is performed. If on the other hand the value in use is less than the carrying
amount, the asset is written down to its recoverable amount.
The Group capitalizes expenditures for patents because they are
expected to generate future economic benefits. If the Group should make the judgment that they will no longer generate future economic
benefits, these assets would be written off against the Group's income.
NOTE 4 SEGMENT INFORMATION
The Group currently has only one segment and
therefore reports no information by segment.
The Group has its registered office in Sweden. All net sales derive
from sales to external customers, and are shown below divided up into product categories and geographic area.
Net sales per product category
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Sales of necessities
|
|
|
172
|
|
|
|
96
|
|
|
|
68
|
|
Royalty revenues
|
|
|
-
|
|
|
|
4,870
|
|
|
|
122
|
|
Sales of goods
|
|
|
-
|
|
|
|
1,207
|
|
|
|
1,880
|
|
Invoiced services
|
|
|
-
|
|
|
|
200
|
|
|
|
-
|
|
Total
|
|
|
172
|
|
|
|
6,373
|
|
|
|
2,070
|
|
Net sales per geographic area
Below allocation of Net Sales per geographic area is based on the
customer’s domicile.
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Russia
|
|
|
-
|
|
|
|
6,019
|
|
|
|
-
|
|
Sweden
|
|
|
172
|
|
|
|
125
|
|
|
|
68
|
|
Other countries
|
|
|
-
|
|
|
|
229
|
|
|
|
2,002
|
|
Total
|
|
|
172
|
|
|
|
6,373
|
|
|
|
2,070
|
|
Net sales in Russia of SEK 6,019 thousand in the financial year
ending April 30, 2016 derive from one specific customer with its registered office in Russia. Revenue from external customers in
other countries amounted to SEK 2,002 thousand in the financial year ended April 30, 2015 and came from sales to a customer based
in the USA.
Non-current assets located in Sweden as per April 30, 2017 amount
to SEK 466,474 thousand compared to SEK 437,297 thousand as of April 30, 2016 and SEK 421,973 thousand as of April 30, 2015 and
non-current assets located in another country as per April 30, 2017 amount to SEK 4,990 thousand compared to SEK 5,713 thousand
as of April 30, 2016 and SEK 5,905 thousand as of April 30, 2015.
NOTE 5 CAPITALIZED DEVELOPMENT COSTS
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
TSEK
|
|
Paclical
|
|
|
Paccal
Vet
|
|
|
Total
|
|
|
Paclical
|
|
|
Paccal
Vet
|
|
|
Total
|
|
|
Paclical
|
|
|
Paccal
Vet
|
|
|
Total
|
|
Opening acquisition cost
|
|
|
300,088
|
|
|
|
109,812
|
|
|
|
409,900
|
|
|
|
290,108
|
|
|
|
103,065
|
|
|
|
393,173
|
|
|
|
280,919
|
|
|
|
95,457
|
|
|
|
376,376
|
|
Adjustment
*)
|
|
|
-
|
|
|
|
(875
|
)
|
|
|
(875
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Capitalized expenditure for the year
|
|
|
7,559
|
|
|
|
338
|
|
|
|
7,897
|
|
|
|
9,980
|
|
|
|
6,747
|
|
|
|
16,727
|
|
|
|
9,189
|
|
|
|
7,608
|
|
|
|
16,797
|
|
Closing accumulated acquisition cost
|
|
|
307,647
|
|
|
|
109,275
|
|
|
|
416,922
|
|
|
|
300,088
|
|
|
|
109,812
|
|
|
|
409,900
|
|
|
|
290,108
|
|
|
|
103,065
|
|
|
|
393,173
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Opening accumulated amortization
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
Amortization for the year
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
Closing accumulated amortization
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Closing carrying amount
|
|
|
307,647
|
|
|
|
109,275
|
|
|
|
416,922
|
|
|
|
300,088
|
|
|
|
109,812
|
|
|
|
409,900
|
|
|
|
290,108
|
|
|
|
103,065
|
|
|
|
393,173
|
|
*)
In some cases the capitalization of development
costs is based on assessments, which may deviate from the actual outcome and then has to be adjusted.
Capitalized development costs amounted to TSEK 7,898 for the financial
year ended April 30, 2017 compared to TSEK 16,727 as of April 30, 2016 and TSEK 16,797 as of April 30, 2015. Research and development
costs which were not capitalized amounted to TSEK 89,964 for the financial year ended April 30, 2017 compared to TSEK 96,884 in
the financial year ending April 30, 2016 and TSEK 74,028 in the financial year ending April 30, 2015. Total cost for research and
development, capitalized and expensed, amounted TSEK 97,862 for the financial year ended 30 April, 2017 compared to TSEK 113,611
as of April 30, 2016 and TSEK 90,825 as of April 30, 2015.
NOTE 6 OTHER OPERATING INCOME
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
- APR 30,
2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Insurance compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
26
|
|
State support (new start jobs)
|
|
|
-
|
|
|
|
-
|
|
|
|
153
|
|
Exchange-rate differences
|
|
|
202
|
|
|
|
2
|
|
|
|
42
|
|
Other
|
|
|
218
|
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
|
420
|
|
|
|
2
|
|
|
|
221
|
|
NOTE 7 INVENTORIES
TSEK
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Raw materials and necessities
|
|
|
5,581
|
|
|
|
7,129
|
|
Work in progress
|
|
|
8,104
|
|
|
|
4,137
|
|
Finished goods
|
|
|
-
|
|
|
|
5,372
|
|
Total
|
|
|
13,685
|
|
|
|
16,638
|
|
During the financial year ended April 30, 2017
goods of TSEK 0 compared to TSEK 2,383 as of April, 2016 and TSEK 2,439 as of April 30, 2015 were carried as an expense and goods
valued at TSEK 5,736 as of April 30, 2017 compared to TSEK 229 as of April 30, 2016 and TSEK 0 as of April 30, 2015 have been written
down, which mainly drives from finished goods intended for the Russian market.
The change in the items “Work in progress”
and “Finished goods” during the year are recognized in the income statement in “Change in inventories of
products in progress and finished goods”.
NOTE 8 REMUNERATION TO AUDITORS
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Ernst & Young AB
|
|
|
|
|
|
|
|
|
|
|
|
|
Auditing
|
|
|
1,729
|
|
|
|
1,390
|
|
|
|
1,405
|
|
Auditing activities in addition to auditing
|
|
|
800
|
|
|
|
2,459
|
|
|
|
1,363
|
|
Tax consulting
|
|
|
10
|
|
|
|
32
|
|
|
|
35
|
|
Other services
|
|
|
59
|
|
|
|
131
|
|
|
|
112
|
|
Total
|
|
|
2,598
|
|
|
|
4,012
|
|
|
|
2,915
|
|
Auditing involves reviews of the Annual Report, of the accounting
records, and of the management of the Board of Directors and CEO, and other tasks that the company’s auditors are required
to undertake. Auditing activities in addition to auditing include review of interim reports and quality assurance services.
NOTE 9 LEASING
The Group has no financial leasing agreements,
but has operational leasing agreements that primarily consist of leases for facilities. There are no variable fees. Leasing costs
(minimum lease payments) were TSEK 6,379 for the financial year ended April 30, 2017 compared to TSEK 5,930 as of April 30, 2016
and TSEK 5,303 as of April 30, 2015. The future minimum lease payments for operational leases are as follows in (TSEK):
|
|
Operational leasing
|
|
Financial year
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
TSEK
|
|
-APR 30, 2017
|
|
|
-APR 30, 2016
|
|
Leasing expensed during the financial year
|
|
|
6,379
|
|
|
|
5,930
|
|
Nominal value of future minimum leasing payments
|
|
|
|
|
|
|
|
|
is divided up as follows:
|
|
|
|
|
|
|
|
|
Due for payment within a year
|
|
|
6,369
|
|
|
|
6,362
|
|
Due for payment later than a year but within five years
|
|
|
13,696
|
|
|
|
17,398
|
|
Due for payment later than five years
*)
|
|
|
2,041
|
|
|
|
2,637
|
|
Total
|
|
|
22,106
|
|
|
|
26,397
|
|
*)
The comparative figure has been adjusted compared
to last year’s financial statements because the category “Due for payment later than five years
”
has
been added.
NOTE 10 EMPLOYEES AND REMUNERATION
Average number of employees
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Women
|
|
|
37
|
|
|
|
35
|
|
|
|
37
|
|
Men
|
|
|
38
|
|
|
|
40
|
|
|
|
38
|
|
Total
|
|
|
75
|
|
|
|
75
|
|
|
|
75
|
|
All employees have their employment and carry out their main duties
in Sweden.
Salaries and benefits
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Board
|
|
|
2,821
|
|
|
|
3,169
|
|
|
|
1,495
|
|
CEO and other senior executives
|
|
|
4,505
|
|
|
|
6,171
|
|
|
|
6,891
|
|
Other employees
|
|
|
35,150
|
|
|
|
32,160
|
|
|
|
28,786
|
|
Defined contribution pension plans, incl. Fora
|
|
|
3,057
|
|
|
|
2,668
|
|
|
|
2,043
|
|
Defined medical benefits
|
|
|
356
|
|
|
|
276
|
|
|
|
39
|
|
Total salary and remuneration
|
|
|
45,890
|
|
|
|
44,445
|
|
|
|
39,256
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Social security contributions by law and agreement
|
|
|
12,076
|
|
|
|
11,677
|
|
|
|
10,492
|
|
Special employer’s contribution, pension expenses
|
|
|
819
|
|
|
|
717
|
|
|
|
488
|
|
Total salaries, remuneration and social security
|
|
|
58,785
|
|
|
|
56,840
|
|
|
|
50,236
|
|
Benefits for senior executives
Board of Directors and Board committees
Remuneration of the Chairman of the Board of Directors and Board
members is decided by the Annual General Meeting. There is no remuneration for participation in the Nomination Committee. Board
fees for Joel Citron are invoiced through wholly-owned Miankoma Partners, Hans Liljeblad is invoiced through wholly-owned Advokatfirman
Liljeblad & Co KB and Lars Bergkvist is invoiced through wholly-owned Axli AB in accordance with the decision of the Annual
General Meeting and by special agreement with Oasmia Pharmaceutical AB. Except for what is described in Transactions with key people
in senior positions in Note 26, no other remuneration such as salary, pension premiums or other benefits has been paid.
The Executive Chairman of the Board is entitled to pension insurance
pursuant to an agreement whereby the company shall pay an amount corresponding to 25 percent of the pensionable annual salary to
any chosen pension insurance company. The Executive Chairman of the Board is also entitled to individual health insurance.
CEO
Remuneration of the CEO consists of a fixed salary. The remuneration
is reviewed annually on April 1. According to the CEO's agreement regarding pension insurance, the company shall pay an annual
amount corresponding to the ITP scale. The CEO is also entitled to individual health insurance. If notice of termination is given
by the employer, a 12-month term of notice applies. If notice of termination is given by the CEO, the term of notice is 3 months.
Terms of employment for other senior executives
Remuneration to other senior executives consists of a fixed salary.
Salaries are reviewed annually on April 1. According to the agreement for other senior executives regarding pension insurance,
the company shall pay an annual amount corresponding to the ITP scale. Other senior executives are also entitled to individual
health insurance.
Remuneration to Board and senior executives
|
|
MAY 1, 2016 – APR 30, 2017
|
|
TSEK
|
|
Base salary/
board fees
|
|
|
Social
security incl.
special
employer’s
contribution
|
|
|
Pension/
sickness
benefits
|
|
|
Variable
remuneration
|
|
Chairman of the Board Anders Lönner
1)
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Chairman of the Board /Vice Chairman of the Board Julian Aleksov
2)
|
|
|
1,698
|
|
|
|
644
|
|
|
|
449
|
|
|
|
23
|
|
Board member, Bo Cederstrand
|
|
|
150
|
|
|
|
25
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Horst Domdey
3)
|
|
|
96
|
|
|
|
30
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Alexander Kotsinas
|
|
|
89
|
|
|
|
28
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Hans Sundin
3)
|
|
|
537
|
|
|
|
88
|
|
|
|
-
|
|
|
|
16
|
|
Board member, Hans Liljeblad
4)
|
|
|
63
|
|
|
|
19
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Lars Bergkvist
|
|
|
150
|
|
|
|
47
|
|
|
|
-
|
|
|
|
-
|
|
CEO Mikael Asp
|
|
|
1,366
|
|
|
|
479
|
|
|
|
230
|
|
|
|
-
|
|
Other senior executives (2 people at end of year, 2 people on average during financial year)
5)
|
|
|
3,127
|
|
|
|
1,134
|
|
|
|
621
|
|
|
|
13
|
|
Total
|
|
|
7,275
|
|
|
|
2,495
|
|
|
|
1,300
|
|
|
|
51
|
|
1)
Elected Chairman of the Board in November 2016 and
resigned in February 2017.
2)
Elected Chairman of the Board in May 2015 and switched
to Vice Chairman in November 21, 2016 to February 27, 2017. Julian Aleksov is the Executive Chairman and receives a salary.
3)
Resigned in November 2016.
4)
Resigned in September 2016.
5)
In November 2016 management team was increased by
one person. One senior executive resigned in March 2017.
|
|
MAY 1, 2015 – APR 30, 2016
|
|
TSEK
|
|
Base salary/
board fees
|
|
|
Social
security incl.
special
employer’s
contribution
|
|
|
Pension/
sickness
benefits
|
|
|
Variable
remuneration
|
|
Chairman of the Board Joel Citron
1)
|
|
|
26
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Chairman of the Board Julian Aleksov
2)
|
|
|
1,635
|
|
|
|
582
|
|
|
|
422
|
|
|
|
35
|
|
Board member, Bo Cederstrand
|
|
|
150
|
|
|
|
20
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Horst Domdey
|
|
|
150
|
|
|
|
47
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Alexander Kotsinas
3)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Hans Sundin
|
|
|
883
|
|
|
|
99
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Hans Liljeblad
4)
|
|
|
200
|
|
|
|
62
|
|
|
|
-
|
|
|
|
-
|
|
Board member, Lars Bergkvist
4)
|
|
|
125
|
|
|
|
39
|
|
|
|
-
|
|
|
|
-
|
|
CEO Mikael Asp
5)
|
|
|
1,299
|
|
|
|
470
|
|
|
|
55
|
|
|
|
1
|
|
Other senior executives (2 people at end of year, 5 people on average during financial year)
6)
|
|
|
4,792
|
|
|
|
1,544
|
|
|
|
615
|
|
|
|
79
|
|
Total
|
|
|
9,260
|
|
|
|
2,863
|
|
|
|
1,092
|
|
|
|
115
|
|
1)
Resigned in May 2015.
2)
Elected Chairman of the Board in May 2015. Julian
Aleksov is the Executive Chairman of the Board and is paid a salary.
3)
Alexander Kotsinas has declined a Board fee.
4)
Elected as Board member in May 2015.
5)
Appointed new CEO in May 2015.
6)
In February 2016 management was increased by one person.
Four senior executives resigned in February and March 2016.
Gender distribution on the Board and in management
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
|
APR 30, 2015
|
|
|
|
Number on
closing day
|
|
|
Number of
men
|
|
|
Number on
closing day
|
|
|
Number of
men
|
|
|
Number on
closing day
|
|
|
Number of
men
|
|
Group (incl subsidiaries)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Board members
*)
|
|
|
12
|
|
|
|
12
|
|
|
|
13
|
|
|
|
13
|
|
|
|
12
|
|
|
|
12
|
|
CEO and other senior executives
|
|
|
3
|
|
|
|
3
|
|
|
|
4
|
|
|
|
4
|
|
|
|
7
|
|
|
|
5
|
|
*)
The comparative figure has been adjusted compared
to last year’s Annual Report. The statement of gender distribution among Board members in the Group as per April 30, 2016
has been adjusted from 7 (of which 7 men) to 13 (of which 13 men) and as per April 30, 2015 has been adjusted from 5 (of which
5 men) to 12 (of which 12 men). This adjustment has been made to show all Board seats as per April 30, 2016 and 2015 respectively.
In the event that the same person is present in the Boards of several companies included in the Group, the person is now counted
as a member of the Board of each company, which was not the case in the previous year’s annual report.
Health care and medical care
Oasmia offers its employees free medical care up to the cost ceiling
and free medicines up to the cost ceiling. Oasmia has also signed an agreement with a provider of occupational health services.
NOTE 11 PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment consist of vehicles, inventory and
production equipment, leasehold improvements, and construction in progress and advance payments for machinery and equipment.
|
|
Group MAY 1, 2016
– APR 30, 2017
|
|
|
|
|
TSEK
|
|
Vehicles
|
|
|
Inventories
and
production
equipment
|
|
|
Leasehold
improvements
|
|
|
Construction in
progress and advance
payments for
machinery and
equipment
|
|
|
Total
|
|
Opening acquisition cost
|
|
|
0
|
|
|
|
43,500
|
|
|
|
8,378
|
|
|
|
100
|
|
|
|
51,977
|
|
Investments for the year
|
|
|
225
|
|
|
|
184
|
|
|
|
60
|
|
|
|
46
|
|
|
|
515
|
|
Reclassifications
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
Sales/disposals
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
Closing accumulated acquisition cost
|
|
|
225
|
|
|
|
43,684
|
|
|
|
8,437
|
|
|
|
146
|
|
|
|
52,492
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Opening depreciation
|
|
|
0
|
|
|
|
(27,898
|
)
|
|
|
(2,907
|
)
|
|
|
0
|
|
|
|
(30,805
|
)
|
Depreciation for the year
|
|
|
(75
|
)
|
|
|
(2,814
|
)
|
|
|
(430
|
)
|
|
|
-
|
|
|
|
(3,319
|
)
|
Sales/disposals
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
Closing accumulated depreciation
|
|
|
(75
|
)
|
|
|
(30,712
|
)
|
|
|
(3,337
|
)
|
|
|
0
|
|
|
|
(34,124
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Closing carrying amount
|
|
|
150
|
|
|
|
12,972
|
|
|
|
5,100
|
|
|
|
146
|
|
|
|
18,368
|
|
|
|
Group MAY 1, 2015 – APR 30,2016
|
|
|
|
|
TSEK
|
|
Vehicles
|
|
|
Inventories
and
production
equipment
|
|
|
Leasehold
improvements
|
|
|
Construction in
progress and advance
payments for
machinery and
equipment
|
|
|
Total
|
|
Opening acquisition cost
|
|
|
148
|
|
|
|
40,557
|
|
|
|
8,205
|
|
|
|
1,241
|
|
|
|
50,151
|
|
Investments for the year
|
|
|
-
|
|
|
|
1,802
|
|
|
|
172
|
|
|
|
|
|
|
|
1,974
|
|
Reclassifications
|
|
|
-
|
|
|
|
1,141
|
|
|
|
-
|
|
|
|
(1,141
|
)
|
|
|
0
|
|
Sales/disposals
|
|
|
(148
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
(148
|
)
|
Closing accumulated acquisition cost
|
|
|
0
|
|
|
|
43,500
|
|
|
|
8,378
|
|
|
|
100
|
|
|
|
51,977
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Opening depreciation
|
|
|
(148
|
)
|
|
|
(24,667
|
)
|
|
|
(2,484
|
)
|
|
|
0
|
|
|
|
(27,299
|
)
|
Depreciation for the year
|
|
|
-
|
|
|
|
(3,231
|
)
|
|
|
(423
|
)
|
|
|
-
|
|
|
|
(3,654
|
)
|
Sales/disposals
|
|
|
148
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
148
|
|
Closing accumulated depreciation
|
|
|
0
|
|
|
|
(27,898
|
)
|
|
|
(2,907
|
)
|
|
|
0
|
|
|
|
(30,805
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Closing carrying amount
|
|
|
0
|
|
|
|
15,602
|
|
|
|
5,471
|
|
|
|
100
|
|
|
|
21,172
|
|
NOTE 12 OTHER INTANGIBLE ASSETS
Other intangible assets consist of the costs of patents and of acquired
research projects.
|
|
Group MAY 1, 2016 – APR 30, 2017
|
|
|
Group MAY 1, 2015 – APR 30, 2016
|
|
TSEK
|
|
Patents
|
|
|
Research
projects
|
|
|
Total
|
|
|
Patents
|
|
|
Research
projects
|
|
|
Total
|
|
Opening acquisition cost
|
|
|
23,615
|
|
|
|
0
|
|
|
|
23,615
|
|
|
|
22,382
|
|
|
|
0
|
|
|
|
22,382
|
|
Purchases for the year
|
|
|
423
|
|
|
|
25,000
|
|
|
|
25,423
|
|
|
|
1,233
|
|
|
|
-
|
|
|
|
1,233
|
|
Divestments
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
Disposals
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0
|
|
Closing accumulated acquisition cost
|
|
|
24,038
|
|
|
|
25,000
|
|
|
|
49,038
|
|
|
|
23,615
|
|
|
|
0
|
|
|
|
23,615
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Opening accumulated amortization
|
|
|
(11,679
|
)
|
|
|
0
|
|
|
|
(11,679
|
)
|
|
|
(10,529
|
)
|
|
|
0
|
|
|
|
(10,529
|
)
|
Amortization for the year
|
|
|
(1,188
|
)
|
|
|
-
|
|
|
|
(1,188
|
)
|
|
|
(1,150
|
)
|
|
|
-
|
|
|
|
(1,150
|
)
|
Disposals
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Closing accumulated amortization
|
|
|
(12,867
|
)
|
|
|
0
|
|
|
|
(12,867
|
)
|
|
|
(11,679
|
)
|
|
|
0
|
|
|
|
(11,679
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Closing carrying amount
|
|
|
11,171
|
|
|
|
25,000
|
|
|
|
36,171
|
|
|
|
11,936
|
|
|
|
0
|
|
|
|
11,936
|
|
NOTE 13 CURRENCY DIFFERENCES – NET
Currency differences are recognized in the income statement as follows:
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Other operating income
|
|
|
202
|
|
|
|
2
|
|
|
|
42
|
|
Raw materials, consumables and goods for resale
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,249
|
)
|
Other external expenses
|
|
|
(1,591
|
)
|
|
|
478
|
|
|
|
-
|
|
Financial items – net
|
|
|
(44
|
)
|
|
|
(480
|
)
|
|
|
(11
|
)
|
Total
|
|
|
(1,433
|
)
|
|
|
0
|
|
|
|
(1,218
|
)
|
NOTE 14 OPERATING INCOME
Operating income for the financial year ending April 30, 2017 was
TSEK (140,481) compared to TSEK (132,691) for the financial year ending April 30, 2016 and TSEK (108,225) for the financial year
ending April 30, 2015. Of the Group's recognized operating expenses of TSEK 146,691 in the financial year ending April 30, 2017,
TSEK 165,273 in the financial year ending April 30, 2016 and TSEK 127,313 in the financial year ending April 30, 2015, TSEK 7,898
was recognized as capitalized development costs in the financial year ending April 30, 2017 compared to TSEK 16,727 in the financial
year ending April 30, 2016 and TSEK 16,797 in the financial year ending April 30, 2015.
NOTE 15 FINANCIAL INCOME AND EXPENSES
|
|
|
|
Group
|
|
|
|
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
Category
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Financial income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bank accounts
|
|
Loans receivable and accounts receivable
|
|
|
4
|
|
|
|
726
|
|
|
|
29
|
|
Short-term investments
|
|
Financial assets valued at fair value
|
|
|
30
|
|
|
|
-
|
|
|
|
153
|
|
Other
|
|
-
|
|
|
51
|
|
|
|
60
|
|
|
|
41
|
|
Total financial income
|
|
|
|
|
85
|
|
|
|
786
|
|
|
|
223
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities to credit institutions
|
|
Financial liabilities valued at amortized cost
|
|
|
(194
|
)
|
|
|
(365
|
)
|
|
|
(1,094
|
)
|
Convertible loans
|
|
Financial liabilities valued at amortized cost
|
|
|
(6,728
|
)
|
|
|
(115
|
)
|
|
|
-
|
|
Other borrowings
|
|
Financial liabilities valued at amortized cost
|
|
|
(6,549
|
)
|
|
|
(7,616
|
)
|
|
|
(8,324
|
)
|
Accounts payable
|
|
Financial liabilities valued at amortized cost
|
|
|
(6
|
)
|
|
|
(134
|
)
|
|
|
(12
|
)
|
Other
|
|
-
|
|
|
(13
|
)
|
|
|
(4
|
)
|
|
|
(1
|
)
|
|
|
|
|
|
(13,490
|
)
|
|
|
(8,234
|
)
|
|
|
(9,431
|
)
|
Other financial expenses and exchange rate differences
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term investments
|
|
Financial assets valued at fair value
|
|
|
-
|
|
|
|
(49
|
)
|
|
|
-
|
|
Bank accounts
|
|
Loans receivable and accounts receivable
|
|
|
(10
|
)
|
|
|
(1,216
|
)
|
|
|
(64
|
)
|
Convertible loans
|
|
Financial liabilities valued at amortized cost
|
|
|
(6,259
|
)
|
|
|
(86
|
)
|
|
|
-
|
|
Other
|
|
-
|
|
|
(88
|
)
|
|
|
(49
|
)
|
|
|
-
|
|
|
|
|
|
|
(6,357
|
)
|
|
|
(1,400
|
)
|
|
|
(64
|
)
|
Total financial expenses
|
|
|
|
|
(19,847
|
)
|
|
|
(9,634
|
)
|
|
|
(9,495
|
)
|
NOTE 16 INCOME TAXES
The Parent Company and two subsidiaries have their fiscal domicile
in Sweden, where the tax rate for the financial year ending April 30, 2017 is 22 % compared to 22 % for the financial years ending
April 30, 2016 and 2015 respectively. In addition, a subsidiary has its fiscal domicile in the USA and one in Hong Kong.
The income tax on Group earnings before tax is shown in the table
below:
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
TSEK
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Income before taxes
|
|
|
(160,243
|
)
|
|
|
(141,539
|
)
|
|
|
(117,497
|
)
|
Issue expenses not included in earnings
|
|
|
(3,605
|
)
|
|
|
(14,706
|
)
|
|
|
0
|
|
Non-taxable revenues
|
|
|
(1
|
)
|
|
|
0
|
|
|
|
(1
|
)
|
Non-deductible expenses
|
|
|
6,087
|
|
|
|
607
|
|
|
|
366
|
|
Impairment of holdings in subsidiaries
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
Taxable income
|
|
|
(157,762
|
)
|
|
|
(155,638
|
)
|
|
|
(117,132
|
)
|
Income tax according to current tax rates in Sweden
|
|
|
34,708
|
|
|
|
34,240
|
|
|
|
25,769
|
|
Taxable deficits for which no deferred tax asset is recognized
|
|
|
(34,708
|
)
|
|
|
(34,240
|
)
|
|
|
(25,769
|
)
|
Tax expense
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
At April 30, 2017 the Group had accumulated loss carry-forward from
previous years and from the financial year amounting to TSEK 878,339 compared to TSEK 720,576 as of April 30, 2016 and TSEK 521,391
as of April 30, 2015. There are at present no sufficiently convincing reasons to assume that loss carry-forward will be able to
be utilized against future profits, and thus no deferred tax asset has been recognized in the balance sheet.
NOTE 17 EARNINGS PER SHARE
Earnings per share are calculated by dividing earnings attributable
to Parent Company shareholders by a weighted number of common shares outstanding during the period.
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Earnings attributable to Parent Company shareholders (TSEK)
|
|
|
(160,243
|
)
|
|
|
(141,539
|
)
|
|
|
(117,497
|
)
|
Weighted average number of common shares outstanding (thousands)
|
|
|
112,994
|
|
|
|
101,753
|
|
|
|
91,655
|
|
Earnings per share (SEK per share)
|
|
|
(1.42
|
)
|
|
|
(1.39
|
)
|
|
|
(1.28
|
)
|
The following instruments outstanding have not given rise to any
dilution effect at April 30, 2017, but may do so in the future:
|
|
Number of
warrants
and
convertibles
|
|
|
Total
possible
number of
shares
|
|
Warrants that can be converted to 3 (three) shares
|
|
|
1,280,750
|
|
|
|
3,842,250
|
|
Warrants that can be converted to 1 (one) share
|
|
|
140,352
|
|
|
|
140,352
|
|
Convertible instruments
|
|
|
68
|
|
|
|
6,750,000
|
|
Total possible number of shares
|
|
|
|
|
|
|
10,732,602
|
|
NOTE 18 FINANCIAL INSTRUMENTS AND FINANCIAL
RISKS
Financial risks
Oasmia’s business, like all business
activities, is subjected to a large number of risks. In general these may be divided into such risks that directly affect the Group’s
financial situation (financial risks) and such risks that only affect the financial situation indirectly (operational risks). What
operational risks Oasmia is subjected to and how these are managed is described in the sections Management Discussion and Analysis
and in Risk Factors.
Financial risks can be divided up into such
risks that affect the Group’s financial instruments and other financial risks. The latter affect other assets and liabilities
and equity.
The financial risks that Oasmia’s financial instruments are
to varying extents subjected to are primarily:
|
·
|
Credit
risk,
meaning the risk that a debtor does not pay its liability to Oasmia.
|
|
·
|
Liquidity
risk,
meaning the risk that Oasmia does not have sufficient funds to pay a liability when it falls due for payment or that
a lack of liquidity significantly limits Oasmia in its business operations.
|
|
·
|
Market
risk,
meaning the risk that values that are dependent on the development of the financial markets affect the value of Oasmia’s
financial instruments negatively.
|
The market risks that affect Oasmia’s financial instruments
are primarily:
– Market price risk: the market price of the fixed
income funds that Oasmia invests surplus liquidity in. There is no such risk as of April 30, 2017.
– Currency risk: exchange rates for the currencies
that Oasmia’s financial instruments are denominated in.
– Interest-rate risk: Stockholm Interbank Offered
Rate (Stibor), which the interest on Oasmia’s bank loans is tied to. There is no such risk as of April 30, 2017.
The following sensitivity analysis shows the
effect in TSEK if each parameter were to change by 1 percent, and, in the case of the interest-rate risk, if the percentage level
were to change by 1 percent:
|
|
|
|
Market price
risk
|
|
|
Currency
risk
|
|
|
Interest-
rate risk
|
|
Financial instrument
|
|
Parameter
|
|
APR
30,
2017
|
|
|
APR
30,
2016
|
|
|
APR
30,
2017
|
|
|
APR
30,
2016
|
|
|
APR
30,
2017
|
|
|
APR
30,
2016
|
|
Short-term investments
|
|
Market price +/- 1 percent
|
|
|
-
|
|
|
|
200
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Financial liabilities
|
|
Interest rate +/- 1 percentage point
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
30
|
|
Accounts payable and other current liabilities
|
|
Currency rate +/- 1 percent
|
|
|
-
|
|
|
|
-
|
|
|
|
170
|
|
|
|
250
|
|
|
|
-
|
|
|
|
-
|
|
These risks, how they are managed and what
financial instruments are affected by them are discussed further below in the sections “Financial risk management”
and “Financial instruments”.
Two main Other financial risks for Oasmia can
be identified at present:
|
·
|
Financing
risk:
Oasmia does not yet find itself in a commercialization stage, which means that revenues and cash flows generated from
sales are not yet sufficient to cover the Group’s capital and liquidity requirements. The financing risk therefore entails
the risk that Oasmia cannot manage to find existing and new owners who are willing to contribute equity and creditors who are
prepared to give loans to a sufficient extent until the company’s own sales have reached a sufficient size.
|
|
·
|
Impairment
risk:
As is described in Note 3 “Significant estimates and assumptions for accounting purposes” the value of “Capitalized
development costs” has been tested in a comprehensive impairment test. This test is based on a number of assumptions concerning
the time for regulatory market approval and the future development of above all market size, market penetration, demand and price
structure in different markets. There is a risk that these parameters later develop in a negative way that could not be foreseen
when the testing was performed and that an impairment requirement thereby then arises for all or parts of the intangible assets.
Bearing in mind that in the Statement of Financial Position at April 30, 2017 these constitute 80%, compared to 80% in previous
year of the total assets, such impairment may have considerable consequences for the Group’s financial position.
|
Financial risk management
The Group financial policy determined by the
Board regulates how management should identify financial risks and, when possible and necessary, take measures to limit risk.
Risk consists of two components:
|
·
|
The
risk that a negative events occurs
|
|
·
|
The
risk that there are great consequences if a negative event were to occur
|
A correct assessment of risk, and thus a decision
on appropriate risk management measures, is based on a true assessment of both these components. Obviously there can be situations
where it is not profitable to actively take measures to prevent a negative event even if there is a risk that it may occur, if
at the same time the consequences of such a negative event are small. In such a case it is probably best to accept the risk.
In other cases, where the consequences of a
negative event may be more extensive, risk management can consist of taking certain measures to try to minimize both components.
Depending on the nature of the risk, these measures can be directed more at one or the other of them. In certain cases, above all
where market risk is concerned, the individual company can often not influence the risk parameters at all. In those cases risk
management is directed entirely at reducing the consequences of negative events.
Credit and liquidity risks are mainly largely
governed by events that can be managed through active preventive work.
The dominant financial risks for Oasmia are
financing and consequently liquidity risks, as described above. This means that most of the financial risk management work is directed
at these two risks. In practice, this means that company management is constantly working on finding and developing different financing
opportunities, through both creditors and owners.
Capital management
The company is still in a development phase and does not yet generate
any profits or positive cash flow, which means that the company's capital management is entirely focused on external capital acquisition.
For the same reasons, no dividend policy has yet been formulated.
The overall objective of the company's capital management is to support operations with capital and liquidity until profitability
and positive cash flow have been achieved. This is done through issues of new shares and convertible loans, supplemented by external
loans. This capital management and this goal have not changed since the previous year and there are no external capital requirements
that must be observed.
Financial instruments
Oasmia’s financial instruments can be
divided into the following categories:
|
·
|
Financial
assets valued at fair value
|
|
·
|
Loans
receivable and accounts receivable
|
|
·
|
Financial
liabilities valued at amortized cost
|
Financial instruments by category
April 30, 2017
TSEK
|
|
Financial assets
valued at fair
value
|
|
|
Loans receivable
and accounts
receivable
|
|
|
Financial
liabilities valued
at amortized cost
|
|
|
Total
|
|
Financial assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
-
|
|
|
|
35
|
|
|
|
-
|
|
|
|
35
|
|
Other current receivables
|
|
|
-
|
|
|
|
14
|
|
|
|
-
|
|
|
|
14
|
|
Short-term investments
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Cash and cash equivalents
|
|
|
-
|
|
|
|
28,001
|
|
|
|
-
|
|
|
|
28,001
|
|
Total financial assets
|
|
|
0
|
|
|
|
28,050
|
|
|
|
0
|
|
|
|
28,050
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities to credit institutions
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Convertible loan
|
|
|
-
|
|
|
|
-
|
|
|
|
66,307
|
|
|
|
66,307
|
|
Other borrowings
|
|
|
-
|
|
|
|
-
|
|
|
|
102,419
|
|
|
|
102,419
|
|
Accounts payable
|
|
|
-
|
|
|
|
-
|
|
|
|
20,837
|
|
|
|
20,837
|
|
Other current liabilities
|
|
|
|
|
|
|
|
|
|
|
197
|
|
|
|
197
|
|
Accrued expenses
|
|
|
-
|
|
|
|
-
|
|
|
|
15,823
|
|
|
|
15,823
|
|
Total financial liabilities
|
|
|
0
|
|
|
|
0
|
|
|
|
205,583
|
|
|
|
205,583
|
|
April 30, 2016
TSEK
|
|
Financial assets
valued at fair
value
|
|
|
Loans receivable
and accounts
receivable
|
|
|
Financial
liabilities valued
at amortized cost
|
|
|
Total
|
|
Financial assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
-
|
|
|
|
4,903
|
|
|
|
-
|
|
|
|
4,903
|
|
Other current receivables
|
|
|
-
|
|
|
|
24
|
|
|
|
-
|
|
|
|
24
|
|
Short-term investments
|
|
|
20,006
|
|
|
|
-
|
|
|
|
-
|
|
|
|
20,006
|
|
Cash and cash equivalents
|
|
|
-
|
|
|
|
26,208
|
|
|
|
-
|
|
|
|
26,208
|
|
Total financial assets
|
|
|
20,006
|
|
|
|
31,135
|
|
|
|
0
|
|
|
|
51,141
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities to credit institutions
|
|
|
-
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
20,000
|
|
Convertible loan
|
|
|
-
|
|
|
|
-
|
|
|
|
25,549
|
|
|
|
25,549
|
|
Other borrowings
|
|
|
-
|
|
|
|
-
|
|
|
|
94,395
|
|
|
|
94,395
|
|
Accounts payable
|
|
|
-
|
|
|
|
-
|
|
|
|
27,236
|
|
|
|
27,236
|
|
Accrued expenses
|
|
|
-
|
|
|
|
-
|
|
|
|
11,693
|
|
|
|
11,693
|
|
Total financial liabilities
|
|
|
0
|
|
|
|
0
|
|
|
|
178,873
|
|
|
|
178,873
|
|
Financial assets valued at fair value
As of April 30, 2016 these consisted of fixed income funds to the
amount of TSEK 20,006 that invest in safe fixed income securities and other fixed income instruments. However, these financial
assets were divested during the financial year ending April 30, 2017.
The fair value of financial instruments can
be calculated according to different valuation techniques, which in turn are based on different inputs. These inputs can be observed
to varying degrees. Calculated fair values are divided into three different levels, primarily depending on how observable these
inputs are.
Level 1: Quoted market prices in active markets
for identical assets or liabilities constitutes the fair value of financial instruments on level 1.
Level 2: The input to fair value calculations
on level 2 consist of other directly or indirectly observable input than market prices.
Level 3: In calculations of fair value on level
3, inputs are not observable, but based, for example, on reasonable estimates.
The fixed income funds as per April 30, 2016
were valued at level 1.
Loans receivable and accounts receivable
|
·
|
Cash
and cash equivalents to the amount of TSEK 28,001 as of April 30, 2017 compared to TSEK 26,208 as of April 30, 2016 consist of
bank balances of TSEK 27,975 as of April 30, 2016 compared to TSEK 26,054 as of April 30, 2016 in Swedish commercial banks. and
of a bank balance of TSEK 26 as of April 30, 2017 compared to TSEK 155 as of April 30, 2016 in foreign commercial banks. Of cash
and cash equivalents, TSEK 47 as of April 30, 2017 compared to TSEK 195 as of April 30, 2016 is balances in foreign currency.
These have been translated using the Swedish Riksbank’s end-of-month quotation at closing day. That part of the liquid assets
which are in other currencies than SEK has an underlying currency risk, which means that there is a risk that the exchange rates
for these currencies develop negatively. As the absolute values are small, it is assessed that this risk is negligible.
|
|
·
|
Accounts receivable of TSEK 35 as of April 30, 2017 compared
to TSEK 4,903 as of April 30, 2016.
|
|
·
|
Other
current receivables and accrued income of TSEK 14 as of April 30, 2017 compared to TSEK 24 as of April 30, 2016.
|
TSEK
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Accounts receivable
|
|
|
35
|
|
|
|
4,903
|
|
Other current receivables
|
|
|
14
|
|
|
|
24
|
|
Total
|
|
|
49
|
|
|
|
4,927
|
|
Accounts receivable
Accounts receivable divided up by currency:
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Currency
|
|
Value in
currency
|
|
|
Recognized
in SEK
|
|
|
Value in
currency
|
|
|
Recognized
in SEK
|
|
EUR
|
|
|
|
|
|
|
|
|
|
|
531
|
|
|
|
4,863
|
|
USD
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
5
|
|
SEK
|
|
|
35
|
|
|
|
35
|
|
|
|
35
|
|
|
|
35
|
|
Total
|
|
|
|
|
|
|
35
|
|
|
|
|
|
|
|
4,903
|
|
Age of accounts receivable relative to due
date:
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Not yet due
|
|
|
35
|
|
|
|
35
|
|
Past due date:
|
|
|
|
|
|
|
|
|
1- 30 days
|
|
|
-
|
|
|
|
-
|
|
31-60 days
|
|
|
-
|
|
|
|
4,868
|
|
Total
|
|
|
35
|
|
|
|
4,903
|
|
Accounts receivable are recognized at the value
at which they are estimated they will be received. Accounts receivable in foreign currency have been translated at the closing
day exchange rate. Accounts receivable include a credit risk and in principle a currency risk as well. However, at April 30, 2017,
all accounts receivable was denominated in SEK, and thus there is no currency risk this year. No provisions have been made for
bad debt losses as the amounts due are expected to be received shortly.
A bad debt loss of TSEK 5,066 as of April 30,
2017 was recognized during the year compared to TSEK 0 as of April 30, 2016. This comprises the account receivable exchange-rate
adjusted up until the time of recognition which as of April 30, 2016 was due for payment in the category 31-60 days past due date.
Of Other current receivables, TSEK 14 as of
April 30, 2016, compared to TSEK 24 as of April 30, 2016, was overdue at closing day. The amount of TSEK 0 as of April 30, 2017
compared to TSEK 24 as of April 30, 2016, is denominated in foreign currency.
These financial instruments are reported at
amortized cost, which in this case means the value which it is estimated will be received. This value equals the fair value of
these financial instruments. They include a credit risk, but no currency risk, as of April 30, 2017.
Financial liabilities valued at amortized cost
|
·
|
Borrowings to the tune of TSEK 102,419 as of April 30,
2017 compared to TSEK 94,395 as of April 30, 2016 comprise a loan from Nexttobe AB, who previously were Oasmia’s second
largest shareholder. The fair value of the loan as of April 30, 2017 amounts to TSEK 100,616 compared to TSEK 93,510 as of April
30, 2016. This has been calculated as the discounted present value of the loan’s future cash flow. In addition, a discount
rate of 10 percent has been used, which is an assumed market interest rate for corresponding loans. This means a value according
to level 3, as described in section “Financial assets valued at fair value”.
|
The loan carries a fixed interest of 3.5%, which is to
be paid when the loan matures on September 30, 2017. During the financial year ending April 30, 2017 interest expenses for this
loan amounting to TSEK 6,549 compared to TSEK 7,616 in financial year ending April 30, 2016 and TSEK 8,324 in financial year ending
April 30, 2015, were reported in the income statement as financial expenses. As the interest rate is fixed up until maturity, there
is no interest-rate risk, but there is a liquidity risk.
In addition to this loan, Oasmia also has a loan commitment
of TSEK 40,000 as of April 30, 2017 compared to TSEK 40,000 as of April 30, 2016 from the largest shareholder, Alceco International
S.A. None of this loan commitment has been made use of.
TSEK
|
|
APR 30,
2017
|
|
|
APR 30,
2016
|
|
Loan
|
|
|
102,419
|
|
|
|
94,395
|
|
Total
|
|
|
102,419
|
|
|
|
94,395
|
|
|
·
|
The
convertible loans of TSEK 66,307 as of April 30, 2016 compared to TSEK 25,549 as of April 30, 2015 and TSEK 0 as of April 30,
2015 comprise 2 convertible loans as follows.
|
Designation
|
|
Number
|
|
|
Amount
per
convertible,
TSEK
|
|
|
Total
loan
amount,
TSEK
|
|
|
Recognized,
TSEK
|
|
|
Interest
|
|
|
Falls
due
|
|
Conversion
price,
SEK/share
|
|
|
Number
of new
shares upon full
conversion
|
|
2016:2
|
|
|
42
|
|
|
|
1,000
|
|
|
|
42,000
|
|
|
|
41,475
|
|
|
|
8.5
|
%
|
|
June 9, 2017
|
|
|
12.00
|
|
|
|
3,500,000
|
|
2017:2
|
|
|
26
|
|
|
|
1,000
|
|
|
|
26,000
|
|
|
|
24,832
|
|
|
|
8.5
|
%
|
|
April 18, 2018
|
|
|
8.00
|
|
|
|
3,250,000
|
|
Total
|
|
|
68
|
|
|
|
|
|
|
|
68,000
|
|
|
|
66,307
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,750,000
|
|
As per April 30, 2017, the fair value of the loan amounts
to TSEK 65,253 compared to TSEK 25,549 as per April 30, 2016. This has been calculated as the discounted present value of the loan’s
future cash flow. In addition, a discount rate of 10 percent has been used, which is an assumed market interest rate for corresponding
loans. This means a value according to level 3, as described in section “Financial assets valued at fair value”.
In addition to these open convertible loans at April 30,
2017, there have been two further convertible loans during the year:
Designation
|
|
Due date
|
|
Total loan
amount,
TSEK
|
|
|
|
2016:1
|
|
April 14, 2017
|
|
|
28,000
|
|
|
This loan was repaid in cash, TSEK 2,000, and the remaining TSEK 26,000 was replaced by 2017:2, see above.
|
2017:1
|
|
April 26, 2017
|
|
|
42,000
|
|
|
This loan was issued in March 2017 and was converted to 7,058,856 new shares on April 26, 2017.
|
Total
|
|
|
|
|
70,000
|
|
|
|
Compared to a bond loan, a convertible loan includes not
only an entitlement to receive interest but also the opportunity to receive a certain number of shares instead of repayment of
the loan. This additional advantage means that the rate of interest of the convertible loan is lower than the market interest rate
for a corresponding bond loan. The fair value of the benefit to Oasmia due to this lower rate of interest is booked, after deductions
for issue expenses, directly against equity. The pure loan part of the convertible instruments, that is to say excluding the above-mentioned
equity part, is recognized, with deductions for issue expenses, at its fair value as a liability in the balance sheet when it is
first booked. Interest expenses are subsequently calculated in accordance with the effective interest method and are charged to
the income statement.
As the interest rate up until maturity is pursuant to
a written agreement, there is a liquidity risk but no interest-rate risk.
TSEK
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Convertible loan
|
|
|
66,307
|
|
|
|
25,549
|
|
Total
|
|
|
66,307
|
|
|
|
25,549
|
|
|
·
|
Liabilities
to credit institutions amounted TSEK 0 as of April 30, 2017 compared to TSEK 20,000 as of April 30, 2016.
|
TSEK
|
|
APR 30,
2017
|
|
|
APR 30,
2016
|
|
Bank loan
|
|
|
-
|
|
|
|
20,000
|
|
Total
|
|
|
-
|
|
|
|
20,000
|
|
Oasmia has a granted but unutilized overdraft
facility amounting to TSEK 5,000 as of April 30, 2017 compared to TSEK 5,000 as of April 30, 2016. A chattel mortgage has been
taken out with the bank as collateral for this overdraft facility. See Note 24 “Contingent liabilities and pledged assets”.
|
·
|
Accounts
payable to the amount of TSEK 20,837 as of April 30, 2017 compared to TSEK 27,236 as of April 30, 2016, Accrued expenses of TSEK
15,823 as of April 30, 2017 compared to TSEK 11,693 as of April 30, 2016, and Other current liabilities of TSEK 197 as of April
30, 2017 compared to TSEK 0 as of April 30, 2016, in total TSEK 36,857 as per April 30, 2017 compared to TSEK 38,929 as of April
30, 2016, comprise small liabilities to a large number of suppliers and accrued interest for the above-mentioned loan. Amortized
cost equals fair value. Of this figure, TSEK 17,016 as of April 30, 2017 compared to TSEK 23,026 as of April 30, 2016 is liabilities
in a currency other than SEK. These involve a currency risk. In addition to this currency risk, there is also a liquidity risk
attached to these liabilities.
|
Remaining maturity of financial liabilities
The Group as per April 30, 2017
TSEK
|
|
< 3 months
|
|
|
3 -6 months
|
|
|
6- 12 months
|
|
|
More than 1
year
|
|
Convertible loans including interest
|
|
|
45,580
|
|
|
|
-
|
|
|
|
28,210
|
|
|
|
-
|
|
Other borrowings including interest
|
|
|
-
|
|
|
|
105,107
|
|
|
|
-
|
|
|
|
-
|
|
Accounts payable
|
|
|
20,837
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Other current liabilities
|
|
|
49
|
|
|
|
49
|
|
|
|
99
|
|
|
|
-
|
|
Accrued expenses
|
|
|
11,392
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
|
77,858
|
|
|
|
105,157
|
|
|
|
28,309
|
|
|
|
0
|
|
The Group as per April 30, 2016
TSEK
|
|
< 3 months
|
|
|
3 -6 months
|
|
|
6- 12 months
|
|
|
More than 1
year
|
|
Liabilities to credit institutions including interest
|
|
|
70
|
|
|
|
20,070
|
|
|
|
|
|
|
|
|
|
Convertible loans
|
|
|
|
|
|
|
|
|
|
|
30,380
|
|
|
|
|
|
Borrowings
|
|
|
|
|
|
|
|
|
|
|
102,462
|
|
|
|
|
|
Accounts payable
|
|
|
27,236
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses
|
|
|
8,839
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
36,145
|
|
|
|
20,070
|
|
|
|
132,842
|
|
|
|
0
|
|
NOTE 19 PREPAID EXPENSES AND ACCRUED INCOME
TSEK
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Prepaid clinical studies
|
|
|
3,643
|
|
|
|
-
|
|
Prepaid rent
|
|
|
1,030
|
|
|
|
1,036
|
|
Prepaid insurance premiums
|
|
|
553
|
|
|
|
578
|
|
Other prepaid expenses
|
|
|
1,782
|
|
|
|
1,271
|
|
Total
|
|
|
7,008
|
|
|
|
2,885
|
|
NOTE 20 OTHER CURRENT RECEIVABLES
TSEK
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
VAT receivable
|
|
|
1,295
|
|
|
|
1,897
|
|
Other current receivables
|
|
|
95
|
|
|
|
32
|
|
Total
|
|
|
1,390
|
|
|
|
1,929
|
|
NOTE 21 SHARE CAPITAL
Specifications of changes in equity are presented
in this report immediately after the statement of financial position. The total number of shares as of April 30, 2017 was 126,098,166
type A compared to 107,209,310 as of April 30, 2016 and 97,858,144 as of April 30, 2015 with a quota value of SEK 0.10 per share.
All issued shares have been fully paid for. The development of the number of shares since May 1, 2014 is shown below.
|
|
Number of shares
|
|
|
Share capital, SEK
|
|
Opening balance, May 1, 2014
|
|
|
85,572,330
|
|
|
|
8,557,233
|
|
2014 Private placement
1)
|
|
|
2,500,000
|
|
|
|
250,000
|
|
2014 Rights issue
|
|
|
9,785,814
|
|
|
|
978,581
|
|
Closing balance, Apr 30, 2015
|
|
|
97,858,144
|
|
|
|
9,785,814
|
|
2015 New share issue
|
|
|
7,684,500
|
|
|
|
768,450
|
|
2016 Private placement
1)
|
|
|
1,666,666
|
|
|
|
166,667
|
|
Closing balance, Apr 30, 2016
|
|
|
107,209,310
|
|
|
|
10,720,931
|
|
2016 Private placement
1)
|
|
|
8,750,000
|
|
|
|
875,000
|
|
2016 Offset issue
2)
|
|
|
3,080,000
|
|
|
|
308,000
|
|
2017 Conversion of convertible loan
3)
|
|
|
7,058,856
|
|
|
|
705,886
|
|
Closing balance, Apr 30, 2017
|
|
|
126,098,166
|
|
|
|
12,609,817
|
|
1)
Private placement to a limited number of investors.
2)
Offset of liability deriving from acquisition of intangible
assets.
3)
The share capital from conversion of the convertible
loan had still not been registered at the Swedish Companies Registration Office as of April 30, 2017. It is therefore recorded
in the Consolidated Statement of Financial Position on a separate row, "Non-registered share capital".
NOTE 22 OTHER CURRENT LIABILITIES
TSEK
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Cash payments for warrants that proved to be invalid, see Note 24
|
|
|
3,053
|
|
|
|
-
|
|
Employee withholding tax/social security contributions
|
|
|
2,106
|
|
|
|
2,068
|
|
Other
|
|
|
197
|
|
|
|
-
|
|
Total
|
|
|
5,356
|
|
|
|
2,068
|
|
NOTE 23 ACCRUED EXPENSES AND DEFERRED INCOME
TSEK
|
|
APR 30,
2017
|
|
|
APR 30,
2016
|
|
Accrued personnel costs
|
|
|
10,471
|
|
|
|
8,585
|
|
Accrued costs for clinical trials
|
|
|
7,747
|
|
|
|
5,030
|
|
Accrued interest expenses
|
|
|
4,431
|
|
|
|
2,890
|
|
Other accrued expenses
|
|
|
2,683
|
|
|
|
2,856
|
|
Deferred income
|
|
|
962
|
|
|
|
917
|
|
Total
|
|
|
26,294
|
|
|
|
20,278
|
|
NOTE 24 CONTINGENT LIABILITIES AND PLEDGED ASSETS
Contingent liabilities
During the year a number of warrants were issued within the framework
of a warrants programme directed at the Board and management. However, these warrants proved to be invalid due to a procedural
error and they have been withdrawn and cancelled. This may result in costs for the company. Nevertheless, it is not possible to
estimate with any degree of certainty the size of these costs, the time when they may arise or the likelihood that they will in
fact arise.
The Parent Company has given a guarantee to a former employee regarding
any costs deriving from employment at Oasmia that might possibly affect this former employee at a later date.
One of Oasmia’s collaboration partners has filed a claim against
Oasmia, that the company has contested in its entirety. It is too early to evaluate any likely outcome or an estimate of the size
of these costs with regards to the claim.
Pledged assets
The Parent Company has taken out a chattel
mortgage of TSEK 8,000 as of April 30, 2017 compared to TSEK 8,000 as of April 30, 2016, with a bank as collateral for an overdraft
facility of TSEK 5,000 as of April 30, 2017 compared to TSEK 5,000 as of April 30, 2016, and as the limit for a foreign currency
derivative of TSEK 3,000 as of April 30, 2017 compared to TSEK 3,000 as of April 30, 2016.
NOTE 25 CASH FLOW ANALYSIS
Adjustments for non-cash items
TSEK
|
|
Note
|
|
|
APR 30,
2017
|
|
|
APR 30,
2016
|
|
Depreciation, amortization and impairment: non-current assets
|
|
11,12
|
|
|
|
4,508
|
|
|
|
4,804
|
|
Impairment of inventories
|
|
7
|
|
|
|
5,736
|
|
|
|
-
|
|
Bad debt loss
|
|
18
|
|
|
|
5,066
|
|
|
|
-
|
|
Total
|
|
|
|
|
|
15,310
|
|
|
|
4,804
|
|
Inflow from convertible loans
TSEK
|
|
Note
|
|
|
APR 30,
2017
|
|
|
APR 30,
2016
|
|
Convertible loan 2016:1
|
|
18
|
|
|
|
-
|
|
|
|
28,000
|
|
Convertible loan 2016:2
|
|
18
|
|
|
|
42,000
|
|
|
|
-
|
|
Convertible loan 2017:1
|
|
18
|
|
|
|
42,000
|
|
|
|
-
|
|
Total
|
|
|
|
|
|
84,000
|
|
|
|
28,000
|
|
Inflow from new share issues
TSEK
|
|
Number of
shares
|
|
|
Note
|
|
|
APR 30,
2017
|
|
|
APR 30,
2016
|
|
New share issue in October and November 2015
|
|
7,684,500
|
|
|
21
|
|
|
|
-
|
|
|
|
88,696
|
|
Private placement in April 2016
|
|
1,666,666
|
|
|
21
|
|
|
|
-
|
|
|
|
17,500
|
|
Private placement in October 2016
|
|
8,750,000
|
|
|
21
|
|
|
|
70,000
|
|
|
|
-
|
|
Total
|
|
|
|
|
|
|
|
|
70,000
|
|
|
|
106,196
|
|
NOTE 26 TRANSACTIONS WITH RELATED PARTIES
Group companies
As per April 30, 2017, the Group consists of the Parent Company
Oasmia Pharmaceutical AB, the Swedish subsidiaries Qdoxx Pharma AB and Oasmia Incentive AB (formerly Oasmia Animal Health AB),
Oasmia Pharmaceutical, Inc. in the US and Oasmia Pharmaceutical Asian Pacific, Ltd based in Hong Kong. The subsidiaries are 100%
owned and thus under the control of the Parent Company. For further information on the Group, please refer to Note 27 Holdings
in Group companies.
Intra-Group transactions
There has been no sale of goods between the
Parent Company and the subsidiaries during the year.
The following table shows the transactions
during the year between the Parent Company and the Swedish subsidiaries and the opening and closing liabilities:
|
|
Qdoxx Pharma
|
|
|
Oasmia Incentive
|
|
TSEK
|
|
MAY 1, 2016–
APR 30, 2017
|
|
|
MAY 1, 2015–
APR 30, 2016
|
|
|
MAY 1, 2016–
APR 30, 2017
|
|
|
MAY 1, 2015–
APR 30, 2016
|
|
Parent Company’s opening liabilities
|
|
|
99
|
|
|
|
116
|
|
|
|
204
|
|
|
|
208
|
|
Transactions during the year
|
|
|
(37
|
)
|
|
|
(17
|
)
|
|
|
1,397
|
|
|
|
(4
|
)
|
Parent Company’s closing liabilities
|
|
|
62
|
|
|
|
99
|
|
|
|
1,601
|
|
|
|
204
|
|
There were no transactions between the Parent
Company and Oasmia Pharmaceutical, Inc. during the year. The Parent Company paid TSEK 65 during the year as a capital contribution
to Oasmia Pharmaceutical Asian Pacific, Ltd. The were no dealings between the Parent Company and any of the foreign subsidiaries
at closing day.
Group contributions from Oasmia Pharmaceutical AB to the subsidiaries
No Group contributions were paid in the financial year ending April
30, 2017 and April 30, 2016.
Transactions with key people in senior positions
For salaries and remuneration to the Board and senior executives,
please refer to Note 10.
During the financial year ending April 30, 2017, warrants were issued
for the Board and senior executives in the amount of TSEK 3,330. However, these warrants proved to be invalid due to a procedural
error. Of the amount paid in, TSEK 278 has been repaid and the remaining TSEK 3,052 is recognized at April 30, 2017 as a liability
to Board members and senior executives.
There were no other transactions with key persons.
Financial loan transactions with related
parties
On April 30, 2017 there was a credit facility of TSEK 40,000 compared
to TSEK 40,000 as if April 30, 2016, available to Oasmia from Alceco International S.A., the company’s largest shareholder.
If the facility is utilized the interest rate is 5%. This credit facility was completely unused at April 30, 2017, as was the case
at April 30, 2016.
Oasmia had a loan of TSEK 94,395 from Nexttobe AB up until December
30, 2016. This loan including accrued interest of TSEK 8,024 was then replaced by a new loan. As per April 30, 2017 the loan amounts
of TSEK 102,419 compared to TSEK 94,395 as per April 30, 2016. The loan which carries interest of 3.5 percent and falls due for
payment on September 30, 2017. The loan is recognized at amortized cost and its fair value based on an estimated market interest
rate of 10 percent amounts to TSEK 100,616.
Nexttobe AB was Oasmia’s second largest shareholder up until
October 31, 2016, with a shareholding of 18.3 percent. However, this shareholding was divested as of November 1, 2016, which means
that the relationship with Nexttobe AB is no longer a related party relationship.
Other transactions with related parties
Ardenia Investment Ltd, which is equally controlled by Oasmia’s
founders Bo Cederstrand and Julian Aleksov, is registered as the applicant for and the holder of the underlying patents for Oasmia’s
business. Pursuant to an agreement between Ardenia and Oasmia, the rights to these patents have been transferred to Oasmia. Ardenia
re-charged for administrative expenses for these patents during the year. These invoices amounted to TSEK 1,373 in the financial
year ending April 30, 2017 compared to TSEK 2,233 in the financial year ending April 30, 2016. As per closing day April 30, 2017
Oasmia had unpaid invoices from Ardenia amounting to TSEK 721 compared to TSEK 0 as per April 30, 2016.
NOTE 27 HOLDINGS IN GROUP COMPANIES
|
|
|
|
|
|
|
|
|
|
|
|
|
Book value
|
|
|
Book value
|
|
Parent Company
|
|
Reg. No.
|
|
|
Domicile
|
|
Owner-
ship %
|
|
|
Votes %
|
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Qdoxx Pharma AB
|
|
|
556609-0154
|
|
|
Uppsala
|
|
|
100
|
|
|
|
100
|
|
|
|
100
|
|
|
|
100
|
|
Oasmia Incentive AB (formerly Animal Health AB)
|
|
|
556519-8818
|
|
|
Uppsala
|
|
|
100
|
|
|
|
100
|
|
|
|
10
|
|
|
|
10
|
|
Oasmia Pharmaceutical, Inc.
|
|
|
E0300362015-6
|
|
|
Nevada, USA
|
|
|
100
|
|
|
|
100
|
|
|
|
0
|
|
|
|
0
|
|
Oasmia Pharmaceutical Asian Pacific, Ltd
|
|
|
2383363
|
|
|
Hong Kong
|
|
|
100
|
|
|
|
100
|
|
|
|
0
|
|
|
|
0
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
110
|
|
|
|
110
|
|
NOTE 28 ALLOCATION OF NON-RESTRICTED EQUITY
The following non-restricted equity is available for distribution
by the Annual General Meeting:
SEK
|
|
APR 30, 2017
|
|
|
APR 30, 2016
|
|
Share premium reserve
|
|
|
1,074,619,456
|
|
|
|
941,960,675
|
|
Retained earnings
|
|
|
-639,377,516
|
|
|
|
-489,921,393
|
|
Income for the year
|
|
|
-160,072,959
|
|
|
|
-141,673,259
|
|
Total
|
|
|
275,168,981
|
|
|
|
310,366,023
|
|
The Board proposes that the 2017 Annual General Meeting adopts a
resolution that the above amount available of SEK 275,168,981 as per April 30, 2017 compared to SEK 310,366,023 as per April 30,
2016 to be carried forward.
NOTE 29 EVENTS AFTER BALANCE SHEET DATE OF APRIL 30, 2017
Oasmia Pharmaceutical to spin-off veterinary
assets
The Board of Oasmia, has made a decision to move all of Oasmia’s
veterinary assets, including Paccal Vet and Doxophos Vet, to a wholly owned subsidiary in the United States. The transfer is made
to provide a solid financial foundation for further development and commercialization of the veterinary business on the US market.
Based on an independent valuation by one of the big four accounting
firms, the fair market value of the registered intellectual property relating to Oasmia’s animal oncology products, Paccal
Vet and Doxophos Vet, is assessed in the range of USD 75 – 80 million. This independent valuation in a potential transaction
could differ from the indicated range.
The Company has appointed New York based advisors to evaluate potential
financial and strategic alternatives for the veterinary business, including private placement, public offering of the common
stock in the U.S. subsidiary and strategic collaborations within the veterinary field. These activities will commence at once.
Extraordinary General Meeting on June 2,
2017
Oasmia held an extra general meeting on June 2, 2017. The general
meeting resolved an issue authorization of 40 million shares. The proposals regarding issue of new warrants that also included
simultaneous cancellation of all warrants issued after the extra general meeting on November 21, 2016 were resolved. The right
to acquire warrants is to accrue to persons of the executive committee and other key employees.
New share issue
On June 11, 2017, the Board of Directors resolved to carry out a
new issue of shares of approximately SEK 164 million with preferential rights for Oasmia’s current shareholders. The prospectus
was published on June 19, 2017.
Convertible loan replaced with non-negotiable promissory notes
The convertibles loan of SEK 42 million (convertible program 2016:2)
that matured June 9, 2017 were replaced by new debt was replaced on the due date by non-negotiable promissory notes carrying the
same amount as the convertibles.
*)
After the closing date, Oasmia
agreed with the holders of the 42 convertible debt instruments to replace these with non-negotiable promissory notes
.
Of these 42 original convertible debt instruments, SEK 9 500 thousand was later repaid during the quarter, while the rest were
replaced with non-negitionable promissory notes, totaling SEK 33,500,000. Those were added as of July 31 at 8.5 percent interest
and expire on June 30, 2018.
The term for the new debt was up to one (1) year, however, the debt
can be pre-paid by Oasmia before they fall due. Interest on the new debt accrue from 9 June 2017 at an interest rate of 8.5% annually,
and therefore, corresponds to the interest rate for the convertibles. see Item 5.A Operating Results Overview - Events after balance
sheet date of April 30, 2017)
New warrants
On June 21, 2017, the warrant programs decided at the Extraordinary
General Meeting of June 2, 2017 were issued. This means that the Board and Management acquired 4 418 182 warrants. Oasmia Incentive
still holds 2 331 818 warrants for the purpose of later being offered to new executives.
New distributor in Russia and other CIS
In June 2017 Oasmia entered into a new exclusive marketing and distribution
agreement with Hetero Group for Russia and the CIS.
Result of the rights issue
The subscription period for
Oasmia Pharmaceutical AB’s (publ) (“Oasmia” or the “Company”) rights issue ended on July 5, 2017.
The result of the rights issue showed that 23,517,699 shares, representing approximately 46.6 per cent of the shares offered, were
subscribed for by the exercise of subscription rights. Additionally, subscription forms corresponding to 2,073,805 shares, representing
approximately 4.1 per cent of the shares offered, have been received for subscription without preferential rights. The remaining
24,847,762 shares, representing approximately 49.3 per cent of the shares offered, will be allotted to those who have committed
to subscribe and pay for any remaining part of the right issue, in accordance with the underwriting agreements entered into with
the Company. The issued amount in the rights issue, which accordingly was fully subscribed, amounted to in total approximately
SEK 164 million (before transaction related costs).
Through
the rights issue, Oasmia’s share capital increased by SEK 5,043,926.60 to SEK 17,653,743.20. The number of shares increased
by 50,439,266 to 176,537,432
.
Oasmia receives market approval for its Anti-Cancer Drug Doxophos®
in Russia
The company has received
marketing approval of Doxophos in Russia, a key milestone following the recently established relationship with Hetero Group, its
new marketing and distribution partner.
Doxophos is a hybrid and
novel nanoparticle formulation of doxorubicin, one of the most commonly used anti-cancer substances in the world, well-recognized
for its treatment of lung, breast and prostate cancer, among others. Doxorubicin is the active substance in the prominent oncology
family of brands including Adriamycin® and Doxil®, totaling an estimated market value of $800 million USD in
2015 and expected to reach $1.4 billion by 2024.
NOTE 30 KEY DEFINITIONS
In addition to the key definitions presented in the financial
statements, following key definitions are used in this annual report.
Earnings per share:
|
Income for the year attributable to Parent Company shareholders divided by the weighted average number of shares, before and after dilution, during the year.
|
Equity per share:
|
Equity as a ratio of the number of shares at the end of the period.
|
Equity/assets ratio:
|
Equity as a ratio of total assets.
|
Net liability:
|
Total borrowings (comprising the balance sheet items Liabilities to credit institutions, Convertible loans and Other borrowings) with deduction of cash and cash equivalents and short-term investments.
|
Debt/equity ratio:
|
Net liability as a ratio of equity.
|
Return on total assets:
|
Income before interest expenses as a percentage of the average balance sheet total.
|
Return on equity:
|
Income before taxes as a ratio of average equity.
|
The key definitions found above are generic definitions often used in analyses and comparisons between different companies. They are therefore given to enable the reader to rapidly and summarily evaluate Oasmia’s financial situation and possibly compare with other companies.
|
These have been calculated as follows:
|
|
MAY 1, 2016
|
|
|
MAY 1, 2015
|
|
|
MAY 1, 2014
|
|
Earnings per share
|
|
- APR 30, 2017
|
|
|
- APR 30, 2016
|
|
|
- APR 30, 2015
|
|
Income for the year attributable to Parent Company shareholders, TSEK
|
|
|
(160,230
|
)
|
|
|
(141,558
|
)
|
|
|
(117,497
|
)
|
Weighted average number of shares, before and after dilution, thousand
|
|
|
112,994
|
|
|
|
101,753
|
|
|
|
91,655
|
|
Earnings per share, SEK
|
|
|
(1.42
|
)
|
|
|
(1.39
|
)
|
|
|
(1.28
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity per share
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity at the end of the period, TSEK
|
|
|
300,371
|
|
|
|
326,053
|
|
|
|
375,710
|
|
Number of shares at the end of the period, thousand
|
|
|
126,098
|
|
|
|
107,209
|
|
|
|
97,858
|
|
Equity per share, SEK
|
|
|
2.38
|
|
|
|
3.04
|
|
|
|
3.84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity/Assets ratio
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity at the end of the period, TSEK
|
|
|
300,371
|
|
|
|
326,053
|
|
|
|
375,710
|
|
Total assets at the end of the period, TSEK
|
|
|
521,583
|
|
|
|
515,579
|
|
|
|
514,569
|
|
Equity/Assets ratio
|
|
|
58
|
%
|
|
|
63
|
%
|
|
|
73
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net liability, TSEK
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities to credit institutions
|
|
|
0
|
|
|
|
20,000
|
|
|
|
20,000
|
|
Convertible loans
|
|
|
66,307
|
|
|
|
25,549
|
|
|
|
-
|
|
Other borrowings
|
|
|
102,419
|
|
|
|
94,395
|
|
|
|
87,000
|
|
Total borrowings
|
|
|
168,725
|
|
|
|
139,944
|
|
|
|
107,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term investments
|
|
|
0
|
|
|
|
20,006
|
|
|
|
50,153
|
|
Cash and cash equivalents
|
|
|
28,001
|
|
|
|
26,208
|
|
|
|
26,837
|
|
Total cash and cash equivalents and short-term investments
|
|
|
28,001
|
|
|
|
46,215
|
|
|
|
76,990
|
|
Net liability
|
|
|
140,724
|
|
|
|
93,730
|
|
|
|
30,010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt/equity ratio
|
|
|
|
|
|
|
|
|
|
|
|
|
Net liability, TSEK
|
|
|
140,724
|
|
|
|
93,730
|
|
|
|
30,010
|
|
Equity, TSEK
|
|
|
300,371
|
|
|
|
326,053
|
|
|
|
375,710
|
|
Debt/equity ratio
|
|
|
47
|
%
|
|
|
29
|
%
|
|
|
8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Return on equity
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before taxes, TSEK
|
|
|
(160,243
|
)
|
|
|
(141,539
|
)
|
|
|
(117,497
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets at the beginning of the period, TSEK
|
|
|
515,579
|
|
|
|
514,569
|
|
|
|
468,383
|
|
Total assets at the end of the period, TSEK
|
|
|
521,583
|
|
|
|
515,579
|
|
|
|
514,569
|
|
Average balance sheet total, TSEK
|
|
|
518,581
|
|
|
|
515,074
|
|
|
|
491,476
|
|
Return on equity
|
|
|
(31
|
)%
|
|
|
(27
|
)%
|
|
|
(24
|
)%
|